

CURRICULUM VITAE

Prof. Marco Valgimigli, MD, PhD



PERSONAL DETAILS

Date of birth	March 6 th , 1972
Place of birth	Forlì (Italy)
Nationality	Italian
Marital Status	Defacto
Children	Riccardo, 25/02/2007 Alessandro, 30/09/2010 Asia, 10/10/2018
Languages	Italian, English, German, French (basic), Dutch (basic)
Office address	Istituto Cardiocentro Ticino Department of Cardiology Via Tesserete 48 CH-6900 Lugano, Switzerland
E-mail	marco.valgimigli@eoc.ch
Business phone	+41 91 811 53 47
Home address	Strada di Fulmignano 25 6977 Ruvigliana, Switzerland

INDEX OF CONTENTS

Education / Further education	3
Professional experience	3
Research activities.....	3
Clinical activities.....	4
Administrative and leadership experience.....	5
Academic appointments	5
Details of occupation	6
Surgical subjects.....	6
Organisational responsibilities	7
Teaching	10
Scientific work and Funding	11
Promotion of junior researchers.....	24
Research methodology	27
Various	28
Awards.....	28
Memberships	28
Publications	29
H-Index	29
List of publications.....	31
Original articles.....	31
Review articles.....	130
Guidelines and consensus articles.....	138
Editorials.....	151
Letter to the editor.....	154
Case reports.....	157
Book chapters.....	158
The six most important original papers.....	160

EDUCATION / FURTHER EDUCATION

Education

1991	High School degree in foreign languages (60/60)
1991-1997	Faculty of Medicine, University of Bologna, Bologna, Italy

University degrees

1997	Doctor in Medicine and Surgery (equivalent to M.D.), University of Bologna, Italy, Magna cum laude Thesis: Piscaglia F, Zironi G, Gaiani S, Mazziotti A, Cavallari A, Gramantieri L, Valgimigli M. , Bolondi L. Systemic and Splanchnic Hemodynamic changes after liver transplantation for cirrhosis: a long term prospective study. Hepatology. 30:58-64, 1999.
2003	Degree in Cardiological Sciences University of Ferrara, Ferrara, Italy, Magna cum laude
2006	PhD degree in Interventional Cardiology Erasmus Medical Center, Rotterdam, The Netherlands with a thesis entitled “High-risk percutaneous intervention in the drug eluting stent era” Promoters Professors P.W. Serruys and P. de Feyter

PROFESSIONAL EXPERIENCE

Research activities

1997-1999	Residency in Internal and Emergency Medicine Sciences, winning a national grant University of Bologna, Bologna, Italy, (Prof Bolondi, Mentor)
2004-2005	Clinical and Research Fellowship in Interventional Cardiology, Erasmus University, Thoraxcenter, Rotterdam, The Netherlands, (Mentor, Prof P.W. Serruys)
2006	Centre Hospitalier Universitaire de Caen, Avenue Côte de Nacre 14033 Caen, Normandy, France, Cedex (under the assistance of Prof M. Hamon)
2006-2013	University Hospital of Ferrara, Cardiology Department, Ferrara, Italy
2013-2015	Erasmus Medical Center, Rotterdam, The Netherlands
2015-May 2020	Bern University Hospital, Cardiology department, Bern, Switzerland
June 2020-Current	Cardiocentro Ticino, Cardiology department, Lugano, Switzerland

Clinical activities:

1995-1997	Student-fellow at 1 Internal Medicine Unit Departement, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
1997-1997	Clerkship in Cardiology at Hospital de Santa Maria, Lisbon, Portugal
1997-1999	Post-graduate fellow at Emergency Medicine Unit, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
1999-2000	Post-graduate fellow at Coronary Care Unit, S. Anna Hospital, University of Ferrara, Ferrara, Italy
2000-2002	Post-graduate fellow at Haemodynamic Unit, Spedali Civili, University of Brescia, Brescia, Italy
2002-2003	Post-graduate Resident-fellow at Haemodynamic Unit, S. Anna Hospital, University of Ferrara, Ferrara, Italy
2004-2005	Research (PhD training) and clinical fellowship in Interventional Cardiology, Erasmus University, Thoraxcenter, Rotterdam, The Netherlands
2006-2006	Training in complex PCI procedures through radial access at the Centre Hospitalier Universitaire de Caen, Avenue Côte de Nacre Caen, Normandy, France, Cedex (under the assistance of Prof M. Hamon)
2006-2009	Senior attending cardiologist at the University Hospital of Ferrara working full time in the catheterization laboratory
2009-2013	Director of the Catheterization Laboratory at the University Hospital of Ferrara, Ferrara, Italy
2013-2015	Associate Professor of Cardiology at Erasmus Medical Center and Senior Interventional Cardiologist, Thoraxcenter, Rotterdam, The Netherlands
2015-May 2020	Head of clinical research of the Cardiology department, and full-time interventional cardiologist at Inselspital, Bern University Hospital, Switzerland.
2016-May 2020	Extraordinary Professor for invasive cardiology Bern University Hospital, Bern, Switzerland.
June 2020-2025	Deputy Chief of Cardiology at Cardiocentro Ticino, Lugano, Switzerland.
January 2026-current	Chief of Cardiology at Istituto Cardiocentro Ticino, Lugano, Switzerland

Administrative and leadership experience

2009-2013	Director of the Catheterization Laboratory at the University Hospital of Ferrara, Ferrara, Italy Responsible of 6 Interventional Cardiologists and 10 Catheterisation Laboratory Nurses and 5 Technicians
2013-2015	Director of Clinical Research in the field of anti-thrombotics and innovative pharmacological treatment modalities at the Thoraxcentrum, Erasmus Medical Center and responsible person for the interaction between the Erasmus University and clinical research organizations (CRO), including Cardialysis for the planning, execution and oversight of all investigator-driven clinical research activities.
2015-May 2020	Director of Clinical Research of the Cardiology department, Inselspital, Bern University Hospital, Switzerland. Responsible for the organization, planning and execution of sponsor- and investigator-initiated clinical research in the field of cardiology and interventional cardiology. Local referent for the Cardiopath PhD program, an international PhD program led by the University of Naples, Federico II, involving the University of Bern, Switzerland and the Cardiovascular center OLV, Aalst, Belgium.
June 2020-2025	Deputy Chief of Cardiology at Cardiocentro Ticino, Lugano, Switzerland and head of clinical research.
January 2026-current	Chief of Cardiology at Istituto Cardiocentro Ticino, Lugano, Switzerland

ACADEMIC APPOINTMENTS

2013-2015	Associated Professor, Erasmus Medical Center, Rotterdam, The Netherlands
2015-May 2020	Extraordinary Professor, Bern University Hospital, Cardiology department, Bern, Switzerland
2021-current	Adjunct Professor of Medicine, Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland
2022-current	Adjunct Professor, University Clinic of Cardiology, Inselspital Bern, Bern, Switzerland

DETAILS OF OCCUPATION

Surgical (Interventional) Subjects

Operation (Intervention) Catalogue

Interventions conducted as operator (2006 – end of June 2025)

17899	Diagnostic coronary angiographies
11234	Percutaneous coronary interventions
789	PFO and LAA closures
787	Transcatheter aortic valve implantations (TAVI)
109	Valvuloplasties
687	Right heart catheterisation
49	Transcatheter edge to edge repairs (Mitral or Tricuspid)
12	Paravalvular leak closures
5	Percutaneous Mitral valve implantations
3	Percutaneous Tricuspid valve implantations
45	Percutaneous treatments for pulmonary embolism (ultra-sound enhanced catheter-direct thrombolysis/mechanical aspiration)
22	Mechanical pulmonary thrombectomy
35	ECMO with percutaneous access
156	Impella 2.5/5.0

Interventions conducted as assistant (2002 – 2006)

1079	Diagnostic coronary angiographies
567	Percutaneous coronary interventions
5	PFO and LAA closures
10	Valvuloplasties
23	Percutaneous trans-spetal myocardial ablations
106	Right heart catheterisations

Interventions conducted as instructor (2006 – end of June 2025)

8867	Diagnostic coronary angiographies
4455	Percutaneous coronary interventions
85	PFO and LAA closures
19	Valvuloplasties
578	Right heart catheterisations
95	TAVIs
15	Percutaneous treatments for pulmonary embolism (ultra-sound enhanced catheter-direct thrombolysis/mechanical aspiration)
5	Mechanical pulmonary thrombectomy
15	ECMO with percutaneous access
33	Impella 2.5/5.0

Organisational responsibilities

2007-2013	Head of Invasive Cardiology, University Hospital Ferrara, Cardiology Department, Ferrara, Italy
2006-2013	Head of Research, University Hospital Ferrara, Cardiology Department, Ferrara, Italy
2013-2015	Group Leader, cardiac research on anti-thrombotic agents, University Clinic for Cardiology, Department Thorax, University Hospital Erasmus Medical Center Rotterdam, The Netherlands
2015-2020	Extraordinary Professorship for invasive cardiology and Head of Clinical Research, Bern University Hospital, Bern, Switzerland
2018	Chief and Professor of Cardiology (succession of Prof. Daniel Wagner) University Hospital Lausanne, Switzerland secondo loco (primo loco: Prof. O. Müller)
2018-2023	Member of Scientific Advisory Board (DKF) University Hospital Basel, Department of Clinical Research
June 2020-current	Deputy Chief of Cardiology at Cardiocentro Ticino, Lugano, Switzerland and head of clinical research.

European Society of Cardiology (ESC)

2006-2017	Committee Member, ESC Press Committee
2007-current	Fellow of the European Society of Cardiology (ESC)
2013-2016	Editor of the ESC Congress News
2013-2015	Committee Member, Congress Program Committee
2015-2017	Chair, Congress Program Committee
2013-2017	European Association of Percutaneous Coronary intervention (EAPCI) Board member
2024-2026	Pillar Chair of the EAPCI Science & Research Pillar, European Association of Percutaneous Coronary intervention (EAPCI)

Clinical Practice Guidelines Committee from the European Society of Cardiology

2011-2011	Reviewer ESC Guidelines for the Diagnosis and Treatment of Non-ST Segment Elevation Acute Coronary Syndromes
-----------	---

2011-2012	Task Force Member ESC Guidelines for the Management of ST-Segment Elevation Myocardial Infarction
2012-2014	Task Force Member ESC Guidelines on Myocardial Revascularization Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)
2012-2014	Reviewer Coordinator ESC Guidelines for the Diagnosis and Treatment of Stable Coronary Artery Disease
2013-2015	Task Force Member (Section Coordinator) ESC Guidelines for the Diagnosis and Treatment of Non-ST Segment Elevation Acute Coronary Syndromes
2015-2017	Chair-Task Force ESC Guidelines DAPT Focused Update on Myocardial Revascularization Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)
2015-2017	Task Force Member (Section Coordinator) ESC Guidelines for the Diagnosis and Treatment of ST Segment Elevation Myocardial Infarction
2016-2018	Reviewer ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018).
2017-2019	Task Force Member of the ESC guidelines for the diagnosis and treatment of patients with stable coronary artery disease.
2019	Task Force Member of the 2020 ESC Guidelines for the management of atrial fibrillation
2019	Reviewer 2020 ESC Guidelines for the management of patients with non-ST segment elevation myocardial infarction
2020	Chair of the Joint EAPCI, ACCA and EAPC Paper on Anti-thrombotic treatment strategies for secondary prevention in patients with established coronary atherosclerotic disease

European Association of Percutaneous Coronary Intervention

2011-2016	Chair, Research Committee from the European Association of Percutaneous Coronary Intervention (EAPCI)
2024-2026	Pillar Chair of the EAPCI Science & Research Pillar

International Courses on Percutaneous Cardiovascular Interventions

2010-2020	Committee Program Member, PCR–course on cardiovascular interventions, EuroPCR, Paris, France
2011-2016	Committee member Program, TCT–course on cardiovascular interventions, New York, USA
2016-2021	Associate director TCT Program Committee–course on cardiovascular interventions, New York, USA

Live-Case Transmissions

2013	Live-case Transmission for Rotterdam Course on Biovascular Scaffold
2014	Live-case Transmission for Rotterdam Course on Biovascular Scaffold
2015	Live-case Transmission for Prague Cardiovascular Course
2023	Live-case Transmission for India Complex Course

Editorial Board Member

2012-2024	Journal of the American College of Cardiology – Cardiovascular Interventions
Since 2013	EuroIntervention
Since 2010	Future Cardiology
Since 2015	Asia Pacific Intervention
Since 2018	Assitant Editor of the European Heart Journal: Acute Cardiovascular Care
Since 2018	Circulation Cardiovascular Intervention

Clinical Event Committee Member

2009	Member, RESOLUTE Trial
2010	Member, NEVO 2 Trial
2011	Member, NEXT Trial
2013	Member, EXECUTIVE Trial
2015	Member, RESERVOIR I Trial
2019	Member, EURO-SHOCK Trial

Data Safety Monitoring Board Committee Chair or Member

2017-2019	DSMB Chair of the Revacept, a Novel Inhibitor of Platelet Adhesion in Patients with Stable Coronary Artery Disease
-----------	--

	Undergoing Elective Percutaneous Coronary Interventions: A Phase II, Multicentre, Randomised, Dose-Finding, Double-Blind and Placebo-Controlled Study
2023-current	DSMB Chair of the IONMAN Trial: First In Human Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System
2022-current	DSMB Chair of the REBOOT Trial: tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)
2024-current	DSMB member of the S The Value of IVL Compared To OPN Non-Compliant Balloons for Treatment of Refractory Coronary Lesions (VICTORY) Trial

Review for Peer Reviewed Journals

Cardiology

Circulation, Journal of the American College of Cardiology (JACC), European Heart Journal (EHJ), EuroIntervention, Circulation Cardiovascular Interventions, Journal of the American College of Cardiology Cardiovascular Interventions, American Heart Journal, American Journal of Cardiology (AJC), Catheterization and Cardiovascular Interventions (CCI), Journal of Invasive Cardiology, Heart, Journal of Cardiovascular, JAMA Cardiology

Internal Medicine

New England Journal of Medicine (NEJM), Lancet, Journal of the American Medical Association (JAMA), British Medicine Journal (BMJ), Archives of Internal Medicine, Annals of Internal Medicine.

Teaching

2013	Contract professor of invasive cardiology for nurses at the University of Ferrara (target audience: care staff)
2013	Contract professor of invasive cardiology for radiology technicians at the University of Ferrara (target audience: care staff)
2013	Contract professor of invasive cardiology for residents in the specialization course of Cardiology at the University Hospital of Ferrara Italy (target audience: Doctors in Medicine attending the specialization course in cardiology)
2014-2015	Responsible Person of the COEUR (Cardiovascular Research School) course on anti-thrombotics devoted to PhD students of the Erasmus Medical Center institution (target audience: PhD students comprising doctors in medicine or biology)
2015-2020	Involved in the organisation and execution of the weekly journal clubs and Grand Rounds with staff members and visiting professors at Inselspital, Bern.

2020-current	Involved in the organisation and execution of the weekly journal clubs and Grand Rounds with staff members and visiting professors at Cardiocentro, Ticino, Lugano.
2020-current	Teacher for invasive cardiology and anti-thrombotics in cardiology courses to residents of Internal medicine/ cardiology and nurses at ICCT Institution, Lugano, Switzerland
2021-current	Professor of Medicine, Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland, regularly involved in providing frontal lessons and in examinations for students in medicine attending USI.

Scientific work and Funding

Marco Valgimigli has raised 71'745'273 million Euros/Swiss Francs as main applicant, of which 64'468'860 million via non-competitive funds and 7'276'413 Euros/Francs as competitive funds, including Swiss National Foundation, Swiss Heart Foundation, Innosuisse, Inselspital, Fondazioni Ticinesi, MURST, and Regione Emilia Romagna.

Investigator Initiated Trials

Financial support of the Ministry for University and Scientific and Technological research [MURST]

Project:	Tailoring the choice of P2Y12 oral receptor blockers by integrating loss of function alleles to phenotype assessment via point of care testing versus standard of care in patients who undergo percutaneous coronary intervention: a randomized multicenter trial
Support:	Ministry for University and Scientific and Technological Research [MURST]
Nr. of partner:	10
Own function:	Principal Investigator
Period:	2012-2015
Total amount:	Euro 336'700.00

Financial support from REGIONE EMILIA ROMAGNA

Project:	Single High-Dose BoluS TiRofibAn and Sirolimus Eluting STent versus Abciximab and Bare Metal Stent in Acute MYocardial Infarction (STRATEGY) Study
Support:	Regione Emilia Romagna
Nr. of partner:	1
Own function:	Principal Investigator
Period:	2003-2006
Total amount:	Euro 250'000.00

Financial support from SNSF – Swiss National Science Foundation

Project: GLASSY: GLOBAL LEADERS Adjudication Sub-Study
Support: SNSF
Nr. of partner: 19 (including Bern)
Own function: Principal Investigator
Period: 2018
Total amount: CHF 19'200.00 (SNF)

Financial support from Swissheart Foundation (Schweizerische Herzstiftung)

Project: Establishing Reference Values for the Diagnosis of Coronary Artery Ectasia in Current
Support: Swiss Foundation of Cardiology
Own function: Principal Investigator
Period: 2019
Total amount: CHF 80'000.00

Financial support from Innosuisse – Agenzia svizzera per la promozione dell'innovazione

Project: MOCA I Microvascular Obstruction with the CoFI™ System Assessment
Support: Innosuisse & CorFlow
Nr. of Partner: 4
Own function: Principal Investigator
Period: 2019 - 2020
Total amount: 265'920.00

Financial support from Merck, USA

Project: MULTISTRATEGY: MULTICentre evaluation of Single high-dose bolus Tirofiban versus Abciximab with sirolimus eluting sTent or Bare Metal Stent in Acute Myocardial Infarction study
Support: University of Ferrara, support from Merck
Nr. of partner: 16
Own function: Principal Investigator
Period: 2004-2008
Total amount: Euro 500'000.00

Financial support from Merck, USA

Project: 3T/2R: Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel
Support: University of Ferrara, industry support from MERCK
Nr. of partner: 12

Own function: Principal Investigator
Period: 2005-2009
Total amount: Euro 700'000.00

Financial support from Eli Lilly, USA

Project: FABOLUS SYNCHRO: Facilitation through Abciximab by dropping infusion line in patients undergoing coronary stenting. Synergy with clopidogrel at high loading dose regimen.
Support: University of Ferrara, industry support from Eli Lilly
Nr. of partner: 1
Own function: Principal Investigator
Period: 2006-2008
Total amount: Euro 150'000.00

Financial support from Correvio, USA

Project: FABOLUS PRO: Facilitation through Aggrastat By drOp-ping or shortening Infusion Line in patients with ST-seg-ment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse
Support: University of Ferrara, industry support from Correvio
Nr. of partner: 1
Own function: Principal Investigator
Period: 2009-2011
Total amount: Euro 250'000.00

Financial support from Sanofi and Abbott Vascular, USA

Project: PRODIGY: PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia study
Support: University of Ferrara, industry support from Sanofi and Abbott Vascular
Nr. of partner: 3
Own function: Principal Investigator
Period: 2005-2008
Total amount: Euro 150'000.00

Financial support from Medtronic, USA

Project: ZEUS: Zotarolimus-eluting Endeavor sprint stent in Un-certain DEScandidates
Support: University of Ferrara, industry support from Medtronic
Nr. of partner: 19
Own function: Principal Investigator
Period: 2009-2011
Total amount: Euro 650'000.00

Financial support from The Spanish Society of Cardiology, Spain

Project: EXAMINATION: Evaluation of the Xience-V stent in Acute Myocardial INfArcTION
Support: Spanish Society of Cardiology
Nr. of partner: 12
Own function: Executive Committee member und National lead investigator for Italy
Period: 2009-2011
Total amount: Euro 767'400.00

Financial support from The Medicines Company, USA and Terumo, Japan

Project: MATRIX: Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX)
Support: Italian Society of Interventional Cardiology, industry support from The Medicines Company and Terumo
Nr. of partner: 79
Own function: Principal Investigator
Period: 2011-2017
Total amount: Euro 3'267'000.00

Financial support from Biosensors, Switzerland, The Medicines Company, USA and Astra Zeneca, Sweden

Project: Global LEADERS: Comparative effectiveness of 1 month of ticagrelor plus aspirin followed by ticagrelor monotherapy versus a current-day intensive dual antiplatelet therapy in all-comers patients undergoing percutaneous coronary intervention with bivalirudin and biomatrix family drug-eluting stent use.
Support: ECRI–European Cardiovascular Research Insitute, industry support from a consortium with Biosensors, Astra Zeneca and The Medicines Company
Nr. of partner: 123
Own function: Co-Principal Investigator
Period: 2013-2018
Total amount: Euro 33'000'000.00

Financial support from Inselspital, Bern and ECRI, Rotterdam

Project: GLASSY: GLOBAL LEADERS Adjudication Sub-Study
Support: Inselspital, Bern University Hospital, and ECRI–European Cardiovascular Research Insitute
Nr. of partner: 19 (including Bern)
Own function: Principal Investigator

Period: 2017-2018
Total amount: CHF 650'000.00

Financial support from Astra Zeneca, Sweden

Project: HIGH-TECH: Hunting for the off-target properties of Ticagrelor on Endothelial function and other circulating biomarkers in humans
Support: Erasmus Medical Center, industry support from Astra Zeneca
Nr. of partner: 5 (including Bern)
Own function: Principal Investigator
Period: 2015-2017
Total amount: Euro 443'000.00

Financial support from Medicure, Canada

Project: FABOLUS FASTER: Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over prasugreL: a mUIticenter Randomized Open-label Trial in patientS With ST-elevation Myocardial inFarction Referred for primAry percutaneous inTERvention
Support: Inselspital, Bern University Hospital, industry support from Medicure
Nr. of partner: 6 (including Bern)
Own function: Chair and Principal Investigator
Period: 2017-2019
Total amount: CHF 707'000.00

Financial support from Terumo, Japan

Project: MASTER-DAPT: Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen
Support: ECRI, Cardialysis, Bern University Hospital, Terumo Medical Corporation
Nr. of partner: 100 (including Bern)
Own function: Chair and Principal Investigator
Period: 2017-2019
Total amount: Euro 16'500'000.00

Financial support from Abbott Vascular, USA

Project: SWISS APERO: Comparison of Amplatzer Amulet vs Watchman device in patients undergoing left atrial appendage closure

Support: Inselspital, Bern University Hospital, industry support from Abbott Vascular
 Nr. of partner: 8
 Own function: Chair and Principal Investigator
 Period: 2018-2019
 Total amount: CHF 400'000.00

Financial support from Daiichi Sankyo, Japan

Project: Edoxaban and/or colchicine for patients with COVID-19 managed in the out-of-hospital setting (CONVINCE):
 Support: Daiichi-Sankyo,
 Nr. of partner: 24
 Own function: Principal Investigator
 Period: 2020-2023
 Total amount: CHF 500'000.00

Financial support from Fondazione Fidiam, Lugano, Switzerland

Project: Edoxaban and/or colchicine for patients with COVID-19 managed in the out-of-hospital setting (CONVINCE):
 Support: Daiichi-Sankyo,
 Nr. of partner: 24
 Own function: Principal Investigator
 Period: 2020-2023
 Total amount: CHF 50'000.00

Financial Support from Innosuisse – Agenzia svizzera per la promozione dell'innovazione

Project: Enhanced blood flow and pressure measurements with PhysioCath-microcatheter for reliable diagnosis of Ischemia with Non-Obstructive Coronary Artery - INOCA study
 Support: Innosuisse
 Nr. of partner: 3
 Own Function: Principal Investigator
 Period: 2024-2026
 Total amount: CHF 1'115'933.00

Financial Support from SNSF - Swiss National Science Foundation

Project: The role of cardiovascular magnetic resonance in non-ST-elevation-myocardial infarction - TITAN-MRI study
 Support: SNSF
 Nr. of partner: 4
 Own Function: Partner
 Period: from 2022
 Total amount: CHF 356'000

Financial Support from Concept Medical Inc., Tampa, FL

Project: TicIn for the Treatment of coronAry lesioNs with Drug Eluting Balloons -TITAN-DEB study
Support: Concept Medical Inc., Tampa, FL
Nr. of partner: 9
Own Function: Principal Investigator
Period: from 2022
Total amount: CHF 806'830

Financial support from Sahajanand Medical Technologies Ireland

Project: Monotherapy with a P2Y12 inhibitor followed by a direct-acting oral anticoagulant in patients with ATRial fibrillation undergoing suprafleX Cruz coronary stent implantation - MATRIX-2
Support: Sahajanand Medical Technologies, Ireland
Nr. of partner: 120
Own Function: Co-Principal Investigator
Period: from 2023
Total amount: EUR 6'000'000

Financial Support from OM Pharma Suisse SA

Project: Minimally INvasive cOronary arTery bypAss sUpported by cangRelor -MINOTAUR study
Support: OM Pharma Suisse SA
Nr. of partner: 1
Own Function: Principal Investigator
Period: from 2023
Total amount: CHF 132'760

Financial Support from Innosuisse – Agenzia svizzera per la promozione dell'innovazione

Project: Blood wave diagnostics of coronary microvascular diseases based on the PyCath pressure-velocity sensing micro-catheter
Support: Innosuisse
Nr. of partner: 3
Own Function: Investigator
Period: 2024-2025
Total amount: CHF 866'560

Financial Support from SNSF – Swiss National Science Foundation

Project: Cerebral LEsions by mAgnetic Resonance in the MATRIX 2 - CLEAR MATRIX 2 study
Support: SNSF

Own Function: Principal Investigator
Period: from 2024
Total amount: CHF 500'000

Financial support from Cordis, USA

Project: TicIn for the Treatment of coronAry lesioNs – PlAque Regression AnD stabilIsation with Sirolimus Elution Pilot Study - TITAN PARADISE Pilot
Support: Cordis, USA
Nr. of partner: 1
Own Function: Principal Investigator
Period: from 2024
Total amount: CHF 158'800

Financial support from Viatris, Switzerland

Project: deFinition of Ischemic patterNs Generated by wEarables through Processing by aRtificial INTelligence in patients with Coronary Artery Disease: the FINGERPRINT-CAD study
Support: Viatris, Switzerland
Nr. of partner: 1
Own Function: Principal Investigator
Period: from 2025
Total amount: CHF 53'960

Financial support from Viatris, Switzerland

Project: Patient-RepOrted appraisal of Myocardial Infarction Symptoms and Experiences: the PROMISE observational study
Support: Viatris, Switzerland
Nr. of partner: 1
Own Function: Principal Investigator
Period: from 2025
Total amount: CHF 49'510

Financial Support from SNSF – Swiss National Science Foundation

Project: TicIn for the Treatment of coronAry lesioNs - PlAque Regression AnD stabilIsation with drug Eluting balloons (TITAN-PARADISE)", 33IC30_229732
Support: SNSF, IICT call
Nr. of partner: 30
Own Function: Main Applicant/Principal Investigator
Period: from 2025 (60-month duration)
Total amount: CHF 2'068'700

Trials Initiated by Industry

Project: EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome
Support: Scheri
Nr. of partner: 140
Own function: Local Principal Investigator
Period: 2007-2009

Project: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome
Support: Anthera Pharmaceuticals
Nr. of partner: 362
Own function: Local Principal Investigator
Period: 2010-2012

Project: LANCELOT-ACS: Lessons from Antagonizing the Cellular Effect of Thrombin-Acute Coronary Syndrome
Support: EISAI
Nr. of partner: 440
Own function: Local Principal Investigator
Period: 2004-2008

Project: STABILITY: Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Unterstützung: GlaxoSmithKline
Nr. of partner: 663
Own function: Local Principal Investigator
Period: 2008-2010

Project: STREAM: Strategic Reperfusion Early after Myocardial Infarction
Support: Boehringer Ingelheim
Nr. of partner: 99
Own function: Local Principal Investigator
Period: 2008-2010

Project: SOLID-TIMI 52: Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52
Support: GlaxoSmithKline
Nr. of partner: 99
Own function: Local Principal Investigator
Period: 2008-2010

Project: TRACER: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome

Support:	Merck
Nr. of partner:	818
Own function:	Steering Committee member und local Principal Investigator
Period:	2009-2011
Project:	FAME 2: Fractional Flow Reserve versus Angiography for Multi- vessel Evaluation 2
Support:	St. Jude
Nr. of partner:	28
Own function:	Local Principal Investigator
Period:	2011-2012
Project:	BIOSOLVE 3: Acute performance of a drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with de novo lesions in native coronary arteries
Support:	Biotronik
Nr. of partner:	8
Own function:	local Principal Investigator
Period:	2015-2020
Project:	P2Y12 Open label, randomized, study to assess the onset of platelet aggregation inhibition after a single subcutaneous injection of ACT-246475 in adults with acute myocardial infarction
Support:	IDORSIA
Nr. of partner:	6
Own function:	Principal Investigator
Period:	2018
Project:	XIENCE 28 SHORT DAPT
Support:	Abbott Vascular
Nr. of partner:	50
Own function:	Co-Principal Investigator
Period:	2018-2019
Project:	BIOFLOW-DAPT (Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk)
Support:	BIOTRONIK
Nr. of partner:	52
Own function:	Principal Investigator
Period:	2019-2023

Executive Committee Member of the following Trials:

ENTRUST-AF-PCI: Evaluation of the Safety and Efficacy of an Edox-aban-based Compared to a Vitamin K Antagonist-based Antithrombotic Regimen in Subjects With Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) With Stent Placement.

Sponsor Daiichi Sankyo, Inc.

National Coordinator and Steering Committee Member of the following Trials:

TRACER: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome

Sponsor: Merck

ODISSEY OUTCOMES: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Sponsor: Sanofi

EXAMINATION: Evaluation of the Xience-V stent in Acute Myocardial INfArcTION

Sponsor: Spanish Society of Cardiology

AUGUSTUS: An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention

Sponsor: Bristol-Myers Squibb

EXCEL: Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial

Sponsor: Abbott Vascular

REGULATE-PCI: Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial.

Sponsor: Regado Biosciences, Inc.

LIBREXIA ACS: A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

Sponsor: Bristol Myers Squibb-Janssen

Executive Committee Member of the following Trials:

ENTRUST-AF-PCI: Evaluation of the Safety and Efficacy of an Edox-aban-based Compared to a Vitamin K Antagonist-based Antithrombotic Regimen in Subjects With Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) With Stent Placement.

Sponsor Daiichi Sankyo, Inc.

ENVISAGE-TAVI-AF: Edoxaban Versus Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation (TAVI) - in Atrial Fibrillation.

Sponsor Daiichi Sankyo, Inc.

GALILEO: Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antiplatelet-based Strategy After Transcatheter aortic valve Replacement (TAVR) to Optimize Clinical Outcomes.

Sponsor Bayer

SOS-AMI: Selatogrel Outcome Study in suspected Acute Myocardial Infarction.

Sponsor: Viatris

Principal Investigator of the following Investigator- or industry-initiated Clinical Trials:

ADVANCE (Investigator-initiated): the additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty

STRATEGY (Investigator-initiated): Single High-Dose Bolus Tirofiban and Sirolimus Eluting Stent versus Abciximab and Bare Metal Stent in Acute Myocardial Infarction

MULTISTRATEGY (Investigator-initiated): Multicentre Evaluation of High-Dose Bolus Tirofiban and Sirolimus Eluting Stent versus Abciximab and Bare Metal Stent in Acute Myocardial Infarction - MULTI-STRATEGY

3T/2R Trial (Investigator-initiated): tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel

Fabulous Synchro Trial (Investigator-initiated): Facilitation through Abciximab By dropping Infusion Line in patients Undergoing coronary Stenting. SYnergy with Clopidogrel at High loading dose Regimen

Fabulous pro Trial (Investigator-initiated): Facilitation through Aggrastat By dropping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of Prasugrel given at loading dose

Fabulous faster Trial (Investigator-initiated): Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over Prasugrel: A Multicenter Randomized Open-Label Trial in Patients with ST-Elevation Myocardial Infarction Referred for Primary Percutaneous Intervention

High-Tech Trial (Investigator-initiated): Hunting for the off-target properties of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH)

ZEUS Trial (Investigator-initiated): Zotarolimus-eluting Endeavor sprint stent in Uncertain DES candidates

PRODIGY Trial (Investigator-initiated): Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study

MATRIX Programme (Investigator-initiated): Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox

GLOBAL-LEADERS Trial (Investigator-initiated): ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation

GLASSY Trial (Investigator-initiated): GLOBAL LEADERS Adjudication Sub-study

XIENCE SHORT DAPT Programme (Industry-initiated): Three or One Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation

IDORSIA Phase II Trial with ACT-246475 P2Y12 (Industry-initiated): Open label, randomized, study to assess the on- set of platelet aggregation inhibition after a single sub- cutaneous injection of ACT-246475 in adults with acute myocardial infarction

BIOFLOW-DAPT (Industry-initiated): Biodegradable-polymer or durable-polymer Stents in Patients at High Bleeding Risk

SWISS-APERO (Investigator-initiated): Comparison of Amplatzer Amulet vs Watchman device in patients undergoing left atrial appendage closure

TITAN-DEB Trial (Investigator-initiated): The TicIn for the Treatment of coronAry lesioNs with Drug Eluting Balloons

MINOTAUR Trial (Investigator-initiated): Minimally INvasive cOronary arTery bypAss sUpported by cangRelor

PARADISE-DEB Trial (Investigator-initiated): TicIn for the Treatment of coronAry lesioNs – PlAque Regression AnD stabIlisation with Sirolimus Elution. Pilot Study

MATRIX-2 Trial (Investigator-initiated): Monotherapy with a P2Y12 inhibitor followed by a direct-acting oral anticoagulant in patients with ATrial fibrillation undergoing suprafleX cruz coronary stent implantation

CLEAR-MATRIX-2 Trial (Investigator-initiated): Cerebral LEsion by mAgnetic Resonance in the MATRIX-2

NATURE Trial (Investigator initiated): NeVa Thrombectomy device as Adjunctive Reperfusion Modality in ST-segment Elevation Myocardial Infarction

Promotion of junior researchers

PhD/Cardiology students

Patrizia Malagutti

Valgimigli M, Ceconi C, **Malagutti P**, Merli E, Soukhomovskaia O, Francolini G, Cicchitelli G, Olivares A, Parri-nello G, Percoco G, Guardigli G, Mele D, Pirani R, Ferrari R. Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study. *Circulation*. 111(7):863-870, 2005.

Elisa Merli

Valgimigli M, **Merli E**, Malagutti P, Soukhomovskaia O, Cicchitelli G, Antelli A, Canistro D, Francolini G, Macri G, Mastroilli F, Paolini M, Ferrari R. Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction. *J Am Coll Cardiol*. 43(11):2000-2008, 2004.

Olga Soukhomovskaia

Valgimigli M, Rigolin GM, Fucili A, Porta MD, **Soukhomovskaia O**, Malagutti P, Bugli AM, Bragotti LZ, Francolini G, Mauro E, Castoldi G, Ferrari R. CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. *Circulation*. 110(10):1209-1212, 2004.

Elisa Cangiano

Cangiano E, Cavazza C, Campo G, Valgimigli M, Francolini G, Malagutti P, Pratola C, Ferrari R. Different clinical models of CD34 + cells mobilization in patients with cardiovascular disease. *J Thromb Thrombolysis*. 32(1):1-8, 2011.

Gianluca Campo

Campo G, Valgimigli M, Frangione A, Luccarelli S, Cangiano E, Cavazza C, Fileti L, Ferrari R; 3T/2R Investigators. Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel). *J Am Coll Cardiol*. 55(3):255-256, 2010.

Carlo Penzo

Valgimigli M, Campo G, **Penzo C**, Tebaldi M, Biscaglia S, Ferrari R; RADAR Investigators. Transradial coronary catheterization and intervention across the whole spectrum of Allen test results. *J Am Coll Cardiol*. 63(18):1833-1841, 2014.

Simone Biscaglia

Effects of pre-hospital clopidogrel administration on early and late residual platelet reactivity in ST-segment elevation myocardial infarction patients undergoing primary intervention.

Biscaglia S, Tebaldi M, Vranckx P, Campo G, Valgimigli M. *J Thromb Haemost*. 2013 Jan;11(1):192-4.

Alessandro Spirito

Comparative Outcomes After Percutaneous Coronary Intervention in Unconscious and Conscious Patients With Out-of-Hospital Cardiac Arrest.

Spirito A, Papadis A, Vaisnora L, Iacovelli F, Sardu C, Kavaliauskaite R, Lanz J, Temperli F, Asatryan B, Heg D, Hunziker L, Windecker S, Räber L, Valgimigli M. *JACC Cardiovasc Interv*. 2022 Jul 11;15(13):1338-1348

Noè Corpateaux

Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk.

Corpateaux N, Spirito A, Gragnano F, Vaisnora L, Galea R, Svab S, Gargiulo G, Zanchin T, Zanchin C, Siontis GCM, Praz F, Lanz J, Hunziker L, Stortecky S, Pilgrim T, Räber L, Capodanno D, Urban P, Pocock S, Heg D, Windecker S, Valgimigli M. *Eur Heart J*. 2020 Oct 7;41(38):3743-3749.

Mentor of medical students (Dr med. titles)

Anna Giulia Pavon (discussed on March 2024)

Sven Lifka Master Thesis (discussed on September 2024)

Sarina Leupp Master Thesis (planned discussion: tba)

Tabea Laasch (planned discussion: tba)

Caterina Lecchi (planned discussion: tba)

Silan Aka (planned discussion: tba)

Marina Santos (planned discussion: tba)

Mentor of PhD students:

Giuseppe Gargiulo (topic of interest: pharmacologic and mechanical strategies to balance ischemic and bleeding complications during and after percutaneous cardiovascular interventions; PhD thesis discussion: January 2019)

Roberto Galea (topic of interest: LAA percutaneous closure; PhD thesis discussion August 2018)

Francesco Costa (topic of interest:pharmaco-mechanical strategies to optimize the balance between ischemia and

bleeding after percutaneous coronary intervention; PhD thesis discussion: April 2018)

Marianna Adamo (topic of interest: effect of different formulations of tirofiban on thrombocytopenia and clinical outcomes in patients with acute coronary syndrome; PhD thesis discussion: April 2019)

Fortunato Iacovelli (topic of interest: angiographic analysis and outcomes of patients undergoing percutaneous coronary interventions; PhD thesis discussion: May 2019)

Marco Angellillis (topic of interest: percutaneous closure of left atrial appendage in patients at high ischemic and bleeding risk; PhD thesis discussion: May 2020)

Luca Bergamaschi (topic of interest: cardiac magnetic resonance imaging of the non-infarcted myocardium in patients with ST-segment elevation myocardial infarction and outcomes, June 2022)

Wensi Zhang ETH student (topic of interest: Automatic ECG Analysis for Occlusion Myocardial Infarction Identification and Outcome Prediction in Patients with Acute Coronary Syndromes; PhD thesis discussion: September 22, 2024)

Antonio Landi (topic of interest: coronary artery disease; percutaneous coronary intervention; revascularization; antithrombotic therapy; antiplatelet therapy)

Mentor for EAPCI fellowship recipients

2014-2015	Dr Francesco Costa, Messina, Italy
2015-2016	Dr. Giuseppe Gargiulo, Naples, Italy
2018-2018	Dr. Andreas Mitsis, Patra Achaias, Greece

External Reviewer/Committee member for PhD Thesis

2010	Dr. Emanuele Meliga Erasmus University Medical Center Rotterdam, The Netherlands
2015	Dr. Lorenz Räber Erasmus University Medical Center Rotterdam, The Netherlands
2015	Dr. Michael Magro Erasmus University Medical Center Rotterdam, The Netherlands
2017	Dr. Christian Puelacher Perioperative Myocardial Injury in Non-cardiac Surgery - Incidence, Patient Characteristics, Outcome, and Possible

	Strategies to Improve Outcome University of Basel, Switzerland
2018	Dr. Francesco Costa Pharmaco-mechanical strategies to optimize the balance between ischemia and bleeding after percutaneous coronary intervention Erasmus Medical Center Rotterdam, The Netherlands
2019	Dr. Rohit Mansingh Coronary vulnerability Erasmus Medical Center Rotterdam, The Netherlands

Habilitation (Member of the committee)

2018	Dr Rebecca Hasler MD MSc Orthopedic Surgery / Traumatology University of Bern Bern, Switzerland
2018	Dr. Jean-Sébastien Rougier PhD Molekulare Medizin University of Bern Bern, Switzerland
2019	Dr. med. Nasser Dhayat Nephrology and Hypertension and Clinical Pharmacology University of Bern Bern, Switzerland

RESEARCH METHODOLOGY

Clinical

Trials:	Planing, organisation and conduction of several randomized controlled studies to investigate the safety and efficacy of percutaneous implanted prostheses (coronary stents, prostheses for congenital defects, heart valves) and/or anti-thrombotics.
Cohort studies:	Cohort studies with large patient numbers to establish, among the others, the long-term safety from stent thrombosis and/or various anti-thrombotic treatment combinations and/or with the purpose to derive and validate score systems for the prediction of bleeding and/or ischemic cardio- and cerebro-vascular events.
Meta-Analysis:	Principal Investigator and Co-investigator of different meta-analysis regarding safety and efficacy of heart devices and anti-thrombotics or diagnostic imaging modalities.

VARIOUS

Awards

Winner of the “**Best Scientific contribution Award**” with a research project entitled: “Apoptotic activity of serum is increased in patients with pancoronary syndrome” October 2002, Verona, Italy, on behalf of GISE (Gruppo Italiano Studi di Emodinamica)

Winner of the “**Scholarship from Italian Society of Cardiology**” with a scientific contribution entitled: “Pathophysiological and clinical implications of bone marrow stem cells spontaneous mobilisation in Acute Coronary Syndromes and Heart Failure” Rome 2003, Italy, SIC (Italian Society of Cardiology)

Finalist **TCT Young Investigator Award**, October 2005, Washington

2025 Vivli Ambassador. Marco Valgimigli has been chosen for his commitment to data transparency and his leadership in advancing clinical research around the world



2026 ESC Andreas Grüntzig Award Lecture, European Society of Cardiology (ESC) – Silver medal ESC

Memberships

Italian Society of Cardiology (SIC)

Associazione Nazionale Medici Cardiologi Ospedalieri (AMNCO)

BIG Registry (Dutch National Society of Medical Doctors)

Fellow of the European Society of Cardiology (FESC)

Italian society of Interventional Cardiology (GISE)

Schweizerische Gesellschaft für Kardiologie/Société Suisse de Cardiologie/
Società Svizzera di Cardiologia

PUBLICATIONS

ORCID ID: <https://orcid.org/0000-0002-4353-7110>

H-index

Publication range 1997-Present

Number of documents: 809

Number of citations: 99747 total citations by 66146 documents

H-INDEX: 123

Source Scopus (accessed on 16.07.2026)

World's Top 2% scientists since 2020 in the Stanford University's list

This prestigious list identifies the world's leading researchers, representing approximately 2% of all scientists worldwide. It encompasses standardized data on citations, h-index, and a wide range of bibliometric indicators.

Highly Cited researcher in the field of Clinical Medicine – 2023

Among the 1% most cited researchers in 2023 (Source ISI Web)



29

Highly Cited researcher in the field of Clinical Medicine – 2022

Among the 1% most cited researchers in 2022 (Source ISI Web)



Highly Cited researcher in the field of Clinical Medicine – 2021
Among the 1% most cited researchers in 2021 (Source ISI Web)



Highly Cited researcher in the field of Clinical Medicine – 2020
Among the 1% most cited researchers in 2020 (Source ISI Web)

Highly Cited researcher in the field of Clinical Medicine – 2019
Among the 1% most cited researchers in 2019 (Source ISI Web)

Highly Cited researcher in the field of Clinical Medicine – 2018
Among the 1% most cited researchers in 2018 (Source ISI Web)

Highly Cited researcher in the field of Clinical Medicine – 2017
Among the 1% most cited researchers in 2017 (Source ISI Web)



Original articles

1. Piscaglia F, Zironi G, Gaiani S, Mazziotti A, Cavallari A, Gramantieri L, **Valgimigli M**, Bolondi L. Systemic and Splanchnic Hemodynamic changes after liver transplplantation for cirrhosis: a long term prospective study. *Hepatology* 1999;30:58-64.
2. Gramantieri L, Chieco P, Di Tommaso M, Masi L, Piscaglia F, Brillanti S, **Valgimigli M**, Mazziotti A., Bolondi L. Aberrant FHIT transcripts in primary hepatocellular carcinoma and liver cirrhosis. *Clin Cancer Res* 1999;5:3468-75.
3. Piscaglia F, Siringo S, Hermida RC, Legnani C, **Valgimigli M**, Donati G, Palareti G, Gramantieri L, Gaiani S, Burroughs AK, Bolondi L. Diurnal changes of fibrynolisis in patients with liver cirrhosis and sophage al varices. *Hepatology* 2000;31:349-57.
4. Valgimigli L, **Valgimigli M**, Gaiani S, Peduli GF, Bolondi L. Measurement of oxidative stress in human liver by EPR spin-probe technique. *Free Radic Res* 2000;33:167-78.
5. Piscaglia F, **Valgimigli M**, Rapezzi C, Ferlito M, Gaiani S, Siringo S, Gramantieri L, Bolondi L. Left ventricular volumes in liver cirrhosis. *Dig Liver Dis* 2000;32:392-7.
6. Battelli MG, Musiani S, **Valgimigli M**, Gramantieri L, Tommassoni F, Bolondi L, Stirpe F. Serum Xanthine Oxidoreductase in Human Liver Disease *Am J Gastroenterol* 2001;96:1194-9.
7. **Valgimigli M**, Valgimigli L, Trerè D, Gaiani S, Pedulli GF, Gramantieri L, Bolondi L. Oxidative stress EPR-measurement in human liver by radical-probe technique. Correlation with etiology, histology, and cell proliferation. *Free Radic Res*,2002;36:939-948.
8. **Valgimigli M**, Merli E, Mastroiilli F, Soukhomovskaia O, Malagutti P, Macrì G. Quale Futuro per il Trattamento dello scompenso cardiaco? *La Cardiologia nella pratica clinica* 2002;9:224-236.
9. **Valgimigli M**, Agnoletti L, Curello S, Comini L, Francolini G, Mastroiilli F, Merli E, Pirani R, Guardagli G, Grigolato PG, Ferrari R. Serum from patients with acute coronary syndromes displays a proapoptotic effect on human endothelial cells. A possible link to pan-coronary syndromes. *Circulation* 2003;107:264-270.
10. **Valgimigli M**, Merli E, Malagutti P, Soukhomoskaia O, Cicchitelli G, Antelli GA, Canistro D, Francolini G, Macrì G, Matrorilli F, Paolini M, Ferrari R. Hydroxyl radical generation, levels of tumor necrosis factor-alpha and progression to heart failure after acute myocardial infarction. *J Am Coll Cardiol* 2004;43(11):2000-8.
11. **Valgimigli M**, Percoco G, Cicchitelli G, Ferrari F, Barbieri D, Ansani L, Guardagli G, Parrinello G, Malagutti P, Soukhomoskaia O, Bettini A, Campo G, Ferrari R. High Dose Bolus Tirofiban And Sirolimus Eluting Stents Versus Abciximab And Bare Metal Stent In Acute Myocardial Infarction (Statregy). Study Protocol Desing And Demography Of The

First 100 Patients. *Cardiovasc Drugs Ther* 2004;18(3):225-30.

12. **Valgimigli M**, Percoco G, Cicchitelli G, Barbieri D, Ferrari F, Ansani L, Guardigli G, Parrinello G, Soukhomoskaia O, Ferrari R. The Additive Value Of Tirofiban Administered With High-Dose Bolus In The Prevention Of Ischemic Complications During High-Risk Coronary Angioplasty. *The Advance Trial. J Am Coll Cardiol* 2004;44 (1):14-19.
13. **Valgimigli M**, Rigolin GM, Fucili A, Della Porta M, Soukhomoskaia O, Malagutti P, Bugli AM, Zenone Bragotti L, Francolini G, Mauro E, Castoldi GL, Ferrari R. CD34+ And Endothelial Progenitor Cells In Patients With Various Degrees Of Congestive Heart Failure. *Circulation* 2004;101:1209-1212.
14. **Valgimigli M**, Ceconi C, Malagutti P, Merli E, Soukhomovskaia O, Francolini G, Cicchitelli G, Olivares A, Parrinello G, Guardigli G, Mele D, Pirani R, Percoco G, Ferrari R. for the Cytokine-Activation and long-term prognosis in Myocardial Infarction (C-ALPHA) Study Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study. *Circulation* 2005;111:1209-1212.
15. **Valgimigli M**, Van Mieghem C, Ong ATL, Aoki J, Rofrieguez-Granillo GA, McFadden EP, Kappetein AP, de Feyter P, Smits PC, Regar E, van der Giessen WJ, Sianos G, de Jaegere P, van Domburg RT, Serruys PW. Short And Long Term Clinical Outcome After Drug-Eluting Stent Implantation For The Percutaneous Treatment Of The Left Main Coronary Artery Disease. Insights From The Rapamycin Eluting- And Taxus- Stent Evaluated At Rotterdam Cardiology Hospital Registries (Research And T-Search). *Circulation* 2005;111:1383-1389.
16. Ong ATL, Serruys PW, Aoki J, Hoye A, Van Mieghem MC, Rodriguez-Granillo GA, **Valgimigli M**, Schennenschein K, Regar E, de Jaegere P, de Feyter P, McFadden EP, Sianos G, van der Giessen WJ, van Domburg RT. The Unrestricted Use Of Paclitaxel- Versus Sirolimus- Eluting Stents For Coornary Artery Disease In An Unselected Population. One Year Results Of The Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-Search) Registry. *J Am Coll Cardiol* 2005;45:1135-1141.
17. Agostoni F, **Valgimigli M**, Van Mieghem CA, Rodriguez-Granillo GA, Aoki J, Ong AT, Tsuchida K, McFadden EP, de Feyter P, Smits PC, Regar E, van der Giessen WJ, Sianos G, de Jaegere P, van Domburg RT, Serruys PW. Comparison Of Early Outcome Of Percutaneous Coronary Intervention For Unprotected Left Main Coronary Artery Disease In The Drug Eluting Stent Era With Versus Without Intravascular Ultrasonic Guidance. *Am J Cardiol* 2005;95(5):644-647.
18. **Valgimigli M**, Rigolin GM, Cittanti C, Malagutti P, Curello S, Percoco GF, Bugli AM, Porta MD, Bragotti LZ, Ansani L, Mauro E, Lanfranchi A, Giganti M, Feggi L, Castoldi GL, Ferrari R. Use Of Granulocyte Colony Stimulating Factor During Acute Myocardial Infaction To En-

hance Bone Marrow Stem Cell Mobilization In Humans: Clinical And Angiographic Safety Profile. *Eur Heart J* 2005 Sep;26(18):1838-45.

19. **Valgimigli M**, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri Cicchitelli G. D, McFadden E, Merlini F, Ansani L, Guardagli G, Bettini A, Parrinello G, Boersma E, Ferrari R. for the STRATEGY Investigators. Tirofiban And Sirolimus Eluting Stent Vs Abciximab And Bare Metal Stent For Acute Myocardial Infarction: A Randomized Trial. *JAMA* 2005; 293(17):2109-17.
20. Hofma SH, Ong ATL, Aoki J, Van Mieghem MC, Rodrieguez-Granillo GA, **Valgimigli M**, Regar E, de Jaegere PP, McFadden EP, Sianos G, van der Giessen WJ, de Feyter P, van Domburg RT, Serruys PW. One Year Clinical Follow-Up Of Paclitaxel- Eluting Stents For Acute Myocardial Infarction Compared To Sirolimus-Eluting Stents. *Heart*. 2005 Sep;91(9):1176-80.
21. Rodrieguez-Granillo GA, Serruys PW, Garcia-Garcia HM, **Valgimigli M**, Van Mieghem C, McFadden EP, de Jaegere PP, de Feyter P, Coronary Artery Remodelling Is Related To Plaque Composition. *Heart*. 2006 Mar;92(3):388-91.
22. Hoyer A, Van Mieghem C, Ong ATL, Aoki J, Rodrieguez-Granillo GA, **Valgimigli M**, Tsuchida K, Sianos G, McFadden E, van der Giessen WJ, de Feyter PJ, van Domburg RT, Serruys PW. Percutaneous Therapy Of Bifurcation Lesions With Drug-Eluting Stent Implantation: The Culotte Technique Revisited. *Int J Cardiovasc Interv* 2005;7(1):36-40.
23. Rodrieguez-Granillo GA, Aoki J, Ong AT, **Valgimigli M**, Van Mieghem MC, Regar E, McFadden EP, de Feyter P, Serruys PW. Methodological Considerations And Approach To Cross-Technique Comparisons Using In Vivo Coronary Plaque Characterization Based On Intravascular Ultrasound Radiofrequency Data Analysis: Insights From The Integrated Biomarker And Imaging Study (Ibis). *Int J Cardiovasc Intervent* 2005;7(1):52-8.
24. Van Mieghem C, Bruining N, Schaar JA, McFadden EP, Mollet N, Cademartiri F, Mastik F, Ligthart JM, Rodrieguez-Granillo GA, **Valgimigli M**, Sianos G, J. Van der Giessen W, Backx B, Morel MA, Es GA, Sawyer J.D, Kaplow J, Zalewski A, Steen AF, de Feyter P, Serruys PW. Rationale and methods of the integrated biomarker and imaging study (IBIS): combining invasive and non invasive imaging with biomarkers to detect subclinical atherosclerosis imaging with biomarkers to detect subclinical atherosclerosis and assess coronary lesion biology. *Int J Cardiovasc Imaging* 2005;21(4):425-41.
25. Ong ATL, Aoki J, Van Mieghem MC, Rodrieguez-Granillo GA, **Valgimigli M**, Tsuchida K, Schennenschein K, Regar E, van der Giessen WJ, de Jaegere P, Sianos G, McFadden EP, de Feyter P, van Domburg RT, Serruys PW. Comparison of Short (one month) and long (twelve month) term outcomes of sirolimus versus paclitaxel eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T SEARCH registries) *Am J Cardiol* 2005;96(3):358-62.

26. Tsuchida K, Ong ATL, Aoki J, Van Mieghem MC, Rodrieguez-Granillo GA, **Valgimigli M**, Sianos G, Regar E, McFadden EP, van der Giessen WJ, de Jaegere P, de Feyter P, van Domburg RT, Serruys PW. Immediate and one-year outcome of percutaneous intervention of Saphenous vein graft disease with paclitaxel-eluting stents. *Am J Cardiol* 2005;96(3):395-8.
27. Rodrieguez-Granillo G.A, **Valgimigli M**, Garcia-Garcia H, Ong A.T.L, Aoki J, Van Mieghem C, Tsuchida K, Sianos G, Regar E, McFadden EP, van der Giessen WJ, de Feyter P, van Domburg RT, Serruys PW. One-year clinical outcome after coronary stenting of very small vessels using 2.25 MM Sirolimus- and Paclitaxel-Eluting Stents: A Comparison between the research and T-Search Registries. *J Invasive Cardiol* 2005;17(8):409-12.
28. Rodrieguez-Granillo GA, **Valgimigli M**, Ong ATL, Aoki J, Van Mieghem C, Hoyer A, Tsuchida K, McFadden EP, de Feyter P, Serruys PW. Paclitaxel-Eluting Stents for the treatment of Angiographically non-significant Atherosclerotic Lesions. *Int J Cardiovasc Interv* 2005;7(2):68-71.
29. Pedone C, Vijayakumar M, Ligthart JM, **Valgimigli M**, Biagini E, De Jong N, Serruys PW, Ten Cate FJ. Intracardiac echocardiography guidance during percutaneous transluminal septal myocardial ablation in patients with obstructive hypertrophic cardiomyopathy. *Int J Cardiovasc Interv* 2005;7(3):134-7.
30. Aoki J, Ong AT, Rodriguez Granillo GA, McFadden EP, van Mieghem CA, **Valgimigli M**, Tsuchida K, Sianos G, Regar E, de Jaegere PP, van der Giessen WJ, de Feyter PJ, van Domburg RT, Serruys PW. Full metal jacket" (stented length > or =64 mm) using drug-eluting stents for de novo coronary artery lesions. *American Heart Journal*. 2005 Nov;150(5):994-9.
31. Rodriguez-Granillo GA, Garcia-Garcia HM, Mc Fadden EP, **Valgimigli M**, Aoki J, de Feyter P, Serruys PW. In vivo intravascular ultrasound-derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis. *J Am Coll Cardiol*. 2005 Dec 6;46(11):2038-42.
32. Hoyer A, van Mieghem CA, Ong AT, Aoki J, Rodriguez Granillo GA, **Valgimigli M**, Tsuchida K, Sianos G, McFadden EP, van der Giessen WJ, de Feyter PJ, van Domburg RT, Serruys PW. Treatment of de novo bifurcation lesion: comparison of Sirolimus- and Paclitaxel- eluting stents. *Eurointervention* 2005 May;1(1):24-30.
33. Hoyer A, Ong AT, Aoki J, van Mieghem, Rodriguez CA, Granillo GA, **Valgimigli M**, Sianos G, McFadden EP, van der Giessen WJ, de Feyter PJ, van Domburg RT, Serruys PW. Drug-eluting stent implantation for chronic total occlusion: comparison between the Sirolimus- and Paclitaxel- eluting stent. *Eurointervention* 2005(1):193-97.
34. Tsuchida K, Garcia-Garcia HM, Ong AT, **Valgimigli M**, Aoki J, Rademaker TA, Morel MA, van Es GA, Bruining N, Serruys PW. Revisiting

late loss and neointimal volumetric measurements in a drug-eluting stent trial: analysis from the SPIRIT FIRST trial. *Cat Cardiovasc Interv.* 2006 Feb;67(2):188-97.

35. **Valgimigli M**, Rodriguez Granillo GA, Garcia-Garcia HM, Malagutti P, Regar E, de Jaegere P, de Feyter PJ, Serruys PW. Distance from the ostium as an independent determinant of coronary plaque composition in vivo: an intravascular ultrasound study based radiofrequency data analysis in humans. *European Heart Journal* 2006 Mar;27(6):655-63.
36. Biondi-Zoccai GG, Lotrionte M, Abbate A, Testa L, Remigi E, Burzotta F, **Valgimigli M**, Romagnoli E, Crea F, Agostoni P. Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study. *BMJ.* 2006 Jan 28;332(7535):202-9.
37. Rodriguez-Granillo GA, Garcia-Garcia HM, Wentzel J, **Valgimigli M**, Tsuchida K, van der Giessen W, de Jaegere P, Regar E, de Feyter PJ, Serruys PW. Plaque composition and its relationship with acknowledged shear stress patterns in coronary arteries. *J Am Coll Cardiol.* 2006 Feb 21;47(4):884-5.
38. Agostoni P, **Valgimigli M**, Abbate A, Cosgrave J, Pilati M, Biondi-Zoccai GG. Is late luminal loss an accurate predictor of the clinical effectiveness of drug-eluting stents in the coronary arteries? *Am J Cardiol.* 2006 Mar 1;97(5):603-5.
39. Biondi-Zoccai GG, Abbate A, Agostoni P, **Valgimigli M**, Sangiorgi GM. Drawbacks of nonrandomized trials in acute coronary syndromes direct and indirect comparison meta-analysis demonstrates the superiority of sirolimus- versus paclitaxel-eluting stents across 5854 patients. *Am J Cardiol.* 2006 Jan 1;97(1):151.
40. Steendijk P, Smits PC, **Valgimigli M**, van der Giessen WJ, Onderwater EE, Serruys PW. Intramyocardial injection of skeletal myoblasts: long-term follow-up with pressure-volume loops. *Nat Clin Pract Cardiovasc Med.* 2006 Mar;3 Suppl 1:S94-100.
41. Agostoni P, **Valgimigli M**, Biondi-Zoccai GG, Abbate A, Garcia Garcia HM, Anselmi M, Turri M, McFadden EP, Vassanelli C, Serruys PW, Colombo A. Clinical effectiveness of bare-metal stenting compared with balloon angioplasty in total coronary occlusions: insights from a systematic overview of randomized trials in light of the drug-eluting stent era. *Am Heart J* 2006 Mar;151(3):682-9.
42. Biagini E, **Valgimigli M**, Smits PC, Poldermans D, Schinkel AF, Rizzello V, Onderwater EE, Bountiukos M, Serruys PW. Stress and tissue Doppler echocardiographic evidence of effectiveness of myoblast transplantation in patients with ischaemic heart failure. *Eur J Heart Fail.* 2006 Oct;8(6):641-8.
43. Van Mieghem CA, McFadden EP, de Feyter PJ, Bruining N, Schaar JA, Mollet NR, Cademartiri F, Goedhart D, de Winter S, Granillo GR, **Val-**

gimigli M, Mastik F, van der Steen AF, van der Giessen WJ, Sianos G, Backx B, Morel MA, van Es GA, Zalewski A, Serruys PW. °Noninvasive detection of subclinical coronary atherosclerosis coupled with assessment of changes in plaque characteristics using novel invasive imaging modalities: the Integrated Biomarker and Imaging Study (IBIS). *J Am Coll Cardiol*. 2006 Mar 21;47(6):1134-42.

44. **Valgimigli M**, Malagutti P, Aoki J, Garcia-Garcia H, Rodrieguez-Granillo GA, Van Mieghem C, Ligthart JM, Ong ATL, Sianos G, Regar E, van Domburg RT, de Feyter P, de Jaegere P, Serruys PW. Sirolimus- Versus Paclitaxel-Eluting Stent Implantation for the Percutaneous Treatment of the Left Main Coronary Artery Disease. A Combined Research and T-Search Long Term Analysis. *J Am Coll Cardiol*, 2006 Feb 7;47(3):507-14.
45. **Valgimigli M**, P.Malagutti, C.A.G.van Mieghem, S.Vania, J.M.Ligthart, G.Sianos, P.W.Serruys. Persistence of neointimal growth 12 months after intervention and occurrence of delayed restenosis in patients with left main coronary artery disease treated with drug eluting stents. *J Am Coll Cardiol*. 2006 Apr 4;47(7):1491-4.
46. PC Smits, Nienaber C, Colombo A, Ince H, Carlino M, Theuns DAMJ, Biagini E, **Valgimigli M**, Onderwater EEM, Steendijk P, Peters NS, Goedhart DM, Serruys PW. Myocardial repair by percutaneous cell transplantation of autologous skeletal myoblast as a stand alone procedure in post myocardial infarction chronic heart failure patients. *EuroIntervention* 2006;(1)417-24.
47. **Valgimigli M**, Campo G, Percoco G, Pellegrino L, Guardigli G, Ferrari R. Tirofiban: a critical reapraisal of the clinical use, recent developments and future perspectives. *Future cardiol* 2006;2(1):17-27.
48. **Valgimigli M**, Malagutti P, Rodrieguez-Granillo GA, Tsuchida K, Garcia-Garcia H, Van Mieghem C, Regar E, van der Giessen WJ, de Feyter P, de Jaegere P, Serruys PW. Single vessel versus bifurcation stenting for the treatment of distal left main coronary artery disease in the drug eluting stent era. clinical and angiographic insights into RESEARCH and T-SEARCH registries. *Am Heart J* 2006,151(5):1025.
49. Campo G, **Valgimigli M**, Gemmati D, Percoco G, Tognazzo S, Cicchitelli G, Catozzi L, Anselmi M, Vassanelli C, Scapoli G, Ferrari R. Value of Platelet Reactivity in Predicting Response to Treatment and Clinical Outcome in Patients Undergoing Primary Coronary Intervention. Insights into the Single High-Dose BoluS TiRofibAn and Sirolimus Eluting STent versus Abciximab and Bare Metal Stent in Acute MYocardial Infarction (STRATEGY) Study. *J Am Coll Cardiol* 2006,48:2178-2185.
50. Rodriguez-Granillo GA, McFadden EP, **Valgimigli M**, Van Mieghem C, Regar E, de Feyter PJ, Serruys PW. Coronary plaque composition of nonculprit lesions, assessed by in vivo intracoronary ultrasound radio frequency data analysis, is related to clinical presentation. *Am Heart J* 2006,151:1020-4.
51. Hamon M, Biondi-Zoccai GGL, Malagutti P, Agostani PF, Morello R, **Valgimigli M**, Hamon M. Diagnostic performance of multislice

spiral computed tomography of coronary arteries as compared with conventional invasive coronary angiography: a meta-analysis. *J Am Coll Cardiol* 2006;48: 1896-1910.

52. Rodriguez-Granillo GA, Garcia-Garcia HM, **Valgimigli M**, Schaar J, Pawar R, van der Giessen WJ, Regar E, van der Steen AFW, de Feyter P, Serruys PW. In vivo relationship between compositional and mechanical imaging of coronary arteries: insights from intravascular ultrasound radiofrequency data analysis. *Am Heart J* 2006;151:1025.e6.
53. Rodriguez-Granillo GA, Vaina S, Garcia-Garcia HM, **Valgimigli M**, Duckers E, van Geuns RJ, Regar E, van der Giessen WJ, Bressers M, Goedhart D, Morel MA, de Feyter PJ, Serruys PW. Reproducibility of intravascular ultrasound radiofrequency data analysis: implications for design of longitudinal studies. *Int J Cardiovasc Imaging* 2006;22:621-631.
54. Campo G, **Valgimigli M**, Ferraresi P, Malagutti P, Baroni M, Arcozzi C, Gemmati D, Percoco G, Parrinello G, Ferrari R, Bernardi F. Tissue factor and coagulation factor VII levels during acute myocardial infarction: association with genotype and adverse events. *Arterioscler Thromb Vasc Biol.* 2006 Dec;26(12):2800-6.
55. Van Mieghem CA, Cademartiri F, Mollet NR, Malagutti P, **Valgimigli M**, Meijboom WB, Pugliese F, McFadden EP, Ligthart J, Runza G, Bruining N, Smits PC, Regar E, van der Giessen WJ, Sianos G, van Domburg R, de Jaegere P, Krestin GP, Serruys PW, de Feyter PJ. Multislice spiral computed tomography for the evaluation of stent patency after left main coronary artery stenting: a comparison with conventional coronary angiography and intravascular ultrasound. *Circulation.* 2006 Aug 15;114(7):645-53.
56. Rodriguez-Granillo GA, Garcia-Garcia HM, **Valgimigli M**, Vaina S, van Mieghem C, van Geuns RJ, van der Ent M, Regar E, de Jaegere P, van der Giessen W, de Feyter P, Serruys PW. Global characterization of coronary plaque rupture phenotype using three-vessel intravascular ultrasound radiofrequency data analysis. *Eur Heart J.* 2006 Aug;27(16):1921-7.
57. Hoyer A, Iakovou I, Ge L, van Mieghem CA, Ong AT, Cosgrave J, Sangiorgi GM, Airolidi F, Montorfano M, Michev I, Chieffo A, Carlino M, Corvaja N, Aoki J, Rodriguez Granillo GA, **Valgimigli M**, Sianos G, van der Giessen WJ, de Feyter PJ, van Domburg RT, Serruys PW, Colombo A. Long-term outcomes after stenting of bifurcation lesions with the "crush" technique: predictors of an adverse outcome. *J Am Coll Cardiol.* 2006 May 16;47(10):1949-58.
58. Biondi-Zoccai GG, Lotrionte M, Abbate A, **Valgimigli M**, Testa L, Burzotta F, Crea F, Agostoni P. Direct and indirect comparison meta-analysis demonstrates the superiority of sirolimus- versus paclitaxel-eluting stents across 5854 patients. *Int J Cardiol.* 2007 Jan 2;114(1):104-5.
59. **Valgimigli M**, Rodriguez-Granillo GA, Garcia-Garcia HM, Vaina S, Tsuchida K, Regar E, De Jaegere P, De Feyter P, Serruys PW. Plaque

Composition in the Left Main Stem Mimics the Distal but not the Proximal Tract of the Left Coronary Artery. Influence of Clinical Presentation, Length of the Left Main Trunk, Lipid Profile and Systemic Inflammatory Status. *J Am Coll Cardiol* 2007;49:23-31.

60. **Valgimigli M**, Dawkins K, Macaca C, de Bruyne B, Teiger E, Fajadet J, Gert R, De Servi S, Ramando A, Wittebols K., Rademaker T, Serruys PW. Impact of Stable versus Unstable coronary artery on 1-year outcome in elective patients undergoing multivessel revascularization with sirolimus-eluting stents. *J Am Coll Cardiol* 2007;49:431-41.
61. **Valgimigli M**, Biondi Zoccai GG, Agostoni P. Keeping a high standard in quantitative analysis, meta-analyses and systematic reviews. *Eur Heart J* 2007 Feb;28(4):516-517.
62. **Valgimigli M**, Chieffo A, Lefevre A, Colombo A, Morice MC, Serruys PW on behalf of the Executive committee of the Syntax Study. Revisiting the incidence and temporal distribution of cardiac and sudden death in patients undergoing elective intervention for unprotected left main coronary artery stenosis in the drug eluting stent era. *EuroIntervention*, 2007 (8) 434-443.
63. Kastrati MA, Mehilli J, Pache J, Kaiser C, **Valgimigli M**, Kelbaek H, Menichelli M, Sabate M, Suttorp MJ, Baumgart D, Seyfarth M, Pfister ME, Schoemig A. Analysis of 14 trials comparing sirolimus-eluting stents versus bare-metal stents. *New England Journal Med.* 2007 Mar 8;356(10):1030-9.
64. **Valgimigli M**, Serruys PW, Tschucida K, Vaina S, Morel MA, van der Brand M, Colombo A, Morice MC, Dawkins K, de Bruyne B, Kornowski R, de Servi S, Guagliumi G, Jukema JW, Mohr FW, Kappetein AP, Wittebols K, Stoll HP, Boersma E, Parrinello G. Cyphering the complexity of coronary artery disease using the Syntax score to predict clinical outcome in patients with three vessel lumen obstruction undergoing percutaneous coronary intervention. *American Journal Cardiology.* 2007 Apr 15;99(8):1072-81.
65. Biondi-Zoccai GG, Lotrionte M, Agostoni P, **Valgimigli M**, Abbate A, Sangiorgi G, Moretti C, Sheiban. Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: evidence from a meta-regression. *American Heart Journal* 2007 Apr;153(4):587-93.
66. **Valgimigli M**, Campo G, Arcozzi C, Malagutti P, Carletti R, Ferrari F, Barbieri D, Parrinello G, Percoco G, Ferrari R. Two-year Clinical Follow-up After Sirolimus-eluting Versus Bare Metal Assisted by Systematic Infusion In Patients with Acute Myocardial Infarction. Results from the Single High-Dose Bolus TiRoFibAn and Sirolimus Eluting STent versus Abciximab and Bare Metal Stent in Acute MYocardial Infarction (STRATEGY) Study. *J Am Coll Cardiol.* 2007 Jul 10;50(2):138-45.
67. **Valgimigli M**, Bolognese L, Anselmi M, Campo G, Rodriguez AE, de Cesare N, Cohen DJ, Sheiban I, Colangelo S, Pasquetto G, Hamon M,

- Vranckx P, Ferrario M, Prati F, Agostoni P, Malagutti P, Arcozzi C, Parrinello G, Vassanelli C, Ferrari R, Percoco G. Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: design and rationale for the MULTI-STRATEGY trial. *Am Heart J* 2007 Jul;154(1):39-45.
68. Chieffo A, Park SJ, **Valgimigli M**, Kim YH, Daemen J, Sheiban I, Truffa A, Montorfano M, Airolidi F, Sangiorgi G, Carlino M, Michev I, Lee CW, Hong MK, Park SW, Moretti C, Bonizzoni E, Rogacka R, Seruys PW, Colombo A. Favorable long-term outcome after drug-eluting stent implantation in nonbifurcation lesions that involve unprotected left main coronary artery: a multicenter registry. *Circulation*. 2007 Jul 10;116(2):158-62.
 69. Gemmati D, Federici F, Campo G, Tognazzo S, Serino ML, De Mattei M, **Valgimigli M**, Malagutti P, Guardigli G, Ferraresi P, Bernardi F, Ferrari R, Scapoli GL, Catozzi L. Factor XIII A-V34L and factor XIII B-H95R gene variants: effects on survival in myocardial infarction patients. *Mol Med*. 2007 Jan-Feb;13(1-2):112-20.
 70. **Valgimigli M**, Mittmann N, Cohen DJ, Campo G, Isogai PK, Seung S J, Dulisse B, Arcozzi C, Squasi P, Percoco G, Ferrari R. A Strategy to Offset the extra cost of Sirolimus-eluting Stent in Patients undergoing Intervention for Acute Myocardial Infarction. *International Journal of Cardiology*. 11 May 2007.
 71. Ince H, **Valgimigli M**, Petzsch M, Suarez de Lezo J, Kuethe F, Dunkelmann S, Biondi-Zoccai G, Nienaber C A. Cardiovascular events and re-stenosis following administration of G-CSF in acute myocardial infarction: systematic review and meta-analysis. *Heart*. 2008 May;94(5):610-6. Epub 2007 Aug 29.
 72. Rodriguez-Granillo GA, de Winter S, Bruining1 N, Ligthart J, Garcia-Garcia HM, **Valgimigli M**, de Feyter PJ. on behalf of the EUROPA/PERSPECTIVE Investigators . Effect of perindopril on coronary remodelling: insights from a multicentre, randomized study. *European Heart Journal* (2007) 28, 2326–2331.
 73. Campo G, **Valgimigli M**, Gemmati D, Percoco G, Catozzi L, Frangione A, Federici F, Ferrari F, Tebaldi M, Luccarelli S, Parrinello G, Ferrari R. Poor Responsiveness to Clopidogrel: Drug-Specific or Class-Effect Mechanism? Evidence from a Clopidogrel to Ticlopidine Crossover Study. *J Am Coll Cardiol*. 2007, Sep 18;50(12):1132-7.
 74. G. Lotrionte M, Biondi-Zoccai GG, Agostoni P, Abbate A, Angiolillo DJ, **Valgimigli M**, Moretti C, Meliga E, Cuisset T, Alessi MC, Montalescot G, Collet JP, Di Sciascio G, Waksman R, Testa L, Sangiorgi G, Laudito A, Trevi GP, Sheiban I. Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. *Am J Cardiol*. 2007 Oct 15;100(8):1199-206.
 75. Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, **Valgimigli M**, Di Lorenzo E, Kaiser C, Tiala I, Mehilli J, Seyfarth M,

Varenne O, Dirksen MT, Percoco G, Varricchio A, Pittl U, Syväne M, Suttorp MJ, Violini R, Schömig A. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. *Eur Heart J* 2007 Nov;28(22):2706-13.

76. De Luca G, Stone GW, Suryapranata H, Laarman GJ, Menichelli M, Kaiser C, **Valgimigli M**, Di Lorenzo E, Dirksen MT, Spaulding C, Pittl U, Violini R, Percoco G, Marino P. Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. *Int J Cardiol* 2008 Apr 2.
77. Meliga E, Steendijk P, **Valgimigli M**, Ten Cate FJ, Serruys PW. Cardiomyopathy on systolic and diastolic left Effects of percutaneous transluminal septal myocardial ablation for obstructive hypertrophic ventricular function assessed by pressure-volume loops. *Am J Cardiol*. 2008 Apr 15;101(8):1179-84.
78. **Valgimigli M**, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, de Cesare N, Rodriguez AE, Ferrario M, Moreno R, Piva T, Sheiban I, Pasquetto G, Prati F, Nazzaro MS, Parrinello G, Ferrari R; for the Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators. Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial Infarction: The MULTISTRATEGY Randomized Trial. *JAMA*. 2008 Mar 30; 299(15):1788-99.
79. Biondi-Zoccai GG, Lotrionte M, Moretti C, Meliga E, Agostoni P, **Valgimigli M**, Migliorini A, Antonucci D, Carrié D, Sangiorgi G, Chieffo A, Colombo A, Price MJ, Teirstein PS, Christiansen EH, Abbate A, Testa L, Gunn JP, Burzotta F, Laudito A, Trevi GP, Sheiban I. A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease. *Am Heart J* 2008 Feb;155(2):274-83.
80. **Valgimigli M**, Campo G, de Cesare N, Vranckx P, Hamon M, Angiolillo D, Sabatè M, Ferrari F, Furgieri A, Tumscitz C, Repetto A, Colangelo S, Meliga E, Kubbajeh M, Parrinello G, Percoco G, Ferrari R. Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R). Rationale for the Study and Protocol Design. *Cardiovasc Drugs Ther* 2008;22:313–320.
81. Biondi-Zoccai G, **Valgimigli M**, Sheiban I, Margheri M, Marzocchi A, Prati F, Vischi M, Lettieri C, Violini R, Sardella G, Stabile A, Clementi F, Romeo F, Colombo A, Sangiorgi G. A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial. *J Cardiovasc Med* 2008;9:9.
82. Steendijk P, Meliga E, **Valgimigli M**, Ten Cate F J, Serruys PW. Acute effects of alcohol septal ablation on systolic and diastolic left

ventricular function in patients with hypertrophic obstructive cardiomyopathy. *Heart*. 2008 Oct;94(10):1318-22.

83. Chieffo A, Park SJ, Meliga E, Sheiban I, Lee MS, Latib A, Kim YH, **Valgimigli M**, Sillano D, Magni V, Biondi-Zoccai G, Montorfano M, Airolidi F, Rogacka R, Carlino M, Michev I, Lee CW, Hong MK, Park SW, Moretti C, Bonizzoni E, Sangiorgi GM, Tobis J, Serruys PW, Colombo A. Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry *Eur Heart J* 2008;29(17):2108-2115.doi: 10.1093.
84. Meliga E, Garcia-Garcia HM, **Valgimigli M**, Chieffo A, Biondi-Zoccai G, MD, O. Maree A, MD, Cook S, MD, Reardon L, MD, Moretti C, MD, De Servi S, MD, Palacios IF, MD, FACC, Windecker S, Colombo A, van Domburg R, PHD, Sheiban I, MD, Serruys PW. Longest Available Clinical Outcomes After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease The DELFT (Drug Eluting stent for LeFT main) Registry. *J Am Coll Cardiol* 2008;51:23.
85. Zohlnhöfer D, Dibra A, Koppa T, de Waha A, Ripa RS, Kastrup J, **Valgimigli M**, Schömig A, Kastrati A. Stem Cell Mobilization by Granulocyte Colony-Stimulating Factor for Myocardial Recovery After Acute Myocardial Infarction: A Meta-Analysis *J Am Coll Cardiol* 2008;51:1429-1437.
86. **Valgimigli M**, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo DJ, Sabatè M, Hamon M, Repetto A, Colangelo S, Brugaletta S, Parrinello G, Percoco G, Ferrari R; Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. *Circulation*. 2009 Jun 30;119(25):3215-22.
87. Iijima R, Byrne RA, Dibra A, Ndrepepa G, Spaulding C, Laarman GJ, Menichelli M, **Valgimigli M**, Di Lorenzo E, Kaiser C, Tierala I, Mehilli J, Suttorp MJ, Violini R, Schömig A, Kastrati A. Drug-eluting stents versus bare-metal stents in diabetic patients with ST-segment elevation acute myocardial infarction: a pooled analysis of individual patient data from seven randomized trials. *Rev Esp Cardiol*. 2009 Apr;62(4):354-64.
88. Merlini PA, **Valgimigli M**. [The FATA study]. *Giornale Italiano Cardiology (Rome)*. 2009 Jun;10.
89. **Valgimigli M**, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo DJ, Sabatè M, Hamon M, Repetto A, Colangelo S, Brugaletta S, Parrinello G, Percoco G, Ferrari R; Intensifying Platelet Inhibition with Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention: results from the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Re-

sistance to Clopidogrel (3T/2R) Investigators. *Circulation*. 2009 Jun 30;119(25):3215-22.

90. Niccoli G, D'amarzio D, Spaziani C, Cosentino N, Marino M, Rigattieri S, Schiavo PL, De Vita MR, Tarantino F, Bartorelli A, Fabbrocchi F, Prati F, Imola F, **Valgimigli M**, Ferrari R, Crea F. Randomized evaluation of intracoronary nitroprusside vs. adenosine after thrombus aspiration during primary percutaneous coronary intervention for the prevention of no-reflow in acute myocardial infarction: the REOPEN-AMI study protocol. *J Cardiovasc Med (Hagerstown)*. 2009 Jul;10.
91. Vranckx P, Schultz CJ, **Valgimigli M**, Eindhoven JA, Kappetein AP, Regar ES, Van Domburg R, Serruys PW. Assisted circulation using the TandemHeart during very high-risk PCI of the unprotected left main coronary artery in patients declined for CABG. *Cath Cardiovasc Interv*. 2009 Aug 1.
92. De Luca G, **Valgimigli M**, Spaulding C, Menichelli M, Brunner-La Rocca HP, van der Hoeven BL, Di Lorenzo E, Diaz de la Llera LS, Pasceri V, Pittl U, Percoco G, Violini R, Stone GW. Short and long-term benefits of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. *J Thromb Thrombolysis*. 2009 Aug;28(2):200-10.
93. **Valgimigli M**, Biondi-Zoccai G, Tebaldi M, van't Hof AW, Campo G, Hamm C, ten Berg J, Bolognese L, Saia F, Danzi GB, Briguori C, Okmen E, King SB, Moliterno DJ, Topol EJ. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. *Eur Heart J* 2010 Jan;31(1):35-49.
94. Campo G, **Valgimigli M**, Carletti R, Fileti L, Ferrari R. Long-term outcome after percutaneous coronary intervention in patients with essential thrombocythemia. *J Thromb Haemost*. 2009 Jul;7.
95. Onuma Y, Girasis C, Piazza N, Garcia-Garcia H, Kukreja N, Garg S, Eindhoven J, Cheng J, **Valgimigli M**, van Domburg R, Serruys P. TRA*CER Executive and Steering Committees. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. *Am Heart J*. 2009 Sep;15.
96. **Valgimigli M**, Airolidi F, Zimarino M. Stent choice in primary percutaneous coronary intervention: drug-eluting stents or bare metal stents? *J Cardiovasc Med (Hagerstown)*. 2009 Oct;10(Suppl.):17-26.
97. Tebaldi M, Arcozzi C, Campo G, Percoco G, Ferrari R, **Valgimigli M**; STRATEGY Investigators. The 5-year clinical outcomes after a randomized comparison of sirolimus-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction. *J Am Coll Cardiol*. 2009;54(20):1900-1.
98. Campo G, **Valgimigli M**, Frangione A, Luccarelli S, Cangiano E, Cavazza C, Fileti L, Ferrari R; 3T/2R Investigators. Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (Tailoring treatment

with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel). *J Am Coll Cardiol*. 2010 Jan 19;55(3):255-6.

99. Dibra A, Tiroch K, Schulz S, Kelbæk H, Spaulding C, Laarman GJ, **Valgimigli M**, Di Lorenzo E, Kaiser C, Tierala I, Mehilli J, Campo G, Thuesen L, Vink MA, Schali J MJ, Violini R, Schömig A, Kastrati A. Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. *Clin Res Cardiol*. 2010;99(6):345-57.
100. Latib A, Ferri L, Ielasi A, Cosgrave J, Godino C, Bonizzoni E, Romagnoli E, Chieffo A, **Valgimigli M**, Penzo C, Carlino M, Michev I, Sangiorgi GM, Montorfano M, Airolidi F, Colombo A. Comparison of the Long-Term Safety and Efficacy of Drug-Eluting and Bare-Metal Stent Implantation in Saphenous Vein Grafts. *Circ Cardiovasc Interv*. 2010;3(3):249-56.
101. Cuisset T, **Valgimigli M**, Mudra H, Muller O, Wijns W, Huber K. Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update. *EuroIntervention*. 2010 May;6(1):39-45. doi: 10.4244.
102. **Valgimigli M**, Campo G, Tebaldi M, Monti M, Gambetti S, Scalone A, Parrinello G, Ferrari R; on behalf of the FABOLUS SYNCHRO (Facilitation through Abciximab By dropping Infusion Line in patients Undergoing coronary Stenting. SYNergy with Clopidogrel at High loading dose Regimen) investigators. Randomized, double blind, comparison of abiciximab bolus only versus on-label regimen on ex vivo platelet inhibition in responders to clopidogrel undergoing coronary stenting. *J Thromb Haemostasis*. 2010;8(9):1903-11.
103. Onuma Y, Girasis C, Piazza N, Garcia-Garcia HM, Kukreja N, Garg S, Eindhoven J, Cheng JM, **Valgimigli M**, van Domburg R, Serruys PW; Interventional Cardiologists at Thoraxcenter 2000-2005. Long-term clinical results following stenting of the left main stem: insights from RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries. *JACC Cardiovascular Intervention* 2010 Jun;3(6):584-94.
104. **Valgimigli M**, MD, PhD, Campo G, MD, Percoco G, MD, Monti M, BSc, Ferrari F, MD, Tumscitz C, MD, Zuffi A, MD, Colombo F, MD, Kubbaheh M, MD, Cavazza C, MD, Cangiano E, MD, Tebaldi M, MD, Minarelli M, MD, Arcozzi C, MD, Scalone A, MD, Borghesi M. MD, Parrinello G, Ph.D, Ferrari R, MD, Ph.D. Randomized comparison of six versus twenty-four months clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all comers patients undergoing percutaneous coronary intervention. Design and rationale for the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). *American Heart Journal* DOI: 10.1016/j.ahj.2010.07.034.
105. Biondi-Zoccai G, Lotrionte M, Agostoni P, Abbate A, Romagnoli E, Sangiorgi G, Angiolillo DJ, **Valgimigli M**, Testa L, Gaita F, Sheiban

- I. Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. *Int J Cardiol* 2010 Sep 7.
106. Sciahbasi A, Biondi-Zoccai G, Romagnoli E, **Valgimigli M**, Rasoul S, Van't Hof A, Lioy E, Stone GW. Routine upstream versus selective downstream administration of glycoprotein IIb/IIIa inhibitors in patients with non-ST-elevation acute coronary syndromes: A meta-analysis of randomized trials. *Int J Cardiol* 2010 Oct 27.
 107. Campo G, Fileti L, de Cesare N, Meliga E, Furgieri A, Russo F, Colangelo S, Brugaletta S, Ferrari R, **Valgimigli M**; 3T/2R Investigators. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. *J Am Coll Cardiol*. 2010 Oct 26;56(18):1447-55.
 108. Zoccai GB, **Valgimigli M**. The SORT OUT III study. *G Ital Cardiol (Rome)*. 2010 Dec;11(12):865-9.
 109. **Valgimigli M**, MD, PHD, Campo G, MD, Malagutti P, MD, Anselmi M, MD, Bolognese L, MD, Ribichini F, MD, Boccuzzi G, MD, de Cesare N, MD, Rodriguez AE, MD, PHD, Russo F, MD, Moreno R, MD, Biondi-Zoccai G, MD, Penzo C, MD, Diaz FJ, MD, Parrinello G, PHD, Ferrari R, MD, PHD. Persistent Coronary No Flow After Wire Insertion Is an Early and Readily Available Mortality Risk Factor Despite Successful Mechanical Intervention in Acute Myocardial Infarction: A Pooled Analysis From the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) Trials. *JACC: Cardiovasc Interv* 2011;10.
 110. Garg S, MB, CHB, MRCP, Sarno G, MD, PHD, Serruys PW, MD, PHD, Rodriguez AE, MD, PHD, Bolognese L, MD, Anselmi M, MD, De Cesare N, MD, Colangelo S, MD, Moreno R, MD, Gambetti S, BSC, Monti M, BSC, Bristot L, BSC, Bressers M, MSC, Garcia-Garcia HM., MD, PHD, Parrinello G, PHD, Campo G, MD, **Valgimigli M**, MD, PHD on behalf of the STRATEGY and MULTISTRATEGY Investigators. Prediction of 1-Year Clinical Outcomes Using the SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) Score in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. *JACC: Cardiovascular Interventions* 2011 Jan;4(1):66-75.
 111. Campo G, MD, Parrinello G, PhD, Ferraresi P, BsC, Lunghi B, BsC, Tebaldi M, MD, Miccoli M, MD, Bernardi F, BsC, PhD, Ferrari R, MD, PhD **Valgimigli M**, MD, PhD. Prospective Evaluation of On-Clopidogrel Platelet Reactivity Over Time in Patients treated with Percutaneous Coronary Intervention. Relationship with Gene Polymorphisms and Clinical Outcome. *J Am Coll Cardiol*. 2011 Jun 21; 57 (25): 2474-83.

112. Cangiano E, Cavazza C, Campo G, **Valgimigli M**, Francolini G, Malagutti P, Pratola C and Ferrari R. Different clinical models of CD34 + cells mobilization in patients with cardiovascular disease. *J Thromb Thrombolysis* DOI: 10.1007/s11239-010-0543-8
113. Verheugt FW, MD, Steinhubl SR, MD, Hamon M, MD, Darius H, MD, PHD, Steg PG, MD, **Valgimigli M**, MD, PHD, Marso SP, MD, Rao SV, MD, Gershlick AH, MD, A. Lincoff M, MD, Mehran R, MD, Stone GW, MD. Incidence, Prognostic Impact, and Influence of Antithrombotic Therapy on Access and Non access Site Bleeding in Percutaneous Coronary Intervention. *JACC: Cardiovasc Interv* 2011;4:2.
114. **Valgimigli M**, MD, PhD, Campo G, MD, Gambetti S, BSc, Bolognese L, MD, Ribichini F, MD, Colangelo S, MD, de Cesare N, MD, Rodriguez AE., MD, PhD, Russo F, MD, Moreno R, MD, Piva T, MD, Sheiban I, MD, Penzo C, MD, Prati F, MD, PhD, Nazzaro MS, MD, PhD, Díaz Fernández JF, MD, Vassanelli C, MD, Parrinello G, PhD, Ferrari R, MD, Ph.D, For the MULTICentre evaluation of Single high-dose bolus TiRoFiban versus Abciximab with sirolimus eluting sTEnt or Bare Metal Stent in Acute Myocardial Infarction study (MULTISTRATEGY) investigators. Three-year Follow-up of the MULTICentre Evaluation of Single high-dose Bolus TiRoFiban Versus Abciximab With Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY). *Int J Cardiol* 2013;165(1):134-41.
115. Brar S, MD MPH FACC, ten Berg J, MD, PhD, Marcucci R, MD, Price M, MD (4), **Valgimigli M**, MD PhD, Kim HS, MD, PhD (6), Patti G, MD, Breet N, DiSciascio G, MD, Cuisset T, MD PhD, Dangas G, MD, PhD. Impact of Platelet Reactivity on Clinical Outcomes after Percutaneous Coronary Intervention: Collaborative Meta-analysis of Individual Participant Data. *J Am Coll Cardiol*. 2011 Nov 1;58(19):1945-54.
116. Garg S, Sarno G, Girasis C, Vranckx P, de Vries T, Swart M, Bressers M, Garcia-Garcia HM, van Es GA, Räber L, Campo G, **Valgimigli M**, Dawkins KD, Windecker S, Serruys PW. A patient-level pooled analysis assessing the impact of the SYNTAX (synergy between percutaneous coronary intervention with taxus and cardiac surgery) score on 1-year clinical outcomes in 6,508 patients enrolled in contemporary coronary stent trials. *JACC Cardiovasc Interv*. 2011 Jun;4(6):645-53.
117. De Servi S, **Valgimigli M**. The BASKET-PROVE study. *G Ital Cardiol (Rome)*. 2011 Oct;12(10):625-9. doi: 10.1714/945.10346. Italian.
118. Briguori C, Visconti G, Focaccio A, Airolidi F, **Valgimigli M**, Sangiorgi GM, Golia B, Ricciardelli B, Condorelli G; REMEDIAL II Investigators. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. *Circulation*. 2011 Sep 13;124(11):1260-9.
119. Meliga E, Fiorina C, **Valgimigli M**, Belli R, Gagnor A, Sheiban I, Resmini C, Tizzani E, Aranzulla T, Scrocca I, DE Benedictis M, Conte MR. Early Angio-Guided Complete Revascularization versus Culprit

Vessel PCI Followed by Ischemia-Guided Staged PCI in STEMI Patients with Multivessel Disease. *J Interv Cardiol* 2011 Oct 20. doi: 10.1111/j.1540-8183.2011.00666.x.

120. Ferrante G, Presbitero P, **Valgimigli M**, Morice MC, Pagnotta P, Belli G, Corrada E, Onuma Y, Barlis P, Locca D, Eeckhout E, Di Mario C, Serruys PW. Percutaneous coronary intervention versus bypass surgery for left main coronary artery disease: a meta-analysis of randomised trials. *EuroIntervention*. 2011 Oct 30;7(6):738-46. doi: 10.4244/EIJV7I6A117.
121. Vranckx P, Boersma E, Garg S, **Valgimigli M**, Van Es GA, Goedhart D, Serruys PW. Cardiovascular risk profile of patients included in stent trials; a pooled analysis of individual patient data from randomised clinical trials: insights from 33 prospective stent trials in Europe. *EuroIntervention*. 2011 Nov 15;7(7):859-71. doi: 10.4244/EIJV7I7A134.
122. Biondi-Zoccai G, Lotrionte M, Agostoni P, Abbate A, Romagnoli E, Sangiorgi G, Angiolillo D, **Valgimigli M**, Testa L, Gaita F, Sheiban I. Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. *Int J Cardiol*. 2011 Aug;150;3:325-331.
123. Ferrante G, MD, Presbitero P, Corrada E, MD Campo G, MD Bolognese L, MD Vassanelli C, MD Colangelo S, MD De Cesare N, MD Rodriguez A, MD, PhD Bramucci E, MD Moreno P, MD Piva T, MD Sheiban I, MD Pasquetto G, MD Prati F, MD Nazzaro M, MD, PhD Ferrari R, MD, PhD **Valgimigli M**, MD, PhD. Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study trial. *Am Heart J*. 2012 Jan; 163;1:104-111.
124. **Valgimigli M**, MD, PHD, Saia F, MD, PHD, Guastaroba P, MSC, Menozzi A, MD, Magnavacchi P, MD, Santarelli A, MD, Passerini F, MD, Sangiorgio P, MD, Manari A, MD, Tarantino F, MD, Margheri M, MD, Benassi A, MD, Sangiorgi M, PHD, Tondi S, MD, Marzocchi A, MD, on behalf of the REAL Registry Investigators. Transradial Versus Transfemoral Intervention for Acute Myocardial Infarction A Propensity Score-Adjusted and -Matched Analysis From the REAL (REgistro regionale AngiopLastiche dell'Emilia-Romagna) Multicenter Registry. *JACC Cardiovascular Interventions*. 2012 Jan;5(1):23-35.
125. Amadesi S, Reni C, Katare R, Meloni M, Oikawa A, Beltrami AP, Avolio E, Cesselli D, Fortunato O, Spinetti G, Ascione R, Cangiano E, **Valgimigli M**, Hunt SP, Emanuelli C, Madeddu P. Role for Substance-P Based Nociceptive Signaling in Progenitor Cell Activation and Angiogenesis during Ischemia in Mice and in Human Subjects. *Circulation*. 2012 Apr 10;125(14):1774-86.2.

126. **Valgimigli M**, Tebaldi M, Campo G, Gambetti S, Bristot L, Monti M, Parrinello G, Ferrari R; FABOLUS PRO Investigators. Prasugrel Versus Tirofiban Bolus With or Without Short Post-Bolus Infusion With or Without Concomitant Prasugrel Administration in Patients With Myocardial Infarction Undergoing Coronary Stenting: The FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dose) Trial. *JACC Cardiovasc Interv*. 2012 Mar;5(3):268-77.
127. **Valgimigli M**, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota F, Colombo F, Tebaldi M, Fucà G, Kubbajeh M, Cangiano E, Minarelli M, Scalone A, Cavazza C, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R. Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- Versus Long-term Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Randomized Multi-centre Trial. *Circulation*. 2012 Apr 24;125(16):2015-26. doi: 10.1161/CIRCULATIONAHA.111.071589.
128. Kalesan B, Pilgrim T, Heinemann K, Räber L, Stefanini GG, **Valgimigli M**, da Costa BR, Mach F, Lüscher TF, Meier B, Windecker S, Jüni P. Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. *Eur Heart J*. 2012 Apr; 33(8):977-87.
129. Vranckx P, Campo G, Anselmi M, Bolognese L, Colangelo S, Biondi-Zoccai G, Moreno R, Piva T, Favero L, Prati F, Nazzaro M, Díaz Fernández JF, Ferrari R, **Valgimigli M**. Does the site of bleeding matter? A stratified analysis on location of TIMI-graded bleedings and their impact on 12-month outcome in patients with ST-segment elevation myocardial infarction. *EuroIntervention*. 2012 May 15;8(1):71-8.
130. Biondi-Zoccai G, **Valgimigli M**, Margheri M, Marzocchi A, Lettieri C, Stabile A, Petronio AS, Binetti G, Bolognese L, Bellone P, Sardella G, Contarini M, Sheiban I, Marra S, Piscione F, Romeo F, Colombo A, Sangiorgi G. Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: The INtegrilin plus STenting to Avoid myocardial Necrosis Trial. *Am Heart J*. 2012 May;163(5):835.e1-7. doi: 10.1016/j.ahj.2012.02.009.
131. Hamon M, Rao SV, Steg G, **Valgimigli M**, Verheugt F, Marso S, Gershlick A, Wang Y, Deliargyris E. Bivalirudin versus unfractionated heparin in percutaneous coronary intervention of patients having received initial fondaparinux treatment: a propensity matched study. *EuroIntervention*. 2012 Aug;8(4):486-92. doi: 10.4244/EIJV8I4A76.
132. Chieffo A, Meliga E, Latib A, Park SJ, Onuma Y, Capranzano P, **Valgimigli M**, Jegere S, Makkar RR, Palacios IF, Kim YH, Buszman PE, Chakravarty T, Sheiban I, Mehran R, Naber C, Margey R, Agnihotri A, Marra S, Capodanno D, Leon MB, Moses JW, Fajadet J, Lefevre T, Morice MC, Erglis A, Tamburino C, Alfieri O, Serruys PW, Colombo

A Drug-Eluting Stent for Left Main Coronary Artery Disease: The DELTA Registry: A Multicenter Registry Evaluating Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Left Main Treatment. *JACC Cardiovasc Interv.* 2012 Jul;5(7):718-27.

133. Sabate M, Cequier A, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, **Valgimigli M**, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Gómez-Hospital JA, Baz JA, Martín-Yuste V, van Geuns RJ, Alfonso F, Bordes P, Tebaldi M, Masotti M, Silvestro A, Backx B, Brugaletta S, van Es GA, Serruys PW. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1-year results of a randomised controlled trial. *Lancet.* 2012 Oct 27;380(9852):1482-90. doi: 10.1016/S0140-6736(12) 61223-9.
134. Farooq V, Vergouwe Y, Räber L, Vranckx P, Garcia-Garcia H, Diletti R, Kappetein AP, Morel MA, de Vries T, Swart M, **Valgimigli M**, Dawkins KD, Windecker S, Steyerberg EW, Serruys PW. Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. *Eur Heart J.* 2012 Oct 19.
135. Sciahbasi A, Biondi-Zoccai G, Romagnoli E, **Valgimigli M**, Rasoul S, van't Hof A, Liou E, Stone GW. Routine upstream versus selective downstream administration of glycoprotein IIb/IIIa inhibitors in patients with non-ST-elevation acute coronary syndromes: a meta-analysis of randomized trials. *Int J Cardiol.* 2012 Mar 8;155(2):243-8. doi: 10.1016/j.ijcard.2010.10.010.
136. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, **Valgimigli M**, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW; TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. *N Engl J Med.* 2012 Jan 5;366(1):20-33. doi: 10.1056/NEJMoa1109719.
137. Biscaglia S, Tebaldi M, Vranckx P, Campo G, **Valgimigli M**. Effects of pre-hospital clopidogrel administration on early and late residual platelet reactivity in ST-segment elevation myocardial infarction patients undergoing primary intervention. *J Thromb Haemost.* 2013 Jan;11(1):192-4. doi: 10.1111/jth.12049.
138. Chieffo A, Latib A, Caussin C, Presbitero P, Galli S, Menozzi A, Varbella F, Mauri F, **Valgimigli M**, Arampatzis C, Sabate M, Erglis A, Reimers B, Airolidi F, Laine M, Palop RL, Mikhail G, Mccarthy P, Romeo F, Colombo A. A prospective, randomized trial of intravascular-ultrasound guided compared to angiography guided stent implantation in complex coronary lesions: the AVIO trial. *Am Heart J.* 2013 Jan;165(1):65-72. doi: 10.1016/j.ahj.2012.09.017.

139. Aradi D, Komócsi A, Price MJ, Cuisset T, Ari H, Hazarbasanov D, Trenk D, Sibbing D, **Valgimigli M**, Bonello L; On behalf of the Tailored Antiplatelet Treatment Study Collaboration. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. *Int J Cardiol.* 2013 Sep 1;167(5):2140-8. doi: 10.1016/j.ijcard.2012.05.100.
140. **Valgimigli M**, Borghesi M, Tebaldi M, Vranckx P, Parrinello G, Ferrari R; PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY) Investigators. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). *Eur Heart J.* 2013 Mar;34(12):909-19. doi: 10.1093/eurheartj/ehs460.
141. Rubboli A, Sciahbasi A, Briguori C, Saia F, Palmieri C, Moroni LA, Calabrò P, Leone AM, Franco N, **Valgimigli M**, Varani E, Santi M, Pasqualini P, Capecchi A, Piccalò G, Margheri M, di Pasquale G, Galvani M, Bolognese L, Gonzini L, Maggioni AP; WARfarin and coronary STENTing registry. In-hospital management and outcome of patients on warfarin undergoing coronary stent implantation: results of the multicenter, prospective WARfarin and coronary STENTing (WAR-STENT) registry. *J Invasive Cardiol.* 2013 Apr;25(4):170-6.
142. Brugaletta S, Sabate M, Martin-Yuste V, Masotti M, Shiratori Y, Alvarez-Contreras L, Cequier A, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, **Valgimigli M**, Tsepili M, den Heijer P, Bethencourt A, Vazquez N, Gomez-Lara J, Backx B, Serruys PW. Predictors and clinical implications of stent thrombosis in patients with ST-segment elevation myocardial infarction: Insights from the EXAMINATION trial. *Int J Cardiol.* 2013 Apr 8. pii: S0167-5273(13)00455-5. doi: 10.1016/j.ijcard.2013.03.036.
143. **Valgimigli M**, Park SJ, Kim HS, Park KW, Park DW, Tricoci P, Ferrante G. Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: A meta-analysis of randomized trials. *Int J Cardiol.* 2013 Apr 13. doi:pii: S0167-5273(13)00466-X. 10.1016/j.ijcard.2013.03.047.
144. Niccoli G, Rigattieri S, De Vita MR, **Valgimigli M**, Corvo P, Fabbiocchi F, Romagnoli E, De Caterina AR, La Torre G, Lo Schiavo P, Tarantino F, Ferrari R, Tomai F, Olivares P, Cosentino N, D'Amario D, Leone AM, Porto I, Burzotta F, Trani C, Crea F. Open-Label, Randomized, Placebo-Controlled Evaluation of Intracoronary Adenosine or Nitroprusside After Thrombus Aspiration During Primary Percutaneous Coronary Intervention for the Prevention of Microvascular Obstruction in Acute Myocardial Infarction: The REOPEN-AMI Study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction). *JACC Cardiovasc Interv.* 2013 Jun;6(6):580-589. doi: 10.1016/j.jcin.2013.02.009.

145. Saia F, Marino M, Campo G, **Valgimigli M**, Guastaroba P, Taglieri N, Tondi S, Manari A, Guiducci V, Sangiorgio P, Varani E, Magnavacchi P, De Palma R, Marzocchi A. Incidence and Outcome of High On-Treatment Platelet Reactivity in Patients With Non-ST Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] Study). *Am J Cardiol*. 2013 Jun 5. doi:pii: S0002-9149(13)01122-3. 10.1016/j.amjcard.2013.05.010.
146. Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, **Valgimigli M**, Frati G, Kedhi E, Smits PC, Kaiser C, Genereux P, Galatius S, Kirtane AJ, Stone GW. Clinical Outcomes with Drug-Eluting and Bare Metal Stents in Patients with ST-Segment Elevation Myocardial Infarction: Evidence from a Comprehensive Network Meta-analysis. *J Am Coll Cardiol*. 2013 Jun 6. doi:pii: S0735-1097(13)02161-X. 10.1016/j.jacc.2013.05.022.
147. Fortunato O, Spinetti G, Specchia C, Cangiano E, **Valgimigli M**, Madeddu P. Migratory activity of circulating progenitor cells and serum SDF-1 α predict adverse events in patients with myocardial infarction. *Cardiovasc Res*. 2013 Nov 1;100(2):192-200. doi: 10.1093/cvr/cvt153.
148. Gomez-Lara J, Brugaletta S, Gomez-Hospital JA, Ferreira JL, Roura G, Romaguera R, Martin-Yuste V, Masotti M, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, **Valgimigli M**, Tsepili M, den Heijer P, Bethencourt A, Vazquez N, Serruys P, Sabate M, Cequier A. Everolimus-eluting stent versus bare metal stent in proximal left anterior descending ST-elevation myocardial infarction: Insights from the EXAMINATION trial. *Am Heart J*. 2013 Jul;166(1):119-126.e1. doi: 10.1016/j.ahj.2013.04.012.
149. Farooq V, Vergouwe Y, G  n  reux P, Bourantas CV, Palmerini T, Caixeta A, Garc  a-Garc  a HM, Diletti R, Morel MA, McAndrew TC, Kappetein AP, **Valgimigli M**, Windecker S, Dawkins KD, Steyerberg EW, Serruys PW, Stone GW. Prediction of 1-Year Mortality in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Validation of the Logistic Clinical SYNTAX (Synergy Between Percutaneous Coronary Interventions With Taxus and Cardiac Surgery) Score. *JACC Cardiovasc Interv*. 2013 Jul;6(7):737-45. doi: 10.1016/j.jcin.2013.04.004.
150. Contini GA, Nicolini F, Fortuna D, Pacini D, Gabbieri D, Vignali L, **Valgimigli M**, Manari A, Zussa C, Guastaroba P, De Palma R, Grilli R, Gherli T. Five-year outcomes of surgical or percutaneous myocardial revascularization in diabetic patients. *Int J Cardiol*. 2013 Sep 30;168(2):1028-33. doi: 10.1016/j.ijcard.2012. 10.030.
151. Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, Sulimov V, Rosell Ortiz F, Ostojic M, Welsh RC, Carvalho AC, Nanas J, Arntz HR, Halvorsen S, Huber K, Grajek S, Fresco C, Bluhmki E, Regelin A, Vandenberghe K, Bogaerts K, Van de

Werf F; STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. *N Engl J Med*. 2013 Apr 11;368(15):1379-87. doi: 10.1056/NEJMoa1301092.

152. Ribichini F, Romano M, Rosiello R, La Vecchia L, Cabianca E, Caramanno G, Milazzo D, Loschiavo P, Rigattieri S, Musarò S, Pironi B, Fiscella A, Amico F, Indolfi C, Spaccarotella C, Bartorelli A, Trabattoni D, Della Rovere F, Rolandi A, Beqaraj F, Belli R, Sangiorgio P, Villani R, Berni A, Sheiban I, Lopera Quijada MJ, Cappi B, Ribaldi L, Vassanelli C; EXECUTIVE Trial Investigators. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease). *JACC Cardiovasc Interv*. 2013 Oct;6(10):1012-22. doi: 10.1016/j.jcin. 2013.05.016.
153. Stefanini GG, Baber U, Windecker S, Morice MC, Sartori S, Leon MB, Stone GW, Serruys PW, Wijns W, Weisz G, Camenzind E, Steg PG, Smits PC, Kandzari D, Von Birgelen C, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, **Valgimigli M**, Kastrati A, Chieffo A, Mehran R. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. *Lancet*. 2013 Dec 7;382(9908):1879-88. doi: 10.1016/S0140-6736(13)61782-1.
154. Mehilli J, Richardt G, **Valgimigli M**, Schulz S, Singh A, Abdel-Wahab M, Tiroch K, Pache J, Hausleiter J, Byrne RA, Ott I, Ibrahim T, Fusaro M, Seyfarth M, Laugwitz KL, Massberg S, Kastrati A; Zotarolimus-versus everolimus-eluting stents for unprotected left main coronary artery disease. ISAR-LEFT-MAIN 2 Study Investigators. *J Am Coll Cardiol*. 2013 Dec 3;62(22):2075-82. doi: 10.1016/j.jacc.2013.07.044.
155. Fortuna D, Nicolini F, Guastaroba P, De Palma R, Di Bartolomeo S, Saia F, Pacini D, Grilli R; RERIC (Regional Registry of Cardiac Surgery); REAL (Regional Registry of Coronary Angioplasties) Investigators. Coronary artery bypass grafting vs percutaneous coronary intervention in a 'real-world' setting: a comparative effectiveness study based on propensity score-matched cohorts. *Eur J Cardiothorac Surg*. 2013 Jul;44(1):e16-24. doi: 10.1093/ejcts/ezt197.
156. Parodi G, La Manna A, Di Vito L, **Valgimigli M**, Fineschi M, Bellandi B, Niccoli G, Giusti B, Valenti R, Cremonesi A, Biondi-Zoccai G, Prati F. Stent-related defects in patients presenting with stent thrombosis: differences at optical coherence tomography between subacute and late/very late thrombosis in the Mechanism Of Stent Thrombosis (MOST) study. *EuroIntervention*. 2013 Dec;9(8):936-44. doi: 10.4244/EIJV9I8A157.
157. Naganuma T, Chieffo A, Meliga E, Capodanno D, Park SJ, Onuma Y, **Valgimigli M**, Jegere S, Makkar RR, Palacios IF, Costopoulos C, Kim YH, Buszman PP, Chakravarty T, Sheiban I, Mehran R, Naber C, Margey R, Agnihotri A, Marra S, Capranzano P, Leon MB, Moses JW, Fajadet J, Lefevre T, Morice MC, Erglis A, Tamburino C, Alfieri

O, Serruys PW, Colombo A. Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for ostial/midshaft lesions in unprotected left main coronary artery from the DELTA registry: a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. *JACC Cardiovasc Interv.* 2014 Apr;7(4):354-61. doi: 10.1016/j.jcin.2013.11.014.

158. **Valgimigli M**, Campo G, Penzo C, Tebaldi M, Biscaglia S, Ferrari R; RADAR Investigators. Transradial coronary catheterization and intervention across the whole spectrum of Allen test results. *J Am Coll Cardiol.* 2014 May 13;63(18):1833-41. doi: 10.1016/j.jacc.2013.12.043.
159. Buchanan GL, Chieffo A, Meliga E, Mehran R, Park SJ, Onuma Y, Capranzano P, **Valgimigli M**, Narbute I, Makkar RR, Palacios IF, Kim YH, Buszman PP, Chakravarty T, Sheiban I, Naber C, Margey R, Agnihotri A, Marra S, Capodanno D, Allgar V, Leon MB, Moses JW, Fajadet J, Lefevre T, Morice MC, Erglis A, Tamburino C, Alfieri O, Serruys PW, Colombo A. Comparison of percutaneous coronary intervention (with drug-eluting stents) versus coronary artery bypass grafting in women with severe narrowing of the left main coronary artery (from the Women-Drug-Eluting stent for Left main coronary Artery disease Registry). *Am J Cardiol.* 2014 Apr 15;113(8):1348-55. doi: 10.1016/j.amjcard.2014.01.409.
160. Manari A, Magnavacchi P, Puggioni E, Vignali L, Fiaccadori E, Menozzi M, Tondi S, Robotti S, Ferrari D, **Valgimigli M**. Acute kidney injury after primary angioplasty: effect of different hydration treatments. *J Cardiovasc Med (Hagerstown).* 2014 Jan;15(1):60-7. doi: 10.2459/JCM.0b013e3283641bb8.
161. Manari A, Varani E, Guastaroba P, Menozzi M, **Valgimigli M**, Menozzi A, Magnavacchi P, Franco N, Marzocchi A, Casella G. Long-term outcome in patients with ST segment elevation myocardial infarction and multivessel disease treated with culprit-only, immediate, or staged multivessel percutaneous revascularization strategies: Insights from the REAL registry. *Catheter Cardiovasc Interv.* 2014 Nov 15;84(6):912-22. doi: 10.1002/ccd.25374.
162. Storey RF, Kotha J, Smyth SS, Moliterno DJ, Rorick TL, Moccetti T, **Valgimigli M**, Dery JP, Cornel JH, Thomas GS, Huber K, Harrington RA, Hord E, Judge HM, Chen E, Strony J, Mahaffey KW, Tricoci P, Becker RC, Jennings LK. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. *Thromb Haemost.* 2014 May 5;111(5):883-91. doi: 10.1160/TH13-07-0624.
163. **Valgimigli M**, Calabrò P, Cortese B, Frigoli E, Garducci S, Rubartelli P, Andò G, Santarelli A, Galli M, Garbo R, Repetto A, Ierna S, Briguori C, Limbruno U, Violini R, Gagnor A; MATRIX investigators. Scientific foundation and possible implications for practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic

Implementation of AngioX (MATRIX) trial. *J Cardiovasc Transl Res*. 2014 Feb;7(1):101-11. doi: 10.1007/s12265-013-9537-1.

164. Sabaté M, Brugaletta S, Cequier A, Iñiguez A, Serra A, Hernández-Antolín R, Mainar V, **Valgimigli M**, Tsepili M, den Heijer P, Bethencourt A, Vázquez N, Backx B, Serruys PW. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial. *JACC Cardiovasc Interv*. 2014 Jan;7(1):64-71. doi: 10.1016/j.jcin.2013.09.006.
165. **Valgimigli M**, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parri-nello G; PRODIGY Investigators. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY). *JACC Cardiovasc Interv*. 2014 Jan;7(1):20-8. doi: 10.1016/j.jcin.2013.09.008.
166. Sabaté M, Räber L, Heg D, Brugaletta S, Kelbaek H, Cequier A, Ostojic M, Iñiguez A, Tüller D, Serra A, Baumbach A, von Birgelen C, Hernandez-Antolin R, Roffi M, Mainar V, **Valgimigli M**, Serruys PW, Jüni P, Windecker S. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArction) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials. *JACC Cardiovasc Interv*. 2014 Jan;7(1):55-63. doi: 10.1016/j.jcin.2013.07.012.
167. Latib A, Takagi K, Chizzola G, Tobis J, Ambrosini V, Niccoli G, Sardella G, DiSalvo ME, Armigliato P, **Valgimigli M**, Tarsia G, Gabrielli G, Lazar L, Maffeo D, Colombo A. Excimer Laser LEsion modification to expand non-dilatable stents: the ELLEMENT registry. *Cardiovasc Revasc Med*. 2014 Jan;15(1):8-12. doi:10.1016/j.carrev.2013.10.005.
168. Nicholls SJ, Kastelein JJ, Schwartz GG, Bash D, Rosenson RS, Cavender MA, Brennan DM, Koenig W, Jukema JW, Nambi V, Wright RS, Menon V, Lincoff AM, Nissen SE; VISTA-16 Investigators. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. *JAMA*. 2014 Jan 15;311(3):252-62. doi: 10.1001/jama.2013.282836.
169. **Valgimigli M**, Patialiakas A, Thury A, Colangelo S, Campo G, Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga E, Testa L, Gabriel HM, Airolidi F, Ferlini M, Liistro F, Dellavalle A, Vranckx P, Briguori C. Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor

Sprint stent in uncertain DES candidates study. *Am Heart J*. 2013 Nov;166(5):831-8. doi: 10.1016/j.ahj.2013.07.033.

170. Campo G, Tebaldi M, Vranckx P, Biscaglia S, Tumscitz C, Ferrari R, **Valgimigli M**. Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia). *J Am Coll Cardiol*. 2014 Feb 18;63(6):506-12. doi: 10.1016/j.jacc.2013.09.043.
171. Hamon M, Bonello L, Marso S, Rao SV, **Valgimigli M**, Verheugt F, Gershlick A, Wang Y, Prats J, Steg GP, Deliargyris E Comparison of bivalirudin versus heparin(s) during percutaneous coronary interventions in patients receiving prasugrel: a propensity-matched study. *Clin Cardiol*. 2014 Jan;37(1):14-20. doi: 10.1002/clc.22208.
172. Montalescot G, van 't Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, Cantor WJ, Cequier A, Chettibi M, Goodman SG, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Zeymer U, Stibbe O, Ecollan P, Heutz WM, Swahn E, Collet JP, Willems FF, Baradat C, Licour M, Tsatsaris A, Vicaute Prehospital ticagrelor in ST-segment elevation myocardial infarction. E, Hamm CW; ATLANTIC Investigators. *N Engl J Med*. 2014 Sep 11;371(11):1016-27. doi: 10.1056/NEJMoa1407024.
173. O'Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP; SOLID-TIMI 52 Investigators, Steen DL. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. *JAMA*. 2014 Sep 10;312(10):1006-15. doi: 10.1001/jama.2014.11061.
174. Campo G, Punzetti S, Malagù M, Ferrari R, **Valgimigli M**. Two-year outcomes after first- or second-generation drug-eluting stent implantation in patients with in-stent restenosis. A PRODIGY trial substudy. *Int J Cardiol*. 2014 May 1;173(2):343-5. doi: 10.1016/j.ijcard.2014.03.028.
175. Prati F, Romagnoli E, **Valgimigli M**, Burzotta F, De Benedictis M, Ramondo A, Mehran R, Stella PR. Randomized comparison between 3-month Cre8 DES vs. 1-month Vision/Multilink8 BMS neointimal coverage assessed by OCT evaluation: the DEMONSTRATE study. *Int J Cardiol*. 2014 Oct 20;176(3):904-9. doi: 10.1016/j.ijcard.2014.08.031.
176. Sinnaeve PR, Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Lambert Y, Danays T, Soulat L, Halvorsen S, Ortiz FR, Vandenberghe K, Regelin A, Bluhmki E, Bogaerts K, Van de Werf F; STREAM investigators. ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up. *Circulation*. 2014 Sep 30;130(14):1139-45. doi: 10.1161/CIRCULATIONAHA.114.009570.

177. Guagliumi G, Capodanno D, Saia F, Musumeci G, Tarantini G, Garbo R, Tumminello G, Sirbu V, Coccato M, Fineschi M, Trani C, De Benedictis M, Limbruno U, De Luca L, Niccoli G, Bezerra H, Ladich E, Costa M, Biondi Zoccai G, Virmani R; OCTAVIA Trial Investigators. Mechanisms of atherothrombosis and vascular response to primary percutaneous coronary intervention in women versus men with acute myocardial infarction: results of the OCTAVIA study. *JACC Cardiovasc Interv.* 2014 Sep;7(9):958-68. doi: 10.1016/j.jcin.2014.05.011.
178. **Valgimigli M**, Tricoci P, Huang Z, Aylward PE, Armstrong PW, Van de Werf F, Leonardi S, White HD, Widimsky P, Harrington RA, Cequier A, Chen E, Lokhnygina Y, Wallentin L, Strony J, Mahaffey KW, Moliterno DJ. Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). *Am J Cardiol.* 2014 Sep 1;114(5):665-73. doi: 10.1016/j.amjcard. 2014.05.054.
179. Windecker S, Stortecky S, Stefanini GG, da Costa BR, Rutjes AW, Di Nisio M, Sillelta MG, Maione A, Alfonso F, Clemmensen PM, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head S, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter D, Schauerte P, Sousa Uva M, Taggart DP, Torracca L, **Valgimigli M**, Wijns W, Witkowski A, Kolh P, Jüni P. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. *BMJ.* 2014 Jun 23;348:g3859. doi: 10.1136/bmj.g3859.
180. Serra A, Hernández-Antolín R, Mainar V, **Valgimigli M**, Tsepili M, den Heijer P, Bethencourt A, Vázquez N, Serruys PW, Sabaté M; EXAMINATION investigators. Optimization in stent implantation by manual thrombus aspiration in ST-segment-elevation myocardial infarction: findings from the EXAMINATION trial. Fernández-Rodríguez D, Regueiro A, Brugaletta S, Martín-Yuste V, Masotti M, Cequier A, Iñiguez A, *Circ Cardiovasc Interv.* 2014 Jun;7(3):294-300. doi: 10.1161 /CIRCINTERVENTIONS.113.000964.
181. Iqbal J, Vergouwe Y, Bourantas CV, Klaveren DV, Zhang YJ, Campos CM, García-García HM, Morel MA, **Valgimigli M**, Windecker S, Steyerberg EW, Serruys PW. Predicting 3-year mortality after percutaneous coronary intervention: updated logistic clinical SYNTAX score based on patient-level data from 7 contemporary stent trials. *JACC Cardiovasc Interv.* 2014 May;7(5):464-70. doi: 10.1016/j.jcin.2014.02.007.
182. Bourantas CV, Zhang YJ, Garg S, Iqbal J, **Valgimigli M**, Windecker S, Mohr FW, Silber S, Vries Td, Onuma Y, Garcia-Garcia HM, Morel MA, Serruys PW. Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials. *Heart.* 2014 Aug;100(15):1158-64. doi: 10.1136/heartjnl-2013-305180.
183. Vranckx P, Leonardi S, Tebaldi M, Biscaglia S, Parrinello G, Rao SV, Mehran R, **Valgimigli M**. Prospective validation of the Bleeding Academ-

ic Research Consortium classification in the all-comer PRODIGY trial. *Eur Heart J*. 2014 Oct 1;35(37):2524-9. doi: 10.1093/eurheartj/ehu161.

184. Sciahbasi A, Calabrò P, Sarandrea A, Rigattieri S, Tomassini F, Sardella G, Zavalloni D, Cortese B, Limbruno U, Tebaldi M, Gagnor A, Rubartelli P, Zingarelli A, **Valgimigli M**. Randomized comparison of operator radiation exposure comparing transradial and transfemoral approach for percutaneous coronary procedures: rationale and design of the minimizing adverse haemorrhagic events by TRansradial access site and systemic implementation of angioX - RAdiation Dose study (RAD-MATRIX). *Cardiovasc Revasc Med*. 2014 Jun;15(4):209-13. doi: 10.1016/j.carrev.2014.03.010.
185. STABILITY Investigators, White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, Budaj A, Harrington RA, Steg PG, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, Chen H, Chen MF, Corbalan R, Dalby AJ, Danchin N, De Winter RJ, Denchev S, Diaz R, Elisaf M, Flather MD, Goudev AR, Granger CB, Grinfeld L, Hochman JS, Husted S, Kim HS, Koenig W, Linhart A, Lonn E, López-Sendón J, Manolis AJ, Mohler ER 3rd, Nicolau JC, Pais P, Parkhomenko A, Pedersen TR, Pella D, Ramos-Corrales MA, Ruda M, Sereg M, Siddique S, Sinnaeve P, Smith P, Sritara P, Swart HP, Sy RG, Teramoto T, Tse HF, Watson D, Weaver WD, Weiss R, Viigimaa M, Vinereanu D, Zhu J, Cannon CP, Wallentin L. Darapladib for preventing ischemic events in stable coronary heart disease. *N Engl J Med*. 2014 May 1;370(18):1702-11. doi: 10.1056/NEJMoa1315878.
186. **Valgimigli M**; MATRIX investigators. Design and rationale for the Minimizing Adverse haemorrhagic events by TRansradial access site and systemic Implementation of angioX program. *Am Heart J*. 2014 Dec;168(6):838-45.e6. doi: 10.1016/j.ahj.2014.08.013.
187. **Valgimigli M**, Sabaté M, Kaiser C, Brugaletta S, de la Torre Hernandez JM, Galatius S, Cequier A, Eberli F, de Belder A, Serruys PW, Ferrante G. Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis. *BMJ*. 2014 Nov 4;349:g6427. doi: 10.1136/bmj.g6427.
188. Rubboli A, Saia F, Sciahbasi A, Bacchi-Reggiani ML, Steffanon L, Briguori C, Calabrò P, Palmieri C, Rizzi A, Imperadore F, Sangiorgi GM, **Valgimigli M**, Carosio G, Steffenino G, Galvani M, Di Pasquale G, La Vecchia L, Maggioni AP, Bolognese L; WARfarin and Coronary STENTing (WAR-STENT) Study Group. Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry. *J Invasive Cardiol*. 2014 Nov;26(11):563-9.
189. De Bruyne B, Fearon WF, Pijls NH, Barbato E, Tonino P, Piroth Z, Jagic N, Mobius-Winckler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engström T, Oldroyd K, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Limacher A, Nüesch E, Jüni P; FAME 2 Trial Investigators. Fractional flow reserve-guided PCI for stable coronary

artery disease. *N Engl J Med*. 2014 Sep 25;371(13):1208-17. doi: 10.1056/NEJMoA1408758. Erratum in: *N Engl J Med*. 2014 Oct 9;371(15):1465.

190. Andò G, Costa F, Boretta I, Trio O, **Valgimigli M**. Benefit of radial approach in reducing the incidence of acute kidney injury after percutaneous coronary intervention: a meta-analysis of 22,108 patients. *Int J Cardiol*. 2015 Jan 20;179:309-11. doi: 10.1016/j.ijcard.2014.11.053.
191. Navarese EP, Schulze V, Andreotti F, Kowalewski M, Kołodziejczak M, Kandzari DE, Rassaf T, Gorny B, Brockmeyer M, Meyer C, Berti S, Kubica J, Kelm M, **Valgimigli M**. Comprehensive Meta-Analysis of Safety and Efficacy of Bivalirudin Versus Heparin With or Without Routine Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndrome. *JACC Cardiovasc Interv*. 2015 Jan;8(1 Pt B):201-13. doi: 10.1016/j.jcin.2014.10.003.
192. Cortese B, **Valgimigli M**. Current know how on the absorb BVS technology: An experts' survey. *Int J Cardiol*. 2015 Feb 1;180:203-5. doi: 10.1016/j.ijcard.2014.11.168.
193. Ielasi A, Brugaletta S, Silvestro A, Cequier A, Iñiguez A, Serra A, Hernandez-Antolin R, Mainar V, **Valgimigli M**, den Heijer P, Bethencourt A, Vazquez N, Serruys P, Sabate M, Tsepili M. Everolimus-eluting stent versus bare-metal stent in elderly (≥ 75 years) versus non-elderly (< 75 years) patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: insights from the examination trial. *Int J Cardiol*. 2015 Jan 20;179:73-8. doi: 10.1016/j.ijcard.2014.10.038.
194. Picchi A, Limbruno U, Andò G, Brugaletta S, Cortese B, De Carlo M, Garcia-Garcia HM, Palmieri C, Regar E, Rigattieri S, Sardella G, Zimarino M, **Valgimigli M**. Optical coherence tomography appraisal of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing intraprocedural versus post-stenting prolonged bivalirudin infusion. Rationale and design of the MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and angioX) OCT substudy. *EuroIntervention*. 2015 Mar 22;10(11):1311-7. doi: 10.4244/EIJY15M02_10.
195. Palmerini T, Sangiorgi D, **Valgimigli M**, Biondi-Zoccai G, Feres F, Abizaid A, Costa RA, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Mariani A, Della Riva D, Genereux P, Leon MB, Bhatt DL, Bendetto U, Rapezzi C, Stone GW. Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis. *J Am Coll Cardiol*. 2015 Mar 24;65(11):1092-102. doi: 10.1016/j.jacc.2014.12.046.
196. Crimi G, Leonardi S, Costa F, Ariotti S, Tebaldi M, Biscaglia S, **Valgimigli M**. Incidence, prognostic impact, and optimal definition of contrast-induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. Insights from the all-comer PRODIGY trial. *Catheter Cardiovasc Interv*. 2015 Feb 20. doi: 10.1002/ccd.25822.

197. Costa F, Vranckx P, Leonardi S, Moscarella E, Ando G, Calabro P, Oreto G, Zijlstra F, **Valgimigli M**. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial. *Eur Heart J*. 2015 May 21;36(20):1242-51. doi: 10.1093/eurheartj/ehv038.
198. **Valgimigli M**, Patialiakas A, Thury A, McFadden E, Colangelo S, Campo G, Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga E, Testa L, Gabriel HM, Airolidi F, Ferlini M, Liistro F, Dellavalle A, Vranckx P, Briguori C; ZEUS Investigators. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. *J Am Coll Cardiol*. 2015 Mar 3;65(8):805-15. doi: 10.1016/j.jacc.2014.11.053.
199. **Valgimigli M**, Gagnor A, Calabrò P, Frigoli E, Leonardi S, Zaro T, Rubartelli P, Briguori C, Andò G, Repetto A, Limbruno U, Cortese B, Sganzerla P, Lupi A, Galli M, Colangelo S, Ierna S, Ausiello A, Presbitero P, Sardella G, Varbella F, Esposito G, Santarelli A, Tresoldi S, Nazzaro M, Zingarelli A, de Cesare N, Rigattieri S, Tosi P, Palmieri C, Brugaletta S, Rao SV, Heg D, Rothenbühler M, Vranckx P, Jüni P; MATRIX Investigators. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. *Lancet*. 2015 Mar 13. pii: S0140-6736(15)60292-6. doi: 10.1016/S0140-6736(15)60292-6.
200. Campos CM, Costa F, Garcia-Garcia HM, Bourantas C, Suwannasom P, **Valgimigli M**, Morel MA, Windecker S, Serruys PW. Anatomic characteristics and clinical implications of angiographic coronary thrombus: insights from a patient-level pooled analysis of SYNTAX, RESOLUTE, and LEADERS Trials. *Circ Cardiovasc Interv*. 2015 Apr;8(4). pii: e002279. doi: 10.1161/CIRCINTERVENTIONS.114.002279.
201. Campos CM, Garcia-Garcia HM, van Klaveren D, Ishibashi Y, Cho YK, **Valgimigli M**, Räber L, Jonker H, Onuma Y, Farooq V, Garg S, Windecker S, Morel MA, Steyerberg EW, Serruys PW. Validity of SYNTAX score II for risk stratification of percutaneous coronary interventions: A patient-level pooled analysis of 5433 patients enrolled in contemporary coronary stent trials. *Int J Cardiol*. 2015 May 6;187:111-5. doi: 10.1016/j.ijcard.2015.03.248.
202. Andò G, Cortese B, Frigoli E, Gagnor A, Garducci S, Briguori C, Rubartelli P, Calabrò P, **Valgimigli M**. MATRIX investigators. Acute kidney injury after percutaneous coronary intervention: Rationale of the AKI-MATRIX (acute kidney injury-minimizing adverse hemorrhagic events by TRansradial access site and systemic implementation of angioX) sub-study. *Catheter Cardiovasc Interv*. 2015 Apr 9. doi: 10.1002/ccd.25932.
203. Navarese EP, Andreotti F, Schulze V, Kołodziejczak M, Buffon A, Brouwer M, Costa F, Kowalewski M, Parati G, Lip GY, Kelm M, **Val-**

gimigli M. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. *BMJ*. 2015 Apr 16;350:h1618. doi: 10.1136/bmj.h1618.

204. Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, Freynhofer MK, Ten Berg J, Janssen P, Angiolillo DJ, Siller-Matula JM, Marcucci R, Patti G, Mangiacapra F, **Valgimigli M**, Morel O, Palmerini T, Price MJ, Cuisset T, Kastrati A, Stone GW, Sibbing D. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. *Eur Heart J*. 2015 Apr 20. pii: ehv104.
205. Buccheri D, **Valgimigli M**, Cortese B. Current-era biovascular scaffolds seen by experts: An experience-based survey. *Int J Cardiol*. 2015 Jun 1;188:16-8. doi: 10.1016/j.ijcard.2015.03.437.
206. Adamo M, Costa F, Vranckx P, Leonardi S, Navarese EP, Garcia-Garcia HM, **Valgimigli M**. Does smoking habit affect the randomized comparison of 6 versus 24-month dual antiplatelet therapy duration? Insights from the PRODIGY trial. *Int J Cardiol*. 2015 Jul 1;190:242-5. doi: 10.1016/j.ijcard.2015.04.159.
207. Ferrante G, **Valgimigli M**, Pagnotta P, Presbitero P. Bivalirudin versus heparin in patients with acute myocardial infarction: A meta-analysis of randomized trials. *Catheter Cardiovasc Interv*. 2015 Apr 24. doi: 10.1002/ccd.25955.
208. Karanasos A, Van Mieghem N, van Ditzhuijzen N, Felix C, Daemen J, Autar A, Onuma Y, Kurata M, Diletti R, **Valgimigli M**, Kauer F, van Beusekom H, de Jaegere P, Zijlstra F, van Geuns RJ, Regar E. Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience. *Circ Cardiovasc Interv*. 2015 May;8(5). pii: e002369. doi: 10.1161/CIRCINTERVENTIONS.114.002369.
209. **Valgimigli M**, Costa F, Byrne R, Haude M, Baumbach A, Windecker S. Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey. *EuroIntervention*. 2015 May 19;11(1):68-74. doi: 10.4244/EIJV11I1A11.
210. **Valgimigli M**, Frigoli E, Leonardi S, Rothenbühler M, Gagnor A, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andó G, Repetto A, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Presbitero P, Santarelli A, Sardella G, Varbella F, Tresoldi S, N de Cesare, Rigattieri S, Zingarelli A, Tosi P, van 't Hof A, Boccuzzi G, Omerovic E, Sabaté M, Heg H, Jüni P, Vranckx P, for the MATRIX Investigators. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. *N Engl J Med*. 2015, Sep 10;373(11):997-1009. doi: 10.1056/NEJMoa1507854.
211. Udell JA, Bonaca MP, Collet JP, Lincoff AM, Kereiakes DJ, Costa F, Lee CW, Mauri L, **Valgimigli M**, Park SJ, Montalescot G, Sabatine

MS, Braunwald E, Bhatt DL. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. *Eur Heart J*. pii: ehv443, 2015.

212. Komajda M, Weidinger F, Kerneis M, Cosentino F, Cremonesi A, Ferrari R, Kownator S, Steg PG, Tavazzi L, **Valgimigli M**, Szwed H, Majda W, Olivari Z, Van Belle E, Shlyakhto EV, Mintale I, Slapikas R, Rittger H, Mendes M, Tsioufis C, Balanescu S, Laroche C, Maggioni AP. EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). *Eur Heart J*. pii: ehv437, 2015.
213. Costa F, Adamo M, Ariotti S, Ferrante G, Navarese EP, Leonardi S, Garcia-Garcia H, Vranckx P, **Valgimigli M**. Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration. *EuroIntervention*. 11(4). pii:20150619_02. doi:10.4244/EIJY15M08_04, 2015.
214. Meloni M, Cesselli D, Caporali A, Mangialardi G, Avolio E, Reni C, Fortunato O, Martini S, Madeddu P, **Valgimigli M**, Nikolaev E, Kaczmarek L, Angelini GD, Beltrami AP, Emanuelli C. Cardiac nerve growth factor overexpression induces bone marrow-derived progenitor cells mobilization and homing to the infarcted heart. *Mol Ther*. doi:10.1038/mt.2015.167, 2015.
215. Costa F, Adamo M, Ariotti S, Ferrante G, Navarese EP, Leonardi S, Garcia-Garcia H, Vranckx P, **Valgimigli M**. Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration. *EuroIntervention*. 2016 Feb;11(11):e1222-30.
216. Meloni M, Cesselli D, Caporali A, Mangialardi G, Avolio E, Reni C, Fortunato O, Martini S, Madeddu P, **Valgimigli M**, Nikolaev E, Kaczmarek 8, Angelini GD, Beltrami AP, Emanuelli C. Cardiac Nerve Growth Factor Overexpression Induces Bone Marrow-derived Progenitor Cells Mobilization and Homing to the Infarcted Heart. *Mol Ther*. 2015 Dec;23(12):1854-66.
217. Costa F, Tijssen JG, Ariotti S, Giatti S, Moscarella E, Guastaroba P, De Palma R, Andò G, Oreto G, Zijlstra F, **Valgimigli M**. Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy. *J Am Heart Assoc*. 2015 Dec 7;4(12).
218. Colombo A, Basavarajaiah S, Limbruno U, Picchi A, Lettieri C, **Valgimigli M**, Sciahbasi A, Prati F, Calabresi M, Pierucci D, Guglielmotti A. A double-blind randomised study to evaluate the efficacy and safety of bindarit in preventing coronary stent restenosis. *EuroIntervention*. 2015 Dec 23;11(8).

219. Sabaté M, Brugaletta S, Cequier A, Iñiguez A, Serra A, Jiménez-Quevedo P, Mainar V, Campo G, Tsepili M, den Heijer P, Bethencourt A, Vazquez N, van Es GA, Backx B, **Valgimigli M**, Serruys PW. Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. *Lancet*. 2016 Jan 23;387(10016):357-66.
220. Lincoff AM, Mehran R, Pocsic TJ, Zelenkofske SL, Huang Z, Armstrong PW, Steg PG, Bode C, Cohen MG, Buller C, Laanmets P, **Valgimigli M**, Marandi T, Fridrich V, Cantor WJ, Merkely B, Lopez-Sendon J, Cornel JH, Kasprzak JD, Aschermann M, Guetta V, Morais J, Sinnaeve PR, Huber K, Stables R, Sellers MA, Borgman M, Glenn L, Levinson AI, Lopes RD, Hasselblad V, Becker RC, Alexander JH; REGULATE-PCI Investigators. Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. *Lancet*. 2016 Jan 23;387(10016):349-56.
221. Vranckx P, **Valgimigli M**, Windecker S, Steg PG, Hamm C, Jüni P, Garcia-Garcia HM, van Es GA, Serruys PW. Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. *EuroIntervention*. 2015 Nov 23;11(7).
222. Mont'Alverne-Filho JR, Rodrigues-Sobrinho CR, Medeiros F, Falcão FC, Falcão JL, Silva RC, Croce KJ, Nicolau JC, **Valgimigli M**, Serruys PW, Lemos PA. Upstream clopidogrel, prasugrel, or ticagrelor for patients treated with primary angioplasty: Results of an angiographic randomized pilot study. *Catheter Cardiovasc Interv*. 2016 Jun;87(7):1187-93.
223. Pighi M, Tomai F, Petrolini A, de Luca L, Tarantini G, Barioli A, Colombo P, Klugmann S, Ferlini M, Ormezzano MF, Loi B, Calabrò P, Bianchi RM, Faggian G, Forni A, Vassanelli C, **Valgimigli M**, Ribichini F. Everolimus-Eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy: the CART (Cardiac Allograft Reparative Therapy) Prospective Multicenter Pilot Study. *J Cardiovasc Transl Res*. 2016 Feb;9(1):40-8.
224. Cassese S, Kufner S, Xhepa E, Byrne RA, Kreutzer J, Ibrahim T, Tiroch K, **Valgimigli M**, Tölg R, Fusaro M, Schunkert H, Laugwitz KL, Mehilli J, Kastrati A. Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials. *Clin Res Cardiol*. 2016 Jul;105(7):575-84.
225. Giustino G, Baber U, Saliński O, Sartori S, Stone GW, Leon MB, Aquino M, Stefanini GG, Steg PG, Windecker S, O'Donoghue M, Wijns W, Serruys PW, **Valgimigli M**, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari D, Von Birgelen C, Dangas GD, Cha JY, Galatius

- S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Genereux P, Chieffo A, Mehran R. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis. *Circ Cardiovasc Interv.* 2016 Jan;9(1):e002995.
226. Baber U, Giustino G, Sartori S, Aquino M, Stefanini GG, Steg PG, Windecker S, Leon MB, Wijns W, Serruys PW, **Valgimigli M**, Stone GW, Dangas GD, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari D, Von Birgelen C, Mastoris I, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Mehran R. Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials. *JACC Cardiovasc Interv.* 2016 Jan 11;9(1):28-38.
 227. Romaguera R, Gómez-Hospital JA, Gomez-Lara J, Brugaletta S, Pinar E, Jiménez-Quevedo P, Gracida M, Roura G, Ferreiro JL, Teruel L, Montanya E, Fernandez-Ortiz A, Alfonso F, **Valgimigli M**, Sabate M, Cequier A. A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With Diabetes Mellitus: The RESERVOIR Clinical Trial. *JACC Cardiovasc Interv.* 2016 Jan 11;9(1):42-50.
 228. Costa F, van Leeuwen MA, Daemen J, Diletti R, Kauer F, van Geuns RJ, Ligthart J, Witberg K, Zijlstra F, **Valgimigli M**, Van Mieghem NM. The Rotterdam Radial Access Research: Ultrasound-Based Radial Artery Evaluation for Diagnostic and Therapeutic Coronary Procedures. *Circ Cardiovasc Interv.* 2016 Feb;9(2):e003129.
 229. Ariotti S, Adamo M, Costa F, Patialiakas A, Briguori C, Thury A, Colangelo S, Campo G, Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga E, Testa L, Gabriel HM, Ferlini M, Vranckx P, **Valgimigli M**; ZEUS Investigators. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial. *JACC Cardiovasc Interv.* 2016 Mar 14;9(5):426-36.
 230. van der Sijde JN, Karanasos A, van Ditzhuijzen NS, Okamura T, van Geuns RJ, **Valgimigli M**, Ligthart JM, Witberg KT, Wemelsfelder S, Fam JM, Zhang B, Diletti R, de Jaegere PP, van Mieghem NM, van Soest G, Zijlstra F, van Domburg RT, Regar E. Safety of optical coherence tomography in daily practice: a comparison with intravascular ultrasound. *Eur Heart J Cardiovasc Imaging.* 2016 Mar 18.
 231. Gargiulo G, Costa F, Ariotti S, Biscaglia S, Campo G, Esposito G, Leonardi S, Vranckx P, Windecker S, **Valgimigli M**. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study trial. *Am Heart J.* 2016 Apr;174:95-102.

232. Franzone A, Heg D, Räber L, **Valgimigli M**, Piccolo R, Zanchin T, Yamaji K, Stortecky S, Blöchliger S, Hunziker L, Praz F, Jüni P, Windecker S, Pilgrim T. External validity of the “all-comers” design: insights from the BIOSCIENCE trial. *Clin Res Cardiol*. 2016 Sep;105(9):744-54.
233. Crimi G, Leonardi S, Costa F, Adamo M, Ariotti S, **Valgimigli M**. Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial. *Int J Cardiol*. 2016 Jun 1;212:110-7.
234. Giustino G, Baber U, Aquino M, Sartori S, Stone GW, Leon MB, Genereux P, Dangas GD, Chandrasekhar J, Kimura T, Salianski O, Stefanini GG, Steg PG, Windecker S, Wijns W, Serruys PW, **Valgimigli M**, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari DE, Galatius S, Von Birgelen C, Saporito R, Jeger RV, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Mehran R. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis. *JACC Cardiovasc Interv*. 2016 Apr 11;9(7):674-84.
235. Janssens GN, van Leeuwen MA, van der Hoeven NW, de Waard GA, Nijveldt R, Diletti R, Zijlstra F, von Birgelen C, Escaned J, **Valgimigli M**, van Royen N. Reducing Microvascular Dysfunction in Revascularized Patients with ST-Elevation Myocardial Infarction by Off-Target Properties of Ticagrelor versus Prasugrel. Rationale and Design of the REDUCE-MVI Study. *J Cardiovasc Transl Res*. 2016 Jun;9(3):249-56.
236. Rao SV, Nolan J, Fraser DG, Mamas MA, Bertrand OF, Pancholy SB, Bernat I, Dharma S, Kedev S, Jolly SS, **Valgimigli M**. Efficacy of Radial Versus Femoral Access in the Acute Coronary Syndrome: Is It the Operator or the Operation That Matters? *JACC Cardiovasc Interv*. 2016 May 9;9(9):978-9.
237. Fam JM, Felix C, van Geuns RJ, Onuma Y, Van Mieghem NM, Karanasos A, van der Sijde J, De Paolis M, Regar E, **Valgimigli M**, Daemen J, de Jaegere P, Zijlstra F, Diletti R. Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction: a propensity-matched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first study. *EuroIntervention*. 2016 May 17;12(1):30-7.
238. Santucci A, Byrne RA, Baumbach A, Colleran R, Haude M, Windecker S, **Valgimigli M**. Appraising the safety and efficacy profile of left atrial appendage closure in 2016 and the future clinical perspectives. Results of the EAPCI LAAC survey. *EuroIntervention*. 2016 May 17;12(1):112-8.
239. Pilgrim T, Vranckx P, **Valgimigli M**, Stefanini GG, Piccolo R, Rat J, Rothenbühler M, Stortecky S, Räber L, Blöchliger S, Hunziker L, Silber S, Jüni P, Serruys PW, Windecker S. Risk and timing of recurrent

ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction. *Am Heart J*. 2016 May;175:56-65.

240. Piccolo R, Franzone A, Koskinas KC, Räber L, Pilgrim T, **Valgimigli M**, Stortecky S, Rat-Wirtzler J, Silber S, Serruys PW, Jüni P, Heg D, Windecker S. Effect of Diabetes Mellitus on Frequency of Adverse Events in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. *Am J Cardiol*. 2016 Aug 1;118(3):345-52.
241. Siontis GC, Piccolo R, Praz F, **Valgimigli M**, Räber L, Mavridis D, Jüni P, Windecker S. Percutaneous Coronary Interventions for the Treatment of Stenoses in Small Coronary Arteries: A Network Meta-Analysis. *JACC Cardiovasc Interv*. 2016 Jul 11;9(13):1324-34.
242. Ferrante G, Rao SV, Jüni P, Da Costa BR, Reimers B, Condorelli G, Anzuini A, Jolly SS, Bertrand OF, Krucoff MW, Windecker S, **Valgimigli M**. Radial Versus Femoral Access for Coronary Interventions Across the Entire Spectrum of Patients With Coronary Artery Disease: A Meta-Analysis of Randomized Trials. *JACC Cardiovasc Interv*. 2016 Jul 25;9(14):1419-34.
243. Sawaya FJ, Morice MC, Spaziano M, Mehran R, Didier R, Roy A, **Valgimigli M**, Kim HS, Woo Park K, Hong MK, Kim BK, Jang Y, Feres F, Abizaid A, Costa RA, Colombo A, Chieffo A, Giustino G, Stone GW, Bhatt DL, Palmerini T, Gilard M. Short-versus long-term Dual Antiplatelet therapy after drug-eluting stent implantation in women versus men: A sex-specific patient-level pooled-analysis of six randomized trials. *Catheter Cardiovasc Interv*. 2016 Jul 18.
244. Pyxaras SA, Hunziker L, Chieffo A, Meliga E, Latib A, Park SJ, Onuma Y, Capranzano P, **Valgimigli M**, Narbute I, Makkar RR, Palacios IF, Kim YH, Buszman PP, Chakravarty T, Sheiban I, Mehran R, Margey R, Agnihotri A, Marra S, Capodanno D, Leon MB, Moses JW, Fajadet J, Lefevre T, Morice MC, Erglis A, Tamburino C, Alfieri O, Serruys PW, Colombo A, Naber CK. Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. *EuroIntervention*. 2016 Aug 5;12(5):e623-31.
245. Xhepa E, Tada T, Kufner S, Ndrepepa G, Byrne RA, Kreutzer J, Ibrahim T, Tiroch K, **Valgimigli M**, Tölg R, Cassese S, Fusaro M, Schunkert H, Laugwitz KL, Mehilli J, Kastrati A. Long-term prognostic value of risk scores after drug-eluting stent implantation for unprotected left main coronary artery: A pooled analysis of the ISAR-LEFT-MAIN and ISAR-LEFT-MAIN 2 randomized clinical trials. *Catheter Cardiovasc Interv*. 2016 Aug 12.
246. Ferko N, Ferrante G, Hasegawa JT, Schikorr T, Soleas IM, Hernandez JB, Sabaté M, Kaiser C, Brugaletta S, de la Torre Hernandez JM, Galatius S, Cequier A, Eberli F, de Belder A, Serruys PW, **Valgimi-**

- gli M.** Cost-effectiveness of percutaneous coronary intervention with cobalt-chromium everolimus eluting stents versus bare metal stents: Results from a patient level meta-analysis of randomized trials. *Catheter Cardiovasc Interv.* 2016 Aug 16.
247. Adamo M, Ariotti S, Costa F, Curello S, Moschovitis A, de Vries T, White HD, Windecker S, **Valgimigli M.** Phosphate- or Citrate-Buffered Tirofiban Versus Unfractionated Heparin and its Impact on Thrombocytopenia and Clinical Outcomes in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the PRISM Trial. *JACC Cardiovasc Interv.* 2016 Aug 22;9(16):1667-76.
 248. Stefanini GG, Behan M, **Valgimigli M,** Oldroyd KG, Leon MB. Will LEADERS-FREE change my practice? A randomised double-blind comparison of the BioFreedom™ drug-coated stent vs. the Gazelle™ bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy. *EuroIntervention.* 2016 Aug 20;12(6):798-800.
 249. Gargiulo G, Ariotti S, Santucci A, Piccolo R, Baldo A, Franzone A, Magnani G, Marino M, Esposito G, Windecker S, **Valgimigli M.** Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial. *JACC Cardiovasc Interv.* 2016 Sep 12;9(17):1780-9.
 250. Franzone A, Piccolo R, Gargiulo G, Ariotti S, Marino M, Santucci A, Baldo A, Magnani G, Moschovitis A, Windecker S, **Valgimigli M.** Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease: A Subgroup Analysis of the PRODIGY Randomized Clinical Trial. *JAMA Cardiol.* 2016 Aug 30.
 251. Giustino G, Chieffo A, Palmerini T, **Valgimigli M,** Feres F, Abizaid A, Costa RA, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Gilard M, Morice MC, Sawaya F, Sardella G, Genereux P, Redfors B, Leon MB, Bhatt DL, Stone GW, Colombo A. Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. *J Am Coll Cardiol.* 2016 Aug 25.
 252. Lee SY, Hong MK, Shin DH, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Kim HS, **Valgimigli M,** Palmerini T, Stone GW. Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors. *Clin Res Cardiol.* 2016 Sep 8.
 253. Giustino G, Mastoris I, Baber U, Sartori S, Stone GW, Leon MB, Seruys PW, Kastrati A, Windecker S, **Valgimigli M,** Dargas GD, Von Birgelen C, Smits PC, Kandzari D, Galatius S, Wijns W, Steg PG, Stefanini GG, Aquino M, Morice MC, Camenzind E, Weisz G, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Chieffo A, Mehran R. Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. *JACC Cardiovasc Interv.* 2016 Sep 26;9(18):1890-901.

254. Leonardi S, Frigoli E, Rothenbühler M, Navarese E, Calabró P, Bellotti P, Briguori C, Ferlini M, Cortese B, Lupi A, Lerna S, Zavalonito-Parenti D, Esposito G, Tresoldi S, Zingarelli A, Rigattieri S, Palmieri C, Liso A, Abate F, Zimarino M, Comeglio M, Gabrielli G, Chieffo A, Brugaletta S, Mauro C, Van Mieghem NM, Heg D, Jüni P, Windecker S, **Valgimigli M**; MATRIX Investigators. Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. *BMJ*. 2016 Sep 27;354:i4935.
255. Adamo M, Byrne RA, Baumbach A, Haude M, Windecker S, **Valgimigli M**. Assessing the cardiology community position on transradial intervention and the use of bivalirudin in patients with acute coronary syndrome undergoing invasive management: results of an EAPCI survey. *EuroIntervention*. 2016 Oct 20;12(9):1154-1163.
256. Lee SY, Hong MK, Shin DH, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Kim HS, **Valgimigli M**, Colombo A, Gilard M, Palmerini T, Stone GW. Association Between Duration of Dual Antiplatelet Therapy and Angiographic Multivessel Disease on Outcomes in Patients Treated With Newer-Generation Drug-Eluting Stents. *Circ Cardiovasc Interv*. 2016 Nov;9(11).
257. Gargiulo G, Windecker S, da Costa BR, Feres F, Hong MK, Gilard M, Kim HS, Colombo A, Bhatt DL, Kim BK, Morice MC, Park KW, Chieffo A, Palmerini T, Stone GW, **Valgimigli M**. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. *BMJ*. 2016 Nov 3;355:i5483.
258. De Maria GL, Fahrni G, Alkhalil M, Cuculi F, Dawkins S, Wolfrum M, Choudhury RP, Forfar JC, Prendergast BD, Yetgin T, van Geuns RJ, Tebaldi M, Channon KM, Kharbanda RK, Rothwell PM, **Valgimigli M**, Banning AP. A tool for predicting the outcome of reperfusion in ST-elevation myocardial infarction using age, thrombotic burden and index of microcirculatory resistance (ATI score). *EuroIntervention*. 2016 Nov 20;12(10):1223-1230.
259. Capodanno D, Gargiulo G, Buccheri S, Chieffo A, Meliga E, Latib A, Park SJ, Onuma Y, Capranzano P, **Valgimigli M**, Narbute I, Makkar RR, Palacios IF, Kim YH, Buszman PE, Chakravarty T, Sheiban I, Mehran R, Naber C, Margey R, Agnihotri A, Marra S, Leon MB, Moses JW, Fajadet J, Lefèvre T, Morice MC, Erglis A, Alfieri O, Serruys PW, Colombo A, Tamburino C; DELTA Investigators. Computing Methods for Composite Clinical Endpoints in Unprotected Left Main Coronary Artery Revascularization: A Post Hoc Analysis of the DELTA Registry. *JACC Cardiovasc Interv*. 2016 Nov 28;9(22):2280-2288.
260. Diletti R, Ishibashi Y, Felix C, Onuma Y, Nakatani S, van Mieghem NM, Regar E, **Valgimigli M**, de Jaegere PP, van Ditzhuijzen N, Fam JM, Ligthart JM, Lenzen MJ, Serruys PW, Zijlstra F, Jan van Geuns

R. Expanded clinical use of everolimus eluting bioresorbable vascular scaffolds for treatment of coronary artery disease. *Catheter Cardiovasc Interv.* 2016 Nov 29. doi: 10.1002/ccd.26832.

261. Piccolo R, Magnani G, Ariotti S, Gargiulo G, Marino M, Santucci A, Franzone A, Tebaldi M, Heg D, Windecker S, **Valgimigli M**. Ischemic and Bleeding Outcomes in Elderly Patients Undergoing a Prolonged versus Shortened Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention. Insights from the PRODIGY randomized trial. *EuroIntervention.* 2017 Jan 3;12(13).
262. Palmerini T, Della Riva D, Benedetto U, Bacchi Reggiani L, Feres F, Abizaid A, Gilard M, Morice MC, **Valgimigli M**, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Colombo A, Chieffo A, Sangiorgi D, Biondi-Zoccai G, G  n  reux P, Angelini GD, Pufulete M, White J, Bhatt DL, Stone GW. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. *Eur Heart J.* 2017 Jan 21. pii: ehw627. doi: 10.1093/eurheartj/ehw627.
263. Franzone A, O'Sullivan CJ, Stortecky S, Heg D, Lanz J, Vollenbroich R, Praz F, Piccolo R, Asami M, Roost E, R  ber L, **Valgimigli M**, Windecker S, Pilgrim T. Prognostic Impact of Invasive Hemodynamic Measurements in Combination with Clinical and Echocardiographic Characteristics on 2-year Clinical Outcomes of Patients undergoing Transcatheter Aortic Valve Implantation. *EuroIntervention.* 2017 Jan 25. pii: EIJ-D-16-00790. doi: 10.4244/EIJ-D-16-00790.
264. Nairooz R, **Valgimigli M**, Rochlani Y, Pothineni NV, Raina S, Sardar P, Mukherjee D, Naidu SS, Shavelle DM. Meta-analysis of clopidogrel pretreatment in acute coronary syndrome patients undergoing invasive strategy. *Int J Cardiol.* 2017 Feb 15;229:82-89.
265. Vollenbroich R, Stortecky S, Praz F, Lanz J, Franzone A, Zuk K, Heg D, **Valgimigli M**, O'Sullivan CJ, Heinisch C, Roost E, Wenaweser P, Windecker S, Pilgrim T. The impact of functional vs degenerative mitral regurgitation on clinical outcomes among patients undergoing transcatheter aortic valve implantation. *Am Heart J.* 2017 Feb;184:71-80.
266. Windecker S, Tijssen J, Giustino G, Guimar  es AH, Mehran R, **Valgimigli M**, Vranckx P, Welsh RC, Baber U, van Es GA, Wildgoose P, Volkl AA, Zazula A, Thomitzek K, Hemmrich M, Dangas GD. Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. *Am Heart J.* 2017 Feb;184:81-87.
267. Gargiulo G, Santucci A, Piccolo R, Franzone A, Ariotti S, Baldo A, Esposito G, Moschovitis A, Windecker S, **Valgimigli M**. Impact of chronic kidney disease on 2-year clinical outcomes in patients treated with 6-month or 24-month DAPT duration: An analysis from the PRODIGY trial. *Catheter Cardiovasc Interv.* 2017 Oct 1;90(4):E73-E84. doi: 10.1002/ccd.26921.

268. Ortega-Paz L, Brugaletta S, Giacchi G, Ishida K, Cequier A, Iñiguez A, Serra A, Jiménez-Quevedo P, Mainar V, Campo G, Tespili M, den Heijer P, **Valgimigli M**, Serruys PW, Sabaté M. Impact of stent overlapping on long-term clinical outcomes in patients with ST-segment elevation myocardial infarction: insights from the 5-year follow-up of the EXAMINATION trial. *EuroIntervention*. 2017 Feb 28. pii: EIJ-D-16-00512. doi: 10.4244/EIJ-D-16-00512.
269. Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, Zanchin T, Palmerini T, Wallentin L, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, **Valgimigli M** for the PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. *Lancet*. 2017 Mar 11;389(10073):1025-1034. doi: 10.1016/S0140-6736(17)30397-5.
270. Vranckx P, Frigoli E, Rothenbühler M, Tomassini F, Garducci S, Andò G, Picchi A, Sganzerla P, Paggi A, Ugo F, Ausiello A, Sardella G, Franco N, Nazzaro M, de Cesare N, Tosi P, Falcone C, Vigna C, Mazzarotto P, Di Lorenzo E, Moretti C, Campo G, Penzo C, Pasquetto G, Heg D, Jüni P, Windecker S, **Valgimigli M**; MATRIX Investigators. Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation. *Eur Heart J*. 2017 Apr 7;38(14):1069-1080. doi: 10.1093/eurheartj/ehx048.
271. Sciahbasi A, Frigoli E, Sarandrea A, Rothenbühler M, Calabrò P, Lupi A, Tomassini F, Cortese B, Rigattieri S, Cerrato E, Zavalloni D, Zingarelli A, Calabria P, Rubartelli P, Sardella G, Tebaldi M, Windecker S, Jüni P, Heg D, **Valgimigli M**. Radiation Exposure and Vascular Access in Acute Coronary Syndromes: The RAD-Matrix Trial. *J Am Coll Cardiol*. 2017 May 23;69(20):2530-2537. doi: 10.1016/j.jacc.2017.03.018.
272. **Valgimigli M**, Costa F, Lokhnygina Y, Clare RM, Wallentin L, Moliterno DJ, Armstrong PW, White HD, Held C, Aylward PE, Van de Werf F, Harrington RA, Mahaffey KW, Tricoci P. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. *Eur Heart J*. 2017 Mar 14;38(11):804-810. doi: 10.1093/eurheartj/ehw525.
273. Palmerini T, Bacchi Reggiani L, Della Riva D, Romanello M, Feres F, Abizaid A, Gilard M, Morice MC, **Valgimigli M**, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Colombo A, Chieffo A, Ahn JM, Park SJ, Schüpke S, Kastrati A, Montalescot G, Steg PG, Diallo A, Vicaut E, Helft G, Biondi-Zoccai G, Xu B, Han Y, Genereux P, Bhatt DL, Stone GW. Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. *J Am Coll Cardiol*. 2017 Apr 25;69(16):2011-2022. doi: 10.1016/j.jacc.2017.02.029.

274. Franzone A, Pilgrim T, Arnold N, Heg D, Langhammer B, Piccolo R, Roost E, Praz F, Räber L, **Valgimigli M**, Wenaweser P, Jüni P, Carrel T, Windecker S, Stortecky S. Rates and predictors of hospital readmission after transcatheter aortic valve implantation. *Eur Heart J*. 2017 Apr 18. doi: 10.1093/eurheartj/ehx182.
275. Head SJ, da Costa BR, Beumer B, Stefanini GG, Alfonso F, Clemmensen PM, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Kappetein AP, Kastrati A, Knuuti J, Kolh P, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Taggart DP, Torracca L, **Valgimigli M**, Wijns W, Witkowski A, Windecker S, Jüni P, Sousa-Uva M. Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis. *Eur J Cardiothorac Surg*. 2017 May 2. doi: 10.1093/ejcts/ezx115.
276. Andò G, Cortese B, Russo F, Rothenbühler M, Frigoli E, Gargiulo G, Briguori C, Vranckx P, Leonardi S, Guiducci V, Belloni F, Ferrari F, de la Torre Hernandez JM, Curello S, Liistro F, Perkan A, De Servi S, Casu G, Dellavalle A, Fischetti D, Micari A, Loi B, Mangiacapra F, Russo N, Tarantino F, Saia F, Heg D, Windecker S, Jüni P, **Valgimigli M**; MATRIX Investigators. Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management: AKI-MATRIX. *J Am Coll Cardiol*. 2017 May 11. pii: S0735-1097(17)36897-3. doi: 10.1016/j.jacc.2017.02.070.
277. Franzone A, Stortecky S, Räber L, Heg D, Yamaji K, Piccolo R, Asami M, Lanz J, Praz F, Koskinas K, Zanchin T, Wenaweser P, **Valgimigli M**, Jüni P, Pilgrim T, Windecker S. Effects of coronary artery disease in patients undergoing transcatheter aortic valve implantation: A study of age- and gender-matched cohorts. *Int J Cardiol*. 2017 May 17. pii: S0167-5273(17)30953-1. doi: 10.1016/j.ijcard.2017.05.071.
278. Piccolo R, Gargiulo G, Franzone A, Santucci A, Ariotti S, Baldo A, Tumscitz C, Moschovitis A, Windecker S, **Valgimigli M**. Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention. *Ann Intern Med*. 2017 Jun 13. doi: 10.7326/M16-2389.
279. Ariotti S, van Leeuwen M, Brugaletta S, Leonardi S, Akkerhuis KM, Rexhaj E, Janssens G, Ortega-Paz L, Rizzotti D, van den Berge JC, Heg D, Francolini G, Windecker S, **Valgimigli M**; HI-TECH Investigators. Rationale and design of the Hunting for the off-target properties of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH) trial. *Am Heart J*. 2017 Jul;189:128-136. doi: 10.1016/j.ahj.2017.03.017.
280. Giustino G, Harari R, Baber U, Sartori S, Stone GW, Leon MB, Windecker S, Serruys PW, Kastrati A, Von Birgelen C, Kimura T, Stefanini GG, Dangas GD, Wijns W, Steg PG, Morice MC, Camenzind E, Weisz G, Smits PC, Sorrentino S, Sharma M, Farhan S, Faggioni M, Kandzari D, Galatius S, Jeger RV, **Valgimigli M**, Itchhaporia D, Mehta L, Kim HS, Chieffo A, Mehran R. Long-term Safety and Efficacy

of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. *JAMA Cardiol.* 2017 Jun 28. doi: 10.1001/jamacardio.2017.1978.

281. van Boven N, van Domburg RT, Kardys I, Umans VA, Akkerhuis KM, Lenzen MJ, **Valgimigli M**, Daemen J, Zijlstra F, Boersma E, van Geuns RJ. Development and validation of a risk model for long-term mortality after percutaneous coronary intervention: The IDEA-BIO Study. *Catheter Cardiovasc Interv.* 2017 Jul 14. doi: 10.1002/ccd.27182.
282. Piccolo R, Pilgrim T, Franzone A, **Valgimigli M**, Haynes A, Asami M, Lanz J, Räber L, Praz F, Langhammer B, Roost E, Windecker S, Stortecky S. Frequency, Timing, and Impact of Access-Site and Non-Access-Site Bleeding on Mortality Among Patients Undergoing Transcatheter Aortic Valve Replacement. *JACC Cardiovasc Interv.* 2017 Jul 24;10(14):1436-1446. doi: 10.1016/j.jcin. 2017.04. 034.
283. Piccolo R, Feres F, Abizaid A, Gilard M, Morice MC, Hong MK, Kim HS, Colombo A, Bhatt DL, Palmerini T, Stone GW, Windecker S, **Valgimigli M**. Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis. *JACC Cardiovasc Interv.* 2017 Aug 28;10(16):1621-1630. doi: 10.1016/j.jcin. 2017. 06. 001.
284. Moscarella E, Spitaleri G, Brugaletta S, Sentí Farrarons S, Pernigotti A, Ortega-Paz L, Cequier A, Iñiguez A, Serra A, Jiménez-Quevedo P, Mainar V, Campo G, Tsepili M, den Heijer P, Bethencourt A, Vazquez N, **Valgimigli M**, Serruys PW, Sabaté M. Impact of Body Mass Index on 5-Year Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction After Everolimus-Eluting or Bare-Metal Stent Implantation. *Am J Cardiol.* 2017 Nov 1;120(9):1460-1466. doi: 10.1016/j.amjcard.2017.07.040.
285. Franzone A, Stortecky S, Pilgrim T, Asami M, Lanz J, Heg D, Langhammer B, Piccolo R, Lee JKT, Praz F, Räber L, **Valgimigli M**, Roost E, Windecker S. Incidence and impact of renal dysfunction on clinical outcomes after transcatheter aortic valve implantation. *Int J Cardiol.* 2017 Oct 3. pii: S0167-5273(17)33885-8. doi: 10.1016/j.ijcard.2017.09.201.
286. Damluji AA, Nelson DW, **Valgimigli M**, Windecker S, Byrne RA, Cohen F, Patel T, Brilakis ES, Banerjee S, Mayol J, Cantor WJ, Alfonso CE, Rao SV, Moscucci M, Cohen MG. Transfemoral Approach for Coronary Angiography and Intervention: A Collaboration of International Cardiovascular Societies. *JACC Cardiovasc Interv.* 2017 Nov 27;10(22):2269-2279. doi: 10.1016/j.jcin. 2017. 08. 035.
287. Iglesias JF, Muller O, Zaugg S, Roffi M, Kurz DJ, Vuilliamenet A, Weilenmann D, Kaiser C, Tapponnier M, Heg D, **Valgimigli M**, Eeckhout E, Jüni P, Windecker S, Pilgrim T. A comparison of an ultrathin strut biodegradable polymer sirolimus-eluting stent with a durable

polymer everolimus-eluting stent for patients with acute stsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial. *EuroIntervention*. 2017 Dec 5. pii: EIJ-D-17-00734. doi: 10.4244/EIJ-D-17-00734.

288. Faggioni M, Baber U, Afshar AE, Giustino G, Sartori S, Sorrentino S, Steg PG, Stefanini GG, Windecker S, Leon MB, Stone GW, Wijns W, Serruys PW, **Valgimigli M**, Camenzind E, Weisz G, Smits PC, Kandzari DE, Galatius S, Von Birgelen C, Jeger RV, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Dangas GD, Morice MC, Mehran R. Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Patient-Level Pooled Analysis of Randomized Controlled Trials. *JACC Cardiovasc Interv*. 2018 Jan 8;11(1):68-76. doi: 10.1016/j.jcin.2017.06.060. Epub 2017 Dec 13 .
289. Spitaleri G, Moscarella E, Brugaletta S, Pernigotti A, Ortega-Paz L, Gomez-Lara J, Cequier A, Iñiguez A, Serra A, Jiménez-Quevedo P, Mainar V, Campo G, Tsepili M, den Heijer P, Bethencourt A, Vazquez N, **Valgimigli M**, Serruys PW, Sabaté M. Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: insights from five-year follow-up of the EXAMINATION trial. *EuroIntervention*. 2018 Mar 20;13(16):1939-1945. doi: 10.4244/EIJ-D-17-00608.
290. Gargiulo G, Heg D, Ferrari F, Percoco G, Campo G, Tumscitz C, Colombo F, Zuffi A, Castriota F, Cremonesi A, Windecker S, **Valgimigli M**. Stent and Dual Antiplatelet Therapy Duration Comparisons in the Setting of a Multicenter Randomized Controlled Trial: Can the Operator Experience Affect the Study Results? *J Am Heart Assoc*. 2017 Dec 23;6(12). pii: e007150. doi: 10.1161/JAHA.117.007150.
291. Gargiulo G, Ariotti S, Vranckx P, Leonardi S, Frigoli E, Ciociano N, Tumscitz C, Tomassini F, Calabrò P, Garducci S, Crimi G, Andò G, Ferrario M, Limbruno U, Cortese B, Sganzerla P, Lupi A, Russo F, Garbo R, Ausiello A, Zavalloni D, Sardella G, Esposito G, Santarelli A, Tresoldi S, Nazzaro MS, Zingarelli A, Petronio AS, Windecker S, da Costa BR, **Valgimigli M**. Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management: Data From the Randomized MATRIX-Access Trial. *JACC Cardiovasc Interv*. 2018 Jan 8;11(1):36-50. doi: 10.1016/j.jcin. 2017.09.014.
292. Chandrasekhar J, Baber U, Sartori S, Stefanini GG, Sarin M, Vogel B, Farhan S, Camenzind E, Leon MB, Stone GW, Serruys PW, Wijns W, Steg PG, Weisz G, Chieffo A, Kastrati A, Windecker S, Morice MC, Smits PC, von Birgelen C, Mikhail GW, Itchhaporia D, Mehta L, Kim HS, **Valgimigli M**, Jeger RV, Kimura T, Galatius S, Kandzari D, Dangas G, Mehran R. Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis

of Randomized Trials From the WIN-DES Initiative. *JACC Cardiovasc Interv.* 2018 Jan 8;11(1):53-65. doi: 10.1016/j.jcin.2017.11.020.

293. A collaboration of international cardiovascular societies. Nelson DW, Damluji AA, Patel N, **Valgimigli M**, Windecker S, Byrne R, Nolan J, Patel T, Brilakis E, Banerjee S, Mayol J, Cantor WJ, Alfonso CE, Rao SV, Moscucci M, Cohen MG. Influence of operator experience and PCI volume on transfemoral access techniques: *Cardiovasc Revasc Med.* 2017 Dec 27. pii: S1553-8389(17)30468-2. doi: 10.1016/j.carrev.2017.12.013.
294. Komajda M, Kerneis M, Tavazzi L, Balanescu S, Cosentino F, Cremonesi A, Ferrari R, Kownator S, Szwed H, Mintale I, Olivari Z, Rittger H, Shlyakhto EV, Slapikas R, Steg PG, **Valgimigli M**, Van Belle E, Tsioufis K, Majda W, Laroche C, Maggioni AP; ESC-CICD Pilot Registry Investigators. The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up. *Eur J Prev Cardiol.* 2018 Mar;25(4):377-387. doi: 10.1177/2047487317751955. Epub 2018 Jan 16.
295. Pilgrim T, Lee JKT, O'Sullivan CJ, Stortecky S, Ariotti S, Franzone A, Lanz J, Heg D, Asami M, Praz F, Siontis GCM, Vollenbroich R, Räber L, **Valgimigli M**, Roost E, Windecker S. Early versus newer generation devices for transcatheter aortic valve implantation in routine clinical practice: a propensity score matched analysis. *Open Heart.* 2018 Jan 20;5(1):e000695. doi: 10.1136/openhrt-2017-000695. eCollection 2018.
296. Vranckx P, Lewalter T, **Valgimigli M**, Tijssen JG, Reimitz PE, Eckardt L, Lanz HJ, Zierhut W, Smolnik R, Goette A. Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial. *Am Heart J.* 2018 Feb;196:105-112. doi: 10.1016/j.ahj.2017.10.009. Epub 2017 Oct 23.
297. Sciahbasi A, Frigoli E, Sarandrea A, Calabrò P, Rubartelli P, Cortese B, Tomassini F, Zavalloni D, Tebaldi M, Calabria P, Rigattieri S, Zingarelli A, Sardella G, Lupi A, Rothenbühler M, Heg D, **Valgimigli M**. Determinants of radiation dose during right transradial access: Insights from the RAD-MATRIX study. *Am Heart J.* 2018 Feb;196:113-118. doi: 10.1016/j.ahj.2017.10.014. Epub 2017 Oct 28.
298. Hwang D, Park KW, Lee JM, Rhee TM, Hong MK, Jang Y, **Valgimigli M**, Colombo A, Gilard M, Palmerini T, Stone GW, Kim HS. Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease. *Am Heart J.* 2018 Mar;197:103-112. doi: 10.1016/j.ahj.2017.11.013. Epub 2017 Dec 6.
299. Spitaleri G, Tebaldi M, Biscaglia S, Westra J, Brugaletta S, Erriquez A, Passarini G, Brieda A, Leone AM, Picchi A, Ielasi A, Girolamo DD, Trani C, Ferrari R, Reiber JHC, **Valgimigli M**, Sabatè M, Campo G. Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients With ST-Segment-Eleva-

tion Myocardial Infarction and Multivessel Disease. *Circ Cardiovasc Interv.* 2018 Feb;11(2):e006023. doi: 10.1161/CIRCINTERVENTIONS.117.006023.

300. Lee SY, Hong MK, Palmerini T, Kim HS, **Valgimigli M**, Feres F, Colombo A, Gilard M, Shin DH, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Stone GW. Short-Term Versus Long-Term Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Elderly Patients: A Meta-Analysis of Individual Participant Data From 6 Randomized Trials. *JACC Cardiovasc Interv.* 2018 Mar 12;11(5):435-443. doi: 10.1016/j.jcin.2017.10.015. Epub 2018 Feb 14.
301. Asami M, Stortecky S, Praz F, Lanz J, Räber L, Franzone A, Piccolo R, Siontis GCM, Heg D, **Valgimigli M**, Wenaweser P, Roost E, Windecker S, Pilgrim T. Prognostic Value of Right Ventricular Dysfunction on Clinical Outcomes After Transcatheter Aortic Valve Replacement. *JACC Cardiovasc Imaging.* 2018 Feb 9. pii: S1936-878X(18)30012-3. doi: 10.1016/j.jcmg.2017.12.015.
302. Asami M, Lanz J, Stortecky S, Räber L, Franzone A, Heg D, Hunziker L, Roost E, Siontis GC, **Valgimigli M**, Windecker S, Pilgrim T. The Impact of Left Ventricular Diastolic Dysfunction on Clinical Outcomes After Transcatheter Aortic Valve Replacement. *JACC Cardiovasc Interv.* 2018 Mar 26;11(6):593-601. doi: 10.1016/j.jcin.2018.01.240. Epub 2018 Mar 2.
303. Andò G, Jolly SS, **Valgimigli M**. Operators' experience with radial access for cardiac catheterization in patients with acute coronary syndromes. *Int J Cardiol.* 2018 Apr 15;257:35. doi: 10.1016/j.ijcard.2017.10.034.
304. Angelillis M, Gargiulo G, Moschovitis A, Fürholz M, Shakir S, Piazza N, Räber L, Meier B, Gloekler S, Windecker S, **Valgimigli M**. Computed tomography detection and quantification of left atrial appendage residual patency as collateral finding after percutaneous closure. *Int J Cardiol.* 2018 Jun 1;260:42-46. doi: 10.1016/j.ijcard.2018.02.108. Epub 2018 Mar 3.
305. Koskinas KC, Nakamura M, Räber L, Colleran R, Kadota K, Capodanno D, Wijns W, Akasaka T, **Valgimigli M**, Guagliumi G, Windecker S, Byrne RA. Current use of intracoronary imaging in interventional practice - Results of a European Association of Percutaneous Cardiovascular Interventions (EAPCI) and Japanese Association of Cardiovascular Interventions and Therapeutics (CVIT) Clinical Practice Survey. *EuroIntervention.* 2018 Mar 15. pii: EIJY18M03_01. doi: 10.4244/EIJY18M03_01.
306. Koskinas KC, Nakamura M, Räber L, Colleran R, Kadota K, Capodanno D, Wijns W, Akasaka T, **Valgimigli M**, Guagliumi G, Windecker S, Byrne RA. Current Use of Intracoronary Imaging in Interventional Practice - Results of a European Association of Percutaneous Cardiovascular Interventions (EAPCI) and Japanese Association of Cardiovascular Interventions and Therapeutics (CVIT) Clinical Practice Survey. *Circ J.* 2018 Mar 15. doi: 10.1253/circj.CJ-17-1144.

307. Gargiulo G, Carrara G, Frigoli E, Vranckx P, Leonardi S, Ciociano N, Campo G, Varbella F, Calabrò P, Garducci S, Iannone A, Briguori C, Andò G, Crimi G, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Zavalloni D, Santarelli A, Sardella G, Tresoldi S, de Cesare N, Sciahbasi A, Zingarelli A, Tosi P, van 't Hof A, Omerovic E, Brugaletta S, Windecker S, **Valgimigli M**. Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes. *J Am Coll Cardiol*. 2018 Mar 20;71(11):1231-1242. doi: 10.1016/j.jacc.2018.01.033.
308. Ariotti S, van Leeuwen M, Brugaletta S, Leonardi S, Akkerhuis KM, Rimoldi SF, Janssens GN, Ortega-Paz L, Gianni U, van den Berge JC, Karagiannis A, Windecker S, **Valgimigli M**; HI-TECH Investigators. Effects of Ticagrelor, Prasugrel, or Clopidogrel at Steady State on Endothelial Function. *J Am Coll Cardiol*. 2018 Mar 20;71(11):1289-1291. doi: 10.1016/j.jacc.2018.01.027.
309. Spitaleri G, Brugaletta S, Scalone G, Moscarella E, Ortega-Paz L, Pernigotti A, Gomez-Lara J, Cequier A, Iñiguez A, Serra A, Jiménez-Quevedo P, Mainar V, Campo G, Tsepili M, den Heijer P, Bethencourt A, Vazquez N, **Valgimigli M**, Serruys PW, Sabaté M. Role of ST-Segment Resolution in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the 5-Year Outcomes of the EXAMINATION [Evaluation of the Xience-V Stent in Acute Myocardial Infarction] Trial). *Am J Cardiol*. 2018 Feb 7. pii: S0002-9149(18) 30157-7. doi: 10.1016/j.amjcard. 2018.01.015.
310. Ortega-Paz L, Brugaletta S, Ariotti S, Akkerhuis KM, Karagiannis A, Windecker S, **Valgimigli M**; Hunting for the off-target properties of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH) Investigators. Adenosine and Ticagrelor Plasma Levels in Patients With and Without Ticagrelor-Related Dyspnea. *Circulation*. 2018 May 24. pii: CIRCULATIONAHA.118.034489.
311. Lupi A, Bona RD, Meliga E, Capodanno D, Schaffer A, Bongo AS, Gaudio G, Guasti L, Alexopoulos D, **Valgimigli M**, Porto I. Early P2Y12 Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry. *Thromb Haemost*. 2018 Apr 4. doi: 10.1055/s-0038-1635578.
312. Bergmeijer TO, Reny JL, Pakyz RE, Gong L, Lewis JP, Kim EY, Aradi D, Fernandez-Cadenas I, Horenstein RB, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, Roden DM, Winter S, Altman RB, Alexopoulos D, Kim HS, Déry JP, Gawaz M, Bliden K, **Valgimigli M**, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Simon T, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, Siller-Matula JM, Ten Berg JM, Gurbel PA, Hulot JS, Mitchell BD, Schwab M, Ritchie MD, Klein TE, Shuldiner AR; ICPC Investigators. Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). *Am Heart J*. 2018 Apr;198:152-159. doi: 10.1016/j.ahj.2017.12.010. Epub 2017 Dec 17.

313. Zanchin T, Temperli F, Karagiannis A, Zanchin C, Räsänen M, Koskinas KC, Stortecky S, Hunziker L, Praz F, Blöchliger S, Moro C, Moschovitis A, Seiler C, Billinger M, Heg D, Pilgrim T, **Valgimigli M**, Windecker S, Räber L. Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice: Results From the Bern Percutaneous Coronary Intervention Registry. *Circ Cardiovasc Interv.* 2018 May;11(5):e006132. doi: 10.1161/CIRCINTERVENTIONS.117.006132.
314. Gargiulo G, da Costa BR, Frigoli E, Palmieri C, Nazzaro MS, Falcone C, Liso A, Vigna C, Abate F, Comeglio M, Diletti R, Gabrielli G, Di Lorenzo E, Mazzarotto P, Zimarino M, Moretti C, Colombo A, Penzo C, Pasquetto G, Brugaletta S, Ferrari F, Casu G, Guiducci V, Dellavalle A, Liistro F, Mauro C, Van't Hof AWJ, Omerovic E, Curello S, de la Torre Hernandez JM, De Servi S, Belloni F, Windecker S, **Valgimigli M**. Impact of Sex on Comparative Outcomes of Bivalirudin versus Unfractionated Heparin in Patients with Acute Coronary Syndromes Undergoing Invasive Management A pre-specified analysis of the MATRIX trial. *EuroIntervention.* 2018 May 15. pii: EIJ-D-18-00247. doi: 10.4244/EIJ-D-18-00247.
315. Morici N, Piccinelli E, Brunelli D, Sacco A, Viola G, Oreglia JA, Oliva F, **Valgimigli M**. Real-world application of currently available decision models for dual antiplatelet therapy duration in acute coronary syndrome. *J Cardiovasc Med (Hagerstown).* 2018 Jun;19(6):310-313.
316. Ariotti S, Ortega-Paz L, van Leeuwen M, Brugaletta S, Leonardi S, Akkerhuis KM, Rimoldi SF, Janssens G, Gianni U, van den Berge JC, Karagiannis A, Windecker S, **Valgimigli M**; HI-TECH Investigators Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study. *JACC Cardiovasc Interv.* 2018 May 17. pii: S1936-8798(18)30946-4
317. Degrauwe S, Roffi M, Lauriers N, Muller O, Giorgio Masci P, **Valgimigli M**, Iglesias JF. Influence of Intravenous Fentanyl Compared with Morphine on Ticagrelor Absorption and Platelet Inhibition in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Rationale and Design of the Perseus Randomized Trial. *Eur Heart J Cardiovasc Pharmacother.* 2018 Aug 8. doi: 10.1093/ehjcvp/pvy031
318. Schur N, Brugaletta S, Cequier A, Iñiguez A, Serra A, Jiménez-Quevedo P, Mainar V, Campo G, Tespili M, den Heijer P, Bethencourt A, Vazquez N, **Valgimigli M**, Serruys PW, Ademi Z, Schwenkglenks M, Sabaté M. Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial. *PLoS One.* 2018 Aug 16;13(8):e0201985. doi: 10.1371/journal.pone.0201985. eCollection 2018
319. Vranckx P, **Valgimigli M**, Jüni P, Hamm C, Steg G, Heg D, van Es GA, McFadden E, Onuma Y, van Meijeren C, Chichareon P, Benit E, Möllmann H, Janssens L, Ferrario M, Moschovitis A, Zurakowski A, Dominici M, Van Geuns RJ, Huber K, Slagboom T, Serruys PW,

Windecker S, on behalf of the GLOBAL LEADERS Investigators Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. *Lancet*. 2018 Aug 24. pii: S0140-6736

320. Ortega-Paz L, **Valgimigli M**. Reply: Pleiotropic Effects of Ticagrelor Beyond Its Potent Antiplatelet Effects Contributing to Additional Clinical Benefits. *JACC Cardiovasc Interv*. 2018 Sep 10;11(17):1785-1786. doi: 10.1016/j.jcin. 2018.06.041.
321. **Valgimigli M**, Frigoli E, Leonardi S, Vranckx P, Rothenbühler M, Tebaldi M, Varbella F, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andó G, Ferrario M, Limbruno U, Garbo R, Sganzerla P, Russo F, Naz-zaro M, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Ferrante G, Santarelli A, Sardella G, de Cesare N, Tosi P, van 't Hof A, Omerovic E, Brugaletta S, Windecker S, Heg D, Jüni P, on behalf of the MATRIX Investigators Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. *Lancet*. 2018 Sep 8;392(10150):835-848
322. Van Mieghem NM, Unverdorben M, **Valgimigli M**, Mehran R, Boersma E, Baber U, Hengstenberg C, Shi M, Chen C, Saito S, Veltkamp R, Vranckx P, Dangas GD. Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial. *Am Heart J*. 2018 Aug 29;205:63-69
323. Andò G, Gragnano F, Calabrò P, **Valgimigli M**. Radial vs femoral access for the prevention of acute kidney injury (AKI) after coronary angiography or intervention: A systematic review and meta-analysis. *Catheter Cardiovasc Interv*. 2018 Sep 23. doi: 10.1002/ccd.27903.
324. Katsikis A, Chichareon P, Cavalcante R, Collet C, Modolo R, Onuma Y, Stankovic G, Louvard Y, Vranckx P, **Valgimigli M**, Windecker S, Serruys PW. Application of the MADS classification system in a “mega mammoth” stent trial: Feasibility and preliminary clinical implications. *Catheter Cardiovasc Interv*. 2018 Oct 5. doi: 10.1002/ccd.27461.
325. Gargiulo G, Patialiakas A, Piccolo R, Thury A, Colangelo S, Campo G, Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga E, Testa L, Gabriel HM, Ferlini M, Liistro F, Dellavalle A, Vranckx P, Briguori C, Windecker S, **Valgimigli M**. Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates. *Int J Cardiol*. 2019 Feb 15; 277:60-65. doi: 10.1016/j.ijcard.2018.09.120. Epub 2018 Oct 2
326. Yamaji K, Zanchin T, Zanchin C, Stortecky S, Koskinas KC, Hunziker L, Praz F, Blöchliger S, Moro C, Moschovitis A, Seiler C, **Valgimigli**

- M**, Billinger M, Pilgrim T, Heg D, Windecker S, Räber L. Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization. *Circ Cardiovasc Interv.* 2018 Sep;11(9):e006741. doi: 10.1161/CIRCINTERVENTIONS.118.006741.
327. Asami M, Pilgrim T, Lanz J, Heg D, Franzone A, Piccolo R, Langhammer B, Praz F, Räber L, **Valgimigli M**, Roost E, Windecker S, Storteky S. Prognostic Relevance of Left Ventricular Myocardial Performance After Transcatheter Aortic Valve Replacement. *Circ Cardiovasc Interv.* 2019 Jan;12(1):e006612. doi: 10.1161/CIRCINTERVENTIONS.118.006612.
 328. Kang J, Park KW, Palmerini T, Stone GW, Lee MS, Colombo A, Chieffo A, Feres F, Abizaid A, Bhatt DL, **Valgimigli M**, Hong MK, Jang Y, Gilard M, Morice MC, Park DW, Park SJ, Jeong YH, Park J, Koo BK, Kim HS. Racial Differences in Ischaemia/Bleeding Risk Trade-Off during Anti-Platelet Therapy: Individual Patient Level Landmark Meta-Analysis from Seven RCTs. *Thromb Haemost.* 2019 Jan;119(1):149-162. Epub 2018 Dec 31.
 329. van Leeuwen MAH, van der Hoeven NW, Janssens GN, Everaars H, Nap A, Lemkes JS, de Waard GA, van de Ven PM, van Rossum AC, Ten Cate TJF, Piek JJ, von Birgelen C, Escaned J, **Valgimigli M**, Diletti R, Riksen NP, Van Mieghem NM, Nijveldt R, van Royen N. Evaluation of Microvascular Injury in Revascularized Patients with ST Elevation Myocardial Infarction Treated with Ticagrelor versus Prasugrel: The REDUCE-MVI Trial. *Circulation.* 2018 Oct 30. doi: 10.1161/CIRCULATIONAHA.118.035931.
 330. Rothenbühler M, **Valgimigli M**, Odutayo A, Frigoli E, Leonardi S, Vranckx P, Turturo M, Moretti L, Amico F, Uguccioni L, Contarini M, Gómez-Hospital JA, Mainar V, Creaco M, Petronio AS, Cremonesi A, Tamburino C, Fresco C, Bonmassari R, Díaz Fernández JF, Romagnoli E, Beyersmann J, Heg D, Jüni P. Association of acute kidney injury and bleeding events with mortality after radial or femoral access in patients with acute coronary syndrome undergoing invasive management: secondary analysis of a randomized clinical trial. *Eur Heart J.* 2019 Jan 26.
 331. Frigoli E, Smits P, Vranckx P, Ozaki Y, Tijssen J, Jüni P, Morice MC, Onuma Y, Windecker S, Frenk A, Spaulding C, Chevalier B, Barbato E, Tonino P, Hildick-Smith D, Roffi M, Kornowski R, Schultz C, Lesiak M, Iñiguez A, Colombo A, Alasnag M, Mallasari A, James S, Stankovic G, Ong PJJ, Rodriguez AE, Mahfoud F, Bartunek J, Moschovitis A, Laanmets P, Leonardi S, Heg D, Sunnåker M, **Valgimigli M**. Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study *Am Heart J.* 2019 Mar;209:97-105.
 332. Costa F, Van Klaveren D, Feres F, James S, Räber L, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, Bhatt DL, Stone GW, Windecker

S, Steyerberg EW, **Valgimigli M**; PRECISE-DAPT Study Investigators. Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. *J Am Coll Cardiol*. 2019 Feb 26;73(7):741-754. doi: 10.1016/j.jacc.2018.11.048.

333. Gargiulo G, Carrara G, Frigoli E, Leonardi S, Vranckx P, Campo G, Varbella F, Calabrò P, Zaro T, Bartolini D, Briguori C, Andò G, Ferrario M, Limbruno U, Colangelo S, Sganzerla P, Russo F, Nazzaro MS, Esposito G, Ferrante G, Santarelli A, Sardella G, Windecker S, **Valgimigli M**. Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome *J Am Coll Cardiol*. 2019 Feb 26;73(7):758-774. doi: 10.1016/j.jacc.2018.12.023.
334. Lanz J, Wyss D, Räber L, Stortecky S, Hunziker L, Blöchliger S, Reineke D, Englberger L, Zanchin T, **Valgimigli M**, Heg D, Windecker S, Pilgrim T. Mechanical complications in patients with ST-segment elevation myocardial infarction: A single centre experience *PLoS One*. 2019 Feb 22;14(2):e0209502. doi: 10.1371/journal.pone.0209502. eCollection 2019.
335. Chichareon P, Modolo R, van Klaveren D, Takahashi K, Kogame N, Chang CC, Katagiri Y, Tomaniak M, Asano T, Spitzer E, Buszman P, Prokopczuk J, Fath-Ordoubadi F, Buysschaert I, Anderson R, Oldroyd KG, Merkely B, Garg S, Wykrzykowska JJ, Piek JJ, Jüni P, Hamm C, Steg PG, **Valgimigli M**, Vranckx P, Windecker S, Onuma Y, Serruys PW. Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS study *Int J Cardiol*. 2019 Feb 20. pii: S0167-5273(18)36315-0. doi: 10.1016/j.ijcard.2019.02.043.
336. Leonardi S, Franzone A, Piccolo R, McFadden E, Vranckx P, Serruys P, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, van Geuns RJ, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopczuk J, Hamm C, Steg G, Heg D, Juni P, Windecker S, **Valgimigli M**. Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-Study (GLASSY). *BMJ Open*. 2019 Mar 9;9(3):e026053. doi: 10.1136/bmjopen-2018-026053
337. Palmerini T, Bruno AG, Gilard M, Morice MC, **Valgimigli M**, Montalescot G, Collet JP, Della Riva D, Bacchi-Reggiani ML, Steg PG, Diallo A, Vicaute E, Helft G, Nakamura M, G  n  reux P, Vahl TP, Stone GW. Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation. *Circ Cardiovasc Interv*. 2019 Mar;12(3):e007541. doi: 10.1161/CIRCINTERVENTIONS.118.007541.
338. Picchi A, Garcia-Garcia HM, Sardella G, Adamo M, Frigoli E, Limbruno U, Rigattieri S, Diletti R, Boccuzzi G, Zimarino M, Contarini M, Russo F, Calabro P, And   G, Varbella F, Garducci S, Palmieri C,

Briguori C, Kuku KO, Rothenbühler M, Karagiannis A, **Valgimigli M**. OCT Appraisal of Residual Thrombus Burden in Patients With STEMI Undergoing Intraprocedural Versus Post-Stenting Prolonged Bivalirudin Infusion: The MATRIX OCT Study. *JACC Cardiovasc Imaging*. 2019 May;12(5):934-936. doi: 10.1016/j.jcmg.2018.10.030. Epub 2019 Jan 16.

339. Garcia-Garcia HM, Picchi A, Sardella G, Adamo M, Frigoli E, Limbruno U, Rigattieri S, Diletti R, Boccuzzi G, Zimarino M, Contarini M, Russo F, Calabro' P, Andò G, Varbella F, Garducci S, Palmieri C, Briguori C, Kuku KO, Rothenbühler M, Karagiannis A, **Valgimigli M**. Comparison of intra-procedural vs. post-stenting prolonged bivalirudin infusion for residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing: the MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and angioX) OCT study. *Eur Heart J Cardiovasc Imaging*. 2019 Dec 1;20(12):1418-1428. doi: 10.1093/ehjci/jez040. PMID: 30920584.
340. Siontis GC, Branca M, Serruys P, Silber S, Räber L, Pilgrim T, **Valgimigli M**, Heg D, Windecker S, Hunziker L. Impact of left ventricular function on clinical outcomes among patients with coronary artery disease. *Eur J Prev Cardiol*. 2019 Aug;26(12):1273-1284. doi: 10.1177/2047487319841939. Epub 2019 Apr 9.
341. Ueki Y, Karagiannis A, Zanchin C, Zanchin T, Stortecky S, Koskinas KC, Siontis GCM, Praz F, Otsuka T, Hunziker L, Heg D, Moschovitis A, Seiler C, Billinger M, Pilgrim T, **Valgimigli M**, Windecker S, Räber L. Validation of High-Risk Features for Stent-Related Ischemic Events as Endorsed by the 2017 DAPT Guidelines. *JACC Cardiovasc Interv*. 2019 May 13;12(9):820-830. doi: 10.1016/j.jcin. 2018.12.005. Epub 2019 Apr 10.
342. Mavranakos TA, Chatzizisis YS, Gariani K, Kereiakes DJ, Gargiulo G, Helft G, Gilard M, Feres F, Costa RA, Morice MC, Georges JL, **Valgimigli M**, Bhatt DL, Mauri L, Charytan DM. Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-Analysis. *Clin J Am Soc Nephrol*. 2019 Jun 7;14(6):810-822. doi: 10.2215/CJN.12901018. Epub 2019 Apr 22.
343. Piccolo R, Bonaa KH, Efthimiou O, Varenne O, Baldo A, Urban P, Kaiser C, Remkes W, Räber L, de Belder A, van 't Hof AWJ, Stankovic G, Lemos PA, Wilsgaard T, Reifart J, Rodriguez AE, Ribeiro EE, Serruys PWJC, Abizaid A, Sabaté M, Byrne RA, de la Torre Hernandez JM, Wijns W, Juni P, Windecker S, **Valgimigli M**; Coronary Stent Trialists' Collaboration. Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. *Lancet*. 2019 Jun 22;393(10190):2503-2510. doi: 10.1016/S0140-6736(19)30474-X. Epub 2019 May 2.
344. Morici N, Tavecchia GA, Antolini L, Caporale MR, Cantoni S, Bertuccio P, Sacco A, Meani P, Viola G, Brunelli D, Oliva F, Lombardi F, Segreto A, Oreglia JA, La Vecchia C, Cattaneo M, **Valgimigli M**, Savonitto

S. Use of PRECISE-DAPT Score and Admission Platelet Count to Predict Mortality Risk in Patients With Acute Coronary Syndrome. *Angiology*. 2019 Oct;70(9):867-877. doi: 10.1177/ 0003319719848547. Epub 2019 May 14.

345. Cammaroto G, Costa F, Ruiz MVG, Andò G, Vicini C, Montevecchi F, Galletti C, Galletti F, **Valgimigli M**. Obstructive sleep apnoea syndrome and endothelial function: potential impact of different treatment strategies-meta-analysis of prospective studies. *Eur Arch Otorhinolaryngol*. 2019 Aug;276(8):2331-2338. doi: 10.1007/s00405-019-05486-6. Epub 2019 Jun 13.
346. Chichareon P, Onuma Y, van Klaveren D, Modolo R, Kogame N, Takahashi K, Chang CC, Tomaniak M, Asano T, Katagiri Y, van Geuns RM, Bolognese L, Tumscitz C, Vrolix M, Petrov I, Garg S, Naber CK, Sabaté M, Iqbal J, Wykrzykowska JJ, Piek JJ, Spitzer E, Jüni P, Hamm C, Steg PG, **Valgimigli M**, Vranckx P, Windecker S, Serruys PW. Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial. *EuroIntervention*. 2019 Aug 9;15(6):e539-e546. doi: 10.4244/EIJ-D-19-00184.
347. Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. *Lancet Diabetes Endocrinol*. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Erratum in: *Lancet Diabetes Endocrinol*. 2019 Jul 8;.. *Lancet Diabetes Endocrinol*. 2019 Jul 29.
348. Baber U, Stefanini GG, Giustino G, Stone GW, Leon MB, Sartori S, Aquino M, Steg PG, Windecker S, Wijns W, Serruys PW, **Valgimigli M**, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari DE, von Birgelen C, Dangas GD, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Mehran R. Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. *Circ Cardiovasc Interv*. 2019 Jul;12(7):e007734. doi: 10.1161 / CIRCINTERVENTIONS. 118.007734. Epub 2019 Jul 10.
349. Serruys PW, Takahashi K, Chichareon P, Kogame N, Tomaniak M, Modolo R, Chang CC, Komiyama H, Soliman O, Wykrzykowska JJ, de Winter RJ, Ferrario M, Dominici M, Buszman P, Bolognese L, Tumscitz C, Benit E, Stoll HP, Hamm C, Steg PG, Onuma Y, Jüni P, Windecker S, Vranckx P, Colombo A, **Valgimigli M**. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. *Eur Heart J*. 2019 Aug 14;40(31):2595-2604. doi: 10.1093/eurheartj/ehz453.

350. Zanchin C, Ueki Y, Zanchin T, Häner J, Otsuka T, Stortecky S, Koskinas KC, Siontis GCM, Praz F, Moschovitis A, Hunziker L, **Valgimigli M**, Pilgrim T, Heg D, Windecker S, Räber L. Everolimus-Eluting Biodegradable Polymer Versus Everolimus-Eluting Durable Polymer Stent for Coronary Revascularization in Routine Clinical Practice. *JACC Cardiovasc Interv.* 2019 Sep 9;12(17):1665-1675. doi: 10.1016/j.jcin.2019.04.046. Epub 2019 Aug 14.
351. Iglesias JF, Muller O, Heg D, Roffi M, Kurz DJ, Moarof I, Weilenmann D, Kaiser C, Tapponnier M, Stortecky S, Losdat S, Eeckhout E, **Valgimigli M**, Odutayo A, Zwahlen M, Jüni P, Windecker S, Pilgrim T. Biodegradable polymer sirolimus- eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. *Lancet.* 2019 Oct 5;394(10205):1243-1253. doi: 10.1016/S0140-6736(19)31877-X. Epub 2019 Sep 2. PMID: 31488372.
352. Costa F, Brugaletta S, Pernigotti A, Flores-Ulmanzor E, Ortega-Paz L, Cequier A, Iniguez A, Serra A, Jiménez-Quevedo P, Mainar V, Campo G, Tsepili M, den Heijer P, Bethencourt A, Vazquez N, van Es GA, Backx B, **Valgimigli M**, Serruys P, Sabaté M. Does Large Vessel Size Justify Use of Bare-Metal Stents in Primary Percutaneous Coronary Intervention? *Circ Cardiovasc Interv.* 2019 Sep;12(9):e007705. doi: 10.1161/CIRCINTERVENTIONS.118.007705. Epub 2019 Aug 27.
353. Iglesias JF, Muller O, Heg D, Roffi M, Kurz DJ, Moarof I, Weilenmann D, Kaiser C, Tapponnier M, Stortecky S, Losdat S, Eeckhout E, **Valgimigli M**, Odutayo A, Zwahlen M, Jüni P, Windecker S, Pilgrim T. Biodegradable polymer sirolimus- eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. *Lancet.* 2019 Oct 5;394(10205):1243-1253. doi: 10.1016/S0140-6736(19)31877-X. Epub 2019 Sep 2. PMID: 31488372.
354. Gragnano F, Spedicato V, Frigoli E, Gargiulo G, Di Maio D, Fimiani F, Fioretti V, Annoiato C, Cimmino M, Esposito F, Chianese S, Scalise M, Fimiani L, Franzese M, Monda E, Schiavo A, Cesaro A, De Michele A, Scalise R, Caracciolo A, Andò G, Stabile E, Windecker S, Calabrò P, **Valgimigli M**. ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial. *J Electrocardiol.* 2019 Nov-Dec;57:44-54. doi: 10.1016/j.jelectrocard.2019.08.045. Epub 2019 Aug 28. PMID: 31491602.
355. Vranckx P, **Valgimigli M**, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, Batushkin V, Campo G, Lysak Z, Vakaliuk I, Milewski K, Laeis P, Reimitz PE, Smolnik R, Zierhut W, Goette A. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. *Lancet.* 2019 Oct 12;394(10206):1335-1343. doi: 10.1016/S0140-6736(19)31872-0. Epub 2019 Sep 3. PMID: 31492505.

356. Tomaniak M, Chichareon P, Onuma Y, Deliargyris EN, Takahashi K, Kogame N, Modolo R, Chang CC, Rademaker-Havinga T, Storey RF, Dangas GD, Bhatt DL, Angiolillo DJ, Hamm C, **Valgimigli M**, Windecker S, Steg PG, Vranckx P, Serruys PW; GLOBAL LEADERS Trial Investigators. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial. *JAMA Cardiol.* 2019 Nov 1;4(11):1092-1101. doi: 10.1001/jamacardio.2019.3355. PMID: 31557763; PMCID: PMC6764000.
357. Takahashi K, Serruys PW, Chichareon P, Chang CC, Tomaniak M, Modolo R, Kogame N, Magro M, Chowdhary S, Eitel I, Zweiker R, Ong P, Ottesen MM, Tijssen JGP, Wykrzykowska JJ, de Winter RJ, Garg S, Stoll HP, Hamm C, Steg PG, Onuma Y, **Valgimigli M**, Vranckx P, Carrie D, Windecker S. Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI. *J Am Coll Cardiol.* 2019 Oct 22;74(16):2015-2027. doi: 10.1016/j.jacc.2019.08.997. PubMed PMID: 31623758.
358. Gragnano F, Manavifar N, Gargiulo G, Sunnåker M, Galea R, Frigoli E, Calabrò P, Windecker S, **Valgimigli M**. Femoral Access With or Without Vascular Closure Device or Radial Access in Acute Coronary Syndrome. *JACC Cardiovasc Interv.* 2019 Oct 28;12(20):2116-2118. doi: 10.1016/j.jcin.2019.06.027. PubMed PMID: 31648772.
359. Franzone A, McFadden E, Leonardi S, Piccolo R, Vranckx P, Serruys PW, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, Diletti R, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopczuk J, Hamm C, Steg PG, Heg D, Jüni P, Windecker S, **Valgimigli M**; GLASSY Investigators. Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. *J Am Coll Cardiol.* 2019 Nov 5;74(18):2223-2234. doi: 10.1016/j.jacc.2019.08.1038. PubMed PMID: 31672177.
360. Okuno T, Khan F, Asami M, Praz F, Heg D, Winkel MG, Lanz J, Huber A, Gräni C, Räber L, Stortecky S, **Valgimigli M**, Windecker S, Pilgrim T. Prosthesis-Patient Mismatch Following Transcatheter Aortic Valve Replacement With Supra-Annular and Intra-Annular Prostheses. *JACC Cardiovasc Interv.* 2019 Nov 11;12(21):2173-2182. doi: 10.1016/j.jcin.2019.07.027. Epub 2019 Sep 26. PubMed PMID: 31564593.
361. Iglesias JF, Heg D, Roffi M, Tüller D, Lanz J, Rigamonti F, Muller O, Moarof I, Cook S, Weilenmann D, Kaiser C, Cuculi F, **Valgimigli M**, Jüni P, Windecker S, Pilgrim T. Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents. *J Am Heart Assoc.* 2019 Nov 19;8(22):e013607. doi: 10.1161/JAHA.119.013607. Epub 2019 Nov 7. PubMed PMID: 31696762; PubMed Central PMCID: PMC6915288.
362. Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P, **Valgimigli M**. Safety and efficacy outcomes of double vs. triple anti-

thrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. *Eur Heart J*. 2019 Dec 7;40(46):3757-3767. doi: 10.1093/eurheartj/ehz732. PubMed PMID: 31651946.

363. Chang CC, Spitzer E, Chichareon P, Takahashi K, Modolo R, Kogame N, Tomaniak M, Komiyama H, Yap SC, Hoole SP, Gori T, Zaman A, Frey B, Ferreira RC, Bertrand OF, Koh TH, Sousa A, Moschovitis A, van Geuns RJ, Steg PG, Hamm C, Jüni P, Vranckx P, **Valgimigli M**, Windecker S, Serruys PW, Soliman O, Onuma Y. Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial). *Am J Cardiol*. 2019 Dec 15;124(12):1833-1840. doi: 10.1016/j.amjcard.2019.08.049. Epub 2019 Sep 26. PubMed PMID: 31648781.
364. Potpara TS, Mujovic N, Proietti M, Dagres N, Hindricks G, Collet JP, **Valgimigli M**, Heidbuchel H, Lip GYH. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. *Europace*. 2020 Jan 1;22(1):33-46. doi: 10.1093/europace/euz259. Erratum in: *Europace*. 2020 Feb 1;22(2):176. PubMed PMID: 31603196.
365. Chang CC, Chichareon P, Modolo R, Takahashi K, Kogame N, Tomaniak M, Gao C, Royaards KJ, Cequier A, Oldroyd K, Steg PG, Hamm C, Jüni P, **Valgimigli M**, Windecker S, Onuma Y, Stables RH, Jan van Geuns R, Serruys PW. Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study. *Eur Heart J Cardiovasc Pharmacother*. 2020 Jan 1;6(1):22-30. doi: 10.1093/ehjcvp/pvz051. PubMed PMID: 31841136.
366. Dargas GD, Tijssen JGP, Wöhrle J, Søndergaard L, Gilard M, Möllmann H, Makkar RR, Herrmann HC, Giustino G, Baldus S, De Backer O, Guimarães AHC, Gullestad L, Kini A, von Lewinski D, Mack M, Moreno R, Schäfer U, Seeger J, Tchétché D, Thomitzek K, **Valgimigli M**, Vranckx P, Welsh RC, Wildgoose P, Volkl AA, Zazula A, van Amsterdam RGM, Mehran R, Windecker S; GALILEO Investigators. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. *N Engl J Med*. 2020 Jan 9;382(2):120-129. doi: 10.1056/NEJMoa1911425. Epub 2019 Nov 16. PubMed PMID: 31733180.
367. Tomaniak M, Chichareon P, Takahashi K, Kogame N, Modolo R, Chang CC, Spitzer E, Neumann FJ, Plante S, Hernández Antolin R, Jambrik Z, Gelev V, Brunel P, Konteva M, Beygui F, Morelle JF, Filipiak KJ, van Geuns RJ, Soliman O, Tijssen J, Rademaker-Havinga T, Storey RF, Hamm C, Steg PG, Windecker S, Onuma Y, **Valgimigli M**, Serruys PW. Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial. *Eur*

Heart J Cardiovasc Pharmacother. 2020 Jul1;6(4):222-230 doi: 10.1093/ehjcvp/pvz052 PubMed PMID: 31876907.

368. Tomaniak M, Chichareon P, Klimczak-Tomaniak D, Takahashi K, Kogame N, Modolo R, Wang R, Ono M, Hara H, Gao C, Kawashima H, Rademaker-Havinga T, Garg S, Curzen N, Haude M, Kochman J, Gori T, Montalescot G, Angiolillo DJ, Capodanno D, Storey RF, Hamm C, Vranckx P, **Valgimigli M**, Windecker S, Onuma Y, Serruys PW, Anderson R. Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. Clin Res Cardiol. 2020 Jul;109(7):930-943. PMID: 31925529.
369. Costa F, van Klaveren D, Colombo A, Feres F, Räber L, Pilgrim T, Hong MK, Kim HS, Windecker S, Steyerberg EW, **Valgimigli M**; PRECISE-DAPT Study Investigators. A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making. Am Heart J. 2020 May;223:44-47 PMID: 32151822.
370. Kleinecke C, Yu J, Neef P, Buffle E, de Marchi S, Fuerholz M, Nietlispach F, **Valgimigli M**, Streit SR, Fankhauser M, Duenninger E, indecker S, Meier B, Gloekler S. Clinical outcomes of Watchman vs. Amplatzer occluders for left atrial appendage closure (WATCH at LAAC). Europace. 2020 Jun1;22(6):916-923 doi: 10.1093/europace/ euaa001. PubMed PMID: 32003774.
371. Ono M, Chichareon P, Tomaniak M, Kawashima H, Takahashi K, Kogame N, Modolo R, Hara H, Gao C, Wang R, Walsh S, Suryapranata H, da Silva PC, Cotton J, Koning R, Akin I, Rensing BJWM, Garg S, Wykrzykowska JJ, Piek JJ, Jüni P, Hamm C, Steg PG, **Valgimigli M**, Windecker S, Storey RF, Onuma Y, Vranckx P, Serruys PW. The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial. Clin Res Cardiol. 2020 Sep;109(9):1125-1139 PMID: 32006156; PMCID: PMC7449952.
372. Bikdeli B, McAndrew T, Crowley A, Chen S, Mehdipoor G, Redfors B, Liu Y, Zhang Z, Liu M, Zhang Y, Francese DP, Erlinge D, James SK, Han Y, Li Y, Kastrati A, Schüpke S, Stables RH, Shahzad A, Steg PG, Goldstein P, Frigoli E, Mehran R, **Valgimigli M**, Stone GW. Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. Thromb Haemost. 2020 Feb;120(2):348-362. doi: 10.1055/s-0039-1700872. Epub 2019 Dec 9. PubMed PMID: 31820428; PubMed Central PMCID: PMC7040882.
373. Chichareon P, Modolo R, Kogame N, Takahashi K, Chang CC, Tomaniak M, Botelho R, Eeckhout E, Hofma S, Trendafilova-Lazarova D, Kőszegi Z, Iñiguez A, Wykrzykowska JJ, Piek JJ, Garg S, Hamm C, Steg PG, Jüni P, Vranckx P, **Valgimigli M**, Windecker S, Onuma Y, Serruys PW. Association of diabetes with outcomes in patients un-

dergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study. *Atherosclerosis*. 2020 Feb;295:45-53. doi: 10.1016/j.atherosclerosis.2020.01.002. Epub 2020 Jan 15. PubMed PMID: 32006758.

374. Bianco M, D'ascenzo F, Raposeiras Roubin S, Kinnaird T, Peyracchia M, Ariza-Solé A, Cerrato E, Manzano-Fernández S, Gravinese C, Templin C, Destefanis P, Velicki L, Luciano A, Xanthopoulou I, Rinaldi M, Rognoni A, Varbella F, Boccuzzi G, Omedè P, Montabone A, Bernardi A, Taha S, Rossini R, Durante A, Gili S, Magnani G, Autelli M, Grosso A, Blanco PF, Giustetto C, Garay A, Quadri G, Queija BC, Srdanovic I, Paz RC, Fernández MC, Pousa IM, Gallo D, Morbiducci U, Dominguez-Rodriguez A, Lopez-Cuenca Á, Cequier A, Alexopoulos D, Iñiguez-Romo A, Pozzi R, Assi EA, **Valgimigli M**. Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor. *Int J Cardiol*. 2020 Feb 15;301:200-206. doi: 10.1016/j.ijcard.2019.11.132. Epub 2019 Nov 22. PubMed PMID: 31785951.
375. Ueki Y, Bär S, Losdat S, Otsuka T, Zanchin C, Zanchin T, Gragnano F, Gargiulo G, Siontis GCM, Praz F, Lanz J, Hunziker L, Stortecky S, Pilgrim T, Heg D, **Valgimigli M**, Windecker S, Räber L. Validation of Bleeding Risk Criteria (ARC-HBR) in Patients Undergoing Percutaneous Coronary Intervention and Comparison with Contemporary Bleeding Risk Scores. *EuroIntervention*. 2020 Aug 28;16(5):371-379. PMID: 32065586.
376. van der Hoeven NW, Janssens GN, Everaars H, Nap A, Lemkes JS, de Waard GA, van de Ven PM, van Rossum AC, Escaned J, Mejia-Renteria H, Ten Cate TJF, Piek JJ, von Birgelen C, **Valgimigli M**, Diletti R, Riksen NP, Van Mieghem NM, Nijveldt R, van Leeuwen MAH, van Royen N. Platelet Inhibition, Endothelial Function, and Clinical Outcome in Patients Presenting With ST-Segment-Elevation Myocardial Infarction Randomized to Ticagrelor Versus Prasugrel Maintenance Therapy: Long-Term Follow-Up of the REDUCE-MVI Trial. *J Am Heart Assoc*. 2020 Mar 3;9(5):e014411. doi: 10.1161/JAHA.119.014411. Epub 2020 Mar 3. PubMed PMID: 32122216.
377. Lopes RD, Leonardi S, Wojdyla DM, Vora AN, Thomas L, Storey RF, Vinereanu D, Granger CB, Goodman SG, Aronson R, Windecker S, Thiele H, **Valgimigli M**, Mehran R, Alexander JH. Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. *Circulation*. 2020 Mar 3;141(9):781-783. doi: 10.1161/CIRCULATIONAHA.119.044584. Epub 2019 Nov 11. PubMed PMID: 31707833.
378. Gargiulo G, **Valgimigli M**, Sunnåker M, Vranckx P, Frigoli E, Leonardi S, Spirito A, Gragnano F, Manavifar N, Galea R, De Caterina AR, Calabrò P, Esposito G, Windecker S, Hunziker L. Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest. *Rev Esp Cardiol (Engl Ed)*. 2020

Nov;73(11):893-901. English, Spanish. doi: 10.1016/j.rec.2020.01.005. Epub 2020 Mar 6. PMID: 32151464.

379. Chichareon P, Modolo R, Kawashima H, Takahashi K, Kogame N, Chang CC, Tomaniak M, Ono M, Walsh S, Suryapranata H, Cotton J, Koning R, Akin I, Kukreja N, Wykrzykowska J, Piek JJ, Garg S, Hamm C, Steg PG, Jüni P, Vranckx P, **Valgimigli M**, Windecker S, Onuma Y, Serruys PW. DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI. *JACC Cardiovasc Interv.* 2020 Mar 9;13(5):634-646. doi: 10.1016/j.jcin.2019.12.018. PubMed PMID: 32139222.
380. Sorrentino S, Claessen BE, Chandiramani R, Guedeney P, Vogel B, Baber U, Rau V, Wang J, Krucoff M, Kozuma K, Ge J, Seth A, Makkar R, Liu Y, Bangalore S, Bhatt DL, Angiolillo DJ, Saito S, Neumann FJ, Hermiller J, **Valgimigli M**, Mehran R. Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies. *Circulation.* 2020 Mar 17;141(11):891-901. doi: 10.1161/CIRCULATIONAHA.119.041619. Epub 2020 Jan 29. PubMed PMID: 31992063.
381. Tomaniak M, Chichareon P, Modolo R, Takahashi K, Chang CC, Kogame N, Spitzer E, Buszman PE, van Geuns RM, Valkov V, Steinwender C, Geisler T, Prokopczuk J, Sabaté M, Zmudka K, Rademaker-Havinga T, Tijssen JGP, Jüni P, Hamm C, Steg PG, Onuma Y, Vranckx P, **Valgimigli M**, Windecker S, Baber U, Anderson R, Dominici M, Serruys PW. Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial. *EuroIntervention.* 2020 Apr 3;15(18):e1605-e1614. doi: 10.4244/EIJ-D-19-00699. PubMed PMID: 31845894.
382. Chandiramani R, Cao D, Claessen BE, Sorrentino S, Guedeney P, Blum M, Goel R, Roumeliotis A, Krucoff M, Kozuma K, Ge J, Seth A, Makkar R, Bangalore S, Bhatt DL, Angiolillo DJ, Ruster K, Wang J, Saito S, Neumann FJ, Hermiller J, **Valgimigli M**, Mehran R. Sex-Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient-Level Pooled Analysis From 4 Postapproval Studies. *J Am Heart Assoc.* 2020 Apr 7;9(7):e014611. doi: 10.1161/JAHA.119.014611. Epub 2020 Mar 30. PubMed PMID: 32223396.
383. Hara H, Kogame N, Takahashi K, Modolo R, Chichareon P, Tomaniak M, Ono M, Kawashima H, Gao C, Wang R, Valkov VD, Vom Dahl J, Steinwender C, Geisler T, Lemos Neto PA, Macaya Miguel C, Garg S, Jüni P, Hamm C, Steg PG, **Valgimigli M**, Vranckx P, Windecker S, Farooq V, Onuma Y, Serruys PW; GLOBAL LEADERS Trial Investigators. Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trial. *Catheter Cardiovasc Interv.* 2020 Nov;96(5):E516-E526.

384. Capodanno D, Morice MC, Angiolillo DJ, Bhatt DL, Byrne RA, Colletan R, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock SJ, Rao SV, Spitzer E, Stockbridge N, **Valgimigli M**, Varenne O, Windhovel U, Krucoff MW, Urban P, Mehran R. Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel. *J Am Coll Cardiol*. 2020 Sep 22;76(12):1468-1483. doi: 10.1016/j.jacc.2020.06.085. PMID: 32943165 Review.
385. Marquis-Gravel G, Neely ML, **Valgimigli M**, Costa F, Van Klaveren D, Altner R, Bhatt DL, Armstrong PW, Fox KAA, White HD, Ohman EM, Roe MT. Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization. *Circ Cardiovasc Qual Outcomes*. 2020 Sep;13(9):e006582. doi: 10.1161/CIRCOUTCOMES.120.006582. Epub 2020 Aug 31. PMID: 32862694.
386. Vranckx P, **Valgimigli M**, Eckardt L, Lewalter T, Unikas R, Marin F, Schiele F, Laeis P, Reimitz PE, Smolnik R, Zierhut W, Tijssen J, Goette A. Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial. *Eur Heart J*. 2020 Dec 14;41(47):4497-4504. PMID: 327767635.
387. Hara H, Takahashi K, Kogame N, Tomaniak M, Kerkmeijer LSM, Ono M, Kawashima H, Wang R, Gao C, Wykrzykowska JJ, de Winter RJ, Neumann FJ, Plante S, Lemos Neto PA, Garg S, Jüni P, Vranckx P, Windecker S, **Valgimigli M**, Hamm C, Steg PG, Onuma Y, Serruys PW. Impact of Bleeding and Myocardial Infarction on Mortality in All-COMER Patients Undergoing Percutaneous Coronary Intervention. *Circ Cardiovasc Interv*. 2020 Sep;13(9):e009177. doi: 10.1161/CIRCINTERVENTIONS.120.009177. Epub 2020 Aug 25. PMID: 32838554.
388. Gargiulo G, Esposito G, Avvedimento M, Nagler M, Minuz P, Campo G, Gragnano F, Manavifar N, Piccolo R, Tebaldi M, Cirillo P, Hunziker L, Vranckx P, Leonardi S, Heg D, Windecker S, **Valgimigli M**. Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial. *Circulation*. 2020 Aug 4;142(5):441-454. doi: 10.1161/CIRCULATIONAHA.120.046928. Epub 2020 Jun 27. PMID: 32795098 Free PMC article.
389. Hara H, van Klaveren D, Takahashi K, Kogame N, Chichareon P, Modolo R, Tomaniak M, Ono M, Kawashima H, Wang R, Gao C, Niethammer M, Fontos G, Angioi M, Ribeiro VG, Barbato E, Leandro S, Hamm C, **Valgimigli M**, Windecker S, Jüni P, Steg PG, Verbeeck J, Tijssen JGP, Sharif F, Onuma Y, Serruys PW; GLOBAL LEADERS Trial Investigators. Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events. *Circ Cardiovasc Qual Outcomes*. 2020 Aug;13(8):e006660. doi: 10.1161/CIRCOUTCOMES.120.006660. Epub 2020 Jul 30. PMID: 32762446.

390. Takahashi K, Wang R, Kawashima H, Tomaniak M, Gao C, Ono M, Hara H, Wykrzykowska JJ, de Winter RJ, Werner N, Teiger E, Almeida M, Barraud P, Lantelme P, Barlis P, Garg S, Hamm C, Steg PG, Onuma Y, Vranckx P, Windecker S, **Valgimigli M**, Serruys PW. Efficacy and safety of one-month DAPT followed by 23-month ticagrelor monotherapy in patients undergoing proximal LAD stenting: Insights from the GLOBAL LEADERS trial. *Int J Cardiol*. 2020 Dec 1;320:27-34.
391. Morici N, Molinari V, Cantoni S, Rubboli A, Antolini L, Sacco A, Cattaneo M, Alicandro G, Oreglia JA, Oliva F, Giannattasio C, Brunelli D, La Vecchia C, **Valgimigli M**, Savonitto S. Long-Term Risk of Major Adverse Cardiovascular Events in Patients With Acute Coronary Syndrome: Prognostic Role of Complete Blood Cell Count. *Angiology*. 2020 Oct;71(9):831-839. doi: 10.1177/0003319720938619. Epub 2020 Jul 8. PMID: 32638621.
392. Marquis-Gravel G, Mehta SR, **Valgimigli M**, Levine GN, Neumann FJ, Granger CB, Costa F, Lordkipanidzé M, Roffi M, Robinson SD, Cantor WJ, Tanguay JF. A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease. *Can J Cardiol*. 2020 Aug;36(8):1298-1307. doi: 10.1016/j.cjca.2019.12.013. Epub 2019 Dec 16. PMID: 32553812 Review.
393. Franzone A, McFadden EP, Leonardi S, Piccolo R, Vranckx P, Serruys PW, Hamm C, Steg PG, Heg D, Branca M, Jüni P, Windecker S, **Valgimigli M**; Collaborators. Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes. *EuroIntervention*. 2020 Oct 23;16(8):627-633.
394. Verma SS, Bergmeijer TO, Gong L, Reny JL, Lewis JP, Mitchell BD, Alexopoulos D, Aradi D, Altman RB, Bliden K, Bradford Y, Campo G, Chang K, Cleator JH, Déry JP, Dridi NP, Fernandez-Cadenas I, Fontana P, Gawaz M, Geisler T, Gensini GF, Giusti B, Gurbel PA, Hochholzer W, Holmvang L, Kim EY, Kim HS, Marcucci R, Montaner J, Backman JD, Pakyz RE, Roden DM, Schaeffeler E, Schwab M, Shin JG, Siller-Matula JM, Ten Berg JM, Trenk D, **Valgimigli M**, Wallace J, Wen MS, Kubo M, Lee MTM, Whaley R, Winter S, Klein TE, Shuldiner AR, Ritchie MD; ICPC Investigators. Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. *Clin Pharmacol Ther*. 2020 Nov;108(5):1067-1077.
395. Sinnaeve P, Fahrni G, Schelfaut D, Spirito A, Mueller C, Frenoux JM, Hmissi A, Bernaud C, Ufer M, Moccetti T, Atar S, **Valgimigli M**. Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction. *J Am Coll Cardiol*. 2020 May 26;75(20):2588-2597. doi: 10.1016/j.jacc.2020.03.059. PMID: 32439008.
396. **Valgimigli M**, Gragnano F. No free lunch-the price of double versus triple antithrombotic therapy in patients with atrial fibrillation after ACS or

PCI. *Ann Transl Med.* 2020 Apr;8(7):516. doi: 10.21037/atm.2020.01.26. PMID: 32395560 Free PMC article. No abstract available.

397. de Faria AP, Modolo R, Chichareon P, Chang CC, Kogame N, Tomaniak M, Takahashi K, Rademaker-Havinga T, Wykrzykowska J, de Winter RJ, Ferreira RC, Sousa A, Lemos PA, Garg S, Hamm C, Juni P, Vranckx P, **Valgimigli M**, Windecker S, Onuma Y, Steg PG, Serruys PW. Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERS. *Can J Cardiol.* 2020 May;36(5):747-755. doi: 10.1016/j.cjca.2019.10.015. Epub 2019 Oct 19. PMID: 32139280.
398. Takahashi K, Kogame N, Tomaniak M, Chichareon P, Chang CC, Modolo R, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, van Geuns RJ, Dominici M, Huber K, Buszman P, Bolognese L, Tumscitz C, Zmudka K, Aminian A, Vrolix M, Petrov I, Wykrzykowska JJ, de Winter RJ, Hamm C, Steg PG, Onuma Y, **Valgimigli M**, Windecker S, Vranckx P, Garg S, Serruys PW. Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial. *Clin Res Cardiol.* 2020 Jul;109(7):918-929. doi: 10.1007/s00392-019-01585-w. Epub 2019 Dec 11. PMID: 31828504.
399. Chichareon P, Modolo R, Kerkmeijer L, Tomaniak M, Kogame N, Takahashi K, Chang CC, Komiyama H, Moccetti T, Talwar S, Colombo A, Mailard L, Barlis P, Wykrzykowska J, Piek JJ, Garg S, Hamm C, Steg PG, Jüni P, **Valgimigli M**, Windecker S, Onuma Y, Mehran R, Serruys PW. Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial. *JAMA Cardiol.* 2020 Jan 1;5(1):21-29. doi: 10.1001/jamacardio.2019.4296. PMID: 31693078 Free PMC article.
400. Serruys PW, Chichareon P, Modolo R, Leaman DM, Reiber JHC, Emanuelsson H, Di Mario C, Pijls NHJ, Morel MA, **Valgimigli M**, Farooq V, van Klaveren D, Capodanno D, Andreini D, Bourantas CV, Davies J, Banning AP, Escaned J, Piek JJ, Echavarría-Pinto M, Taylor CA, Thomsen B, Collet C, Pompilio G, Bartorelli AL, Glocker B, Dressler O, Stone GW, Onuma Y. The SYNTAX score on its way out or ... towards artificial intelligence: part I. *EuroIntervention.* 2020 May 20;16(1):44-59. doi: 10.4244/EIJ-D-19-00543A. PMID: 31651399 No abstract available.
401. Serruys PW, Chichareon P, Modolo R, Leaman DM, Reiber JHC, Emanuelsson H, Di Mario C, Pijls NHJ, Morel MA, **Valgimigli M**, Farooq V, van Klaveren D, Capodanno D, Andreini D, Bourantas CV, Davies J, Banning AP, Escaned J, Piek JJ, Echavarría-Pinto M, Taylor CA, Thomsen B, Collet C, Pompilio G, Bartorelli AL, Glocker B, Dressler O, Stone GW, Onuma Y. The SYNTAX score on its way out or ... towards artificial intelligence: part II. *EuroIntervention.* 2020 May 20;16(1):60-75. doi: 10.4244/EIJ-D-19-00543B. PMID: 31651398.

402. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, **Valgimigli M**, Achenbach S, Bax JJ; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J*. 2020 Jan 14;41(3):407-477. doi: 10.1093/eurheartj/ehz425. PMID: 31504439 No abstract available.
403. Lewis JP, Backman JD, Reny JL, Bergmeijer TO, Mitchell BD, Ritchie MD, Déry JP, Pakyz RE, Gong L, Ryan K, Kim EY, Aradi D, Fernandez-Cadenas I, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, Roden DM, Winter S, Altman RB, Alexopoulos D, Kim HS, Gawaz M, Bliden KP, **Valgimigli M**, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, Siller-Matula JM, Ten Berg JM, Gurbel PA, Schwab M, Klein TE, Shuldiner AR; ICPC Investigators. Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. *Eur Heart J Cardiovasc Pharmacother*. 2020 Jul 1;6(4):203-210. doi: 10.1093/ehjcvp/pvz045. PMID: 31504375.
404. Kogame N, Chichareon P, De Wilder K, Takahashi K, Modolo R, Chang CC, Tomaniak M, Komiyama H, Chieffo A, Colombo A, Garg S, Louvard Y, Jüni P, G Steg P, Hamm C, Vranckx P, **Valgimigli M**, Windecker S, Stoll HP, Onuma Y, Janssens L, Serruys PW. Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial. *Catheter Cardiovasc Interv*. 2020 Jul;96(1):100-111. doi: 10.1002/ccd.28428. Epub 2019 Aug 13. PMID: 31410968.
405. Okuno T, Asami M, Khan F, Praz F, Heg D, Lanz J, Kassir M, Khalique OK, Gräni C, Brugger N, Räber L, Stortecky S, **Valgimigli M**, Windecker S, Pilgrim T. Does isolated mitral annular calcification in the absence of mitral valve disease affect clinical outcomes after transcatheter aortic valve replacement? *Eur Heart J Cardiovasc Imaging*. 2020 May 1;21(5):522-532. doi: 10.1093/ehjci/jez208. PMID: 31408104.
406. Gao C, Tomaniak M, Takahashi K, Kawashima H, Wang R, Hara H, Ono M, Montalescot G, Garg S, Haude M, Slagboom T, Vranckx P, **Valgimigli M**, Windecker S, van Geuns RJ, Hamm C, Steg PG, Onuma Y, Angiolillo DJ, Serruys PW. Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. *Cardiovasc Diabetol*. 2020 Oct 16;19(1):179. doi: 10.1186/s12933-020-01153-x. PMID: 33066794 Free PMC article.
407. Iglesias JF, Muller O, Losdat S, Roffi M, Kurz DJ, Weilenmann D, Kaiser C, **Valgimigli M**, Windecker S, Pilgrim T. Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents for Primary PCI: A Subgroup Analysis of the BIOSTEMI Randomized Trial. *JACC Cardiovasc In-*

terv. 2020 Oct 12;13(19):2314-2316. doi: 10.1016/j.jcin.2020.07.038. PMID: 33032722 No abstract available.

408. Wiebe J, Kuna C, Ibrahim T, Lösl M, Cassese S, Kufner S, Schunkert H, Byrne RA, Laugwitz KL, **Valgimigli M**, Richardt G, Mehilli J, Kastrati A. Long-Term Prognostic Impact of Restenosis of the Unprotected Left Main Coronary Artery Requiring Repeat Revascularization. *JACC Cardiovasc Interv*. 2020 Oct 12;13(19):2266-2274. doi: 10.1016/j.jcin.2020.07.017. PMID: 33032714.
409. Corpataux N, Spirito A, Gragnano F, Vaisnora L, Galea R, Svab S, Gargiulo G, Zanchin T, Zanchin C, Siontis GCM, Praz F, Lanz J, Hunziker L, Stortecky S, Pilgrim T, Räber L, Capodanno D, Urban P, Pocock S, Heg D, Windecker S, **Valgimigli M**. Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. *Eur Heart J*. 2020 Oct 7;41(38):3743-3749. doi: 10.1093/eurheartj/ehaa671. PMID: 33029615.
410. Takahashi K, Chichareon P, Modolo R, Kogame N, Chang CC, Tomaniak M, Moschovitis A, Curzen N, Haude M, Jung W, Holmvang L, Garg S, Tijssen JGP, Wykrzykowska JJ, de Winter RJ, Hamm C, Steg PG, Stoll HP, Onuma Y, **Valgimigli M**, Vranckx P, Windecker S, Serruys PW. Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial. *EuroIntervention*. 2020 Oct 23;16(8):634-644. doi: 10.4244/EIJ-D-19-00498. PMID: 31498113 Clinical Trial..
411. Garcia-Garcia HM, Adamo M, Soud M, Yacob O, Picchi A, Sardella G, Frigoli E, Limbruno U, Rigattieri S, Diletti R, Boccuzzi G, Zimarino M, Contarini M, Russo F, Calabrò P, Andò G, Varbella F, Garducci S, Palmieri C, Briguori C, Karagiannis A, **Valgimigli M**. Assessment of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse hemorrhagic events by transradial access site and angioX) OCT study. *Catheter Cardiovasc Interv*. 2020 Nov;96(6):1156-1171. doi: 10.1002/ccd.28661. Epub 2019 Dec 28. PMID: 31883294.
412. Garg S, Chichareon P, Kogame N, Takahashi K, Modolo R, Chang CC, Tomaniak M, Fath-Ordoubadi F, Anderson R, Oldroyd KG, Stables RH, Kukreja N, Chowdhary S, Galasko G, Hoole S, Zaman A, Hamm CW, Steg PG, Jüni P, **Valgimigli M**, Windecker S, Onuma Y, Serruys PW. Impact of established cardiovascular disease on outcomes in the randomized global leaders trial. *Catheter Cardiovasc Interv*. 2020 Dec;96(7):1369-1378. doi: 10.1002/ccd.28649. Epub 2019 Dec 19. PMID: 31854112
413. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, Brauer M, Brodmann M, Cahill TJ, Carapetis J, Catapano AL, Chugh SS, Cooper LT, Coresh J, Criqui M, DeCleene N, Eagle KA, Emmons-Bell S, Feigin VL, Fernández-Solà J, Fowkes G, Gakidou E, Grundy SM, He FJ, Howard G, Hu F, Inker L, Karthikeyan G, Kassebaum N, Koroshetz

W, Lavie C, Lloyd-Jones D, Lu HS, Mirijello A, Temesgen AM, Mokdad A, Moran AE, Muntner P, Narula J, Neal B, Ntsekhe M, Moraes de Oliveira G, Otto C, Owolabi M, Pratt M, Rajagopalan S, Reitsma M, Ribeiro ALP, Rigotti N, Rodgers A, Sable C, Shakil S, Sliwa-Hahnle K, Stark B, Sundström J, Timpel P, Tleyjeh IM, **Valgimigli M**, Vos T, Whelton PK, Yacoub M, Zuhlke L, Murray C, Fuster V; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. *J Am Coll Cardiol*. 2020 Dec 22;76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010. PMID: 33309175; PMCID: PMC7755038.

414. Iglesias JF, **Valgimigli M**, Carbone F, Lauriers N, Giorgio Masci P, Degrauwe S. Effects of Fentanyl Versus Morphine on Ticagrelor-Induced Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: The PERSEUS Randomized Trial. *Circulation*. 2020 Dec 22;142(25):2479-2481. doi: 10.1161/CIRCULATION-AHA.120.049287. Epub 2020 Dec 21. PMID: 33347326.
415. Serruys PW, Chichareon P, Modolo R, Leaman DM, Reiber JHC, Emanuelsson H, Di Mario C, Pijls NHJ, Morel MA, **Valgimigli M**, Farooq V, van Klaveren D, Capodanno D, Andreini D, Bourantas CV, Davies J, Banning AP, Escaned J, Piek JJ, Echavarría-Pinto M, Taylor CA, Thomsen B, Collet C, Pompilio G, Bartorelli AL, Glocker B, Dressler O, Stone GW, Onuma Y. The SYNTAX score on its way out or ... towards artificial intelligence: part II. *EuroIntervention*. 2020 May 20;16(1):60-75. doi: 10.4244/EIJ-D-19-00543B. PMID: 31651398.
416. Montalto C, Crimi G, Morici N, Piatti L, Grosseto D, Sganzerla P, Tortorella G, De Rosa R, De Luca L, De Luca G, Palmerini T, **Valgimigli M**, Savonitto S, De Servi S. Bleeding risk prediction in elderly patients managed invasively for acute coronary syndromes: External validation of the PRECISE-DAPT and PARIS scores. *Int J Cardiol*. 2021 Apr 1;328:22-28. doi: 10.1016/j.ijcard.2020.11.065. Epub 2020 Dec 3. PMID: 33279593.
417. Giaccoppo D, Matsuda Y, Fovino LN, D'Amico G, Gargiulo G, Byrne RA, Capodanno D, **Valgimigli M**, Mehran R, Tarantini G. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. *Eur Heart J*. 2021 Jan 21;42(4):308-319. doi: 10.1093/eurheartj/ehaa739. PMID: 33284979.
418. Kawashima H, Tomaniak M, Ono M, Wang R, Hara H, Gao C, Takahashi K, Sharif F, Thury A, Suryapranata H, Walsh S, Cotton J, Carrie D, Sabate M, Steinwender C, Leibundgut G, Wykrzykowska J, de Winter RJ, Garg S, Hamm C, Steg PG, Jüni P, Vranckx P, **Valgimigli M**, Windecker S, Onuma Y, Serruys PW. Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS). *Am J Cardiol*. 2021 Jan 1;138:1-10. PMID: 33065080.

419. Urban P, Gregson J, Owen R, Mehran R, Windecker S, **Valgimigli M**, Varenne O, Krucoff M, Saito S, Baber U, Chevalier B, Capodanno D, Morice MC, Pocock S. Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation: The ARC-High Bleeding Risk Trade-off Model. *JAMA Cardiol.* 2021 Apr 1;6(4):410-419. doi: 10.1001/jamacardio.2020.6814. PMID: 33404627; PMCID: PMC7788509.
420. **Valgimigli M**, Cao D, Makkar RR, Bangalore S, Bhatt DL, Angiolillo DJ, Saito S, Ge J, Neumann FJ, Hermiller J, Picon H, Toelg R, Maksoud A, Chehab BM, Wang LJ, Wang J, Mehran R. Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent. *Am Heart J.* 2021 Jan;231:147-156. PMID: 33031789.
421. Sweda R, Dobner S, Heg D, Lanz J, Malebranche D, Langhammer B, Okuno T, Praz F, Räber L, **Valgimigli M**, Reineke D, Pilgrim T, Windecker S, Stortecky S. Discharge Location and Outcomes After Transcatheter Aortic Valve Implantation. *Am J Cardiol.* 2021 Feb 1;140:95-102 PMID: 33144166.
422. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, **Valgimigli M**, Van Gelder IC, Van Putte BP, Watkins CL. Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J.* 2021 Oct 21;42(40):4194. doi: 10.1093/eurheartj/ehab648. Erratum for: *Eur Heart J.* 2021 Feb 1;42(5):373-498. PMID: 34520521.
423. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, **Valgimigli M**, Van Gelder IC, Van Putte BP, Watkins CL. Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J.* 2021 Sep 14;ehab648. doi: 10.1093/eurheartj/ehab648. Epub ahead of print. Erratum for: *Eur Heart J.* 2021 Feb 1;42(5):373-498. PMID: 34520521.
424. Gao C, Takahashi K, Garg S, Hara H, Wang R, Kawashima H, Ono M, Montalescot G, Haude M, Slagboom T, Vranckx P, **Valgimigli**

- M, Windecker S, Hamm C, Steg PG, Storey R, van Geuns RJ, Tao L, Onuma Y, Serruys PW. Regional variation in patients and outcomes in the GLOBAL LEADERS trial. *Int J Cardiol.* 2021 Feb 1;324:30-37. doi: 10.1016/j.ijcard.2020.09.039. Epub 2020 Sep 15. PMID: 32941872.
425. Komajda M, Cosentino F, Ferrari R, Laroche C, Maggioni A, Steg PG, Tavazzi L, Kerneis M, **Valgimigli M**, Gale CP; CICD Investigators Group. The ESC-EORP Chronic Ischaemic Cardiovascular Disease Long Term (CICD LT) registry. *Eur Heart J Qual Care Clin Outcomes.* 2021 Jan 25;7(1):28-33. doi: 10.1093/ehjqcco/qcz057. PMID: 31605146.
 426. Leonardi S, Gragnano F, Carrara G, Gargiulo G, Frigoli E, Vranckx P, Di Maio D, Spedicato V, Monda E, Fimiani L, Fioretti V, Esposito F, Avvedimento M, Magliulo F, Leone A, Chianese S, Franzese M, Scalise M, Schiavo A, Mazzone P, Esposito G, Andò G, Calabrò P, Windecker S, **Valgimigli M**. Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes. *J Am Coll Cardiol.* 2021 Feb 2;77(4):375-388. doi: 10.1016/j.jacc.2020.11.046. PMID: 33509394.
 427. Gargiulo G, Esposito G, Cirillo P, Nagler M, Minuz P, Campo G, Gragnano F, Manavifar N, Piccolo R, Avvedimento M, Tebaldi M, Wahl A, Hunziker L, Billinger M, Heg D, Windecker S, **Valgimigli M**. Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over Prasugrel: a MULTicenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimARy Percutaneous InTERvention (FABOLUS FASTER) Trial: Design and Rationale : The FABOLUS FASTER Trial. *J Cardiovasc Transl Res.* 2021 Feb;14(1):110-119. doi: 10.1007/s12265-020-09969-4. Epub 2020 Feb 24. PMID: 32096064.
 428. Leonardi S, Branca M, Franzone A, McFadden E, Piccolo R, Jüni P, Vranckx P, Steg PG, Serruys PW, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, Diletti R, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopcuk J, Hamm C, Heg D, Windecker S, Valgimigli M. Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY. *Circ Cardiovasc Qual Outcomes.* 2021 Feb;14(2):e006581. doi: 10.1161/CIRCOUTCOMES.120.006581. Epub 2021 Feb 4. PMID: 33535773.
 429. Goel R, Cao D, Chandiramani R, Roumeliotis A, Blum M, Bhatt DL, Angiolillo DJ, Ge J, Seth A, Saito S, Krucoff M, Kozuma K, Makkar RM, Bangalore S, Wang L, Koo K, Neumann FJ, Hermiller J, Stefanini G, **Valgimigli M**, Mehran R. Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus-eluting stents. *Catheter Cardiovasc Interv.* 2021 Nov 15;98(6):1111-1119. doi: 10.1002/ccd.29314. Epub 2020 Oct 10. PMID: 33038061.
 430. Chichareon P, van Klaveren D, Modolo R, Kogame N, Takahashi K, Chang CC, Tomaniak M, Yuan J, Xie L, Song Y, Qiao S, Yang Y, Guan

C, Zurakowski A, van Geuns RJ, Sabate M, Ong PJ, Wykrzykowska JJ, Piek JJ, Garg S, Hamm C, Steg G, Vranckx P, **Valgimigli M**, Windecker S, Juni P, Onuma Y, Steyerberg E, Xu B, Serruys PW. Predicting 2-year all-cause mortality after contemporary PCI: Updating the logistic clinical SYNTAX score. *Catheter Cardiovasc Interv*. 2021 Dec 1;98(7):1287-1297. doi: 10.1002/ccd.29490. Epub 2021 Feb 4. PMID: 33539048.

431. Spirito A, Gargiulo G, Siontis GCM, Mitsis A, Billinger M, Windecker S, **Valgimigli M**. Cardiovascular mortality and morbidity in patients undergoing percutaneous coronary intervention after out-of-hospital cardiac arrest: a systematic review and meta-analysis. *EuroIntervention*. 2021 Feb 5;16(15):e1245-e1253. doi: 10.4244/EIJ-D-20-00221. PMID: 32624462.
432. Gragnano F, Branca M, Frigoli E, Leonardi S, Vranckx P, Di Maio D, Monda E, Fimiani L, Fioretti V, Chianese S, Esposito F, Franzese M, Scalise M, D'Angelo C, Scalise R, De Blasi G, Andò G, Esposito G, Calabrò P, Windecker S, Pedrazzini G, **Valgimigli M**; MATRIX Trial Investigators. Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management. *JACC Cardiovasc Interv*. 2021 Feb 22;14(4):361-373. doi: 10.1016/j.jcin.2020.11.042. PMID: 33602431.
433. **Valgimigli M**, Mehran R, Franzone A, da Costa BR, Baber U, Piccolo R, McFadden EP, Vranckx P, Angiolillo DJ, Leonardi S, Cao D, Dangas GD, Mehta SR, Serruys PW, Gibson CM, Steg GP, Sharma SK, Hamm C, Shlofmitz R, Liebetrau C, Briguori C, Janssens L, Huber K, Ferrario M, Kunadian V, Cohen DJ, Zurakowski A, Oldroyd KG, Yaling H, Dudek D, Sartori S, Kirkham B, Escaned J, Heg D, Windecker S, Pocock S, Jüni P; SIDNEY Collaboration. Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. *JACC Cardiovasc Interv*. 2021 Feb 22;14(4):444-456. doi: 10.1016/j.jcin.2020.11.046. PMID: 33602441.
434. Schwartz GG, Szarek M, Bittner VA, Bhatt DL, Diaz R, Goodman SG, Jukema JW, Loy M, Manvelian G, Pordy R, White HD, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. *Diabetes Care*. 2021 May;44(5):1219-1227. doi: 10.2337/dc20-2842. Epub 2021 Mar 15. PMID: 33722880; PMCID: PMC8132323.
435. Kuno T, Claessen B, Cao D, Chandiramani R, Guedeney P, Sorrentino S, Krucoff M, Kozuma K, Ge J, Seth A, Makkar R, Bangalore S, Bhatt DL, Angiolillo DJ, Saito S, Neumann FJ, Hermiller J, Rau V, Ruster K, Wang J, **Valgimigli M**, Mehran R. Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies. *J Thromb Thrombolysis*. 2021 Aug;52(2):419-428. doi: 10.1007/s11239-020-02321-2. Epub 2021 Mar 11. PMID: 33709255.

436. Leonardi S, Capodanno D, Sousa-Uva M, Vrints C, Rex S, Guarracino F, Bueno H, Lettino M, Price S, **Valgimigli M**, Jeppsson A. Composition, structure, and function of heart teams: a joint position paper of the ACVC, EAPCI, EACTS, and EACTA focused on the management of patients with complex coronary artery disease requiring myocardial revascularization. *Eur Heart J Acute Cardiovasc Care*. 2021 Mar 5;10(1):83-93. doi: 10.1093/ehjacc/zuaa013. PMID: 33721018.
437. Pilgrim T, Muller O, Heg D, Roffi M, Kurz DJ, Moarof I, Weilenmann D, Kaiser C, Tapponnier M, Losdat S, Eeckhout E, **Valgimigli M**, Jüni P, Windecker S, Iglesias JF. Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOS-TEMI Trial. *JACC Cardiovasc Interv*. 2021 Mar 22;14(6):639-648. doi: 10.1016/j.jcin.2020.12.011. PMID: 33727005.
438. Otsuka T, Ueki Y, Kavaliauskaite R, Zanchin T, Bär S, Stortecky S, Pilgrim T, **Valgimigli M**, Meier B, Heg D, Windecker S, Räber L. Single antiplatelet therapy with use of prasugrel in patients undergoing percutaneous coronary intervention. *Catheter Cardiovasc Interv*. 2021 Aug 1;98(2):E213-E221. doi: 10.1002/ccd.29650. Epub 2021 Mar 22. PMID: 33754441.
439. Gargiulo G, Nagler M, **Valgimigli M**. Response by Gargiulo et al to Letter Regarding Article, “Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial”. *Circulation*. 2021 Mar 30;143(13):e797-e798. doi: 10.1161/CIRCULATIONAHA.120.051945. Epub 2021 Mar 29. PMID: 33779272.
440. Yacob O, Garcia-Garcia HM, Dan K, Soud M, Adamo M, Picchi A, Sardella G, Frigoli E, Limbruno U, Rigattieri S, Diletti R, Boccuzzi G, Zimarino M, Contarini M, Russo F, Calabro P, Ando G, Varbella F, Garducci S, Palmieri C, Briguori C, Kuku KO, Karagiannis A, **Valgimigli M**. Impact of optical coherence tomography findings on clinical outcomes in ST-segment elevation myocardial infarction patients: a MATRIX (Minimizing Adverse Hemorrhagic Events by Trans- radial Access Site and angioX) OCT sub-study. *Int J Cardiovasc Imaging*. 2021 Apr;37(4):1143-1150. doi: 10.1007/s10554-020-02098-8. Epub 2020 Nov 22. PMID: 33225426.
441. Piccolo R, Oliva A, Avvedimento M, Franzone A, Windecker S, **Valgimigli M**, Esposito G, Jüni P. Mortality after bleeding versus myocardial infarction in coronary artery disease: a systematic review and meta-analysis. *EuroIntervention*. 2021 Sep 20;17(7):550-560. doi: 10.4244/EIJ-D-20-01197. PMID: 33840639.
442. Galea R, De Marco F, Aminian A, Meneveau N, Anselme F, Gräni C, Huber AT, Teiger E, Iriart X, Angelillis M, Brugger N, Spirito A, Corpataux N, Franzone A, Vranckx P, Fischer U, Pedrazzini G, Bedogni F, Windecker S, Räber L, **Valgimigli M**. Design and Rationale of the Swiss-Apero Randomized Clinical Trial: Comparison

of Amplatzer Amulet vs Watchman Device in Patients Undergoing Left Atrial Appendage Closure. *J Cardiovasc Transl Res*. 2021 Oct;14(5):930-940. doi: 10.1007/s12265-020-10095-4. Epub 2021 Apr 21. PMID: 33884564.

443. Iglesias JF, Muller O, Losdat S, Roffi M, Kurz DJ, Weilenmann D, Kaiser C, Heg D, **Valgimigli M**, Windecker S, Pilgrim T. Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial. *Int J Cardiol*. 2021 Jul 1;334:37-41. doi: 10.1016/j.ij-card.2021.04.034. Epub 2021 Apr 20. PMID: 33887341.
444. Komajda M, Cosentino F, Ferrari R, Kerneis M, Kosmachova E, Laroche C, Maggioni AP, Rittger H, Steg PG, Szwed H, Tavazzi L, **Valgimigli M**, Gale CP; CICD investigators group. Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. *Eur J Prev Cardiol*. 2021 May 8;28(4):432-445. doi: 10.1177/2047487320912491. PMID: 33966083.
445. Zimarino M, Angiolillo DJ, Dangas G, Capodanno D, Barbato E, Hahn JY, Giustino G, Watanabe H, Costa F, Cuisset T, Rossini R, Sibbing D, Burzotta F, Louvard Y, Shehab A, Renda G, Kimura T, Gwon HC, Chen SL, Costa RA, Koo BK, Storey RF, **Valgimigli M**, Mehran R, Stankovic G. Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions. *EuroIntervention*. 2021 May 17;17(1):59-66. doi: 10.4244/EIJ-D-20-00885. PMID: 32928716.
446. Navarese EP, Lansky AJ, Kereiakes DJ, Kubica J, Gurbel PA, Gorog DA, **Valgimigli M**, Curzen N, Kandzari DE, Bonaca MP, Brouwer M, Umińska J, Jaguszewski MJ, Raggi P, Waksman R, Leon MB, Wijns W, Andreotti F. Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. *Eur Heart J*. 2021 Dec 1;42(45):4638-4651. doi: 10.1093/eurheartj/ehab246. PMID: 34002203; PMCID: PMC8669551.
447. Landi A, Faletra FF, Pavon AG, Pedrazzini G, **Valgimigli M**. From secondary to tertiary mitral regurgitation: the paradigm shifts, but uncertainties remain. *Eur Heart J Cardiovasc Imaging*. 2021 Jul 20;22(8):835-843. doi: 10.1093/ehjci/jeab080. PMID: 33982052.
448. Sedaghat A, Vij V, Al-Kassou B, Gloekler S, Galea R, Fürholz M, Meier B, **Valgimigli M**, O'Hara G, Arzamendi D, Agudelo V, Asmarats L, Freixa X, Flores- Umanzor E, De Backer O, Søndergaard L, Nombela-Franco L, McInerney A, Korsholm K, Nielsen-Kudsk JE, Afzal S, Zeus T, Operhalski F, Schmidt B, Montalescot G, Guedeney P, Iriart X, Miton N, Saw J, Gilhofer T, Fauchier L, Veliqi E, Meincke F, Petri N, Nordbeck P, Rycerz S, Ognerubov D, Merkulov E, Cruz-González I, Gonzalez-Ferreiro R, Bhatt DL, Laricchia A, Mangieri A, Omran H, Schrickel JW,

Rodes-Cabau J, Nickenig G. Device-Related Thrombus After Left Atrial Appendage Closure: Data on Thrombus Characteristics, Treatment Strategies, and Clinical Outcomes From the EUROCD-DRT-Registry. *Circ Cardiovasc Interv.* 2021 May;14(5):e010195. doi: 10.1161/CIRCINTERVENTIONS.120.010195. Epub 2021 May 18. PMID: 34003661.

449. Ono M, Kawashima H, Hara H, Gamal A, Wang R, Gao C, O'Leary N, Soliman O, Piek JJ, van Geuns RJ, Jüni P, Hamm CW, **Valgimigli M**, Vranckx P, Windecker S, Steg PG, Fox KA, Onuma Y, Serruys PW. External validation of the GRACE risk score 2.0 in the contemporary all-comers GLOBAL LEADERS trial. *Catheter Cardiovasc Interv.* 2021 Oct;98(4):E513-E522. doi: 10.1002/ccd.29772. Epub 2021 May 17. PMID: 34000088.
450. Seo M, White IR, Furukawa TA, Imai H, **Valgimigli M**, Egger M, Zwahlen M, Efthimiou O. Comparing methods for estimating patient-specific treatment effects in individual patient data meta-analysis. *Stat Med.* 2021 Mar 15;40(6):1553-1573. doi: 10.1002/sim.8859. Epub 2020 Dec 27. PMID: 33368415; PMCID: PMC7898845.
451. Mohamed MO, Rashid M, Timmis A, Clarke S, Lawson C, Michos ED, Kwok CS, De Belder M, **Valgimigli M**, Mamas MA. Sex differences in distribution, management and outcomes of combined ischemic-bleeding risk following acute coronary syndrome. *Int J Cardiol.* 2021 Apr 15;329:16-22. doi: 10.1016/j.ijcard.2020.12.063. Epub 2020 Dec 31. PMID: 33388397.
452. Gargiulo G, Cannon CP, Gibson CM, Lopes RD, Vranckx P, **Valgimigli M**. The multiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events? *Eur Heart J Cardiovasc Pharmacother.* 2021 May 23;7(3):e29-e30. doi: 10.1093/ehjcvp/pvaa141. PMID: 33340322.
453. **Valgimigli M**, Landi A. Large-Bore Radial Access for Complex PCI: A Flash of COLOR With Some Shades of Gray. *JACC Cardiovasc Interv.* 2021 Jun 28;14(12):1304-1307. doi: 10.1016/j.jcin.2021.04.013. Epub 2021 May 18. PMID: 34020926.
454. Goette A, Eckardt L, **Valgimigli M**, Lewalter T, Laeis P, Reimitz PE, Smolnik R, Zierhut W, Tijssen JG, Vranckx P. Clinical risk predictors in atrial fibrillation patients following successful coronary stenting: ENTRUST-AF PCI sub-analysis. *Clin Res Cardiol.* 2021 Jun;110(6):831-840. doi: 10.1007/s00392-020-01760-4. Epub 2020 Oct 24. PMID: 33098470; PMCID: PMC8166657.
455. Kawashima H, Hara H, Wang R, Ono M, Gao C, Takahashi K, Suryapranata H, Walsh S, Cotton J, Carrie D, Sabate M, Steinwender C, Leibundgut G, Wykrzykowska J, Hamm C, Jüni P, Vranckx P, **Valgimigli M**, Windecker S, de Winter RJ, Sharif F, Onuma Y, Serruys PW. Usefulness of updated logistic clinical SYNTAX score based on

MI-SYNTAX score in patients with ST-elevation myocardial infarction. *Catheter Cardiovasc Interv*. 2021 Jun 1;97(7):E919-E928. doi: 10.1002/ccd.29383. Epub 2020 Nov 11. PMID: 33175478.

456. Häner JD, Fürholz M, Kleinecke C, Galea R, Streit SR, Fankhauser M, Cherni T, **Valgimigli M**, Windecker S, Meier B, Gloekler S. Impact of individual stroke risk on outcome after Amplatzer left atrial appendage closure in patients with atrial fibrillation. *Catheter Cardiovasc Interv*. 2021 Jun 1;97(7):E1002-E1010. doi: 10.1002/ccd.29318. Epub 2020 Oct 6. PMID: 33022121.
457. Gragnano F, Spirito A, Corpataux N, Vaisnora L, Galea R, Gargiulo G, Siontis GCM, Praz F, Lanz J, Billinger M, Hunziker L, Stortecky S, Pilgrim T, Bär S, Ueki Y, Capodanno D, Urban P, Pocock SJ, Mehran R, Heg D, Windecker S, Räber L, **Valgimigli M**. Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition. *EuroIntervention*. 2021 Dec 3;17(11):e898-e909. doi: 10.4244/EIJ-D-21-00181. PMID: 34105513.
458. Spirito A, Gragnano F, Corpataux N, Vaisnora L, Galea R, Svab S, Gargiulo G, Siontis GCM, Praz F, Lanz J, Billinger M, Hunziker L, Stortecky S, Pilgrim T, Capodanno D, Urban P, Pocock S, Mehran R, Heg D, Windecker S, Räber L, **Valgimigli M**. Sex-Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria. *J Am Heart Assoc*. 2021 Jun 15;10(12):e021965. doi: 10.1161/JAHA.121.021965. Epub 2021 Jun 8. PMID: 34098740.
459. Crea F, Thiele H, Sibbing D, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Siontis GCM, Barbato E, Collet JP, Giannitsis E, Hamm CW, Böhm M, Cornel JH, Ferreiro JL, Frey N, Huber K, Kubica J, Navarese EP, Mehran R, Morais J, Storey RF, **Valgimigli M**, Vranckx P, James S. Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTEMI-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy. *Eur Heart J*. 2021 Aug 17;42(31):2973-2985. doi: 10.1093/eurheartj/ehab277. PMID: 34110420.
460. Al Raisi S, Protty M, Raposeiras-Roubín S, D'Ascenzo F, Abu-Assi E, Ariza- Solé A, Manzano-Fernández S, Templin C, Velicki L, Xanthopoulos I, Cerrato E, Quadri G, Rognoni A, Boccuzzi G, Montabone A, Taha S, Durante A, Gili S, Magnani G, Autelli M, Grosso A, Flores-Blanco P, Varbella F, Cespón-Fernández M, Gallo D, Morbiducci U, Domínguez-Rodríguez A, Cequier Á, Gaita F, Alexopoulos D, **Valgimigli M**, Íñiguez-Romo A, Kinnaird T. Ticagrelor versus prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI Registry. *Minerva Cardiol Angiol*. 2021 Aug;69(4):408-416. doi: 10.23736/S2724-5683.21.05591-5. Epub 2021 Jun 17. PMID: 34137238.

461. De Luca L, **Valgimigli M**. Unravelling the puzzle of antithrombotic therapies for complex percutaneous coronary intervention. *Eur Heart J Cardiovasc Pharmacother*. 2021 Jul 23;7(4):352-359. doi: 10.1093/ehjcvp/pvaa107. PMID: 33175148.
462. Landi A, Quagliana A, Leo LA, Faletra FF, Pedrazzini G, **Valgimigli M**. Intimal Flap Sealing and Healing of Spontaneous Coronary Artery Dissection With Drug- Eluting Balloons. *JACC Cardiovasc Interv*. 2021 Aug 23;14(16):1843-1845. doi: 10.1016/j.jcin.2021.06.017. Epub 2021 Jul 28. PMID: 34332937.
463. **Valgimigli M**, Landi A. Subcutaneous RUC-4 for acute myocardial infarction: a new treatment on the horizon for pre-hospital care? *Euro-Intervention*. 2021 Aug 6;17(5):e362-e363. doi: 10.4244/EIJV17I5A63. PMID: 34356031.
464. Gragnano F, Jolly SS, Mehta SR, Branca M, van Klaveren D, Frigoli E, Gargiulo G, Leonardi S, Vranckx P, Di Maio D, Monda E, Fimiani L, Fioretti V, Chianese S, Andò G, Esposito G, Sangiorgi GM, Biondi-Zoccai G, Heg D, Calabrò P, Windecker S, Romagnoli E, **Valgimigli M**. Prediction of radial crossover in acute coronary syndromes: derivation and validation of the MATRIX score. *EuroIntervention*. 2021 Dec 17;17(12):e971-e980. doi: 10.4244/EIJ-D-21-00441. PMID: 34374343.
465. Bhatt DL, Kaski JC, Delaney S, Alasnag M, Andreotti F, Angiolillo DJ, Ferro A, Gorog DA, Lorenzatti AJ, Mamas M, McNeil J, Nicolau JC, Steg PG, Tamargo J, Tan D, **Valgimigli M**. Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. *Int J Cardiol*. 2021 Aug 15;337:1-8. doi: 10.1016/j.ijcard.2021.05.012. Epub 2021 May 15. PMID: 34000356.
466. Galea R, Räber L, Fuerholz M, Häner JD, Siontis GCM, Brugger N, Moschovitis A, Heg D, Fischer U, Meier B, Windecker S, **Valgimigli M**. Impact of Echocardiographic Guidance on Safety and Efficacy of Left Atrial Appendage Closure: An Observational Study. *JACC Cardiovasc Interv*. 2021 Aug 23;14(16):1815-1826. doi: 10.1016/j.jcin.2021.05.042. PMID: 34412799.
467. Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, López-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Gabriel Steg P; ODYSSEY Outcomes Committees and Investigators. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. *J Am Coll Cardiol*. 2021 Aug 3;78(5):421-433. doi: 10.1016/j.jacc.2021.04.102. PMID: 34325831.
468. Van Mieghem NM, Unverdorben M, Hengstenberg C, Möllmann H, Mehran R, López- Otero D, Nombela-Franco L, Moreno R, Nordbeck P, Thiele H, Lang I, Zamorano JL, Shawl F, Yamamoto M,

Watanabe Y, Hayashida K, Hambrecht R, Meincke F, Vranckx P, Jin J, Boersma E, Rodés-Cabau J, Ohlmann P, Capranzano P, Kim HS, Pilgrim T, Anderson R, Baber U, Duggal A, Laeis P, Lanz H, Chen C, **Valgimigli M**, Veltkamp R, Saito S, Dangas GD; ENVIS-AGE-TAVI AF Investigators. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. *N Engl J Med*. 2021 Dec 2;385(23):2150-2160. doi: 10.1056/NEJMoa2111016. Epub 2021 Aug 28. PMID: 34449183.

469. **Valgimigli M**, Frigoli E, Heg D, Tijssen J, Jüni P, Vranckx P, Ozaki Y, Morice MC, Chevalier B, Onuma Y, Windecker S, Tonino PAL, Roffi M, Lesiak M, Mahfoud F, Bartunek J, Hildick-Smith D, Colombo A, Stanković G, Iñiguez A, Schultz C, Kornowski R, Ong PJJ, Alasnag M, Rodriguez AE, Moschovitis A, Laanmets P, Donahue M, Leonardi S, Smits PC; MASTER DAPT Investigators. Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. *N Engl J Med*. 2021 Oct 28;385(18):1643-1655. doi: 10.1056/NEJMoa2108749. Epub 2021 Aug 28. PMID: 34449185.
470. Smits PC, Frigoli E, Tijssen J, Jüni P, Vranckx P, Ozaki Y, Morice MC, Chevalier B, Onuma Y, Windecker S, Tonino PAL, Roffi M, Lesiak M, Mahfoud F, Bartunek J, Hildick-Smith D, Colombo A, Stankovic G, Iñiguez A, Schultz C, Kornowski R, Ong PJJ, Alasnag M, Rodriguez AE, Moschovitis A, Laanmets P, Heg D, **Valgimigli M**; MASTER DAPT Investigators. Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial. *Circulation*. 2021 Oct 12;144(15):1196-1211. doi: 10.1161/CIRCULATIONAHA.121.056680. Epub 2021 Aug 29. PMID: 34455849; PMCID: PMC8500374.
471. Montalto C, Crimi G, Morici N, Palmerini T, **Valgimigli M**, Savonitto S, De Servi S. Validation and Additive Predictive Value of the Academic Research Consortium-High Bleeding Risk Criteria in Older Adults. *Thromb Haemost*. 2021 Sep;121(9):1255-1257. doi: 10.1055/a-1342-3750. Epub 2020 Dec 22. PMID: 33352592.
472. Landi A, Branca M, Andò G, Russo F, Frigoli E, Gargiulo G, Briguori C, Vranckx P, Leonardi S, Gragnano F, Calabrò P, Campo G, Ambrosio G, Santucci A, Varbella F, Zaro T, Heg D, Windecker S, Jüni P, Pedrazzini G, **Valgimigli M**; MATRIX Investigators. Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial. *Eur Heart J Acute Cardiovasc Care*. 2021 Dec 18;10(10):1170-1179. doi: 10.1093/ehjacc/zuab080. PMID: 34491323.
473. Mehran R, Cao D, Angiolillo DJ, Bangalore S, Bhatt DL, Ge J, Hermiller J, Makkar RR, Neumann FJ, Saito S, Picon H, Toelg R, Maksoud A, Chehab BM, De la Torre Hernandez JM, Kunadian V, Sardella G, Thiele

- H, Varenne O, Vranckx P, Windecker S, Zhou Y, Krucoff MW, Ruster K, Wang J, **Valgimigli M**; XIENCE 90 and XIENCE 28 Investigators. 3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation. *JACC Cardiovasc Interv*. 2021 Sep 13;14(17):1870-1883. doi: 10.1016/j.jcin.2021.07.016. PMID: 34503737.
474. Vranckx P, **Valgimigli M**, Odutayo A, Serruys PW, Hamm C, Steg PG, Heg D, Mc Fadden EP, Onuma Y, Benit E, Janssens L, Diletti R, Ferrario M, Huber K, Räber L, Windecker S, Jüni P; GLOBAL LEADERS Investigators. Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial. *J Am Heart Assoc*. 2021 Sep 21;10(18):e015560. doi: 10.1161/JAHA.119.015560. Epub 2021 Sep 17. PMID: 34533034.
 475. Calabrò P, Gragnano F, Niccoli G, Marcucci R, Zimarino M, Spaccarella C, Renda G, Patti G, Andò G, Moscarella E, Mancone M, Cesaro A, Giustino G, De Caterina R, Mehran R, Capodanno D, Valgimigli M, Windecker S, Dangas GD, Indolfi C, Angiolillo DJ. Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. *Circulation*. 2021 Oct 19;144(16):1323-1343. doi: 10.1161/CIRCULATIONAHA.121.054305. Epub 2021 Oct 18. PMID: 34662163.
 476. Piccolo R, Bona KH, Efthimiou O, Varenne O, Urban P, Kaiser C, Räber L, de Belder A, Remkes W, Van't Hof AWJ, Stankovic G, Lemos PA, Wilsgaard T, Reifart J, Rodriguez AE, Ribeiro EE, Serruys PWJC, Abizaid A, Sabaté M, Byrne RA, de la Torre Hernandez JM, Wijns W, Esposito G, Jüni P, Windecker S, **Valgimigli M**; Coronary Stent Trialists' (CST) Collaboration. Drug-Eluting or Bare-Metal Stents for Left Anterior Descending or Left Main Coronary Artery Revascularization. *J Am Heart Assoc*. 2021 Oct 19;10(20):e018828. doi: 10.1161/JAHA.120.018828. Epub 2021 Oct 8. PMID: 34622669.
 477. **Valgimigli M**, Landi A. Ischaemic and bleeding risk in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: is it time to REACT? *Eur Heart J Acute Cardiovasc Care*. 2021 Dec 18;10(10):1125-1128. doi: 10.1093/ehjacc/zuab090. PMID: 34625804.
 478. **Valgimigli M**, Cao D, Angiolillo DJ, Bangalore S, Bhatt DL, Ge J, Hermler J, Makkar RR, Neumann FJ, Saito S, Picon H, Toelg R, Maksoud A, Chehab BM, Choi JW, Campo G, De la Torre Hernandez JM, Kunadian V, Sardella G, Thiele H, Varenne O, Vranckx P, Windecker S, Zhou Y, Krucoff MW, Ruster K, Zheng Y, Mehran R; XIENCE 90 and XIENCE 28 Investigators. Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI. *J Am Coll Cardiol*. 2021 Nov 23;78(21):2060-2072. doi: 10.1016/j.jacc.2021.08.074. PMID: 34794687.
 479. Palmerini T, Bruno AG, Redfors B, **Valgimigli M**, Taglieri N, Feres F, Abizaid A, Costa R, Gilard M, Morice MC, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Colombo A, Chieffo A, Nakamura M, Kotinkaduwa

- LN, Nardi E, Saia F, Gasparini M, Rizzello G, Weisz G, Kirtane AJ, Mehran R, Witzenebichler B, Galiè N, Stone GW. Risk-Benefit of 1-Year DAPT After DES Implantation in Patients Stratified by Bleeding and Ischemic Risk. *J Am Coll Cardiol*. 2021 Nov 16;78(20):1968-1986. doi: 10.1016/j.jacc.2021.08.070. PMID: 34763774.
480. Dan K, Garcia-Garcia HM, Yacob O, Kuku KO, Diaz-Torres MA, Picchi A, Sardella G, Adamo M, Frigoli E, Limbruno U, Rigattieri S, Diletti R, Boccuzzi G, Zimarino M, Contarini M, Russo F, Calabro P, Andò G, Varbella F, Garducci S, Palmieri C, Briguori C, Karagiannis A, Dijkstra J, **Valgimigli M**. Ultra-Short Term Evaluation of Coronary Vessel Wall Changes in Reference Segments Adjacent to Culprit Lesions in ST-Segment Elevation Myocardial Infarction. *J Invasive Cardiol*. 2021 Dec;33(12):E923-E930. Epub 2021 Nov 18. PMID: 34792483.
 481. Araco M, Quagliana A, Pedrazzini G, **Valgimigli M**. A new iteration for the single-access large-bore technique during Impella supported complex and high- risk coronary intervention: a case report. *Eur Heart J Case Rep*. 2021 Oct 26;5(11):yt428. doi: 10.1093/ehjcr/yt428. PMID: 34917876; PMCID: PMC8669554.
 482. Allard L, Bernhard B, Windecker S, **Valgimigli M**, Gräni C. Left ventricular thrombus in ischaemic heart disease: diagnosis, treatment, and gaps of knowledge. *Eur Heart J Qual Care Clin Outcomes*. 2022 Aug 17;8(5):496-509. doi: 10.1093/ehjqcco/qcab097. PMID: 34928322.
 483. Landi A, **Valgimigli M**. Antithrombotic Therapy After Left Atrial Appendage Occlusion: Half-Dose DOAC Monotherapy Is Really Enough? *JACC Cardiovasc Interv*. 2022 Jan 10;15(1):113-114. doi: 10.1016/j.jcin.2021.11.001. PMID: 34991816.
 484. Landi A, Gargiulo G, **Valgimigli M**. The Effects of Cangrelor on Platelet Aggregation in STEMI Patients: Methodological or Pharmacological Issues? *JACC Cardiovasc Interv*. 2022 Jan 24;15(2):229-230. doi: 10.1016/j.jcin.2021.11.016. PMID: 35057997.
 485. Iglesias JF, Heg D, Roffi M, Degrauwe S, Tüller D, Muller O, Brinkert M, Cook S, Weilenmann D, Kaiser C, Cuculi F, **Valgimigli M**, Jüni P, Windecker S, Pilgrim T. Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial. *Cardiovasc Revasc Med*. 2022 Jan;34:3-10. doi: 10.1016/j.carrev.2021.02.008. Epub 2021 Feb 25. PMID: 33653633.
 486. Vranckx P, Angiolillo DJ, **Valgimigli M**. Patients With Atrial Fibrillation and PCI or ACS: Does Predicted Risk Matter? *J Am Coll Cardiol*. 2022 Feb 8;79(5):428-431. doi: 10.1016/j.jacc.2021.11.034. PMID: 35115098.
 487. **Valgimigli M**, Gragnano F, Branca M, Franzone A, Baber U, Jang Y, Kimura T, Hahn JY, Zhao Q, Windecker S, Gibson CM, Kim BK, Watanabe H, Song YB, Zhu Y, Vranckx P, Mehta S, Hong SJ, Ando

- K, Gwon HC, Serruys PW, Dangas GD, McFadden EP, Angiolillo DJ, Heg D, Jüni P, Mehran R. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. *BMJ*. 2021 Jun 16;373:n1332. doi: 10.1136/bmj.n1332. PMID: 34135011.
488. Gragnano F, Heg D, Franzone A, McFadden EP, Leonardi S, Piccolo R, Vranckx P, Branca M, Serruys PW, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, Diletti R, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopczyk J, Hamm C, Steg PG, Jüni P, Windecker S, **Valgimigli M**. PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY. *Eur Heart J Cardiovasc Pharmacother*. 2022 Jan 5;8(1):28-38. doi: 10.1093/ehjcvp/pvaa106. PMID: 32941620.
 489. **Valgimigli M**, Storey RF, Sinnaeve PR, Riederer MA, Bernaud C, Frenoux JM. Selatogrel and Other P2Y12 Inhibitors' Putative Off-Target Effects. *J Cardiovasc Pharmacol*. 2022 Feb 1;79(2):153-154. doi: 10.1097/FJC.0000000000001135. PMID: 34475343.
 490. Bongiovanni D, Klug M, **Valgimigli M**, Bernlochner I. Not only lungs: COVID-19 hits platelets as well. *Eur Heart J*. 2022 Jun 6;43(22):2092-2093. doi: 10.1093/eurheartj/ehac076. PMID: 35178570.
 491. Ueki Y, Zanchin T, Losdat S, Karagiannis A, Otsuka T, Siontis GCM, Häner J, Stortecky S, Pilgrim T, **Valgimigli M**, Windecker S, Räber L. Self-reported non-adherence to P2Y12 inhibitors in patients undergoing percutaneous coronary intervention: Application of the medication non-adherence academic research consortium classification. *PLoS One*. 2022 Feb 16;17(2):e0263180. doi: 10.1371/journal.pone.0263180. PMID: 35171913; PMCID: PMC8849552.
 492. Pavon AG, Masci PG, Pucci L, Landi A, Bermano A, Vaxman A, Gotsman C, Rutz T, Monney P, Godinho R, Saraiva Rodrigues D, Muller O, **Valgimigli M**, Schwitter J. Left atrial adaptation in ischemic heart disease: insights from a cardiovascular magnetic resonance study. *Int J Cardiovasc Imaging*. 2022 Feb 17. doi: 10.1007/s10554-022-02536-9. Epub ahead of print. PMID: 35174427.
 493. Spirito A, Quagliana A, Coiro M, Melaku GD, Vandenberghe S, Leibundgut G, Häner J, Moccetti M, Araco M, Garcia-Garcia HM, **Valgimigli M**. A prospective, first-in-human use of the NeVa mechanical thrombectomy device for patients with acute coronary syndromes. *EuroIntervention*. 2022 Jun 24;18(3):242-252. doi: 10.4244/EIJ-D-21-00741. PMID: 34992050.
 494. **Valgimigli M**, Landi A. Distal Transradial Access for Coronary Procedures: Old Certainties, Novel Challenges, and Future Horizons.

JACC Cardiovasc Interv. 2022 Jan 10;15(1):33-38. doi: 10.1016/j.jcin.2021.10.032. Epub 2021 Dec 15. PMID: 34922887.

495. Moroni F, Beneduce A, Giustino G, Briede I, Park SJ, Daemen J, Claude Morice M, Nakamura S, Meliga E, Cerrato E, Makkar RR, D'Ascenzo F, Lucarelli C, Capranzano P, Tchetché D, Templin C, Kirtane A, Buzman P, Alfieri O, **Valgimigli M**, Mehran R, Colombo A, Montorfano M, Chieffo A; DELTA, DELTA 2 Investigators* *. Sex Differences in Outcomes After Percutaneous Coronary Intervention or Coronary Artery Bypass Graft for Left Main Disease: From the DELTA Registries. *J Am Heart Assoc*. 2022 Mar;11(5):e022320. doi: 10.1161/JAHA.121.022320. Epub 2022 Feb 22. PMID: 35189691.
496. Lüscher TF, Davies A, Beer JH, **Valgimigli M**, Nienaber CA, Camm JA, Baumgartner I, Diener HC, Konstantinides SV. Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum. *Eur Heart J*. 2022 Mar 7;43(10):940-958. doi: 10.1093/eurheartj/ehab642. PMID: 34624084.
497. Galea R, De Marco F, Meneveau N, Aminian A, Anselme F, Gräni C, Huber AT, Teiger E, Iriart X, Babongo Bosombo F, Heg D, Franzone A, Vranckx P, Fischer U, Pedrazzini G, Bedogni F, Räber L, **Valgimigli M**. Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical Trial. *Circulation*. 2022 Mar 8;145(10):724-738. doi: 10.1161/CIRCULATIONAHA.121.057859. Epub 2021 Nov 6. PMID: 34747186.
498. Galea R, Mahmoudi K, Gräni C, Elhadad S, Huber AT, Heg D, Siontis GCM, Brugger N, Sebag F, Windecker S, **Valgimigli M**, Landolf Q, Roten L, Amabile N, Räber L. Watchman FLX vs. Watchman 2.5 in a Dual-Center Left Atrial Appendage Closure Cohort: the WATCH-DUAL study. *Europace*. 2022 Mar 7;euac021. doi: 10.1093/europace/euac021. Epub ahead of print. PMID: 35253840.
499. Gragnano F, Zwahlen M, Vranckx P, Heg D, Schmidlin K, Hamm C, Steg PG, Gargiulo G, McFadden EP, Onuma Y, Chichareon P, Benit E, Möllmann H, Janssens L, Leonardi S, Zurakowski A, Arrivi A, Van Geuns RJ, Huber K, Slagboom T, Calabrò P, Serruys PW, Jüni P, **Valgimigli M**, Windecker S; GLOBAL LEADERS Investigators [Link]. Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial. *J Am Heart Assoc*. 2022 May 17;11(10):e024291. doi: 10.1161/JAHA.121.024291. Epub 2022 Mar 1. PMID: 35229616.
500. Ono M, Hara H, Kawashima H, Gao C, Wang R, Wykrzykowska JJ, Piek JJ, Garg S, Hamm C, Steg PG, **Valgimigli M**, Windecker S, Vranckx P, Onuma Y, Serruys PW. Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial. *EuroIntervention*. 2022 Aug 5;18(5):e377-e388. doi: 10.4244/EIJ-D-21-00870. PMID: 35260381.

501. Morici N, De Servi S, De Luca L, Crimi G, Montalto C, De Rosa R, De Luca G, Rubboli A, **Valgimigli M**, Savonitto S. Management of acute coronary syndromes in older adults. *Eur Heart J*. 2022 Apr 19;43(16):1542-1553. doi: 10.1093/eurheartj/ehab391. PMID: 34347065.
502. Heramvand N, Masyuk M, Muessig JM, Nia AM, Karathanos A, Polzin A, **Valgimigli M**, Gurbel PA, Tantry US, Kelm M, Jung C. Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens. *J Thromb Thrombolysis*. 2022 Aug;54(2):301-308. doi: 10.1007/s11239-022-02654-0. Epub 2022 Apr 28. PMID: 35482154; PMCID: PMC9363357.
503. Costa F, **Valgimigli M**, Steg PG, Bhatt DL, Hohnloser SH, Ten Berg JM, Miede C, Nordaby M, Lip GYH, Oldgren J, Cannon CP. Anti-thrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. *Eur Heart J Cardiovasc Pharmacother*. 2022 May 5;8(3):216-226. doi: 10.1093/ehjcvp/pvaa135. PMID: 33258897
504. Kerneis M, Cosentino F, Ferrari R, Georges JL, Kosmachova E, Laroche C, Maggioni AP, Rittger H, Steg PG, Maczynska J, Tavazzi L, **Valgimigli M**, Gale CP, Komajda M; CICD investigators group. Impact of chronic coronary syndromes on cardiovascular hospitalization and mortality: the ESC-EORP CICD-LT registry. *Eur J Prev Cardiol*. 2022 Nov 8;29(15):1945-1954. doi: 10.1093/eurjpc/zwac089. PMID: 35653582.
505. Okuno T, Lanz J, Stortecky S, Heg D, Bernhard B, Gräni C, Huber A, Praz F, Räber L, **Valgimigli M**, Siontis GCM, Windecker S, Pilgrim T. Clinical impact of left atrial appendage filling defects in patients undergoing transcatheter aortic valve implantation. *Eur Heart J Cardiovasc Imaging*. 2022 Sep 10;23(10):1354-1364. doi: 10.1093/ehjci/jeab142. PMID: 34463717.
506. **Valgimigli M**, Smits PC, Frigoli E, Bongiovanni D, Tijssen J, Hovasse T, Mafragi A, Ruifrok WT, Karageorgiev D, Aminian A, Garducci S, Merkely B, Routledge H, Ando K, Diaz Fernandez JF, Cuisset T, Nesa Malik FT, Halabi M, Belle L, Din J, Beygui F, Abhyankar A, Reczuch K, Pedrazzini G, Heg D, Vranckx P; MASTER DAPT Investigators. Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis. *Eur Heart J*. 2022 Sep 1;43(33):3100-3114. doi: 10.1093/eurheartj/ehac284. PMID: 35580836.
507. Valenti R, Muraca I, Marcucci R, Ciatti F, Berteotti M, Gori AM, Carrabba N, Migliorini A, Marchionni N, **Valgimigli M**. “Tailored” antiplatelet bridging therapy with cangrelor: moving toward personalized medicine. *Platelets*. 2022 Jul 4;33(5):687-691. doi: 10.1080/09537104.2021.1983162. Epub 2021 Oct 21. PMID: 34672898.

508. Capodanno D, Bhatt DL, Gibson CM, James S, Kimura T, Mehran R, Rao SV, Steg PG, Urban P, **Valgimigli M**, Windecker S, Angiolillo DJ. Bleeding avoidance strategies in percutaneous coronary intervention. *Nat Rev Cardiol*. 2022 Feb;19(2):117-132. doi: 10.1038/s41569-021-00598-1. Epub 2021 Aug 23. PMID: 34426673
509. Iglesias JF, **Valgimigli M**, Carbone F, Lauriers N, Masci PG, Degrauwe S. Comparative effects of fentanyl versus morphine on platelet inhibition induced by ticagrelor in patients with ST-segment elevation myocardial infarction: Full results of the PERSEUS randomized trial. *Cardiol J*. 2022;29(4):591-600. doi: 10.5603/CJ.a2022.0049. Epub 2022 Jun 28. PMID: 35762079; PMCID: PMC9273249.
510. Landi A, Branca M, Vranckx P, Leonardi S, Frigoli E, Heg D, Calabro P, Esposito G, Sardella G, Tumscitz C, Garducci S, Andò G, Limbruno U, Sganzerla P, Santarelli A, Briguori C, de la Torre Hernandez JM, Pedrazzini G, Windecker S, **Valgimigli M**; MATRIX Investigators. Radial vs Femoral Access in ACS Patients Undergoing Complex PCI Is Associated With Consistent Bleeding Benefit and No Excess of Risks. *Can J Cardiol*. 2022 Oct;38(10):1488-1500. doi: 10.1016/j.cjca.2022.06.014. Epub 2022 Jun 24. PMID: 35753631
511. Spirito A, Papadis A, Vaisnora L, Iacovelli F, Sardu C, Kavaliauskaite R, Lanz J, Temperli F, Asatryan B, Heg D, Hunziker L, Windecker S, Räber L, **Valgimigli M**. Comparative Outcomes After Percutaneous Coronary Intervention in Unconscious and Conscious Patients With Out-of-Hospital Cardiac Arrest. *JACC Cardiovasc Interv*. 2022 Jul 11;15(13):1338-1348. doi: 10.1016/j.jcin.2022.04.024. Epub 2022 Jun 15. PMID: 35798477
512. Spirito A, Quagliana A, Coiro M, Melaku GD, Vandenberghe S, Leibundgut G, Häner J, Moccetti M, Araco M, Garcia-Garcia HM, Valgimigli M. A prospective, first-in-human use of the NeVa mechanical thrombectomy device for patients with acute coronary syndromes. *EuroIntervention*. 2022 Jun 24;18(3):242-252. doi: 10.4244/EIJ-D-21-00741. PMID: 34992050.
513. Vij V, Piayda K, Nelles D, Gloekler S, Galea R, Fürholz M, Meier B, **Valgimigli M**, O'Hara G, Arzamendi D, Agudelo V, Asmarats L, Freixa X, Flores- Umanzor E, De Backer O, Sondergaard L, Nombela-Franco L, McInerney A, Korsholm K, Nielsen-Kudsk JE, Afzal S, Zeus T, Operhalski F, Schmidt B, Montalescot G, Guedeney P, Iriart X, Miton N, Saw J, Gilhofer T, Fauchier L, Veliqi E, Meincke F, Petri N, Nordbeck P, Ognerubov D, Merkulov E, Cruz-González I, Gonzalez-Ferreiro R, Bhatt DL, Laricchia A, Mangieri A, Omran H, Schrickel JW, Rodes- Cabau J, Sievert H, Nickenig G, Sedaghat A. Clinical and echocardiographic risk factors for device-related thrombus after left atrial appendage closure: an analysis from the multicenter EURO-ROC-DRT registry. *Clin Res Cardiol*. 2022 Nov;111(11):1276-1285. doi: 10.1007/s00392-022-02065-4. Epub 2022 Jul 18. PMID: 35849156.

514. Vranckx P, **Valgimigli M**. Antithrombotic therapy in patients with atrial fibrillation undergoing PCI remains a moving target, yet with a clearer direction! *EuroIntervention*. 2022 Jul 22;18(4):e267-e268. doi: 10.4244/EIJ-E-22-00004. PMID: 35866255.
515. Tavenier AH, Mehran R, Chiarito M, Cao D, Pivato CA, Nicolas J, Beerkens F, Nardin M, Sartori S, Baber U, Angiolillo DJ, Capodanno D, **Valgimigli M**, Hermanides RS, van 't Hof AWJ, Ten Berg JM, Chang K, Kini AS, Sharma SK, Dangas G. Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis. *Eur Heart J Cardiovasc Pharmacother*. 2022 Aug 11;8(5):492-502. doi: 10.1093/ehjcvp/pvab068. PMID: 34459481.
516. Biasco L, Valotta A, Klersy C, **Valgimigli M**, Gabutti L, Bruna RD, Pagnamenta A, Ruinelli L, Senatore G, Pedrazzini GB. Association among myocardial injury and mortality in Influenza: A prospective cohort study. *Int J Cardiol*. 2022 Dec 15;369:48-53. doi: 10.1016/j.ijcard.2022.08.016. Epub 2022 Aug 6. PMID: 35944772.
517. Ono M, Onuma Y, Kawashima H, Hara H, Gao C, Wang R, O'Leary N, Benit E, Janssens L, Ferrario M, Żurkowski A, Dominici M, Huber K, Buszman P, Garg S, Wykrzykowska JJ, Piek JJ, Jüni P, Hamm C, Windecker S, Vranckx P, Deliargyris EN, Bhatt DL, Storey RF, **Valgimigli M**, Serruys PW; GLOBAL LEADERS trial investigators. Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial. *Catheter Cardiovasc Interv*. 2022 Jul;100(1):72-82. doi: 10.1002/ccd.30217. Epub 2022 May 2. PMID: 35500171.
518. **Valgimigli M**, Frigoli E, Vranckx P, Ozaki Y, Morice MC, Chevalier B, Onuma Y, Windecker S, Delorme L, Kala P, Kedev S, Abhaichand RK, Velchev V, Dewilde W, Podolec J, Leibundgut G, Topic D, Schultz C, Stankovic G, Lee A, Johnson T, Tonino PAL, Klotzka A, Lesiak M, Lopes RD, Smits PC, Heg D; MASTER DAPT Investigators. Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy. *J Am Coll Cardiol*. 2022 Aug 23;80(8):766-778. doi: 10.1016/j.jacc.2022.04.065. PMID: 35981821.
519. Hagström E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. *Circulation*. 2022 Aug 30;146(9):657-672. doi: 10.1161/CIRCULATIONAHA.121.057807. Epub 2022 Jun 30. PMID: 35770629; PMCID: PMC9422774.
520. Okuno T, Dangas GD, Hengstenberg C, Sartori S, Herrmann HC, de Winter R, Gilard M, Tchétché D, Möllmann H, Makkar RR, Baldus

S, De Backer O, Bendz B, Kini A, von Lewinski D, Mack M, Moreno R, Schäfer U, Wöhrle J, Seeger J, Snyder C, Nicolas J, Tijssen JGP, Welsh RC, Vranckx P, **Valgimigli M**, Mehran R, Kapadia S, Sondergaard L, Windecker S. Two-year clinical outcomes after successful transcatheter aortic valve implantation with balloon-expandable versus self-expanding valves: A subanalysis of the GALILEO trial. *Catheter Cardiovasc Interv.* 2022 Oct;100(4):636-645. doi: 10.1002/ccd.30370. Epub 2022 Aug 30. PMID: 36040717.

521. Gargiulo G, Giacoppo D, Jolly SS, Cairns J, Le May M, Bernat I, Romagnoli E, Rao SV, van Leeuwen MAH, Mehta SR, Bertrand OF, Wells GA, Meijers TA, Siontis GCM, Esposito G, Windecker S, Jüni P, **Valgimigli M**; Radial Trialists' Collaboration. Effects on Mortality and Major Bleeding of Radial Versus Femoral Artery Access for Coronary Angiography or Percutaneous Coronary Intervention: Meta-Analysis of Individual Patient Data From 7 Multicenter Randomized Clinical Trials. *Circulation.* 2022 Nov;146(18):1329-1343. doi: 10.1161/CIRCULATIONAHA.122.061527. Epub 2022 Aug 29. PMID: 36036610.
522. Piccolo R, Bonaa KH, Efthimiou O, Varenne O, Baldo A, Urban P, Kaiser C, de Belder A, Lemos PA, Wilsgaard T, Reifart J, Ribeiro EE, Serruys PW, Byrne RA, de la Torre Hernandez JM, Esposito G, Wijns W, Jüni P, Windecker S, **Valgimigli M**; Coronary Stent Trialists' (CST) Collaboration. Individual Patient Data Meta-analysis of Drug-eluting Versus Bare-metal Stents for Percutaneous Coronary Intervention in Chronic Versus Acute Coronary Syndromes. *Am J Cardiol.* 2022 Nov 1;182:8-16. doi: 10.1016/j.amjcard.2022.07.035. Epub 2022 Sep 6. PMID: 36075755.
523. Smits PC, Frigoli E, Vranckx P, Ozaki Y, Morice MC, Chevalier B, Onuma Y, Windecker S, Tonino PAL, Roffi M, Lesiak M, Mahfoud F, Bartunek J, Hildick-Smith D, Colombo A, Stankovic G, Iñiguez A, Schultz C, Kornowski R, Ong PJJ, Alasnag M, Rodriguez AE, Paradies V, Kala P, Kedev S, Al Mafragi A, Dewilde W, Heg D, **Valgimigli M**; MASTER DAPT Investigators. Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk. *J Am Coll Cardiol.* 2022 Sep 27;80(13):1220-1237. doi: 10.1016/j.jacc.2022.07.016. PMID: 36137672.
524. Ferrante G, Condello F, Rao SV, Maurina M, Jolly S, Stefanini GG, Reimers B, Condorelli G, Lefèvre T, Pancholy SB, Bertrand O, **Valgimigli M**. Distal vs Conventional Radial Access for Coronary Angiography and/or Intervention: A Meta-Analysis of Randomized Trials. *JACC Cardiovasc Interv.* 2022 Nov 28;15(22):2297-2311. doi: 10.1016/j.jcin.2022.09.006. PMID: 36423974.
525. Capodanno D, Baber U, Bhatt DL, Collet JP, Dangas G, Franchi F, Gibson CM, Gwon HC, Kastrati A, Kimura T, Lemos PA, Lopes RD, Mehran R, O'Donoghue ML, Rao SV, Rollini F, Serruys PW, Steg PG, Storey

- RF, **Valgimigli M**, Vranckx P, Watanabe H, Windecker S, Angiolillo DJ. P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. *Nat Rev Cardiol*. 2022 Dec;19(12):829-844. doi: 10.1038/s41569-022-00725-6. Epub 2022 Jun 13. PMID: 35697777.
526. Landi A, Pavon AG, **Valgimigli M**. Sailing in the complexity of the 'shark-fin' sign. *Heart*. 2022 Dec 13;109(1):25-78. doi: 10.1136/heart-jnl-2022-321654. PMID: 36598074.
527. Bongiovanni D, Loizzi F, Landi A, Utsch L, Araco M, Joner M, **Valgimigli M**. EnVast Mechanical Thrombectomy After Thrombus Aspiration Failure in a STEMI With a Massive Thrombotic Burden. *JACC Cardiovasc Interv*. 2023 Jan 9;16(1):112-115. doi: 10.1016/j.jcin.2022.09.050. Epub 2022 Dec 14. PMID: 36599578.
528. Costa F, Montalto C, Branca M, Hong SJ, Watanabe H, Franzone A, Vranckx P, Hahn JY, Gwon HC, Feres F, Jang Y, De Luca G, Kedhi E, Cao D, Steg PG, Bhatt DL, Stone GW, Micari A, Windecker S, Kimura T, Hong MK, Mehran R, **Valgimigli M**. Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials. *Eur Heart J*. 2023 Mar 14;44(11):954-968. doi: 10.1093/eurheartj/ehac706. PMID: 36477292
529. Gargiulo G, Marenni A, Sperandeo L, Manzi L, Avvedimento M, Simonetti F, Canonico ME, Paolillo R, Spinelli A, Borgia F, Diserafino L, Franzone A, Stabile E, Piccolo R, Cirillo P, **Valgimigli M**, Esposito G. Pharmacodynamic effects of cangrelor in elective complex PCI: insights from the POMPEII Registry. *EuroIntervention*. 2023 Mar 20;18(15):1266-1268. doi: 10.4244/EIJ-D-22-00594. PMID: 36512429; PMCID: PMC10015295.
530. Landi A, Branca M, Leonardi S, Frigoli E, Vranckx P, Tebaldi M, Varbella F, Calabró P, Esposito G, Sardella G, Garducci S, Andò G, Limbruno U, Sganzerla P, Santarelli A, Briguori C, Colangelo S, Brugaletta S, Adamo M, Omerovic E, Heg D, Windecker S, **Valgimigli M**; MATRIX Investigators. Transient vs In-Hospital Persistent Acute Kidney Injury in Patients With Acute Coronary Syndrome. *JACC Cardiovasc Interv*. 2023 Jan 23;16(2):193-205. doi: 10.1016/j.jcin.2022.10.009. Epub 2022 Dec 28. PMID: 36697156.
531. Ferrante G, Rao SV, **Valgimigli M**. Reply: Distal Transradial Access in Acute Coronary Syndromes Should We Give the First Try? *JACC Cardiovasc Interv*. 2023 Jan 23;16(2):239-240. doi: 10.1016/j.jcin.2022.12.011. PMID: 36697168.
532. Spirito A, Vaisnora L, Papadis A, Iacovelli F, Sardu C, Selberg A, Bär S, Kavaliauskaite R, Temperli F, Asatryan B, Pilgrim T, Hunziker L, Heg D, **Valgimigli M**, Windecker S, Räber L. Acute Coronary Occlusion in Patients With Non-ST-Segment Elevation Out-of-Hospital Cardiac Arrest. *J Am Coll Cardiol*. 2023 Feb 7;81(5):446-456. doi: 10.1016/j.jacc.2022.10.039. PMID: 36725173.

533. Landi A, Caglioni S, **Valgimigli M**. De-escalation in intensity or duration of dual antiplatelet therapy in patients with coronary artery disease: More than alternative treatment options. *Eur J Intern Med*. 2023 Apr;110:16-18. doi: 10.1016/j.ijim.2023.02.006. Epub 2023 Feb 19. PMID: 36804412.
534. Gragnano F, Mehran R, Branca M, Franzone A, Baber U, Jang Y, Kimura T, Hahn JY, Zhao Q, Windecker S, Gibson CM, Kim BK, Watanabe H, Song YB, Zhu Y, Vranckx P, Mehta S, Hong SJ, Ando K, Gwon HC, Calabrò P, Serruys PW, Dangas GD, McFadden EP, Angiolillo DJ, Heg D, **Valgimigli M**. Single Versus Dual Antiplatelet Therapy (Sidney-2) Collaboration. P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions. *J Am Coll Cardiol*. 2023 Feb 14;81(6):537-552. doi: 10.1016/j.jacc.2022.11.041. PMID: 36754514.
535. Montalto C, Costa F, Leonardi S, Micari A, Oreglia JA, Vranckx P, Capodanno D, Ten Berg J, Lopes RD, **Valgimigli M**. Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials. *Eur Heart J Cardiovasc Pharmacother*. 2023 Apr 10;9(3):220-230. doi: 10.1093/ehjcvp/pvac065. PMID: 36427063.
536. Twine CP, Kakkos SK, Aboyans V, Baumgartner I, Behrendt CA, Bellmunt-Montoya S, Jilma B, Nordanstig J, Saratzis A, Reekers JA, Zlatanovic P; ESVS Guidelines Committee; Antoniou GA, de Borst GJ, Bastos Gonçalves F, Chakfé N, Coscas R, Dias NV, Hinchliffe RJ, Kolh P, Lindholt JS, Mees BME, Resch TA, Trimarchi S, Tulamo R, Vermassen FEG, Wanhainen A; Document Reviewers; Koncar I, Fitridge R, Matsagkas M, **Valgimigli M**. Editor's Choice - European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases. *Eur J Vasc Endovasc Surg*. 2023 May;65(5):627-689. doi: 10.1016/j.ejvs.2023.03.042. Epub 2023 Apr 3. PMID: 37019274
537. Spirito A, **Valgimigli M**, Cao D, Baber U, Mehta SR, Gibson CM, Steg GP, Sharma SK, Goel R, Huber K, Kunadian V, Escaned J, Franzone A, Yaling H, Collier T, Kaul U, Kornowski R, Krucoff M, Moliterno D, Sartori S, Owen R, Zhang Z, Dangas GD, Kastrati A, Angiolillo DJ, Cohen DJ, Vranckx P, Windecker S, Pocock S, Mehran R. Biolimus-eluting vs. other limus-eluting stents in NSTEMI-ACS: A pooled analysis of GLASSY and TWILIGHT. *Int J Cardiol*. 2023 Jul 15;383:24-32. doi: 10.1016/j.ijcard.2023.04.027. Epub 2023 Apr 18. PMID: 37080466.
538. Landi A, Heg D, Frigoli E, Vranckx P, Windecker S, Siegrist P, Cayla G, Włodarczak A, Cook S, Gómez-Blázquez I, Feld Y, Seung-Jung P, Mates M, Lotan C, Gunasekaran S, Nanasato M, Das R, Kelbæk H,

- Teiger E, Escaned J, Ishibashi Y, Montalescot G, Matsuo H, Debeljacki D, Smits PC, **Valgimigli M**; MASTER DAPT Investigators. Abbreviated or Standard Antiplatelet Therapy in HBR Patients: Final 15-Month Results of the MASTER-DAPT Trial. *JACC Cardiovasc Interv.* 2023 Apr 10;16(7):798-812. doi: 10.1016/j.jcin.2023.01.366. PMID: 37045500.
539. Landi A, **Valgimigli M**. Antithrombotic therapy in patients with established atherosclerotic coronary disease. *Heart.* 2023 May 4;heartjnl-2022-321603. doi: 10.1136/heartjnl-2022-321603. Epub ahead of print. PMID: 37142399.
 540. Gragnano F, Mehran R, Calabrò P, **Valgimigli M**. Single Versus Dual Antiplatelet Therapy (Sidney-2) Collaboration. Reply: DAPT Shortening After Complex PCI: Examining the Fine Print. *J Am Coll Cardiol.* 2023 Jun 6;81(22):e193. doi: 10.1016/j.jacc.2023.03.425. PMID: 37257959.
 541. Gragnano F, **Valgimigli M**, Calabrò P. Dibattito sulla monoterapia antiplastrinica: La monoterapia con inibitori del P2Y12: un nuovo paradigma nel trattamento dei pazienti con malattia coronarica [Debate on antiplatelet monotherapy: P2Y12 inhibitor monotherapy in patients with coronary artery disease]. *G Ital Cardiol (Rome).* 2023 Apr;24(4 Suppl 2):19S-20S. Italian. doi: 10.1714/4035.40101. PMID: 37158027.
 542. Steg PG, Szarek M, **Valgimigli M**, Islam S, Zeiher AM, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Goodman SG, Gotcheva N, Harrington RA, Jukema JW, Kim HS, Kim SH, Morais J, Pordy R, Scemama M, White HD, Schwartz GG; ODYSSEY OUTCOMES Investigators. Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome. *Can J Cardiol.* 2023 Oct;39(10):1315-1324. doi: 10.1016/j.cjca.2023.04.018. Epub 2023 Apr 26. PMID: 37116789..
 543. **Valgimigli M**, Aboyans V, Angiolillo D, Atar D, Capodanno D, Halvorsen S, James S, Jüni P, Kunadian V, Landi A, Leonardi S, Mehran R, Montalescot G, Navarese EP, Niebauer J, Oliva A, Piccolo R, Price S, Storey RF, Völler H, Vranckx P, Windecker S, Fox KAA. Anti-thrombotic treatment strategies in patients with established coronary atherosclerotic disease. *Eur Heart J Cardiovasc Pharmacother.* 2023 Jul 29;9(5):462-496. doi: 10.1093/ehjcvp/pvad032. PMID: 37120728.
 544. Landi A, Wlodarczak A, Tölg R, Kelbæk H, Legutko J, Galli S, Godin M, Toth GG, Lhermusier T, Honton B, Dietrich PL, Stammen F, Ferdinande B, Silvain J, Capodanno D, Cayla G, **Valgimigli M**; BIOFLOW-DAPT investigators. Design and Rationale of the BIOFLOW-DAPT Trial: a Prospective, Randomized, Multicenter Study to Assess the Safety of the Orsiro Mission Stent Compared to the Resolute Onyx Stent in Subjects at High Risk for Bleeding in Combination with 1-Month Dual Antiplatelet Therapy. *J Cardiovasc Transl Res.* 2023 Oct;16(5):1135-1143. doi: 10.1007/s12265-023-10400-x. Epub 2023 Jun 1. PMID: 37264295.

545. Spirito A, Itchhaporia D, Sartori S, Camenzind E, Chieffo A, Dangas GD, Galatius S, Jeger RV, Kandzari DE, Kastrati A, Kim HS, Kimura T, Leon MB, Mehta LS, Mikhail GW, Morice MC, Nicolas J, Pileggi B, Serruys PW, Smits PC, Steg PG, Stone GW, **Valgimigli M**, Vogel B, von Birgelen C, Weisz G, Wijns W, Windecker S, Mehran R. Impact of chronic kidney disease and diabetes on clinical outcomes in women undergoing PCI. *EuroIntervention*. 2023 Aug 21;19(6):493-501. doi: 10.4244/EIJ-D-23-00086. PMID: 37382924; PMCID: PMC10436070.
546. Guimarães PO, Franken M, Tavares CAM, Silveira FS, Antunes MO, Bergo RR, Joaquim RM, Hirai JCS, Andrade PB, Pitta FG, Mariani J Jr, Nascimento BR, de Paula JET, Silveira MS, Costa TAO, Dall'Orto FTC, Serpa RG, Sampaio FBA, Ohe LN, Mangione FM, Furtado RHM, Sarmiento-Leite R, Monfardini F, Assis SRL, Nicolau JC, Sposito AC, Lopes RD, Onuma Y, **Valgimigli M**, Angiolillo DJ, Serruys PW, Bervanger O, Bacal F, Lemos PA. P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMIND-SET Trial. *EuroIntervention*. 2023 Jul 17;19(4):e323-e329. doi: 10.4244/EIJ-D-23-00125. PMID: 37306039; PMCID: PMC10333918.
547. Galea R, Aminian A, Meneveau N, De Marco F, Heg D, Anselme F, Gräni C, Huber AT, Teiger E, Iriart X, Franzone A, Vranckx P, Fischer U, Pedrazzini G, Bedogni F, **Valgimigli M**, Räber L. Impact of Pre-procedural Computed Tomography on Left Atrial Appendage Closure Success: A Swiss-Apero Trial Subanalysis. *JACC Cardiovasc Interv*. 2023 Jun 12;16(11):1332-1343. doi: 10.1016/j.jcin.2023.02.027. Epub 2023 May 3. PMID: 37316145.
548. Gragnano F, Cao D, Pirondini L, Franzone A, Kim HS, von Scheidt M, Pettersen AR, Zhao Q, Woodward M, Chiarito M, McFadden EP, Park KW, Kastrati A, Seljeflot I, Zhu Y, Windecker S, Kang J, Schunkert H, Arnesen H, Bhatt DL, Steg PG, Calabrò P, Pocock S, Mehran R, **Valgimigli M**; PANTHER Collaboration. P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events. *J Am Coll Cardiol*. 2023 Jul 11;82(2):89-105. doi: 10.1016/j.jacc.2023.04.051. PMID: 37407118.
549. Meijers TA, Aminian A, **Valgimigli M**, Dens J, Agostoni P, Iglesias JF, Gasparini GL, Seto AH, Saito S, Rao SV, van Royen N, Brilakis ES, van Leeuwen MAH. Vascular Access in Percutaneous Coronary Intervention of Chronic Total Occlusions: A State-of-the-Art Review. *Circ Cardiovasc Interv*. 2023 Aug;16(8):e013009. doi: 10.1161/CIRCINTERVENTIONS.123.013009. Epub 2023 Jul 17. PMID: 37458110.
550. Bonanni M, Angelini G, Leo LA, Schlossbauer SA, Bergamaschi L, Landi A, Sangiorgi GM, Forleo C, Pasotti E, Pedrazzini G, **Valgimigli M**, Faletra FF, Guglielmo M, Pavon AG. Multimodality Imaging Evaluation to Detect Subtle Right Ventricular Involvement in Patients with Acute Myocarditis and Preserved Left Ventricular Ejection Fraction.

tion. *J Clin Med*. 2023 Jun 27;12(13):4308. doi: 10.3390/jcm12134308. PMID: 37445342; PMCID: PMC10342404.

551. Munafò AR, Montalto C, Franzino M, Pistelli L, Di Bella G, Ferlini M, Leonardi S, D'Ascenzo F, Gragnano F, Oreglia JA, Oliva F, Ortega-Paz L, Calabrò P, Angiolillo DJ, **Valgimigli M**, Micari A, Costa F. External validity of the PRECISE-DAPT score in patients undergoing PCI: a systematic review and meta-analysis. *Eur Heart J Cardiovasc Pharmacother*. 2023 Dec 14;9(8):709-721. doi: 10.1093/ehjcvp/pvad063. PMID: 37634083.
552. Landi A, Chiarito M, Branca M, Frigoli E, Gagnor A, Calabrò P, Briguori C, Andò G, Repetto A, Limbruno U, Sganzerla P, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Ferrante G, Santarelli A, Sardella G, Varbella F, Heg D, Mehran R, **Valgimigli M**. Validation of a Contemporary Acute Kidney Injury Risk Score in Patients With Acute Coronary Syndrome. *JACC Cardiovasc Interv*. 2023 Aug 14;16(15):1873-1886. doi: 10.1016/j.jcin.2023.06.015. PMID: 37587595.
553. Biasco L, Klersy C, Benfari G, Biaggi P, Corti R, Curti M, Gaemperli O, Jeger R, Maisano F, Mueller O, Naegeli B, Noble S, Praz F, Tersalvi G, Toggweiler S, **Valgimigli M**, Enriquez-Sarano M, Pedrazzini G. Restoration of Life Expectancy After Transcatheter Edge-to-Edge Mitral Valve Repair. *JACC Cardiovasc Interv*. 2023 Sep 25;16(18):2231-2241. doi: 10.1016/j.jcin.2023.06.014. Epub 2023 Aug 23. PMID: 37632476.
554. Rognoni C, Segantin G, Scarsini R, **Valgimigli M**, Loizzi F, Costa F, Armeni P. Cost-effectiveness analysis of pressure-controlled intermittent coronary sinus occlusion in elective percutaneous coronary intervention. *Expert Rev Pharmacoecon Outcomes Res*. 2023 Jul-Dec;23(9):1101-1111. doi: 10.1080/14737167.2023.2249612. Epub 2023 Aug 28. PMID: 37589294.
555. Montalto C, Costa F, Leonardi S, Micari A, Oreglia JA, Vranckx P, Capodanno D, Ten Berg J, Lopes RD, **Valgimigli M**. Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials. *Eur Heart J Cardiovasc Pharmacother*. 2023 Apr 10;9(3):220-230. doi: 10.1093/ehjcvp/pvac065. PMID: 36427063
556. **Valgimigli M**, Wlodarczak A, Tölg R, Merkely B, Kelbæk H, Legutko J, Galli S, Godin M, Toth GG, Lhermusier T, Honton B, Dietrich PL, Stammen F, Ferdinande B, Silvain J, Capodanno D, Cayla G; Bioflow-DAPT Investigators. Biodegradable- Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial. *Circulation*. 2023 Sep 26;148(13):989-999. doi: 10.1161/CIRCULATIONAHA.123.065448. Epub 2023 Aug 25. PMID: 37624364; PMCID: PMC10516164.

557. Verbeeck J, De Backer M, Verwerft J, Salvaggio S, **Valgimigli M**, Vranckx P, Buyse M, Brunner E. Generalized Pairwise Comparisons to Assess Treatment Effects: JACC Review Topic of the Week. *J Am Coll Cardiol*. 2023 Sep 26;82(13):1360-1372. doi: 10.1016/j.jacc.2023.06.047. PMID: 37730293.
558. Yamamoto M, Hayashida K, Hengstenberg C, Watanabe Y, Van Mieghem NM, Jin J, Saito S, **Valgimigli M**, Nicolas J, Mehran R, Moreno R, Kimura T, Chen C, Unverdorben M, Dangas GD. Predictors of All-Cause Mortality After Successful Transcatheter Aortic Valve Implantation in Patients With Atrial Fibrillation. *Am J Cardiol*. 2023 Nov 15;207:150-158. doi: 10.1016/j.amjcard.2023.08.067. Epub 2023 Sep 21. PMID: 37741105.
559. Bikdeli B, Erlinge D, **Valgimigli M**, Kastrati A, Han Y, Steg PG, Stables RH, Mehran R, James SK, Frigoli E, Goldstein P, Li Y, Shahzad A, Schüpke S, Mehdipour G, Chen S, Redfors B, Crowley A, Zhou Z, Stone GW. Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials. *Circulation*. 2023 Oct 17;148(16):1207-1219. doi: 10.1161/CIRCULATIONAHA.123.063946. Epub 2023 Sep 25. PMID: 37746717.
560. Angiolillo DJ, Galli M, Landi A, **Valgimigli M**. DAPT guided by platelet function tests or genotyping after PCI: pros and cons. *EuroIntervention*. 2023 Sep 18;19(7):546-548. doi: 10.4244/EIJ-E-23-00022. PMID: 37720965; PMCID: PMC10493773.
561. Landi A, Morici N, Vranckx P, Frigoli E, Bonacchini L, Omazzi B, Tresoldi M, Camponovo C, Moccetti T, **Valgimigli M**. Edoxaban and/or colchicine in outpatients with COVID-19: rationale and design of the CONVINCe trial. *J Cardiovasc Med (Hagerstown)*. 2023 Dec 1;24(12):920-930. doi: 10.2459/JCM.0000000000001556. Epub 2023 Nov 3. PMID: 37942793.
562. **Valgimigli M**, Spirito A, Sartori S, Angiolillo DJ, Vranckx P, de la Torre Hernandez JM, Krucoff MW, Bangalore S, Bhatt DL, Campo G, Cao D, Chehab BM, Choi JW, Feng Y, Ge J, Hermiller J, Kunadian V, Lupo S, Makkar RR, Maksoud A, Neumann FJ, Picon H, Saito S, Sardella G, Thiele H, Toelg R, Varenne O, Vogel B, Zhou Y, Windecker S, Mehran R. 1- or 3-Month DAPT in Patients With HBR With or Without Oral Anticoagulant Therapy After PCI. *JACC Cardiovasc Interv*. 2023 Oct 23;16(20):2498-2510. doi: 10.1016/j.jcin.2023.08.014. Epub 2023 Oct 4. PMID: 37804290.
563. Sanz-Sanchez J, Garcia-Garcia HM, Branca M, Frigoli E, Leonardi S, Gagnor A, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andò G, Repetto A, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Santarelli A, Sardella G, Varbella F, Tresoldi S, de Cesare N, Rigattieri S, Zingarelli A, Tosi P, van 't Hof A, Boccuzzi G, Omerovic E, Sabaté M, Heg D, Vranckx P, **Valgimigli M**. Coronary calcification in patients presenting with

acute coronary syndromes: insights from the MATRIX trial. *Eur Heart J Acute Cardiovasc Care*. 2023 Nov 16;12(11):782-791. doi: 10.1093/ehjacc/zuad122. PMID: 37812760.

564. Garg M, Garcia-Garcia HM, Calderón AT, Gupta J, Sortur S, Levine MB, Singla P, Picchi A, Sardella G, Adamo M, Frigoli E, Limbruno U, Rigattieri S, Diletti R, Boccuzzi G, Zimarino M, Contarini M, Russo F, Calabro P, Andò G, Varbella F, Garducci S, Palmieri C, Briguori C, Sánchez JS, **Valgimigli M**. Reproducibility of an artificial intelligence optical coherence tomography software for tissue characterization: Implications for the design of longitudinal studies. *Cardiovasc Revasc Med*. 2024 Jan;58:79-87. doi: 10.1016/j.carrev.2023.07.003. Epub 2023 Jul 16. PMID: 37474355.
565. Galea R, Meneveau N, De Marco F, Aminian A, Heg D, Chalkou K, Gräni C, Anselme F, Franzone A, Vranckx P, Fischer U, Bedogni F, Räber L, **Valgimigli M**. One-Year Outcomes After Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: A Prespecified Analysis of the SWISS-APERO Randomized Clinical Trial. *Circulation*. 2024 Feb 6;149(6):484-486. doi: 10.1161/CIRCULATIONAHA.123.067599. Epub 2023 Oct 24. PMID: 37875064.
566. Costa F, Montalto C, **Valgimigli M**. One or 3 months dual antiplatelet therapy in high bleeding risk patients: splitting hair or aiming at the bullseye? *Eur Heart J*. 2024 Jan 1;45(1):71-72. doi: 10.1093/eurheartj/ehad729. PMID: 37981898.
567. Landi A, Alasnag M, Heg D, Frigoli E, Malik FTN, Gomez-Blazquez Landi A, Alasnag M, Heg D, Frigoli E, Malik FTN, Gomez-Blazquez I, Pourbaix S, Chieffo A, Spaulding C, Sainz F, Routledge H, Andò G, Testa L, Sciahbasi A, Contractor H, Jepson N, Mieres J, Imran SS, Noor H, Smits PC, **Valgimigli M**; MASTER DAPT Investigators. Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial. *JAMA Cardiol*. 2024 Jan 1;9(1):35-44. doi: 10.1001/jamacardio.2023.4316. PMID: 37991745; PMCID: PMC10666042.
568. Gragnano F, Calabrò P, Mehran R, **Valgimigli M**; PANTHER Collaboration. Reply: Unconvinced by Data or Resistance to Change? *J Am Coll Cardiol*. 2024 Jan 2;83(1):e11-e12. doi: 10.1016/j.jacc.2023.10.027. PMID: 38171714.
569. Landi A, Aboyans V, Angiolillo DJ, Atar D, Capodanno D, Fox KAA, Halvorsen S, James S, Juni P, Leonardi S, Mehran R, Montalescot G, Navarese EP, Niebauer J, Oliva A, Piccolo R, Price S, Storey RF, Völler H, Vranckx P, Windecker S, **Valgimigli M**. Antithrombotic therapy in patients with acute coronary syndrome: similarities and differences between a European expert consensus document and the 2023 European Society of Cardiology guidelines. *Eur Heart J Acute Cardiovasc Care*. 2024 Feb 9;13(1):173-180. doi: 10.1093/ehjacc/zuad158. PMID: 38170562.

570. Sardella G, Spirito A, Sartori S, Angiolillo DJ, Vranckx P, Hernandez JMT, Krucoff MW, Bangalore S, Bhatt DL, Campo G, Cao D, Chehab BM, Choi JW, Feng Y, Ge J, Godfrey K, Hermiller J, Kunadian V, Makkar RR, Maksoud A, Neumann FJ, Picon H, Saito S, Thiele H, Toelg R, Varenne O, Vogel B, Zhou Y, **Valgimigli M**, Windecker S, Mehran R. 1- Versus 3-Month DAPT in Older Patients at a High Bleeding Risk Undergoing PCI: Insights from the XIENCE Short DAPT Global Program. *Am J Cardiol*. 2024 Mar 1;214:94-104. doi: 10.1016/j.amjcard.2023.12.049. Epub 2024 Jan 6. PMID: 38185438.
571. Landi A, Pedrazzini G, Wild L, Beele A, Nafi M, Joner M, **Valgimigli M**. Coronary embolisation of native aortic valve debris during transcatheter aortic valve replacement: mechanical embolectomy and histopathological analysis. *Lancet*. 2024 Jan 13;403(10422):e5-e6. doi: 10.1016/S0140-6736(23)02623-5. PMID: 38218613.
572. Moreno R, Souza J, Smolnik R, Nombela-Franco L, Van Mieghem NM, Hengstenberg C, **Valgimigli M**, Jin J, Ohlmann P, Dangas G, Unverdorben M, Möllmann H. Outcomes after TAVI in patients with atrial fibrillation and a history of recent PCI: Results from the ENVISAGE-TAVI AF trial. *Clin Res Cardiol*. 2024 Jan 31. doi: 10.1007/s00392-024-02379-5. Epub ahead of print. PMID: 38294497.
573. Ozaki Y, Hong SJ, Heg D, Frigoli E, Vranckx P, Morice MC, Chevalier B, Onuma Y, Windecker S, Di Biasi M, Whitbourn R, Dudek D, Raffel OC, Shimizu K, Calabrò P, Fröbert O, Cura F, Berg JT, Smits PC, **Valgimigli M**. Geographical Variations in the Effectiveness and Safety of Abbreviated or Standard Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients at High Bleeding Risk. *Can J Cardiol*. 2024 Sep;40(9):1671-1674. doi: 10.1016/j.cjca.2024.01.032. Epub 2024 Feb 2. PMID: 38309468.
574. Bergamaschi L, Landi A, Maurizi N, Pizzi C, Leo LA, Arangalage D, Iglesias JF, Eeckhout E, Schwitter J, **Valgimigli M**, Pavon AG. Acute Response of the Noninfarcted Myocardium and Surrounding Tissue Assessed by T2 Mapping After STEMI. *JACC Cardiovasc Imaging*. 2024 Jun;17(6):610-621. doi: 10.1016/j.jcmg.2023.11.014. Epub 2024 Jan 24. PMID: 38276932.
575. Baber U, Jang Y, Oliva A, Cao D, Vogel B, Dangas G, Sartori S, Spirito A, Smith KF, Branca M, Collier T, Pocock S, **Valgimigli M**, Kim BK, Hong MK, Mehran R. Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-Analysis of TWILIGHT and TICO Randomized Trials. *Circulation*. 2024 Feb 20;149(8):574-584. doi: 10.1161/CIRCULATIONAHA.123.067283. Epub 2023 Oct 23. PMID: 37870970.
576. **Valgimigli M**, Gragnano F, Branca M, Franzone A, da Costa BR, Baber U, Kimura T, Jang Y, Hahn JY, Zhao Q, Windecker S, Gibson

CM, Watanabe H, Kim BK, Song YB, Zhu Y, Vranckx P, Mehta S, Ando K, Hong SJ, Gwon HC, Serruys PW, Dangas GD, McFadden EP, Angiolillo DJ, Heg D, Calabrò P, Jüni P, Mehran R; Single Versus Dual Antiplatelet Therapy (Sidney-3) Collaboration. Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis. *JAMA Cardiol.* 2024 May 1;9(5):437-448. doi: 10.1001/jamacardio.2024.0133. PMID: 38506796; PMCID: PMC10955340.

577. Gargiulo G, Cirillo P, Sperandeo L, Forzano I, Castiello DS, Florimonte D, Simonetti F, Paolillo R, Manzi L, Spinelli A, Spaccarotella CAM, Piccolo R, Di Serafino L, Franzone A, Capranzano P, **Valgimigli M**, Esposito G. Cangrelor in contemporary patients with ST-segment elevation myocardial infarction pretreated with Ticagrelor: Pharmacodynamic data from the POMPEII study. *Int J Cardiol Heart Vasc.* 2024 Jan 23;50:101344. doi: 10.1016/j.ijcha.2024.101344. PMID: 38419600; PMCID: PMC10899723.
578. Licordari R, Costa F, Garcia-Ruiz V, Mamas MA, Marquis-Gravel G, de la Torre Hernandez JM, Gomez Doblas JJ, Jimenez-Navarro M, Rodriguez-Capitan J, Urbano- Carrillo C, Ortega-Paz L, Piccolo R, Versace AG, Di Bella G, Andò G, Angiolillo DJ, **Valgimigli M**, Micari A. The Evolving Field of Acute Coronary Syndrome Management: A Critical Appraisal of the 2023 European Society of Cardiology Guidelines for the Management of Acute Coronary Syndrome. *J Clin Med.* 2024 Mar 25;13(7):1885. doi: 10.3390/jcm13071885. PMID: 38610650; PMCID: PMC11012418.
579. Landi A, Gargiulo G, Esposito G, Campo G, Biscaglia S, Heg D, **Valgimigli M**. Does morphine attenuate the Inhibition of Platelet Aggregation for both oral and parenteral P2Y₁₂ inhibitors? *Thromb Res.* 2024 May;237:31-33. doi: 10.1016/j.thromres.2024.03.015. Epub 2024 Mar 15. PMID: 38547691.
580. **Valgimigli M**, Landi A. Clopidogrel Monotherapy for Double-Risk Acute Coronary Syndrome. *JAMA Cardiol.* 2024 Jun 1;9(6):532-533. doi: 10.1001/jamacardio.2024.0547. PMID: 38630487.
581. Vranckx P, **Valgimigli M**. Comparison of 1-month vs. 12-month dual antiplatelet therapy after implantation of drug-eluting stents in patients with acute coronary syndrome: the ULTIMATE-DAPT trial. *Eur Heart J Acute Cardiovasc Care.* 2024 May 7;13(4):368-369. doi: 10.1093/ehjacc/zuae048. PMID: 38598480.
582. De Maria GL, Greenwood JP, Zaman AG, Carrié D, Coste P, **Valgimigli M**, Behan M, Berry C, Erglis A, Panoulas VF, Van Belle E, Juhl Terkelsen C, Hunziker Munsch L, Jain AK, Lassen JF, Palmer N, Stone GW, Banning AP. Pressure- Controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Acute Myocardial Infarction: The PiCSO-AMI-I Trial. *Circ Cardiovasc Interv.* 2024 Apr;17(4):e013675. doi: 10.1161/CIRCINTERVENTIONS.123.013675. Epub 2024 Apr 16. PMID: 38626079.

583. Garin D, Degrauwe S, Carbone F, Musayeb Y, Lauriers N, **Valgimigli M**, Iglesias JF. Differential impact of fentanyl and morphine doses on ticagrelor-induced platelet inhibition in ST-segment elevation myocardial infarction: a subgroup analysis from the PERSEUS randomized trial. *Front Cardiovasc Med*. 2024 Apr 2;11:1324641. doi: 10.3389/fcvm.2024.1324641. PMID: 38628315; PMCID: PMC11018886.
584. Campos CM, Mehran R, Capodanno D, Owen R, Windecker S, Varenne O, Stone GW, **Valgimigli M**, Hajjar LA, Kalil Filho R, Oldroyd K, Morice MC, Urban P, Abizaid A. Risk Burden of Cancer in Patients Treated With Abbreviated Dual Antiplatelet Therapy After PCI: Analysis of Multicenter Controlled High-Bleeding Risk Trials. *Circ Cardiovasc Interv*. 2024 Apr;17(4):e013000. doi: 10.1161/CIRCINTERVENTIONS.122.013000. Epub 2024 Apr 16. PMID: 38626080.
585. Landi A, Heg D, Frigoli E, Routledge H, Malik FT, Pourbaix S, Alasnag M, Smits PC, **Valgimigli M**. Negative selection bias for women inclusion in a clinical trial. *Int J Cardiol*. 2024 Aug 1;408:132138. doi: 10.1016/j.ijcard.2024.132138. Epub 2024 May 3. PMID: 38705207.
586. Guarnieri G, Constantin FD, Pedrazzini G, Ruffino MA, Sürder D, Petrino R, Zucconi EC, Gabutti L, Ognà A, Balestra B, **Valgimigli M**. Integrating Pharmacomechanical Treatments for Pulmonary Embolism Management within a Hub- and-Spoke System in the Swiss Ticino Region. *J Clin Med*. 2024 Apr 23;13(9):2457. doi: 10.3390/jcm13092457. PMID: 38730985; PMCID: PMC11084835.
587. Landi A, Heg D, Frigoli E, Tonino PAL, Vranckx P, Pourbaix S, Chevalier B, Iñiguez A, Pinar E, Lesiak M, Kala P, Donahue M, Windecker S, Roffi M, Smits PC, **Valgimigli M**; MASTER DAPT Investigators. Consecutive or selectively included high bleeding risk patients in the MASTER DAPT screening log and trial. *Eur J Intern Med*. 2024 Aug;126:89-94. doi: 10.1016/j.ejim.2024.04.016. Epub 2024 May 3. PMID: 38704291.
588. Cao D, Vranckx P, **Valgimigli M**, Sartori S, Angiolillo DJ, Bangalore S, Bhatt DL, Feng Y, Ge J, Hermiller J, Makkar RR, Neumann FJ, Saito S, Picon H, Toelg R, Maksoud A, Chehab BM, Choi JW, Campo G, De la Torre Hernandez JM, Krucoff MW, Kunadian V, Sardella G, Spirito A, Thiele H, Varenne O, Vogel B, Zhou Y, Windecker S, Mehran R. One- versus three-month dual antiplatelet therapy in high bleeding risk patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndromes. *EuroIntervention*. 2024 May 20;20(10):e630-e642. doi: 10.4244/EIJ-D-23-00658. PMID: 38776146.
589. Landi A, Morici N, Vranckx P, Frigoli E, Bonacchini L, Omazzi B, Tresoldi M, Camponovo C, Moccetti T, Windecker S, **Valgimigli M**. Edoxaban and/or colchicine for patients with coronavirus disease 2019 managed in the out-of-hospital setting (CONVINCE): a randomized clinical trial. *J Cardiovasc Med (Hagerstown)*. 2024 Jul 1;25(7):565-568. doi: 10.2459/JCM.0000000000001639. Epub 2024 May 28. PMID: 38809247.

590. Torre T, Pozzoli A, **Valgimigli M**, Leo LA, Toto F, Muretti M, Birova S, Ferrari E, Pedrazzini G, Demertzis S. Minimally Invasive Isolated and Hybrid Surgical Revascularization for Multivessel Coronary Disease: A Single-Center Long-Term Follow-Up. *J Pers Med*. 2024 May 15;14(5):528. doi: 10.3390/jpm14050528. PMID: 38793110; PMCID: PMC11122097.
591. Biasco L, Tersalvi G, Klersy C, Benfari G, Biaggi P, Corti R, Curti M, Gaemperli O, Jeger R, Maisano F, Mueller O, Naegeli B, Noble S, Praz F, Toggweiler S, **Valgimigli M**, Cristoforetti Y, Enriquez-Sarano M, Pedrazzini G. Technical and Clinical Outcomes After Transcatheter Edge-to-Edge Repair of Mitral Regurgitation in Male and Female Patients: Is Equality Achieved? *J Am Heart Assoc*. 2024 Jun 4;13(11):e032706. doi: 10.1161/JAHA.123.032706. Epub 2024 May 28. PMID: 38804217.
592. Ueki Y, Häner JD, Losdat S, Gargiulo G, Shibutani H, Bär S, Otsuka T, Kavaliauskaite R, Mitter VR, Temperli F, Spirk D, Stortecky S, Siontis GCM, **Valgimigli M**, Windecker S, Gutmann C, Koskinas KC, Mayr M, Räber L. Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity and Noncoding RNAs in Patients with AMI: A Substudy of the PACMAN-AMI Trial. *Thromb Haemost*. 2024 Jun;124(6):517-527. doi: 10.1055/a-2156-7872. Epub 2023 Aug 18. PMID: 37595625.
593. Mankarious N, Toelg R, Vogel B, Sartori S, Angiolillo DJ, Vranckx P, Feng Y, de la Torre Hernandez JM, Krucoff MW, Bhatt DL, Spirito A, Cao D, Chehab BM, Kunadian V, Maksoud A, Picon H, Sardella G, Thiele H, Varenne O, Windecker S, Richardt G, **Valgimigli M**, Mehran R. One-Month Versus Three-Month Dual- Antiplatelet Therapy in High Bleeding Risk Patients With Chronic Kidney Disease. *Am J Cardiol*. 2024 Aug 15;225:25-34. doi: 10.1016/j.amjcard.2024.06.003. Epub 2024 Jun 12. PMID: 38871156
594. Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Harrington RA, Jukema JW, White HD, Zeiher AM, Manvelian G, Pordy R, Poulouin Y, Stipek W, Garon G, Schwartz GG; ODYSSEY OUTCOMES Investigators. Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation. *Eur Heart J Cardiovasc Pharmacother*. 2024 Jul 16;10(4):342-352. doi: 10.1093/ehjcvp/pvae025. PMID: 38658193; PMCID: PMC11249957.
595. Galli M, Laudani C, Occhipinti G, Spagnolo M, Gragnano F, D'Amario D, Navarese EP, Mehran R, **Valgimigli M**, Capodanno D, Angiolillo DJ. P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis. *Eur Heart J Cardiovasc Pharmacother*. 2024 Nov 6;10(7):588-598. doi: 10.1093/ehjcvp/pvae057. PMID: 39054275.
596. Milzi A, Thomsen TÁ, Landi A, Dettori R, Marx N, Kahles F, Escaned J, Mejía- Rentería H, Burgmaier M, **Valgimigli M**. Diagnostic accura-

cy of quantitative flow ratio in patients with arrhythmias. *EuroIntervention*. 2024 Aug 19;20(16):1039-1041. doi: 10.4244/EIJ-D-24-00144. PMID: 39155760; PMCID: PMC11317827.

597. Stone GW, **Valgimigli M**, Erlinge D, Han Y, Steg PG, Stables RH, Frigoli E, James SK, Li Y, Goldstein P, Mehran R, Mehdipoor G, Crowley A, Chen S, Redfors B, Snyder C, Zhou Z, Bikdeli B. Bivalirudin vs Heparin Anticoagulation in STEMI: Confirmation of the BRIGHT-4 Results. *J Am Coll Cardiol*. 2024 Oct 15;84(16):1512-1524. doi: 10.1016/j.jacc.2024.07.045. PMID: 39384262.
598. Carvalho PEP, Gewehr DM, Nascimento BR, Melo L, Burkhardt G, Rivera A, Braga MAP, Guimarães PO, Mehran R, Windecker S, **Valgimigli M**, Angiolillo DJ, Bhatt DL, Sandoval Y, Chen SL, Stone GW, Lopes RD. Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis. *JAMA Cardiol*. 2024 Dec 1;9(12):1094-1105. doi: 10.1001/jamacardio.2024.3216. PMID: 39382876; PMCID: PMC11581547.
599. Gragnano F, van Klaveren D, Heg D, Räber L, Krucoff MW, Raposeiras-Roubín S, Ten Berg JM, Leonardi S, Kimura T, Corpataux N, Spirito A, Hermiller JB, Abu- Assi E, Chan Pin Yin D, Azzahhafi J, Montalto C, Galazzi M, Bär S, Kavaliauskaite R, D'Ascenzo F, De Ferrari GM, Watanabe H, Steg PG, Bhatt DL, Calabrò P, Mehran R, Urban P, Pocock S, Windecker S, Valgimigli M. Derivation and Validation of the PRECISE-HBR Score to Predict Bleeding After Percutaneous Coronary Intervention. *Circulation*. 2025 Feb 11;151(6):343-355. doi: 10.1161/CIRCULATIONAHA.124.072009. Epub 2024 Oct 27. PMID: 39462482.
600. Roffi M, Landi A, Heg D, Frigoli E, Chalkou K, Chevalier B, Ijsselmuiden AJJ, Kastberg R, Komiyama N, Morice MC, Onuma Y, Ozaki Y, Peace A, Pyxaras S, Sganzerla P, Williams R, Xaplanteris P, Vranckx P, Windecker S, Smits PC, Valgimigli M; MASTER DAPT Investigators. Abbreviated or Standard Antiplatelet Therapy After PCI in Diabetic Patients at High Bleeding Risk. *JACC Cardiovasc Interv*. 2024 Nov 25;17(22):2664-2677. doi: 10.1016/j.jcin.2024.08.030. PMID: 39603779.
601. Milzi A, Rodriguez AE, Piccolo R, Bona KH, Varenne O, Landi A, Kaiser C, Remkes W, Räber L, de la Torre Hernandez JM, **Valgimigli M**. Do Drug-eluting Stents Increase Noncardiac Mortality? *Can J Cardiol*. 2025 Aug;41(8):1612-1614. .
602. Bergamaschi L, Arangalage D, Maurizi N, Pizzi C, **Valgimigli M**, Iglesias JF, Landi A, Leo LA, Eekhout E, Schwitter J, Pavon AG. Hepatic T1 mapping as a novel cardio-hepatic axis imaging biomarker early after ST-elevation myocardial infarction. *Eur Heart J Cardiovasc Imaging*. 2025 Jan 31;26(2):229-238. doi: 10.1093/ehjci/jeae256. PMID: 39364943.

603. Ingraham BS, **Valgimigli M**, Angiolillo DJ, Capodanno D, Rao SV, Urban P, Singh M. Relevance of High Bleeding Risk and Postdischarge Bleeding in Patients Undergoing Percutaneous Coronary Intervention. *Mayo Clin Proc.* 2025 Feb;100(2):304-331. doi: 10.1016/j.mayocp.2024.09.010. PMID: 39909670.
604. Wiebe J, Kuna C, Ibrahim T, Kufner S, Hintz I, Justenhoven P, Kessler T, Schunkert H, **Valgimigli M**, Richardt G, Bresha J, Laugwitz KL, Kastrati A, Cassese S. Ten-year clinical outcomes after left main coronary artery stenting with new-generation or early-generation DES. *Rev Esp Cardiol (Engl Ed).* 2025 Sep;78(9):811-819. English, Spanish. doi: 10.1016/j.rec.2025.02.003. Epub 2025 Feb 15. PMID: 39961399
605. Kunadian V, Gitto M, Vogel B, Sartori S, Angiolillo DJ, Bhatt DL, Chehab BM, Feng Y, de la Torre Hernandez JM, Krucoff MW, Maksoud A, Mankerious N, Oliva A, Picon H, Richardt G, Sardella G, Thiele H, Toelg R, Varenne O, Vranckx P, Windecker S, **Valgimigli M**, Mehran R. 1-Month or 3-Month DAPT in Women and Men at High Bleeding Risk Undergoing PCI. *JACC Cardiovasc Interv.* 2025 Apr 14;18(7):866-878. doi: 10.1016/j.jcin.2025.01.424. Epub 2025 Feb 19. PMID: 39969452.
606. Woelders ECI, Onuma Y, Ninomiya K, O'Leary N, Damman P, Peeters DAM, Hof AWJV, **Valgimigli M**, Vranckx P, Windecker S, Serruys PWJC, van Geuns RM. Parsimonious versus extensive bleeding score: can we simplify risk stratification after percutaneous coronary intervention and reduce bleeding events by de-escalation of the antiplatelet strategy? *Open Heart.* 2025 Jan 28;12(1):e003083. doi: 10.1136/openhrt-2024-003083. PMID: 39875171; PMCID: PMC11781092.
607. Steg PG, Szarek M, Jukema JW, Bhatt DL, Bittner VA, Diaz R, Fazio S, Garon G, Goodman SG, Harrington RA, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES. *Circulation.* 2025 Apr 8;151(14):1047-1050. doi: 10.1161/CIRCULATIONAHA.124.071269. Epub 2025 Apr 7. PMID: 40193536.
608. Minuz P, Giorgetti A, Meneguzzi A, Taus F, Ribeiro RP, Baldessari F, Gargiulo G, Gragnano F, Landi A, Castelli M, Gottardo R, Bortolotti F, Verlato G, Fava C, Cattaneo M, Tagliaro F, **Valgimigli M**. Prasugrel Intermediate Metabolite Modulates Platelet Inhibition by Negatively Interfering With an Active Metabolite: An Ex Vivo, In Vitro, and In Silico Study. *Arterioscler Thromb Vasc Biol.* 2025 May;45(5):792-804. doi: 10.1161/ATVBAHA.124.321916. Epub 2025 Mar 20. PMID: 40109258; PMCID: PMC12017596.
609. Moreno R, Souza J, Smolnik R, Nombela-Franco L, Van Mieghem NM, Hengstenberg C, **Valgimigli M**, Jin J, Ohlmann P, Dangas G,

- Unverdorben M, Möllmann H. Outcomes after TAVI in patients with atrial fibrillation and a history of recent PCI: Results from the EN-VISAGE-TAVI AF trial. *Clin Res Cardiol*. 2025 Mar;114(3):313-322. doi: 10.1007/s00392-024-02379-5. Epub 2024 Jan 31. PMID: 38294497; PMCID: PMC11914355.
610. Bongiovanni D, Landi A, Frigoli E, Heg D, Chalkou K, Bartunek J, Delorme L, Dewilde W, Hildick-Smith D, Leibundgut G, Leonardi S, Lesiak M, Kala P, Kedev S, Roffi M, Stankovic G, Tonino PAL, Velchev V, Vranckx P, Windecker S, Smits PC, **Valgimigli M**; MASTER DAPT Investigators. Recurrent Events Analysis of MASTER DAPT: Total Ischemic and Bleeding Events After Abbreviated vs Prolonged DAPT in HBR Patients. *J Am Coll Cardiol*. 2025 Aug 19;86(7):485-498. doi: 10.1016/j.jacc.2025.05.010. Epub 2025 May 22. PMID: 40406944.
 611. Gargiulo G, Cirillo P, Sperandeo L, Castiello DS, Manzi L, Forzano I, Florimonte D, Simonetti F, Canonico ME, Avvedimento M, Paolillo R, Spinelli A, Buongiorno F, Serafino LD, Spaccarotella CAM, Franzone A, Piccolo R, Stabile E, **Valgimigli M**, Esposito G. Pharmacodynamic effects of cangrelor in patients with acute or chronic coronary syndrome undergoing percutaneous coronary intervention: the POMPEII Registry. *EuroIntervention*. 2025 May 16;21(10):560-570. doi: 10.4244/EIJ-D-24-00757. PMID: 40375762; PMCID: PMC12063553..
 612. Gargiulo G, Piccolo R, Park DW, Nam GB, Okumura Y, Esposito G, **Valgimigli M**. Single vs. dual antithrombotic therapy in patients with oral anticoagulation and stabilized coronary artery disease: a systematic review and meta-analysis of randomized-controlled trials. *J Cardiovasc Med (Hagerstown)*. 2025 Jun 1;26(6):258-265. doi: 10.2459/JCM.0000000000001723. Epub 2025 May 2. PMID: 40472168.
 613. Milzi A, Landi A, Sürder D, Pedrazzini G, **Valgimigli M**. Validation of different acute kidney injury scores in patients undergoing transcatheter aortic valve implantation. *Eur J Intern Med*. 2025 May 29;S0953-6205(25)00186-4. doi: 10.1016/j.ejim.2025.05.003. Epub ahead of print. PMID: 40447466.
 614. Mehran R, Oliva A, **Valgimigli M**. The 2025 ACS Guideline Update Endorses Ticagrelor Monotherapy ≥ 1 Month After DAPT Post-PCI: The Unbearable Lightness of Ticagrelor Monotherapy. *J Am Coll Cardiol*. 2025 Jun 10;85(22):2088-2091. doi: 10.1016/j.jacc.2025.04.046. PMID: 40467135.
 615. Giaccoppo D, Gragnano F, Watanabe H, Kimura T, Kang J, Park KW, Kim HS, Pettersen AA, Bhatt DL, Pocock S, Mehran R, **Valgimigli M**. P2Y12 inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials. *BMJ*. 2025 Jun 4;389:e082561. doi: 10.1136/bmj-2024-082561. PMID: 40467090; PMCID: PMC12135077.

616. Oliva A, Angiolillo DJ, **Valgimigli M**, Cao D, Sartori S, Bangalore S, Bhatt DL, Campo G, Chehab BM, Choi JW, de la Torre Hernandez JM, Feng Y, Ge J, Gitto M, Hermiller J, Krucoff MW, Kunadian V, Makkar RR, Maksoud A, Neumann FJ, Picon H, Saito S, Sardella G, Thiele H, Toelg R, Varenne O, Vogel B, Vranckx P, Windecker S, Mehran R. One- versus three-month DAPT after everolimus-eluting stent implantation in diabetic patients at high bleeding risk: results from the XIENCE Short DAPT programme. *EuroIntervention*. 2025 Jun 16;21(12):e668-e680. doi: 10.4244/EIJ-D-24-00897. PMID: 40522307; PMCID: PMC12151164.
617. Milzi A, Benenati S, Landi A, Kahles F, Porto I, **Valgimigli M**. Optimal revascularization strategy in patients with acute coronary syndrome and multivessel disease: insights from a network meta-analysis. *Clin Res Cardiol*. 2025 Jun 30. doi: 10.1007/s00392-025-02693-6. Epub ahead of print. PMID: 40586898.
618. Galea R, De Marco F, Aminian A, Meneveau N, Chalkou K, Anselme F, Gräni C, Franzone A, Vranckx P, Fischer U, **Valgimigli M**, Räber L. 3-Year Clinical Outcomes Comparing the Amulet vs Watchman FLX for Left Atrial Appendage Closure in Patients With Atrial Fibrillation: Results From the SWISS-APERO Randomized Clinical Trial. *J Am Coll Cardiol*. 2025 Jul 8;86(1):3-14. doi: 10.1016/j.jacc.2025.03.535. PMID: 40602941.
619. Galea R, Krsnik JP, Peters AA, de Marco F, Aminian A, Meneveau N, Chalkou K, Gräni C, Anselme F, Franzone A, Vranckx P, Fischer U, Bedogni F, Räber L, **Valgimigli M**. Evolution and Clinical Relevance of Left Atrial Appendage Residual Patency After Percutaneous Closure: A Prespecified Analysis of the SWISS-APERO Trial. *JACC Cardiovasc Imaging*. 2025 Sep;18(9):1059-1061. doi: 10.1016/j.jcmg.2025.05.004. Epub 2025 Jul 3. PMID: 40608039.
620. De Sio V, Gragnano F, Cesaro A, Moscarella E, Guarnaccia N, Capolongo A, Maddaluna P, Verde G, Acerbo V, Scherillo G, Sabouret P, Giacoppo D, Galli M, Gargiulo G, Esposito G, **Valgimigli M**, Angiolillo DJ, Calabrò P. Cangrelor in percutaneous coronary interventions: advances in evidence, clinical applications, and future directions. *Expert Rev Cardiovasc Ther*. 2025 Sep;23(9):507-519. doi: 10.1080/14779072.2025.2544816. Epub 2025 Aug 12. PMID: 40779402.
621. Galea R, Perich Krsnik J, Peters AA, De Marco F, Aminian A, Meneveau N, Heg D, Gräni C, Anselme F, Franzone A, Vranckx P, Fischer U, Bedogni F, Räber L, **Valgimigli M**. Incidence and predictors of persistent left atrial appendage patency and its subtypes after percutaneous closure: a pre-specified analysis of the SWISS-APERO trial. *Eur Heart J Cardiovasc Imaging*. 2025 Oct 30;26(11):1795-1803. doi: 10.1093/ehjci/jeaf232. PMID: 40795219.

622. Guimarães PO, Franken M, Tavares CAM, Antunes MO, Silveira FS, Andrade PB, Bergo RR, Joaquim RM, Tinoco de Paula JE, Nascimento BR, Pitta FG, Arruda JA, Serpa RG, Ohe LN, Mangione FM, Furtado RHM, Ferreira E, Sampaio FBA, T do Nascimento C, Genelhu LOO, Bezerra CG, Sarmiento-Leite R, Maia LN, Oliveira FRA, Wainstein MV, Dall'Orto FTC, Monfardini F, Assis SRL, Nicolau JC, Sposito AC, Lopes RD, Onuma Y, **Valgimigli M**, Angiolillo DJ, Serruys PWJC, Berwanger O, Bacal F, Lemos PA; NEO-MINDSET Trial Investigators. Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes. *N Engl J Med*. 2025 Aug 31. doi:10.1056/NEJMoa2507980. Epub ahead of print. PMID: 40888723
623. Zito A, Landi A, Milzi A, Frigoli E, Leonardi S, Vranckx P, Vant'Hof AWJ, de la Torre Hernández JM, Campo G, Varbella F, Calabrò P, Andò G, Boccuzzi G, Russo F, **Valgimigli M**. In-hospital platelet count dynamics in patients with acute coronary syndrome. *Rev Esp Cardiol (Engl Ed)*. 2026 Mar;79(3):257-269. English, Spanish. doi: 10.1016/j.rec.2025.09.002. Epub 2025 Sep 16. PMID: 40967571
624. **Valgimigli M**, Choi KH, Giaccoppo D, Gragnano F, Kimura T, Watanabe H, Kim HS, Kang J, Park KW, Pettersen AA, Woodward M, Bhatt DL, Calabrò P, Angiolillo DJ, Mehran R, Song YB, Hahn JY. Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis. *Lancet*. 2025 Sep 13;406(10508):1091-1102. doi:10.1016/S0140-6736(25)01562-4. Epub 2025 Aug 31. PMID: 40902613
625. Landi A, Zito A, Singh M, Angiolillo DJ, Capodanno D, Frigoli E, Milzi A, Rao SV, Urban P, **Valgimigli M**. Validation of the Mayo Clinic Percutaneous Coronary Intervention Risk Prediction Score in Patients With Acute Coronary Syndrome. *J Am Heart Assoc*. 2025 Oct 21;14(20):e043012. doi: 10.1161/JAHA.125.043012. Epub 2025 Oct 9. PMID: 41065238.
626. Tavares CAM, Guimarães PO, Franken M, Junior JM, Lemos S, Almeida BO, Martins EB, Figueiredo EL, da Rocha AM, Soares AA, Marino MA, Paolino B, Santos MO, Caramori PRA, Joaquim RM, Quintella EF, Antonangelo AF, Fonseca AGT, Silveira MS, Fonseca MRD, Monfardini F, Assis SRL, Costa LR, Nicolau JC, Sposito AC, Lopes RD, Onuma Y, **Valgimigli M**, Angiolillo DJ, Serruys PWJC, Berwanger O, Santos RD, Bacal F, Lemos PA; NEO-MINDSET Trial Investigators. Potent P2Y₁₂ Inhibitor Monotherapy vs DAPT After PCI in Patients With and Without STEMI: The NEO-MINDSET Substudy. *J Am Coll Cardiol*. 2026 Jan 27;87(3):297-308. doi: 10.1016/j.jacc.2025.10.058. Epub 2025 Nov 18. PMID: 41384891.
627. Bresha J, Ndrepepa G, Kuna C, Kessler T, Hintz I, Justenhoven P, Ibrahim T, Kufner S, Schunkert H, **Valgimigli M**, Richardt G, Laugwitz KL, Cassese S, Kastrati A, Wiebe J. Ten-Year Outcomes of Pa-

tients with Left Main Coronary Artery Disease and Diabetes Mellitus Treated with Percutaneous Coronary Intervention. *J Clin Med*. 2025 Dec 14;14(24):8851. doi: 10.3390/jcm14248851. PMID: 41464751; PMCID: PMC12734061.

628. Landi A, Mahfoud F, Frigoli E, Chalkou K, Heg D, Abhaichand RK, Abhyankar AD, Barbato E, Beygui F, Danse PW, Garachemani A, Del Blanco BG, Huber K, Koning R, Kukreja N, Piot C, Quang NN, Tirouvanziam A, Valla M, Smits PC, **Valgimigli M**, Master Dapt Investigators OBOT. Abbreviated or standard antiplatelet therapy after PCI in HBR patients with chronic kidney disease: a prespecified analysis from the MASTER DAPT trial. *EuroIntervention*. 2025 Dec 1;21(23):e1445-e1455. doi: 10.4244/EIJ-D-25-00566. PMID: 41342080; PMCID: PMC12641549.
629. Viani GM, Lifka S, Viccaro V, Bergamaschi L, Landi A, Milzi A, Caporali E, Leo LA, Conte G, Suerder D, Caretta A, Caputo ML, Oezkartal T, Pizzi C, Fedele D, Angeli F, Armillotta M, Valotta A, Pedrazzini G, **Valgimigli M**, Pavon AG. Impaired left atrial strain as a predictor of bradyarrhythmias and clinical outcomes following TAVI. *Int J Cardiovasc Imaging*. 2026 Feb;42(2):303-311. doi: 10.1007/s10554-025-03588-3. Epub 2025 Dec 13. PMID: 41389107.
630. Leonardi S, Landi A, Zito A, Branca M, Frigoli E, Ando' G, Briguori C, Calabro P, Gagnor A, Garbo R, Heg D, Limbruno U, Milzi A, Omerovic E, Russo F, Sabaté M, Santarelli A, Sardella G, Tosi P, Van't Hof AWJ, Vranckx P, **Valgimigli M**. Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome. *Circulation*. 2026 Jan 27;153(4):230-242. doi: 10.1161/CIRCULATIONAHA.125.077174. Epub 2026 Jan 6. PMID: 41493005.
631. Gragnano F, Giacoppo D, Choi KH, Kimura T, Watanabe H, Kim HS, Kang J, Park KW, Pettersen AÅ, Woodward M, Bhatt DL, Calabrò P, Angiolillo DJ, Mehran R, Song YB, Hahn JY, **Valgimigli M**. Clopidogrel Versus Aspirin Monotherapy in Coronary Artery Disease: A Sex-Stratified Individual Patient Data Meta-Analysis of Randomized Trials. *Circulation*. 2026 Feb 17;153(7):543-546. doi: 10.1161/CIRCULATIONAHA.126.079221. Epub 2026 Feb 16. PMID: 41697985.
632. Leupp S, Sarzilla S, Caruzzo CA, Landi A, **Valgimigli M**, Milzi A. Refining risk stratification in acute pulmonary embolism: A comparative validation of six prognostic scores in a real-life cohort. *Int J Cardiol*. 2026 May 15;451:134247. doi: 10.1016/j.ijcard.2026.134247. Epub 2026 Feb 18. PMID: 41720405.
633. Carvalho PEP, Antunes VLJ, Bittar de Pontes V, Gomes WF, Polachini Assunes Goncalves B, Caixeta A, Strepkos D, Alexandrou M, Mutlu D, Gibson CM, Stone GW, Bhatt DL, Windecker S, Patel MR, Angiolillo D, Mehran R, **Valgimigli M**, Costa MA, Sandoval Y, Brilakis ES,

Lopes RD, Nascimento BR. IVUS, OCT, or Angiography as Guidance for PCI in Complex Coronary Artery Lesions: Network Meta-Analysis of Randomized Controlled Trials. *JACC Cardiovasc Interv*. 2026 Jan 12;19(1):31-43. doi: 10.1016/j.jcin.2025.11.021. PMID: 41534986

634. Caruzzo CA, Sarzilla SLS, Landi A, **Valgimigli M**, Milzi A. Clinical outcomes after catheter-directed therapies for pulmonary embolism in a regional hub-and-spoke system: lessons learned from a real-world experience. *J Cardiovasc Med (Hagerstown)*. 2026 Mar 1;27(3):194-203. doi: 10.2459/JCM.0000000000001848. Epub 2026 Mar 12. PMID: 41860768
635. Gargiulo G, Narciso V, Forzano I, Sperandeo L, Castiello DS, Simonetti F, Manzi L, Florimonte D, Canonico ME, Avvedimento M, Paolillo R, Spinelli A, Di Serafino L, Spaccarotella CAM, Franzone A, Piccolo R, Stabile E, Cirillo P, **Valgimigli M**, Esposito G. Pharmacodynamic effects of cangrelor in patients with or without STEMI undergoing percutaneous coronary intervention: insights from the POMPEII study. *Eur Heart J Acute Cardiovasc Care*. 2026 Jul 8;15(7):524-534. doi: 10.1093/ehjacc/zuag056. PMID: 41982207; PMCID: PMC13344179.
636. Armillotta M, Bodega F, Bergamaschi L, Paolisso P, Belmonte M, Angeli F, Fedele D, Amicone S, Canton L, Sansonetti A, Cavallo D, Tattilo FP, Di Iuorio O, Ryabenko K, Vasumini N, Maida A, Di Leo M, Manaresi T, Basile M, Rinaldi A, Saia F, Casella G, Fabbri E, Rucci P, Foà A, **Valgimigli M**, Pizzi C. Impact of P2Y₁₂ inhibitor pretreatment on periprocedural (type 4a) myocardial infarction and bleeding in NSTEMI. *Rev Esp Cardiol (Engl Ed)*. 2026 Jun;79(6):557-567. English, Spanish. doi: 10.1016/j.rec.2025.12.002. Epub 2025 Dec 4. PMID: 41352657
637. Zito A, Landi A, Bhatt DL, Chen SL, De Luca G, Franzone A, Gwon HC, Kang J, Hahn JY, Hong SJ, Jang Y, Kim BK, Kim HS, Kimura T, Mehran R, Park KW, Steg PG, Stone GW, Vranckx P, Windecker S, **Valgimigli M**. Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk: A Systematic Review and Meta-Analysis. *JAMA Cardiol*. 2026 Aug 1;11(8):758-766. doi: 10.1001/jamacardio.2026.1922. PMID: 42340698; PMCID: PMC13470303.
638. Cisnal A, Podder I, Grossmann L, Dheman K, Elgendi M, **Valgimigli M**, Paez-Granados D. Towards trustworthy AI-driven cuffless blood pressure monitoring. *NPJ Digit Med*. 2026 Jun 25. doi: 10.1038/s41746-026-02898-7. Epub ahead of print. PMID: 42350588.
639. Chevalier B, Cao D, Smits PC, Brunel P, Frigoli E, Heg D, Higuchi Y, Kauer F, Landi A, Lopes RD, Mainar V, Mamas MA, Mateev H, McDonald J, McFadden EP, Mulassary A, Munir S, Polad J, Reimers B, Sardella G, Ungi I, von Birgerlen C, Weidinger F, Paradies V, **Valgimigli M**; MASTER DAPT Investigators. Abbreviated Dual Antiplatelet Therapy in Patients With High Bleeding Risk Undergoing

PCI of Bifurcation Lesions: A Prespecified Substudy of the MASTER DAPT Trial. *Circ Cardiovasc Interv.* 2026 Jul 13:e016222. doi: 10.1161/CIRCINTERVENTIONS.125.016222. Epub ahead of print. PMID: 42439019.

640. Cao D, Oliva A, Mehran R, Sartori S, Feng Y, Gragnano F, van Klaveren D, Angiolillo DJ, Bangalore S, Bhatt DL, Ge J, Hermiller J, Makkar RR, Neumann FJ, Saito S, Picon H, Toelg R, Maksoud A, Chehab BM, Choi JW, Campo G, de la Torre Hernandez JM, Krucoff MW, Kunadian V, Sardella G, Thiele H, Varenne O, Vranckx P, Windecker S, **Valgimigli M**. Abbreviated DAPT Regimens Across the Entire Spectrum of Bleeding Risk According to the PRECISE-HBR Score. *JACC Cardiovasc Interv.* 2026 Jul 13;19(13):1766-1777. doi: 10.1016/j.jcin.2026.04.051. PMID: 42442892
641. Marquis-Gravel G, Cao D, Taylor D, Pocock SJ, Oliva A, Sartori S, Stefanini GG, Urban P, Varenne O, Windecker S, Smits PC, **Valgimigli M**, Mehran R, Krucoff MW. Timing of Bleeding and Ischemic Events in High-Bleeding Risk Patients Treated With 1-Month DAPT. *JACC Cardiovasc Interv.* 2026 Jul 27;19(14):1910-1922. doi: 10.1016/j.jcin.2026.05.027. PMID: 42508848.
642. Montalescot G, Ferrari E, Souteyrand G, Bouleti C, Range G, Batiast-Moreau L, Chioccioli M, Picchi A, Dillinger JG, Esposito G, Patti G, Vincent F, Braik N, Ederhy S, Coste P, Hannachi S, Redjimi N, Zeitouni M, Duband B, Fourrier E, Guedeney P, Procopi N, Sabouret P, Diallo A, Brochard K, Chamam A, Vignolles N, Kerneis M, Silvain J, Jukema JW, Mach F, Cequier-Fillat A, Thiele H, Bartus S, Bolognese L, Vicaute E; AMUNDSEN Investigators of the ACTION Study Group. LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction: The AMUNDSEN Randomized Clinical Trial. *JAMA.* 2026 Aug 29:e2617302. doi: 10.1001/jama.2026.17302. Epub ahead of print. PMID: 42666092; PMCID: PMC13526255.
643. Di Muro FM, Sartori S, Angiolillo DJ, Bhatt DL, Cao D, Chehab BM, Dangas G, Feng Y, De la Torre Hernandez JM, Krucoff MW, Kunadian V, Maksoud A, Mankarious N, Oliva A, Picon H, Richardt G, Sardella G, Thiele H, Toelg R, Varenne O, Vranckx P, Windecker S, **Valgimigli M**, Mehran R. Baseline Anemia and Short Dual Antiplatelet Therapy in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention. *Eur J Prev Cardiol.* 2026 Jul 23:zwag384. doi: 10.1093/eurjpc/zwag384. Epub ahead of print. PMID: 42490611.
644. **Valgimigli M**, Frigoli E, Landi A, Covani M, Biscaglia S, Cuculi F, Erriquez A, Bossard M, Mangieri A, Meuwissen M, Iglesias JF, Sangiorgi G, Lipšic E, Oreglia JA, Häner JD, Paradies V, Pavon AG, Leo LA, Gragnano F, Fuentes F, Viccaro V, Colombo A, Branca S, Leonardi S, Garcia-Garcia HM; NATURE Investigators. Stent Retriever

Thrombectomy in Patients With Myocardial Infarction The Open-label, Multicenter NATURE Superiority trial. *J Am Coll Cardiol*. 2026 Aug 29;S0735-1097(26)07586-8. doi: 10.1016/j.jacc.2026.08.034. Epub ahead of print. PMID: 42670735.

645. Chiarito M, Mehran R, Gibson MC, Cannon CP, Lopes RD, Sartori S, Oliva A, Smith K, Feng Y, Lampert J, Goette A, Kastrati A, Owen R, Ten Berg JM, Verheugt FWA, Vranckx P, **Valgimigli M**, Bhatt DL, Alexander J, Pocock S. Antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation: an individual patient data network meta-analysis. *Eur Heart J*. 2026 Aug 30;ehag740. doi: 10.1093/eurheartj/ehag740. Epub ahead of print. PMID: 42669062.
646. Milzi A, Landi A, Leonardi S, Frazzetto M, Covani M, Frigoli E, Vant'Hof AWJ, Vranckx P, **Valgimigli M**; MATRIX investigators. Impact of guidelines- directed very-high-risk criteria in the identification and management of occlusion myocardial infarction in patients with NSTEMI-ACS. *Eur Heart J Acute Cardiovasc Care*. 2026 Aug 17;zuag096. doi: 10.1093/ehjacc/zuag096. Epub ahead of print. PMID: 42613587.
647. Mankarious N, Hemetsberger R, Wlodarczak A, Merkely B, Kelbæk H, Cayla G, Legutko J, Galli S, Godin M, Toth GG, Lhermusier T, Saad M, Honton B, Sanguineti F, Dietrich PL, Frank D, Stammen F, Ferdinande B, Silvain J, Capodanno D, Nef H, Richardt G, Toelg R, **Valgimigli M**. Biodegradable polymer sirolimus-eluting or durable polymer zotarolimus-eluting stents in high bleeding-risk patients with acute coronary syndrome: the BIOFLOW-DAPT randomized trial. *Eur Heart J Acute Cardiovasc Care*. 2026 Aug 29;15(8):596-607. doi: 10.1093/ehjacc/zuag089. PMID: 42555546.
648. Gibson CM, Steg PG, Bahit MC, Al-Lamee R, Mehta SR, Mehran R, Weitz JI, Goto S, Nicolau JC, Lopes RD, Ge J, Tasic N, Angiolillo DJ, Baron SJ, Kirtane AJ, Xavier D, Yasuda S, Lewis BS, Park DW, Cornel JH, Johnson TW, Trebacz J, Duerschmied D, Bode C, Merkely B, Dorobantu M, Vinereanu D, Motovska Z, Bueno H, Lopez-Sendon JL, Ducrocq G, Ambrosio G, Burgess L, Bohm A, Chiang CE, Morais J, Fong A, Guray U, Leiva-Pons JL, Vranckx P, White HD, Kedev S, **Valgimigli M**, Cerovec D, Tousoulis D, Figtree G, Ho TD, Sy RG, Böttcher M, Huber K, Slapikas R, Erglis A, Tan JWC, Pincetti C, Pieper KS, Mahaffey KW, Lam CSP, Johnston SC, Hankey GJ, Zheng L, Aronson R, Li D, Notani R, Vieira Pires P, Povsic TJ, Lindsay AC, Plotnikov A, Deng H, Barnathan ES, Harrington RA; LIBREXIA ACS Committees and Investigators. Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event. *N Engl J Med*. 2026 Aug 29. doi: 10.1056/NEJMoa2608717. Epub ahead of print. PMID: 42670965.

Review articles

1. Ferrari R, Guardigli G, Cicchitelli G, **Valgimigli M**, Soukhomovskaia O, Ceconi C. Cardioprotection with ACE inhibitors: non-angiotensin II-related mechanisms. *Eur Heart J* 2000;2(Suppl I):I22-I28.
2. **Valgimigli M**, Curello S, Ceconi C, Agnoletti L, Comini L, Bachetti T, E. Merli R. Ferrari Neurohormones, Cytokines and Programmed cell death in heart failure. A new paradigm for the remodeling heart. *Cardiovasc Drugs Ther.* 2001 Nov;15(6):529-37.
3. Agnoletti L, Curello S, Malacarne F, Airo P, Cargnoni A, **Valgimigli M**, Ferrari R. Immune activation in severe heart failure. Does etiology play a role? *Eur Heart J.* 2004;6(Suppl F):F22-F29.
4. **Valgimigli M**, Ferrari R. Myocardial Regeneration Through Stem cells. The new frontier. www.guidant.com/hf-contakt/vol-13/stem.htm
5. Ferrari R, Guardigli G, Cicchitelli G, **Valgimigli M**, Merli E, Soukhomoiaskaia O, Ceconi C. Angiotensin II overproduction: enemy of the vessel wall. *Eur Heart J.* 2002;4 (Suppl A):A26-A30.
6. Ferrari R, **Valgimigli M**. Quanto si estende la finestra terapeutica nell'infarto miocardico trattato con trombolisi. *Conoscere e curare il Cuore* 2002:139-144.
7. Ferrara R, Mastrorilli F, Pasanisi G, Censi S, D'Aiello N, Fucili A, **Valgimigli M**, Ferrari R. Neurohormonal modulation in chronic heart failure. *Eur Heart J. Suppl.* 2002;4:D3-D11.
8. **Valgimigli M**, Ferrari R, Masson S, Latini R. Advanced Heart Failure. Tumor Necrosis Factor-alfa and endothelin I antagonisms in humans: two promises still to be taken. *Ital Heart J* 2002;3(8):793-803 Suppl.
9. Ferrari R, Guardigli G, Mele D, **Valgimigli M**, Ceconi C. Myocardial ischaemia: new evidence for angiotensin-converting enzyme inhibition *Eur Heart J.* 2003 Jul;5:E11-E17 Suppl.
10. **Valgimigli M**, Merli E, Malagutti P, Soukhomoskaia O, Cicchitelli G, Macri G, Ferrari R. Endothelial Dysfunction in acute and chronic coronary syndromes. Evidence for a pathogenetic role of oxidative stress. *Archives in Biochemistry and Biophysics.* 2003;420(2):255-261.
11. Malagutti P, **Valgimigli M**, de Feyter PJ. EuroPCR highlights 2005. *EuroIntervention*, 2005 Sep; 2.
12. **Valgimigli M**, Percoco GF, Cicchitelli G, Campo G, Gardini E, Pellegrino L, Malagutti P, Giretti C, Ferrari R. New and old strategies to afford the liberal use of drug-eluting stents in real-life scenarios. *Eur Heart J* 2005 Oct;7:K31-K35 Suppl.
13. **Valgimigli M**, Squasi PA, Gaitani S, Arcozzi C, Martano S, Ferrari R. Markers of coronary damage. From diagnosis to prognosis. *Recenti Prog Med.* 2005 Nov;96(11):566-72. Italian.
14. M. Valgimigli, P. Agostoni, P.W. Serruys. Acute coronary syndrome: emphasis shift from treatment to prevention. The enduring challenge of

vulnerable plaque detection in the cardiac catheterization laboratory. *J Cardiovasc Med (Hagerstown)*. 2007 Apr;8(4):221-9.

15. Van 't Hof AW, **Valgimigli M**. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. *Drugs*. 2009;69(1):85-100.
16. Leone AM, **Valgimigli M**, Giannico MB, Zacccone V, Perfetti M, D'Amario D, Rebuzzi AG, Crea F. From bone marrow to the arterial wall: the ongoing tale of endothelial progenitor cells. *Eur Heart J* 2009 Apr;30(8):890-9.
17. **Valgimigli M**, DE SERVI S. I Nuovi Antitrombotici Possono Influenzare La Vostra Pratica Interventistica? *Giornale Italiano Di Cardiologia* 2010 Feb; 11:1 n. 2.
18. Campo G, Fileti L, **Valgimigli M**, Tebaldi M, Cangiano E, Cavazza C, Marchesini J, Ferrari R. Poor response to clopidogrel: Current and Future Options For its Management. *The Journal of Thrombosis and Thrombolysis*. 2010 Oct;30(3):319-31.
19. Testa L, Bhindi R, Van Gaal WJ, Latini RA, Pizzocri S, Lanotte S, Biondi Zoccai GG, **Valgimigli M**, Laudisa ML, Brambilla N, Banning AP, Bedogni F. What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel. *QJM*. 2010 Jun;103(6):367-77.
20. **Valgimigli M**, Tebaldi M. Safety Evaluation of Tirofiban. *Expert Opinion Drug Safety* 2010 Sep;9(5):801-19.PMID: 20670206.
21. **Valgimigli M**, De Servi S. I nuovi atitrombotici possano influenzare la vostra pratica interventistica? *G Ital Cardiol* 2010;11(1Suppl 2).
22. **Valgimigli M**, Minarelli M. Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: balancing safety and efficacy. *American Heart Journal* 2010 Dec;160(6 Suppl):S36-41.
23. Testa L, Biondi Zoccai GG, **Valgimigli M**, Latini RA, Pizzocri S, Lanotte S, Laudisa ML, Brambilla N, Ward MR, Figtree GA, Bedogni F, Bhindi R. Current concepts on antiplatelet therapy: focus on the novel thienopyridine and non-thienopyridine agents. *Advances in Hematology*. 2010;2010:595934. Epub 2010 Dec 5.
24. Fileti L, Campo G, **Valgimigli M**, Marchesini J, Ferrari R. Current options to manage clopidogrel poor responsiveness. *G Ital Cardiol (Rome)*. 2010 Dec;11(12):881-9.
25. Campo G, Miccoli M, Tebaldi M, Marchesini J, Fileti L, Monti M, **Valgimigli M**, Ferrari R. Genetic determinants of on-clopidogrel high platelet reactivity. *Platelets*. 2011;22(6):399-407.
26. Vranckx P, **Valgimigli M**, Serruys P. Looking back into the future: desirudin in acute coronary syndromes and coronary stenting. *Euro Intervention*. 2011 Jun;7(2):263-9. doi: 10.4244.
27. **Valgimigli M**. Clinical dilemmas on managing antiplatelet therapies after percutaneous coronary intervention: benefits versus risks. *Current Opinion Cardiology*. 2011 Dec;26 Suppl 1.

28. **Valgimigli M**, Minarelli M. Triple antiplatelet therapy in acute coronary syndromes. *Drugs*. 2011 Sep 10;71(13):1703-19.
29. Musumecia G, Di Lorenzo E, **Valgimigli M**. Dual antiplatelet therapy duration: what are the drivers? *Current Opinion Cardiology*. 2011 Dec;26 Suppl 1:S4-14.
30. Fileti L, Campo G, **Valgimigli M**. Latest clinical data on testing for high on-treatment platelet reactivity. *Rev Cardiovasc Med*. 2011;12 Suppl 1:S14-22.
31. **Valgimigli M**. Identifying responsiveness to oral P2Y₁₂ receptor blockers: platelet function assays and genetic tests. *J Cardiovasc Med (Hagerstown)*. 2013 Dec;14 Suppl 1:S8-S15. doi:10.2459/JCM.0b013e328364bd25.
32. Rodriguez-Granillo GA, Rodriguez AE, Bruining N, Milei J, Aoki J, Tsuchida K, del Valle-Fernández R, Arampatzis CA, Ong AT, Lemos PA, Ayala F, Garcia-Garcia HM, Saia F, **Valgimigli M**, Regar E, McFadden E, Biondi-Zoccai G, Barbenza E, Schoenhagen P, Serruys PW. Quantification of scientific output in cardiovascular medicine: a perspective based on global data. *EuroIntervention*. 2013 Dec;9(8):975-8. doi: 10.4244/EIJV9I8A163.
33. **Valgimigli M**, Biscaglia S. Stable angina pectoris. *Curr Atheroscler Rep*. 2014 Jul;16(7):422. doi: 10.1007/s11883-014-0422-4.
34. Wallentin L, Kristensen SD, Anderson JL, Tubaro M, Sendon JL, Granger CB, Bode C, Huber K, Bates ER, **Valgimigli M**, Steg PG, Ohman EM. How can we optimize the processes of care for acute coronary syndromes to improve outcomes? *Am Heart J*. 2014 Nov;168(5):622-31. doi: 10.1016/j.ahj.2014.07.006.
35. Huber K, Bates ER, **Valgimigli M**, Wallentin L, Kristensen SD, Anderson JL, Lopez Sendon JL, Tubaro M, Granger CB, Bode C, Ohman EM, Steg PG. Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold? *Am Heart J*. 2014 Nov;168(5):611-21. doi: 10.1016/j.ahj.2014.06.014.
36. **Valgimigli M**. Pretreatment with P2Y₁₂ inhibitors in non-ST-segment-elevation acute coronary syndrome is clinically justified. *Circulation*. 2014 Nov 18;130(21):1891-903; discussion 1903. doi: 10.1161/CIRCULATIONAHA.114.011319. R.
37. Romaguera R, Brugaletta S, Gomez-Lara J, Pinar E, Jiménez-Quevedo P, Gracida M, Roura G, Ferreiro JL, Teruel L, Gómez-Hospital JA, Montanya E, Alfonso F, **Valgimigli M**, Sabate M, Cequier A. Rationale and study design of the RESERVOIR trial: A randomized trial comparing reservoir-based polymer-free amphiphilic-eluting stents versus everolimus-eluting stents with durable polymer in patients with diabetes mellitus. *Cat Cardiovasc Interv*. 2014 Nov 7. doi: 10.1002/ccd.25728.
38. Cortese B, Sebik R, **Valgimigli M**. The conundrum of antithrombotic drugs before, during and after primary PCI. *EuroIntervention*. 2014 Aug;10 Suppl T:T64-73. doi: 10.4244/EIJV10STA11.

39. Felix C, Everaert B, Diletti R, Van Mieghem N, Daemen J, **Valgimigli M**, de Jaegere PP, Zijlstra F, Regar E, Simsek C, Onuma Y, van Geuns RJ. Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions. *Neth Heart J*. 2015 Mar;23(3):153-60. doi: 10.1007/s12471-015-0652-2.
40. Costa F, Ariotti S, **Valgimigli M**, Kolh P, Windecker S; Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Perspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization: Fifty Years of Revascularization: Where Are We and Where Are We Heading? *J Cardiovasc Transl Res*. 2015 May 19.
41. Gargiulo G, Collet JP, **Valgimigli M**. Antithrombotic therapy in TAVI patients: changing concepts. *EuroIntervention*. 2015 Sep;11 Suppl W:W92-5.
42. Gargiulo G, Moschovitis A, Windecker S, **Valgimigli M**. Developing drugs for use before, during and soon after percutaneous coronary intervention. *Expert Opin Pharmacother*. 2016;17(6):803-18.
43. Santucci A, Gargiulo G, Ariotti S, Marino M, Magnani G, Baldo A, Piccolo R, Franzone A, **Valgimigli M**. Radial versus femoral approach in STEMI: what do we know so far? *Minerva Cardioangiol*. 2016 Jun;64(3):219-37.
44. Andò G, Costa F, Trio O, Oreto G, **Valgimigli M**. Impact of vascular access on acute kidney injury after percutaneous coronary intervention. *Cardiovasc Revasc Med*. 2016 Jul-Aug;17(5):333-8.
45. Gargiulo G, **Valgimigli M**. Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation. *G Ital Cardiol (Rome)*. 2016 Jun;17(6):4-10.
46. Gargiulo G, Windecker S, Vranckx P, Gibson CM, Mehran R, **Valgimigli M**. A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More? *Circulation*. 2016 Dec 6;134(23):1881-1906.
47. Ariotti S, Gargiulo G, **Valgimigli M**. Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease. *Curr Cardiol Rep*. 2017 Jan;19(1):2.
48. Gargiulo G, **Valgimigli M**, Capodanno D, Bittl JA. State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation - past, present and future perspectives. *EuroIntervention*. 2017 Aug 25;13(6):717-733. doi: 10.4244/EIJ-D-17-00468.
49. Costa F, Windecker S, **Valgimigli M**. Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies. *Drugs*. 2017 Oct;77(16):1733-1754. doi: 10.1007/s40265-017-0806-1.
50. Vranckx P, Windecker S, Welsh RC, **Valgimigli M**, Mehran R, Dangas G. Thrombo-embolic prevention after transcatheter aortic valve implantation. *Eur Heart J*. 2017 Jul 25. doi: 10.1093/eurheartj/ehx390.
51. Gaudino M, Burzotta F, Bakaeen F, Bertrand O, Crea F, Di Franco A, Fremes S, Kiemeneij F, Louvard Y, Rao SV, Schwann TA, Tatoulis

- J, Tranbaugh RF, Trani C, **Valgimigli M**, Vranckx P, Taggart DP; The Radial Artery for Percutaneous Coronary Procedures or Surgery? Arterial Grafting International Consortium Alliance. *J Am Coll Cardiol*. 2018 Mar 13;71(10):1167-1175. doi: 10.1016/j.jacc.2018.01.013.
52. Vranckx P, **Valgimigli M**, Heidbuchel H. The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation. *Arrhythm Electrophysiol Rev*. 2018 Mar;7(1):55-61. doi: 10.15420/aer.2017.50.1.
 53. Capodanno D, Mehran R, **Valgimigli M**, Baber U, Windecker S, Vranckx P, Dangas G, Rollini F, Kimura T, Collet JP, Gibson CM, Steg PG, Lopes RD, Gwon HC, Storey RF, Franchi F, Bhatt DL, Serruys PW, Angiolillo DJ. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. *Nat Rev Cardiol*. 2018 Aug;15(8):480-496. doi: 10.1038/s41569-018-0049-1.
 54. Costa F, **Valgimigli M**. The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short. *Cardiovasc Diagn Ther*. 2018 Oct;8(5):630-646. doi: 10.21037/cdt.2018.10.01.
 55. Capodanno D, Alfonso F, Levine GN, **Valgimigli M**, Angiolillo DJ. ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison. *J Am Coll Cardiol*. 2018 Dec 11;72(23 Pt A):2915-2931. doi: 10.1016/j.jacc.2018.09.057.
 56. Gragnano F, Manavifar N, **Valgimigli M**. A call for action in bleeding prevention. *Aging (Albany NY)*. 2019 Jan 11. doi: 10.18632/aging.101745.
 57. Mitsis A, Spirito A, **Valgimigli M**. Complete revascularisation in STEMI: mconsider the benefits but do not forget the risks! *Ann Transl Med*. 2019 Dec;7(Suppl 8):S331. doi: 10.21037/atm.2019.09.121. PubMed PMID: 32016049; PubMed Central PMCID: PMC6976442.
 58. Mitsis A, **Valgimigli M**. Device profile of the XIENCE V and XIENCE Sierra stents for the treatment of coronary artery disease: an overview of safety and efficacy. *Expert Rev Med Devices*. 2020 May;17(5):383-390. doi:10.1080/17434440.2020.1747434. Epub 2020 Apr 10. PubMed PMID: 32274941.
 59. De Luca L, **Valgimigli M**. Unravelling the puzzle of antithrombotic therapies for complex percutaneous coronary intervention. *Eur Heart J Cardiovasc Pharmacother*. 2020 Sep 16:pvaa107. doi: 10.1093/ehjcvp/pvaa107. Online ahead of print. PMID: 33175148.
 60. Banning AP, Sabate M, **Valgimigli M**. The impact of the COVID-19 pandemic upon patients, staff, and on the future practices of percutaneous coronary intervention. *Eur Heart J Suppl*. 2020 Dec 23;22(Suppl Pt t):P13-P18. doi: 10.1093/eurheartj/suaa171. PMID: 33390864; PMCID: PMC7757716.
 61. Rubboli A, **Valgimigli M**, Capodanno D, Lip GYH. Choices in anti-thrombotic management for patients with atrial fibrillation undergo-

ing percutaneous coronary intervention: questions (and answers) in chronological sequence. *Eur Heart J Cardiovasc Pharmacother*. 2021 Jan 16;7(1):68-73. doi: 10.1093/ehjcvp/pvaa047. PMID: 32379867.

62. van der Sangen NMR, Rozemeijer R, Chan Pin Yin DRPP, **Valgimigli M**, Windecker S, James SK, Buccheri S, Ten Berg JM, Henriques JPS, Voskuil M, Kikkert WJ. Patient-tailored antithrombotic therapy following percutaneous coronary intervention. *Eur Heart J*. 2021 Mar 7;42(10):1038-1046. doi: 10.1093/eurheartj/ehaa1097. PMID: 33515031.
63. **Valgimigli M**, Landi A, Angiolillo DJ, Baber U, Bhatt DL, Bonaca MP, Capodanno D, Cohen DJ, Gibson CM, James S, Kimura T, Lopes RD, Mehta SR, Montalescot G, Sibbing D, Steg PG, Stone GW, Storey RF, Vranckx P, Windecker S, Mehran R. Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome. *Circulation*. 2024 Jul 23;150(4):317-335. doi: 10.1161/CIRCULATIONAHA.124.069012. Epub 2024 Jul 22. PMID: 39038086
64. Galli M, Gragnano F, Berteotti M, Marcucci R, Gargiulo G, Calabrò P, Terracciano F, Andreotti F, Patti G, De Caterina R, Capodanno D, **Valgimigli M**, Mehran R, Perrone Filardi P, Cirillo P, Angiolillo DJ; Working Group of Thrombosis of the Italian Society of Cardiology. Antithrombotic Therapy in High Bleeding Risk, Part II: Noncardiac Percutaneous Interventions. *JACC Cardiovasc Interv*. 2024 Oct 28;17(20):2325-2336. doi: 10.1016/j.jcin.2024.09.011. PMID: 39477636.
65. Galli M, Gragnano F, Berteotti M, Marcucci R, Gargiulo G, Calabrò P, Terracciano F, Andreotti F, Patti G, De Caterina R, Capodanno D, **Valgimigli M**, Mehran R, Perrone Filardi P, Cirillo P, Angiolillo DJ; Working Group of Thrombosis of the Italian Society of Cardiology. Antithrombotic Therapy in High Bleeding Risk, Part I: Percutaneous Cardiac Interventions. *JACC Cardiovasc Interv*. 2024 Oct 14;17(19):2197-2215. doi: 10.1016/j.jcin.2024.08.022. PMID: 39415380.
66. Landi A, **Valgimigli M**. Antithrombotic therapy in patients with chronic coronary syndrome: a focus on the 2024 European Society of Cardiology guidelines. *Eur Heart J Acute Cardiovasc Care*. 2025 Mar 22;14(3):178-182. doi: 10.1093/ehjacc/zuae134. PMID: 39657008.
67. Landi A, Gorog DA, **Valgimigli M**. Swinging Pendulum Between Risks and Benefits of Antiplatelet Agents: A Call for Consistency in the Interpretation of Evidence and Guideline Recommendations. *Circulation*. 2025 Jan 14;151(2):126-128. doi: 10.1161/CIRCULATIONAHA.124.070797. Epub 2025 Jan 13. PMID: 39804904.
68. Singh M, **Valgimigli M**. Pretreatment With P2Y₁₂ Inhibitors in Contemporary Practice: Where Do We Stand? *Mayo Clin Proc*. 2025 May;100(5):868-881. doi: 10.1016/j.mayocp.2024.09.031. PMID: 40318906.

69. Byrne RA, **Valgimigli M**, Bhatt DL, Coughlan JJ, Gibson CM, Rossello X, Gorog DA, Ibanez B, James S, Landi A, Steg PG, Stone GW, Andreotti F. Great debate: default duration of dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndrome should be 12 months. *Eur Heart J*. 2025 Mar 8;ehaf070. doi: 10.1093/eurheartj/ehaf070. Epub ahead of print. PMID: 40056109.
70. Vranckx P, **Valgimigli M**, Aleksic M. Shaping the future of acute coronary syndrome management: a look back at 2024. *Eur Heart J Acute Cardiovasc Care*. 2025 Jan 31;14(1):40-43. doi: 10.1093/ehjacc/zuae143. PMID: 39691036.
71. Guarnieri G, Landi A, Barco S, Cassina T, Merlani P, Milzi A, Petrinno R, Rigamonti E, Sürder D, Zucconi E, Pedrazzini G, **Valgimigli M**. Contemporary management of acute pulmonary embolism. *Int J Cardiol*. 2025 Oct 1;436:133422. doi: 10.1016/j.ijcard.2025.133422. Epub 2025 May 25. PMID: 40425077.
72. Viccaro V, Valotta A, Checcoli E, Landi S, Cattaneo F, Milzi A, Duchini M, Viani GM, Caretta A, Schlossbauer S, Landi A, Leo LA, Treglia G, Pedrazzini G, **Valgimigli M**, Pavon AG. Multimodality Imaging in Eosinophilic Myocarditis: A Rare Cause of Heart Failure. *J Cardiovasc Dev Dis*. 2025 Aug 21;12(8):320. doi: 10.3390/jcdd12080320. PMID: 40863386; PMCID: PMC12386955.
73. Galli M, Ten Berg J, **Valgimigli M**, Capodanno D, Gragnano F, Kimura T, Bhatt DL, Gibson CM, Mehran R, Angiolillo DJ. Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease? *Eur Heart J*. 2026 Feb 9;47(5):558-573. doi: 10.1093/eurheartj/ehaf718. PMID: 41211721.
74. Cortese B, Mohammed AA, Malakouti S, Sivalingam J, Chaddad R, El-Mokdad R, Gurgoglione FL, **Valgimigli M**. Antiplatelet treatment after drug-coated balloon treatment: Review of the current evidence and future perspectives. *Am Heart J*. 2026 Jun;296:107361. doi: 10.1016/j.ahj.2026.107361. Epub 2026 Feb 4. PMID: 41651102.
75. Galli M, Simeone B, Ten Berg J, Capodanno D, **Valgimigli M**, Sciarretta S, Greco E, Kastrati A, Montalescot G, Gibson CM, Gorog DA, Mehran R, Angiolillo DJ. Managing bleeds on anticoagulant therapy: a practical guide for clinicians. *Eur Heart J Acute Cardiovasc Care*. 2026 Jul 8;15(7):557-572. doi:10.1093/ehjacc/zuag035. PMID: 41818678; PMCID: PMC13344178.
76. Landi A, Biscaglia S, Cuculi F, Erriquez A, Bossard M, Colombo A, Mangieri A, Meuwissen M, Iglesias JF, Sangiorgi G, Lipšic E, Oreglia JA, Häner JD, Paradies V, Crimi G, Milzi A, Pavon AG, Leo LA, Frigoli E, **Valgimigli M**. The use of mechanical thrombectomy in patients with STEMI and large thrombus burden: design and rationale of the NATURE trial. *Cardiovasc Revasc Med*. 2026 Mar

4:S1553-8389(26)00082-5. doi: 10.1016/j.carrev.2026.03.002. Epub ahead of print. PMID: 41820070

77. Gorog DA, Ten Berg JM, Campo G, Geisler T, Gigante B, Grove EL, Halvorsen S, Huber K, Jeong YH, Lip GYH, Navarese EP, Rubboli A, Siller Matula JM, Storey RF, **Valgimigli M**, Vandenbriele C, Vilahur G, Ahrens I, Ferreira JL. Antithrombotic therapy for secondary prevention in patients with acute coronary syndromes treated with percutaneous coronary intervention: options for personalization to reduce bleeding or ischaemic risks. *Eur Heart J Acute Cardiovasc Care*. 2026 Apr 28;15(4):337-363. doi: 10.1093/ehjacc/zuag021. PMID: 41914626. PMID: 41914626.
78. Angiolillo DJ, Erlinge D, Gale CP, Gorog DA, Ibañez B, Musumeci G, **Valgimigli M**. Real-world adoption of the 2023 European Society of Cardiology guidelines regarding antiplatelet strategies in acute coronary syndromes: Insights from the European READAPT-2 survey. *Int J Cardiol*. 2026 Jun 15;453:134288. doi: 10.1016/j.ijcard.2026.134288. Epub 2026 Mar 10. PMID: 41819190.
79. Pavon AG, Bergamaschi L, Guglielmo M, Angeli F, Armillotta M, Fedele D, Barile L, Cassotta A, di Taranto P, Costantini P, Pedrazzini G, van der Harst P, Schwitter J, **Valgimigli M**, Pizzi C, Nijveldt R. Multiparametric Cardiac Magnetic Resonance Characterization of the Noninfarcted Myocardium: Definition, Assessment, and Clinical Significance. *JACC Cardiovasc Imaging*. 2026 May 19:S1936-878X(26)00228-7. doi: 10.1016/j.jcmg.2026.03.015. Epub ahead of print. PMID: 42165778
80. Galli M, Capodanno D, Berg JT, Cavallari LH, Rao SV, Lemos PA, **Valgimigli M**, Gaudino M, Kastrati A, Steg PG, Lopes RD, Gibson CM, Mehran R, Angiolillo DJ. Aspirin Withdrawal in Patients With Coronary Artery Disease. *J Am Coll Cardiol*. 2026 Jul 8:S0735-1097(26)06769-0. doi: 10.1016/j.jacc.2026.06.003. Epub ahead of print. PMID: 42455105.
81. Berry C, **Valgimigli M**, Patrono C, Gragnano F, Landi A, Gorog DA. Great debate: clopidogrel should now replace aspirin for long-term secondary prevention of coronary artery disease. *Eur Heart J*. 2026 Aug 27:ehag673. doi: 10.1093/eurheartj/ehag673. Epub ahead of print. PMID: 42658047.

Guidelines and Consensus articles

1. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, **Valgimigli M**, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. *Circulation*. 2011 Jun 14;123(23):2736-47.
2. Authors/Task Force Members, Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D; ESC Committee for Practice Guidelines, Bax JJ, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Torbicki A, Vahanian A, Windecker S; Document Reviewers, Windecker S, Achenbach S, Badimon L, Bertrand M, Bøtker HE, Collet JP, Crea F, Danchin N, Falk E, Goudevenos J, Gulba D, Hambrecht R, Herrmann J, Kastrati A, Kjeldsen K, Kristensen SD, Lancellotti P, Mehilli J, Merkely B, Montalescot G, Neumann FJ, Neyses L, Perk J, Roffi M, Romeo F, Ruda M, Swahn E, **Valgimigli M**, Vrints CJ, Widimsky P. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2011 Dec;32(23):2999-3054.
3. Autores/Miembros del Grupo de Trabajo, Steg G, James SK, Atar D, Badano LP, Blomstrom Lundqvist C, A Borger M, di Mario C, Dickstein K, Ducrocq G, Fernández-Avilés F, Hershlick A, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, J Lenzen M, W Mahaffey K, **Valgimigli M**, Van't Hof A, Widimsky P, Zahger D; Comité de la ESC para guías de práctica clínica (CGPC), J Bax J, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S; Revisores del Documento: David Hasdai (Coordinador de la Revisión del CGPC) (Israel), Astin F, Astrom-Olsson K, Budaj A, Clemmensen P, Collet JP, Fox KA, Fuat A, Gustiene O, Hamm CW, Kala P, Lancellotti P, Pietro Maggioni A, Merkely B, Neumann FJ, Piepoli MF, Werf FV, Verheugt F, Wallentin L. Grupo de Trabajo para el manejo del infarto agudo de miocardio con elevación del segmento ST de la Sociedad Europea de Cardiología (ESC). *Rev Esp Cardiol*. 2013 Jan;66(1):53.e1-53.e46. doi: 10.1016/j.recesp.2012.10.014.
4. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti

J, Lenzen MJ, Mahaffey KW, **Valgimigli M**, van 't Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J*. 2012 Oct;33(20):2569-619. doi: 10.1093/eurheartj/ehs215.

5. 2013 Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, Senior R, Taggart DP, van der Wall EE, Vrints CJ; ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers, Knuuti J, **Valgimigli M**, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirim A, Zamorano JL. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J*. 2013 Oct;34(38):2949-3003. doi: 10.1093/eurheartj/ehs296. Erratum in: *Eur Heart J*. 2014 Sep 1;35(33):2260-1.
6. De Luca L, Bolognese L, **Valgimigli M**, Ceravolo R, Danzi GB, Piccaluga E, Rakar S, Cremonesi A, Bovenzi FM; Gruppo di Lavoro dell'Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO); Societa Italiana di Cardiologia Invasiva (SICI-GISE).[ANMCO/SICI-GISE document on antiplatelet therapy in patients with acute coronary syndrome]. *G Ital Cardiol (Rome)*. 2013 Dec;14(12):839-66. doi: 10.1714/1371.15242. Italian.
7. Gorenk B, Blomström Lundqvist C, Brugada Terradellas J, Camm AJ, Hindricks G, Huber K, Kirchhof P, Kuck KH, Kudaiberdieva G, Lin T, Raviele A, Santini M, Tilz RR, **Valgimigli M**, Vos MA, Vrints C, Zeymer U, Lip GY, Potpara T, Fauchier L, Sticherling C, Roffi M, Widimsky P, Mehili J, Lettino M, Schiele F, Sinnaeve P, Boriani G, Lane D, Savelieva I. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. *Europace*. 2014 Nov;16(11):1655-73. doi: 10.1093/europace/euu208. Epub 2014 Aug 29.
8. Gorenk B, Lundqvist CB, Terradellas JB, Camm AJ, Hindricks G, Huber K, Kirchhof P, Kuck KH, Kudaiberdieva G, Lin T, Raviele A, Santini M, Tilz RR, **Valgimigli M**, Vos MA, Vrints C, Zeymer U. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. *Eur Heart J Acute Cardiovasc Care*. 2014 Sep 1. pii: 2048872614550583.
9. Gorenk B, Blomström Lundqvist C, Brugada Terradellas J, Camm AJ, Hindricks G, Huber K, Kirchhof P, Kuck KH, Kudaiberdieva G,

Lin T, Raviele A, Santini M, Tilz RR, **Valgimigli M**, Vos MA, Vrints C, Zeymer U. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. *EuroIntervention*. 2015 Jan 22;10(9):1095-108.

10. Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, Haeusler KG, Boriani G, Capodanno D, Gilard M, Zeymer U, Lane D; Document Reviewers, Storey RF, Bueno H, Collet JP, Fauchier L, Halvorsen S, Lettino M, Morais J, Mueller C, Potpara TS, Rasmussen LH, Rubboli A, Tamargo J, **Valgimigli M**, Zamorano JL. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). *Eur Heart J*. 2014 Dec 1;35(45):3155-79. doi: 10.1093/eurheartj/ehu298.
11. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, **Valgimigli M**, Wijns W, Witkowski A. 2014 ESC/EACTS guidelines on myocardial revascularization. *EuroIntervention*. 2015 Jan;10(9):1024-94. doi: 10.4244/EIJY14M09_01.
12. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Uva MS, Stefanini GG, Taggart DP, Torracca L, **Valgimigli M**, Wijns W, Witkowski A. 2014 ESC/EACTS guidelines on myocardial revascularization. *Rev Esp Cardiol (Engl Ed)*. 2015 Feb;68(2):144.
13. Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, **Valgimigli M**, Wijns W, Witkowski A; ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol Ç, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; EACTS Clinical Guidelines Committee, Sousa Uva M, Achenbach S, Pepper J, Anyanwu A, Badimon L, Bauersachs J, Baumbach A, Beygui F, Bonaros N, De Carlo M, Deaton C, Dobrev D, Dunning J, Eeckhout E, Gielen S, Hasdai D, Kirchhof P, Luckraz H, Mahrholdt H, Montalescot G, Paparella D, Rastan AJ, Sanmartin M, Sergeant P, Silber S, Tamargo J, ten Berg J, Thiele H, van Geuns RJ, Wagner HO, Wassmann S, Wendler O, Zamorano JL. 2014 ESC/

EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur J Cardiothorac Surg*. 2014 Oct;46(4):517-92. doi: 10.1093/ejcts/ezu366.

14. Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kaptein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, **Valgimigli M**, Wijns W, Witkowski A; Authors/Task Force members. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J*. 2014 Oct 1;35(37):2541-619. doi: 10.1093/eurheartj/ehu278.
15. Capodanno D, Lip GY, Windecker S, Huber K, Kirchhof P, Boriani G, Lane D, Gilard M, Collet JP, **Valgimigli M**, Byrne RA. Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement. *EuroIntervention*. 2015 Jan 22;10(9):1015-21. doi: 10.4244/EIJV10I9A174.
16. Barbato E, Carrié D, Dardas P, Fajadet J, Gaul G, Haude M, Khashaba A, Koch K, Meyer-Gessner M, Palazuelos J, Reczuch K, Ribichini FL, Sharma S, Sipötz J, Sjögren I, Suetsch G, Szabó G, Valdés-Chávarri M, Vaquerizo B, Wijns W, Windecker S, de Belder A, **Valgimigli M**, Byrne RA, Colombo A, Di Mario C, Latib A, Hamm C. European expert consensus on rotational atherectomy. *EuroIntervention*. 2015 May 19;11(1):30-6. doi: 10.4244/EIJV11I1A6.
17. **Valgimigli M**, Patrono C, Collet JP, Mueller C, Roffi M; Authors. Questions and answers on coronary revascularization: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J*. 2015 Aug 29.
18. Mueller C, Patrono C, **Valgimigli M**, Collet JP, Roffi M. Questions and answers on diagnosis and risk assessment: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation†. *Eur Heart J*. 2015 Aug 29.
19. Collet JP, Roffi M, Mueller C, **Valgimigli M**, Patrono C, Baumgartner H, Gaemperli O, Zamorano JL. Questions and answers on antithrombotic therapy: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation†. *Eur Heart J*. 2015 Aug 29.

20. Roffi M, Patrono C, Collet JP, Mueller C, **Valgimigli M**, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S. 2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. *Rev Esp Cardiol (Engl Ed)*. 2015 Dec;68(12):1125.
21. Roffi M, Patrono C, Collet JP, Mueller C, **Valgimigli M**, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S, Baumgartner H, Gaemperli O, Achenbach S, Agewall S, Badimon L, Baigent C, Bueno H, Bugiardini R, Carerj S, Casselman F, Cuisset T, Erol Ç, Fitzsimons D, Halle M, Hamm C, Hildick-Smith D, Huber K, Iliodromitis E, James S, Lewis BS, Lip GY, Piepoli MF, Richter D, Rosemann T, Sechtem U, Steg PG, Vrints C, Luis Zamorano J; Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2016 Jan 14;37(3):267-315.
22. Roffi M, Müller C, **Valgimigli M**, Windecker S, Gencer B. [Highlights from the 2015 ESC NSTEMI-ACS Guidelines]. *Rev Med Suisse*. 2016 May 25;12(520):1014-9.
23. Adamo M, Bonmassari R, Bernardi G, Colombo P, Esposito G, Ferlini M, La Manna AG, Limbruno U, Marchese A, Mauro C, Menozzi A, Nicosia A, Rigattieri S, Tarantini G, Tarantino F, **Valgimigli M**, Varbella F, Musumeci G. Bioequivalence and excipients: the case of tirofiban. A warning from the Italian Society of Interventional Cardiology (SICI-GISE). *G Ital Cardiol (Rome)*. 2017 Feb;18(2 Suppl 1):35S-36S.
24. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevanos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, **Valgimigli M**, Varenhorst C, Vranckx P, Widimský P; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2017 Aug 26.
25. **Valgimigli M**, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet ther-

- apy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J*. 2017 Aug 26. doi: 10.1093/eurheartj/ehx419.
26. Jeppsson A, Petricevic M, Kolh P, **Valgimigli M**. 2017 European Society of Cardiology (ESC) focused update on dual antiplatelet therapy in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *Eur J Cardiothorac Surg*. 2017 Sep 26. doi: 10.1093/ejcts/ezx333.
 27. **Valgimigli M**, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN; ESC Scientific Document Group. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). *Eur J Cardiothorac Surg*. 2017 Aug 26. doi: 10.1093/ejcts/ezx334.
 28. International Expert Consensus on Switching Platelet P2Y₁₂ Receptor-Inhibiting Therapies. Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, Sibbing D, So DYF, Trenk D, Alexopoulos D, Gurbel PA, Hochholzer W, De Luca L, Bonello L, Aradi D, Cuisset T, Tantry US, Wang TY, **Valgimigli M**, Waksman R, Mehran R, Montalescot G, Franchi F, Price MJ. *Circulation*. 2017 Nov 14;136(20):1955-1975. doi: 10.1161/CIRCULATIONAHA.117.031164.
 29. Collet JP, Roffi M, Byrne RA, Costa F, **Valgimigli M**; Task Force for the Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC); ESC Scientific Document Group; Task Force for the Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC). Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease: The Task Force for the Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J*. 2017 Aug 26. doi: 10.1093/eurheartj/ehx503.
 30. Damluji AA, Nelson DW, **Valgimigli M**, Windecker S, Byrne RA, Cohen F, Patel T, Brilakis ES, Banerjee S, Mayol J, Cantor WJ, Alfonso CE, Rao SV, Moscucci M, Cohen MG. Transfemoral Approach for Coronary Angiography and Intervention: A Collaboration of International Cardiovascular Societies. *JACC Cardiovasc Interv*. 2017 Nov 27;10(22):2269-2279. doi: 10.1016/j.jcin. 2017.08.035.
 31. Jeppsson A, Petricevic M, Kolh P, **Valgimigli M**. 2017 European Society of Cardiology (ESC) focused update on dual antiplatelet therapy in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *Eur J Cardiothorac Surg*. 2018 Jan 1;53(1):3-4. doi: 10.1093/ejcts/ezx333.

32. **Valgimigli M**, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN; 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. ESC Scientific Document Group. *Eur J Cardiothorac Surg*. 2018 Jan 1;53(1):34-78. doi: 10.1093/ejcts/ezx334.
33. Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, Sibbing D, So DYF, Trenk D, Alexopoulos D, Gurbel PA, Hochholzer W, De Luca L, Bonello L, Aradi D, Cuisset T, Tantry US, Wang TY, **Valgimigli M**, Waksman R, Mehran R, Montalescot G, Franchi F, Price MJ. International Expert Consensus on Switching Platelet P2Y₁₂ Receptor-Inhibiting Therapies. *Circulation*. 2017 Nov 14;136(20):1955-1975. doi:10.1161/CIRCULATIONAHA.117.031164. Epub 2017 Oct 30.
34. Collet JP, Roffi M, Byrne RA, Costa F, **Valgimigli M**; Task Force for the Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) ; ESC Scientific Document Group ; Task Force for the Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) . Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. *Eur Heart J*. 2018 Jan 14;39(3):e1-e33. doi: 10.1093/eurheartj/ehx503.
35. Ibáñez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, **Valgimigli M**, Varenhorst C, Vranckx P, Widimský P. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Rev Esp Cardiol (Engl Ed)*. 2017 Dec;70(12):1082. doi: 10.1016/j.rec.2017.11.010. English, Spanish.
36. **Valgimigli M**, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. *Kardiol Pol*. 2017;75(12):1217-1299. doi: 10.5603/KP.2017.0224.
37. **Valgimigli M**, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL. Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. *Rev Esp Cardiol (Engl Ed)*. 2018 Jan;71(1):42. doi: 10.1016/j.rec.2017.11.020. English, Spanish. No abstract available. Erratum in: *Rev Esp Cardiol (Engl Ed)*. 2018 Apr 11.
38. **Valgimigli M**. The ESC DAPT Guidelines 2017. *Eur Heart J*. 2018 Jan 14;39(3):187-188. doi: 10.1093/eurheartj/ehx768.

39. **Valgimigli M.** 'Ten Commandments' of the 2017 ESC DAPT focused update Guidelines. *Eur Heart J.* 2018 Jan 14;39(3):186. doi: 10.1093/eurheartj/ehy007.
40. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, **Valgimigli M**, Varenhorst C, Vranckx P, Widimský P. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Kardiol Pol.* 2018;76(2):229-313. doi: 10.5603/KP. 2018.0041.
41. Pristipino C, Sievert H, D'Ascenzo F, Louis Mas J, Meier B, Scacciatella P, Hildick-Smith D, Gaita F, Toni D, Kyrle P, Thomson J, Derumeaux G, Onorato E, Sibbing D, Germonpré P, Berti S, Chessa M, Bedogni F, Dudek D, Hornung M, Zamorano J; Evidence Synthesis Team; Eapci Scientific Documents and Initiatives Committee; International Experts. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. *Eur Heart J.* 2018 Oct 25. doi: 10.1093/eurheartj/ehy649.
42. Lip GYH, Collet JP, Haude M, Byrne R, Chung EH, Fauchier L, Halvorsen S, Lau D, Lopez-Cabanillas N, Lettino M, Marin F, Obel I, Rubboli A, Storey RF, **Valgimigli M**, Huber K; ESC Scientific Document Group 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). *Europace.* 2018 Jul 21.
43. Pristipino C, Sievert H, D'Ascenzo F, Mas JL, Meier B, Scacciatella P, Hildick-Smith D, Gaita F, Toni D, Kyrle P, Thomson J, Derumeaux G, Onorato E, Sibbing D, Germonpré P, Berti S, Chessa M, Bedogni F, Dudek D, Hornung M, Zamorano J; European Association of Percutaneous Cardiovascular Interventions (EAPCI); European Stroke Organisation (ESO); European Heart Rhythm Association (EHRA); European Association for Cardiovascular Imaging (EACVI); Association for European Paediatric and Congenital Cardiology (AEPC); ESC Working group on GUCH; ESC Working group on Thrombosis; European Haematological Society (EHA); European Underwater and Baromedical Society (EUBS). European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. *EuroIntervention.* 2018 Aug 25. pii: EIJ-D-18-00622. doi: 10.4244/EIJ-D-18-00622.

44. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; ESC Scientific Document Group. Reviewer **Valgimigli M**. Fourth universal definition of myocardial infarction (2018). *Eur Heart J*. 2018 Aug 25. doi: 10.1093/eurheartj/ehy462. Reviewer.
45. Rossini R, Tarantini G, Musumeci G, Masiero G, Barbato E, Calabrò P, Capodanno D, Leonardi S, Lettino M, Limbruno U, Menozzi A, Marchese UOA, Saia F, **Valgimigli M**, Ageno W, Falanga A, Corcione A, Locatelli A, Montorsi M, Piazza D, Stella A, Bozzani A, Parolari A, Carone R, Angiolillo DJ; Italian Society of Interventional Cardiology (SICI-GISE); Italian Society for the Study of Haemostasis and Thrombosis (SISST); Italian Society of Anesthesia and Intensive Care Medicine (SIAARTI); Italian Society of Surgery (SIC); Italian Society for Cardiac Surgery (SICC); Italian Society of Vascular and Endovascular Surgery (SICVE); Italian Society of Urology (SIU); Italian Orthopaedic Society (SIOT); Italian Society of Thoracic Surgeons (SICT); Italian Federation of Scientific Societies of Digestive System Diseases (FISMAD); Italian Society of Digestive Endoscopy (SIED); Italian Association of Hospital Gastroenterology and Digestive Endoscopy (AIGO); Italian Association of Gastroenterology and Digestive Endoscopy (SIGE); Italian Society of Maxillofacial Surgery (SICMF); Italian Society of Reconstructive Plastic Surgery and Aesthetics (SICPRE); Italian Society of Gynecology and Obstetrics (SIGO); Italian Society of Neurosurgery (SINch); Italian Association of Hospital Pulmonologist (AIPO); Italian Society of Periodontology (SIdP); Italian Society of Ophthalmology (SOI); Italian Association of Hospital Otorhinolaryngologist (AOOD); Italian Association of Hospital Surgeons (ACOI); Association of Obstetricians Gynecologists Italian Hospital (AOGOI). A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2 JACC Cardiovasc Interv. 2018 Mar 12;11(5):417-434. doi: 10.1016/j.jcin.2017.10.051. Review.
46. **Valgimigli M**, Garcia Garcia H, Vrijens B, Vranckx P, McFadden EP, Costa F, Pieper K, Vock DM, Zhang M, Van Es GA, Tricoci P, Baber U, Steg G, Montalescot G, Angiolillo DJ, Serruys PW, Farb A, Windecker S, Kastrati A, Colombo A, Feres F, Jüni P, Stone GW, Bhatt DL, Mehran R, Tijssen JGP. Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). *Eur Heart J*. 2018 Jul 9. doi: 10.1093/eurheartj/ehy377.
47. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, **Valgimigli M**, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining high bleeding risk in patients undergoing percutaneous

coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. *Eur Heart J*. 2019 Aug 14;40(31):2632-2653. doi: 10.1093/eurheartj/ehz372. PMID: 31116395; PMCID: PMC6736433.

48. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, **Valgimigli M**, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. *Circulation*. 2019 Jul 16;140(3):240-261. doi: 10.1161/CIRCULATIONAHA.119.040167. Epub 2019 May 22.
49. Sibbing D, Aradi D, Alexopoulos D, Ten Berg J, Bhatt DL, Bonello L, Collet JP, Cuisset T, Franchi F, Gross L, Gurbel P, Jeong YH, Mehran R, Moliterno DJ, Neumann FJ, Pereira NL, Price MJ, Sabatine MS, So DYF, Stone GW, Storey RF, Tantry U, Trenk D, **Valgimigli M**, Waksman R, Angiolillo DJ. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y₁₂ Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. *JACC Cardiovasc Interv*. 2019 Aug 26;12(16):1521-1537. doi: 10.1016/j.jcin.2019.03.034. Epub 2019 Jun 12. PMID: 31202949.
50. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, **Valgimigli M**, Achenbach S, Bax JJ; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J*. 2020 Jan 14;41(3):407-477. doi: 10.1093/eurheartj/ehz425. PMID: 31504439.
51. Bernat I, Aminian A, Pancholy S, Mamas M, Gaudino M, Nolan J, Gilchrist IC, Saito S, Hahalis GN, Ziakas A, Louvard Y, Montalescot G, Sgueglia GA, van Leeuwen MAH, Babunashvili AM, **Valgimigli M**, Rao SV, Bertrand OF; RAO International Group. Best Practices for the Prevention of Radial Artery Occlusion After Transradial Diagnostic Angiography and Intervention: An International Consensus Paper. *JACC Cardiovasc Interv*. 2019 Nov 25;12(22):2235-2246. doi: 10.1016/j.jcin.2019.07.043. Review. PubMed PMID: 31753298.
52. Leonardi S, Capodanno D, Sousa-Uva M, Vrints C, Rex S, Guarracino F, Bueno H, Lettino M, Price S, **Valgimigli M**, Jeppsson A. Composition, structure, and function of heart teams: a joint position paper of the ACVC, EAPCI, EACTS, and EACTA focused on the management of patients with complex coronary artery disease requiring myocardial revascularization. *Eur J Cardiothorac Surg*. 2021 Apr 13;59(3):522-531. doi: 10.1093/ejcts/ezaa402. PMID: 33459337.
53. Pristipino C, Germonpré P, Toni D, Sievert H, Meier B, D'Ascenzo F, Berti S, Onorato EM, Bedogni F, Mas JL, Scacciatella P, Hildick-Smith

D, Gaita F, Kyrle PA, Thomson J, Derumeaux G, Sibbing D, Chessa M, Hornung M, Zamorano J, Dudek D; EVIDENCE SYNTHESIS TEAM, D'Ascenzo F, Omedè P, Ballocca F, Barbero U, Giordana F, Gili S, Iannaccone M; INTERNATIONAL EXPERTS, Akagi T, Anzola G, Carroll J, Dalvi B, Angelis C, Junbo G, Kasner SE, Michel-Behnke I, Musumeci G, Søndergaard L, Tarantini G, Biondi-Zoccai GGL; joint task force of European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Stroke Organisation (ESO), European Heart Rhythm Association (EHRA), European Association for Cardiovascular Imaging (EACVI), European Paediatric and Congenital Cardiology (AEPC), ESC Working Group on Adult Congenital Heart Disease, ESC Working Group on Thrombosis, European Haematological Society (EHA), European Underwater and Baromedical Society (EUBS); EAPCI SCIENTIFIC DOCUMENTS AND INITIATIVES COMMITTEE, Capodanno D, **Valgimigli M**, Byrne R, Kunadian V. European position paper on the management of patients with patent foramen ovale. Part II - Decompression sickness, migraine, arterial deoxygenation syndromes and select high-risk clinical conditions. *Eur Heart J*. 2021 Apr 21;42(16):1545-1553. doi: 10.1093/eurheartj/ehaa1070. PMID: 33507260.

54. Gorog DA, Ferreiro JL, Ahrens I, Ako J, Geisler T, Halvorsen S, Huber K, Jeong YH, Navarese EP, Rubboli A, Sibbing D, Siller-Matula JM, Storey RF, Tan JWC, Ten Berg JM, **Valgimigli M**, Vandenbriele C, Lip GYH. De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis. *Nat Rev Cardiol*. 2023 Dec;20(12):830-844. doi: 10.1038/s41569-023-00901-2. Epub 2023 Jul 20. PMID: 37474795.
55. Capodanno D, Mehran R, Krucoff MW, Baber U, Bhatt DL, Capranzano P, Collet JP, Cuisset T, De Luca G, De Luca L, Farb A, Franchi F, Gibson CM, Hahn JY, Hong MK, James S, Kastrati A, Kimura T, Lemos PA, Lopes RD, Magee A, Matsumura R, Mochizuki S, O'Donoghue ML, Pereira NL, Rao SV, Rollini F, Shirai Y, Sibbing D, Smits PC, Steg PG, Storey RF, Ten Berg J, **Valgimigli M**, Vranckx P, Watanabe H, Windecker S, Serruys PW, Yeh RW, Morice MC, Angiolillo DJ. Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium. *Circulation*. 2023 Jun 20;147(25):1933-1944. doi: 10.1161/CIRCULATIONAHA.123.064473. Epub 2023 Jun 19. PMID: 37335828.
56. Navarese EP, Landi A, Oliva A, Piccolo R, Aboyans V, Angiolillo D, Atar D, Capodanno D, Fox KAA, Halvorsen S, James S, Jüni P, Kunadian V, Leonardi S, Mehran R, Montalescot G, Niebauer J, Price S, Storey RF, Völler H, Vranckx P, Windecker S, **Valgimigli M**. Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion

network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC). *Eur Heart J Cardiovasc Pharmacother*. 2023 Apr 10;9(3):271-290. doi: 10.1093/ehjcvp/pvad016. PMID: 36869784.

57. Antithrombotic Therapy in High Bleeding Risk, Part I: Percutaneous Cardiac Interventions. Galli M, Gragnano F, Berteotti M, Marcucci R, Gargiulo G, Calabrò P, Terracciano F, Andreotti F, Patti G, De Caterina R, Capodanno D, **Valgimigli M**, Mehran R, Perrone Filardi P, Cirillo P, Angiolillo DJ; Working Group of Thrombosis of the Italian Society of Cardiology. *JACC Cardiovasc Interv*. 2024 Oct 14;17(19):2197-2215. doi: 10.1016/j.jcin.2024.08.022.
58. Antithrombotic Therapy in High Bleeding Risk, Part II: Noncardiac Percutaneous Interventions. Galli M, Gragnano F, Berteotti M, Marcucci R, Gargiulo G, Calabrò P, Terracciano F, Andreotti F, Patti G, De Caterina R, Capodanno D, **Valgimigli M**, Mehran R, Perrone Filardi P, Cirillo P, Angiolillo DJ; Working Group of Thrombosis of the Italian Society of Cardiology. *JACC Cardiovasc Interv*. 2024 Oct 28;17(20):2325-2336. doi: 10.1016/j.jcin.2024.09.011.
59. Angiolillo DJ, Galli M, Alexopoulos D, Aradi D, Bhatt DL, Bonello L, Capodanno D, Cavallari LH, Collet JP, Cuisset T, Ferreira JL, Franchi F, Geisler T, Gibson CM, Gorog DA, Gurbel PA, Jeong YH, Marcucci R, Siller-Matula JM, Mehran R, Neumann FJ, Pereira NL, Rizas KD, Rollini F, So DYF, Stone GW, Storey RF, Tantry US, Berg JT, Trenk D, **Valgimigli M**, Waksman R, Sibbing D. International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary Intervention: 2024 Update. *JACC Cardiovasc Interv*. 2024 Nov 25;17(22):2639-2663. doi: 10.1016/j.jcin.2024.08.027. PMID: 39603778.
82. Atar D, Vandenbriele C, Agewall S, Gigante B, Goette A, Gorog DA, Holme PA, Krychtiuk KA, Rocca B, Siller-Matula JM, **Valgimigli M**, Rubboli A, Klamroth R. Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy. *Eur Heart J Cardiovasc Pharmacother*. 2025 May 2;11(3):275-289. doi: 10.1093/ehjcvp/pvaf006. PMID: 40145128; PMCID: PMC12046583.
83. Gorog DA, Ten Berg JM, Campo G, Geisler T, Gigante B, Grove EL, Halvorsen S, Huber K, Jeong YH, Lip GYH, Navarese EP, Rubboli A, Siller Matula JM, Storey RF, **Valgimigli M**, Vandenbriele C, Vilahur G, Ahrens I, Ferreira JL. Antithrombotic therapy for secondary prevention in patients with acute coronary syndromes treated with percutaneous coronary intervention: options for personalization to reduce bleeding or ischaemic risks. A Clinical Consensus Statement of the ESC Working Group on Thrombosis, the Association for Acute CardioVascular Care of the ESC, the European Association of Percutaneous Cardiovascular Interventions of the ESC, and the ESC Working

Group on Cardiovascular Pharmacology A Clinical Consensus Statement of the ESC Working Group on Thrombosis, the Association for Acute CardioVascular Care of the ESC, the European Association of Percutaneous Cardiovascular Interventions of the ESC, and the ESC Working Group on Cardiovascular Pharmacology. *EuroIntervention*. 2026 Jun 15;22(12):e653-e677. doi: 10.4244/EIJ-E-26-00003. PMID: 42290315; PMCID: PMC13254929

Editorials

1. **Valgimigli M.** Direct comparisons of sirolimus-eluting and paclitaxel-eluting stents are needed. *Evid Based Cardiovasc Med.* 2005 Dec;9(4):294-6.
2. Garcia-Garcia H. M, **Valgimigli M.** Beyond crossing a chronic total occlusion. Are the drug-eluting stents the solution for this old problem? *Eurointervention* 2005(2):129-31.
3. **Valgimigli M.** AMI on the move. *EuroIntervention.* 2011 Aug;7(4):415, 417,419. doi: 10.4244/EIJV7I4A68.
4. **Valgimigli M,** Leonardi S. Peri-procedural myocardial infarction and troponism: a quick journey through the land of confusion. *Heart.* 2012 Oct;98(19):1400-1. doi: 10.1136/heartjnl-2012-302612.
5. Biondi-Zoccai G, **Valgimigli M.** Deferred angioplasty and stenting in primary percutaneous coronary intervention: one step back, two steps forward? *EuroIntervention.* 2013 Feb 22;8(10):1119-23. doi: 10.4244/EIJV8I10A173.
6. **Valgimigli M.** Shifting the focus to recurrences: so good we can afford it or too bad we cannot avoid it? *JACC Cardiovasc Interv.* 2014 Oct;7(10):1114-6. doi: 10.1016/j.jcin.2014.07.006.
7. **Valgimigli M,** Ariotti S, Costa F. Duration of dual antiplatelet therapy after drug-eluting stent implantation: will we ever reach a consensus? *Eur Heart J.* 2015 May 21;36(20):1219-22.
8. Ariotti S, Gargiulo G, Windecker S, **Valgimigli M.** Time for science to catch up with clinical practice? *J Thorac Dis.* 2015 Dec;7(12):E603-6
9. **Valgimigli M,** Gargiulo G. Bivalirudin in Current Practice: Melius Abundare Quam Deficere? *JACC Cardiovasc Interv.* 2016 Jul 11;9(13):1321-3.
10. Gargiulo G, **Valgimigli M.** Bivalirudin Versus Unfractionated Heparin for Acute Coronary Syndromes: Do We Have a Winner? *Rev Esp Cardiol (Engl Ed).* 2016 Aug;69(8):721-4.
11. **Valgimigli M,** Gargiulo G. Deciding on the Duration of Dual Antiplatelet Therapy-When the Choice Between 2 Evils Is Still Evil. *JAMA Cardiol.* 2017 May 1;2(5):488-489.
12. **Valgimigli M,** Gargiulo G. DAPT Duration After Drug-Eluting Stent Implantation: No News Is Good News. *JACC Cardiovasc Interv.* 2017 Jun 26;10(12):1211-1214.
13. Ukena C, Leonardi S, Palmerini T, Lansky A, Montalescot G, **Valgimigli M.** Will PIONEER AF-PCI change my practice? *EuroIntervention.* 2017 Aug 4;13(5):e609-e612. doi: 10.4244/EIJV13I5A95.
14. Gargiulo G, **Valgimigli M.** Long-term dual antiplatelet therapy and concomitant optimal medical therapy following percutaneous coronary intervention. *Cardiovasc Diagn Ther.* 2017 Jun;7(Suppl 2):S102-S106.
15. Gargiulo G, **Valgimigli M.** Antithrombotic therapy after transcatheter aortic valve implantation: a new piece of the still unresolved puzzle. *J Thorac Dis.* 2017 Nov;9(11):4260-4265. doi: 10.21037/jtd.2017.10.28.

16. **Valgimigli M**, Costa F. Chronic Thrombocytopenia and Percutaneous Coronary Intervention: The Virtue of Prudence. *JACC Cardiovasc Interv.* 2018 Sep 24;11(18):1869-1879. doi:10.1016/j.jcin.2018.06.051 Epub 2018 Aug 29.
17. Jolly SS, **Valgimigli M**. Transradial left main PCI is safe and effective EuroIntervention. 2018 Nov 20;14(10):1073-1075. doi: 10.4244/EIJV14I10A192.
18. **Valgimigli M**, Gargiulo G Activated Clotting Time During Unfractionated Heparin-Supported Coronary Intervention: Is Access Site the New Piece of the Puzzle? *JACC Cardiovasc Interv.* 2018 Jun 11;11(11):1046-1049. doi: 10.1016/j.jcin. 2018.02.022. Epub 2018 May 16.
19. **Valgimigli M**. The remarkable story of a wonder drug, which now comes to an end in the primary prevention setting: say bye-bye to aspirin! *Eur Heart J.* 2019 Feb 14;40(7):618-620. doi: 10.1093/eurheartj/ehy872.
20. **Valgimigli M**, Gragnano F. The Use of Radial Access for Cardiac Catheterization: Slowly, But Yet it Moves. *JACC Cardiovasc Interv.* 2019 Nov 25;12(22):2257-2259. doi: 10.1016/j.jcin.2019.06.052. Epub 2019 Aug 28. PMID: 31473234.
21. **Valgimigli M**, Gragnano F. The benefit and harm of treating STEMI: Between ischemia, bleeding, and reperfusion injury. *Eur Heart J Acute Cardiovasc Care.* 2020 Jun;9(4):259-261. doi: 10.1177/2048872620934298. PMID: 33025813 No abstract available.
22. Fabris E, Sinagra G, **Valgimigli M**. Antithrombotic therapy in heart failure and sinus rhythm: the ongoing search for a better match of patients to therapy. *Eur J Heart Fail.* 2021 Apr;23(4):657-660. doi: 10.1002/ejhf.2045. Epub 2020 Nov 12. PMID: 33131202.
23. Landi A, Milzi A, **Valgimigli M**. Intravascular Ultrasound Guidance during Primary Percutaneous Coronary Intervention: No Time for Excuses. *Cardiology.* 2024;149(3):193-195. doi: 10.1159/000538600. Epub 2024 Apr 22. PMID: 38648733.
24. **Valgimigli M**, Landi A. Bleeding risk should guide antithrombotic treatment after percutaneous coronary intervention: a Copernican revolution. *Eur Heart J.* 2024 Aug 28;ehae542. doi: 10.1093/eurheartj/ehae542. Epub ahead of print. PMID: 39193814.
25. Vranckx P, **Valgimigli M**, Aleksic M. Shaping the future of acute coronary syndrome management: a look back at 2024. *Eur Heart J Acute Cardiovasc Care.* 2025 Jan 31;14(1):40-43. doi: 10.1093/ehjacc/zuae143. PMID: 39691036..
26. Bikdeli B, Angiolillo DJ, **Valgimigli M**. Incorporating the Totality of Ischemic and Hemorrhagic Events: The Case of the AUGUSTUS Trial. *J Am Coll Cardiol.* 2025 Mar 25;85(11):1169-1172. doi: 10.1016/j.jacc.2024.11.047. Epub 2025 Feb 5. PMID: 39918471.
27. Landi A, **Valgimigli M**. Novel Global Platelet Reactivity Biomarker for a More Precise Ischemic Risk Stratification. *Circ Cardiovasc*

Interv. 2025 Apr;18(4):e015282. doi: 10.1161/CIRCINTERVENTIONS.125.015282. Epub 2025 Mar 26. PMID: 40135345.

28. **Valgimigli M**, Landi A. Radial access for percutaneous coronary intervention: the good, the better, and the ugly. *Eur Heart J*. 2025 Aug 1;ehaf424. doi: 10.1093/eurheartj/ehaf424. Epub ahead of print. PMID: 40748617.
29. Galli M, Gragnano F, **Valgimigli M**. Seeking for the Boundaries of De-escalation in Antiplatelet Therapy for Acute Coronary Syndromes. *Eur Heart J Cardiovasc Pharmacother*. 2025 Sep 19:pva070. doi: 10.1093/ehjcvp/pva070. Epub ahead of print. PMID: 40973644. Editorial/commentary
30. **Valgimigli M**, Morrow DA. In perspective: slow is safe, fast is final-timing matters in fractional flow reserve-guided complete revascularization for ST segment elevation myocardial infarction with multivessel disease. *Eur Heart J Acute Cardiovasc Care*. 2025 Oct 7;14(9):565-567. doi: 10.1093/ehjacc/zuaf115. PMID: 40905132
31. **Valgimigli M**, Hong SJ, Gragnano F, Hong MK. Ticagrelor monotherapy for acute coronary syndromes - Authors' reply. *Lancet*. 2025 Apr 26;405(10488):1463-1464. doi: 10.1016/S0140-6736(25)00365-4. PMID: 40287232. Editorial/commentary
32. **Valgimigli M**, Landi A. Radial access for percutaneous coronary intervention: the good, the better, and the ugly. *Eur Heart J*. 2026 Feb 9;47(5):637-639. doi: 10.1093/eurheartj/ehaf424. PMID: 40748617
33. Vranckx P, Frazzetto M, **Valgimigli M**. Mind the gap in acute coronary syndrome: looking back and into the future-the best of 2025 in the EHJ-ACVC series. *Eur Heart J Acute Cardiovasc Care*. 2026 Mar 10;15(1):55-58. doi: 10.1093/ehjacc/zuaf160. PMID: 41557515
34. Angiolillo DJ, Kastrati A, Frazzetto M, **Valgimigli M**. Prasugrel should be preferred over ticagrelor in acute coronary syndromes: pros and cons. *EuroIntervention*. 2026 May 15;22(10):526-529. doi: 10.4244/EIJ-E-26-00004. PMID: 42137923; PMCID: PMC13158679
35. **Valgimigli M**, Covani M, Angiolillo DJ. Bivalirudin in Primary PCI: Time to Implement the Overwhelming Evidence? *J Am Coll Cardiol*. 2026 Jul 28;S0735-1097(26)07129-9. doi: 10.1016/j.jacc.2026.07.012. Epub ahead of print. PMID: 42663361

Letter to the editor

1. **Valgimigli M**, Piscaglia F, Bolondi L. Splanchnic arterial Doppler parameters in portal hypertension. *Hepatology*, 1999; 29 (5):1610-16123.
2. **Valgimigli M**, Agostoni P, Biondi Zoccai GG. Complete Myocardial Revascularisation: Between Myth And Reality. *Eur Heart J*.2005 Sep;26 (17):1809-10.
3. Tricoci P, Harrington RA, **Valgimigli M**. Letter regarding article by Patti et al, "Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study". *Circulation*. 2005 Oct 25;112(17).
4. **Valgimigli M**, GF Percoco, L. Bolognese. Drug-Eluting Stents in Primary PCI. *New England Journal Med* 2006;355(23)2483-2486
5. **Valgimigli M**, Biondi Zoccai GG, Agostoni P. Clinical implications of the PROTECT-TIMI 30 trial. *J Am Coll Cardiol* 2007;49(6):729-730.
6. Ferraresi P, Campo G, Marchetti G, Pinotti M, **Valgimigli M**, Gemmati D, Ferrari R, Bernardi F. Temporal and genotype-driven variation of factor VII levels in patients with acute myocardial infarction. *Clin Appl Thromb Hemost*. 2009 Feb;15(1):119-22.
7. Vranckx P, **Valgimigli M**. Letter by Vranckx and Valgimigli regarding article, "validation of the bleeding academic research consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention". *Circulation*. 2012 Oct 23;126(17):e276; author reply e277. [doi:10.1161/CIRCULATIONAHA.112.105023](https://doi.org/10.1161/CIRCULATIONAHA.112.105023).
8. Cortese B, **Valgimigli M**. Letter by Cortese and Valgimigli regarding article, "Antithrombotic therapy in patients with chronic kidney disease". *Circulation*. 2012 Nov 20;126(21):e333; author reply e334. [doi: 10.1161/CIRCULATIONAHA.112.124180](https://doi.org/10.1161/CIRCULATIONAHA.112.124180).
9. Costa F, **Valgimigli M**. Impact of Clinical Presentation on Dual Antiplatelet Therapy Duration: Let's Re-Evaluate Our Priorities. *J Am Coll Cardiol*. 2015 Sep 8;66(10):1203-4.
10. Costa F, **Valgimigli M**. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. *N Engl J Med*. 2015 Sep 24;373(13):1271-2.
11. **Valgimigli M**, Gargiulo G, Jüni P. Radial versus femoral access for cardiac catheterisation - Authors' reply. *Lancet*. 2015 Dec 12;386(10011):2394.
12. **Valgimigli M**, Santucci A. Bivalirudin in Acute Coronary Syndromes. Authors reply. *N Engl J Med*. 2016 Jan 21;374(3):285-6.
13. Santucci A, **Valgimigli M**. Digital Gangrene Following Transradial Coronary Angiogram. *JACC Cardiovasc Interv*. 2016 May 9;9(9):980-1.
14. Costa F, Daemen J, Diletti R, Kauer F, Geuns RJ, Ligthart J, Witberg K, Zijlstra F, **Valgimigli M**, Van Mieghem NM, van Leeuwen MA. Response by Costa et al to Letter Regarding Article, "The Rotterdam Radial Access

Research: Ultrasound-Based Radial Artery Evaluation for Diagnostic and Therapeutic Coronary Procedures”. *Circ Cardiovasc Interv*. 2016 Jul;9(7).

15. **Valgimigli M**, Gargiulo G. Response by Valgimigli and Gargiulo to Letter Regarding Article, “A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More?” *Circulation*. 2017 May 9;135(19):e1037-e1038.
16. Gragnano F, Calabrò P, **Valgimigli M**. Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention? *Eur Heart J*. 2019 Jan 7;40(2):216-217. doi: 10.1093/eurheartj/ehy675.
17. Costa F, van Klaveren D, Steyerberg E, **Valgimigli M**; PRECISE-DAPT Study Investigators. Reply: Use of Clinical Risk Score in an Elderly Population: Need for Ad Hoc Validation and Calibration. *J Am Coll Cardiol*. 2019 Jul 9;74(1):162-163. doi: 10.1016/j.jacc.2019.05.005.
18. Storey RF, **Valgimigli M**, Cuisset T, Capodanno D, Wijns W, Knuuti J. Intolerance to aspirin in patients undergoing percutaneous coronary intervention in the setting of chronic coronary syndromes: perspectives from the ESC 2019 Chronic Coronary Syndromes guidelines. *Eur Heart J*. 2020 Jan 14;41(3):483-484. doi: 10.1093/eurheartj/ehz894. PubMed PMID: 31872254.
19. Vranckx P, **Valgimigli M**, Eckardt L, Gargiulo G, Goette A. Anti-thrombotic treatment strategies after PCI - Authors’ reply. *Lancet*. 2020 Mar 14;395(10227):867-868. doi: 10.1016/S0140-6736(20)30033-7. PubMed PMID: 32171407.
20. Gargiulo G, Goette A, Vranckx P, **Valgimigli M**. Higher risk of stent thrombosis with double therapy with direct oral anticoagulants: cherry picking the populations of interest does not help. *Eur Heart J*. 2020 May 1;41(17):1701-1702. doi: 10.1093/eurheartj/ehaa076. PubMed PMID: 32060541.
21. Gargiulo G, Cannon CP, Gibson CM, Goette A, Lopes RD, Oldgren J, Korjian S, Windecker S, Esposito G, Vranckx P, **Valgimigli M**. Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. *Eur Heart J Cardiovasc Pharmacother*. 2021 Apr 9;7(FI1):f50-f60. doi: 10.1093/ehjcvp/pvaa116. PMID: 33119069.
22. **Valgimigli M**, Hong SJ, Gragnano F, Hong MK. Ticagrelor monotherapy for acute coronary syndromes - Authors’ reply. *Lancet*. 2025 Apr 26;405(10488):1463-1464. doi: 10.1016/S0140-6736(25)00365-4. PMID: 40287232.
23. Gragnano F, Landi A, Calabrò P, van Klaveren D, **Valgimigli M**. From Discordance to Precision: The PRECISE-HBR Score Refines Bleeding Risk Prediction After PCI. *JACC Cardiovasc Interv*. 2025

Jul 1:S1936-8798(25)01439-6. doi: 10.1016/j.jcin.2025.02.030. Epub ahead of print. PMID: 40778891

24. Bongiovanni D, **Valgimigli M**. Reply: Reassessing Risk-Recurrent Event Analysis in High Bleeding Risk Patients Post-PCI. *J Am Coll Cardiol*. 2025 Oct 14;86(15):e125. doi: 10.1016/j.jacc.2025.08.048. PMID: 41062233
25. Landi A, **Valgimigli M**. Unveiling the PRODIGY of P2Y₁₂ Inhibitor Over Aspirin Monotherapy After Acute Coronary Syndrome. *JACC Cardiovasc Interv*. 2025 Dec 8;18(23):2970. doi: 10.1016/j.jcin.2025.09.046. PMID: 41371796
26. **Valgimigli M**, Gragnano F, Giacoppo D. Clopidogrel versus aspirin for coronary artery disease - Authors' reply. *Lancet*. 2026 Feb 28;407(10531):853-854. doi: 10.1016/S0140-6736(26)00186-8. PMID: 41763741

Case reports

1. Casali A, Gaiani S, Piscaglia F, Gramantieri L, Masi L, **Valgimigli M**, Bolondi L. A case of extracranial vertebral artery dissection with spontaneous recovery diagnosis and follow up by duplex and color doppler. *Eur J Ultrasound*. 1997 Dec 1;6(3):197-201.
2. Piscaglia F, **Valgimigli M**, Serra C, Donati G, Gramantieri L, Bolondi L. Duplex Doppler Findings in Splenic Arteriovenous Fistula. *J Clin Ultrasound* 1998;26(2):103-105.
3. Placci A, Melandri G, Cecilioni L, **Valgimigli M**, Bolondi L, Branzi A. Late appearing cholestaticicterus after a month of treatment with ticlopidine *Ital Heart J Suppl* 2001; 2 (11): 1240-1242.
4. **Valgimigli M**, Steendijk P, Sianos G, Onderwater E, Serruys PW. Left Ventricular Unloading And Concomitant Total Cardiac Output Increase By The Use Of Percutaneous Impella Recover Lp 2.5 Assist Device During High-Risk Coronary Intervention. *Cath Cardio Int* 2005;65(2):263-7.
5. Biondi-Zoccai GG, Abbate A, **Valgimigli M**, Testa L, Agostoni P. From chaotic to coordinated clinical research: the case of acetylcysteine. *Arch Intern Med*. 2006 Aug 14-28;166(15):1668.
6. Malagutti P, Ligthart JMR, Cademartiri F, Meijboom WB, **Valgimigli M**. Plaque sealing: are the benefits outweighing the risks? *Int J Cardiol*. 2007 Feb 7;115(2):265-6.
7. **Valgimigli M**, Malagutti P. The heart of coronary arteries. *Eur Heart J* 2007 Mar 16.
8. Campo G, **Valgimigli M**, Carrescia C, Carletti R, Ferrari R. Tailored Medical and Interventional Therapy Against Recurrent Stent Thrombosis After Drug-Eluting Stenting. *Clin Appl Thromb Hemost*. 2009 Jun 10.
9. Malik V, Safaa A, Clugston R, Noc M, Fister M, Vranckx P, **Valgimigli M**, Heidebuchel H. How should I treat this unusual anterolateral ST-elevation myocardial infarction with recurrent ventricular fibrillation and cardiac arrest? *EuroIntervention*. 2016 Sep 18;12(7):928-32.
10. Franchetti Pardo L, Rigamonti E, Scopigni FR, Pedrazzini G, **Valgimigli M**. Myocardial Infarction and Pulmonary Embolism: Causal or Temporal Association? *JACC Case Rep*. 2024 Sep 18;29(18):102534. doi: 10.1016/j.jaccas.2024.102534. PMID: 39359999; PMCID: PMC11442240.

Book chapters

1. Gargiulo G, **Valgimigli M**. Stent and Tent Thrombosis. *Interventional Cardiology 1133 Questions: An International Board Review*. Chapt 20, pages 218 – 236 Ed: Wolters Kluwer third edition 2019.
2. **Valgimigli M**, Vant'Hof A, Hamm C. Tirofiban From: Antiplatelet therapy in Cardiovascular disease 2014, edited by Ron Waskmann, Paul A. Gurbel, Michale A. Gaglia Jr, Wiley Blackwell ISBN: 978118275757.
3. Ceconi C, **Valgimigli M**. Inibizione del Sistema Renina-Angiotensina e Cardiprotezione. From “Infarto Miocardico Acuto. Fisiopatologia, Clinica e Terapia”, pages (233-248) Ed: Salvatore Fabio Vajola Press, 2001.
4. Bolondi L, Piscaglia F, **Valgimigli M**, Gaiani S. Doppler Ultrasound in Portal Hypertension Pages (57-76) from P Rossi (Ed.) Portal Hypertension. Diagnostic imaging and imaging-guided therapy. Springer-Verlag, 2001, ISBN 3-540-65797-5.
5. **Valgimigli M**, Siminiak T, Kurpysz M, Giessen W, Serruys PW, Clinical Utilization of Skeletal Myoblasts. In *An essential guide to cardiac cell therapy*. Edited by Emerson C. Perin, Guilherme V. Silva, James.T. Willerson. (ISBN: 10: 1 841844719) 2006 Informa UK limited.
6. Tebaldi M, **Valgimigli M**. Fractional Flow Reserve. *Diagnostica Coronarica e Cardiaca Avanzata 2011* Vol 1, Chapt. 4, p;98 .
7. Cavazza C, **Valgimigli M**. Tomografia a Coerenza Ottica (OCT) Diagnostica Coronarica e Cardiaca Avanzata 2011 Vol 1, Chapt. 5, p;126.
8. Vranckx P, **Valgimigli M**, Serruys PW. Aortic Counterpulsation. *Encyclopedia of intensive care medicine*, DOI 10.1007.
9. Biscagli S, **Valgimigli M**. Thrombectomy and distal protection devices. *EuroPCR*.
10. **Valgimigli M**. Stenting in Acute Myocardial Infarction, Edited by Matthew J. Price 181 Questions and Answers in Heart Failure. Authors: R. Ferrari, L Tavazzi, C. Opasich. David Masson Editor, 2003.
11. Come è cambiata la percezione dei farmaci cardiovascolari: dagli effetti farmacologici a quelli biologici (How the perception of cardiovascular pharmacology has changed: from pharmacological to biological action of drugs) Editor R. Ferrari Pacini Editore, 2003.
12. Cardiac Remodeling. Authors: R. Ferrari and Collaborators, Italian Society of Cardiology.
13. **Valgimigli M** and Gargiulo G. Post-Procedural Management and Antithrombotic therapy. Chapter 4 “Post-Procedural Care: Post-Procedural Management and Antithrombotic Therapy” of the CathSAP 5 (fifth edition of the self-assessment program covering cardiac catheterization and interventional cardiology) from the American College of Cardiology, 2017. Editors: Sunil Rao, David Kandzari. Sunil V. Rao (Editor in Chief), Ajay J. Kirtane (Chair, Question Writing Group),

Subhash Banerjee, Alope V. Finn, Allen Jeremias, David E. Kandzari, Matthew J. Price, Arnold H. Seto, Mehdi H. Shishehbor.

14. Gargiulo G and **Valgimigli M**. Chapter 20 “Stents and Stent Thrombosis” of the 3rd Edition of “1003 Questions: An Interventional Cardiology Board Review” 2017. Editors: Debabrata Mukherjee, Richard Lange, Leslie Cho, Saurav Chatterjee, and David J. Moliterno.
15. Costa F and **Valgimigli M**. “Radial and Femoral access in percutaneous intervention”. Controversies in Cardiology Textbook.
16. Costa F, **Valgimigli M**. “Parental Antiplatelet Agents”. Kapadia: Interventional Cardiology Textbook.

The six most important original papers

1. **Valgimigli M**, Hong SJ, Gagnano F, Chalkou K, Franzone A, da Costa BR, Baber U, Kim BK, Jang Y, Chen SL, Stone GW, Hahn JY, Windecker S, Gibson MC, Song YB, Ge Z, Vranckx P, Mehta S, Gwon HC, Lopes RD, Dangas GD, McFadden EP, Angiolillo DJ, Leonardi S, Heg D, Calabrò P, Jüni P, Mehran R, Hong MK; Single Versus Dual Antiplatelet Therapy (Sidney-4) collaborator group. De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient- level meta-analysis of randomised trials. *Lancet*. 2024 Sep 7;404(10456):937-948. doi: 10.1016/S0140-6736(24)01616-7. Epub 2024 Aug 31. PMID: 39226909
2. **Valgimigli M**, Frigoli E, Heg D, Tijssen J, Jüni P, Vranckx P, Ozaki Y, Morice MC, Chevalier B, Onuma Y, Windecker S, Tonino PAL, Roffi M, Lesiak M, Mahfoud F, Bartunek J, Hildick-Smith D, Colombo A, Stanković G, Iñiguez A, Schultz C, Kornowski R, Ong PJJ, Alasnag M, Rodriguez AE, Moschovitis A, Laanmets P, Donahue M, Leonardi S, Smits PC; MASTER DAPT Investigators. Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. *N Engl J Med*. 2021 Aug 28. doi: 10.1056/NEJMoa2108749. Epub ahead of print. PMID: 34449185.
3. **Valgimigli M**, Frigoli E, Leonardi S, Rothenbühler M, Gagnor A, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andò G, Repetto A, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Presbitero P, Santarelli A, Sardella G, Varbella F, Tresoldi S, de Cesare N, Rigattieri S, Zingarelli A, Tosi P, van 't Hof A, Boccuzzi G, Omerovic E, Sabaté M, Heg D, Jüni P, Vranckx P; MATRIX Investigators. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. *N Engl J Med*. 2015 Sep 10;373(11):997-1009. doi: 10.1056/NEJMoa1507854.
4. Piccolo R, Bona KH, Efthimiou O, Varenne O, Baldo A, Urban P, Kaiser C, Remkes W, Räber L, de Belder A, van 't Hof AWJ, Stankovic G, Lemos PA, Wilsgaard T, Reifart J, Rodriguez AE, Ribeiro EE, Seruys PWJC, Abizaid A, Sabaté M, Byrne RA, de la Torre Hernandez JM, Wijns W, Jüni P, Windecker S, **Valgimigli M**; Coronary Stent Trialists' Collaboration. Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. *Lancet*. 2019 Jun 22;393(10190):2503-2510. doi: 10.1016/S0140-6736(19)30474-X. Epub 2019 May 2
5. **Valgimigli M**, Frigoli E, Leonardi S, Vranckx P, Rothenbühler M, Tebaldi M, Varbella F, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andó G, Ferrario M, Limbruno U, Garbo R, Sganzerla P, Russo F, Nazaro M, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Ferrante G, Santarelli A, Sardella G, de Cesare N, Tosi P, van 't Hof A, Omerovic E, Brugaletta S, Windecker S, Heg D, Jüni P, on behalf of the MATRIX

Investigators Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. *Lancet*. 2018 Sep 8;392(10150):835-848.

6. Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, Zanchin T, Palmerini T, Wallentin L, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, **Valgimigli M**; PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. *Lancet*. 2017 Mar 11;389(10073):1025-1034.